[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Nusinersen is a 2'-O-methoxyethyl phosphorothioate-modified antisense drug being developed to treat spinal muscular atrophy. Nusinersen is specifically designed to alter splicing of SMN2 pre-mRNA and thus increase the amount of functional survival motor neuron (SMN) protein that is deficient in patients with spinal muscular atrophy. This open-label, phase 2, escalating dose clinical study assessed the safety and tolerability, pharmacokinetics, and clinical efficacy of multiple intrathecal doses of nusinersen (6 mg and 12 mg dose equivalents) in patients with infantile-onset spinal muscular atrophy. Eligible participants were of either gender aged between 3 weeks and 7 months old with onset of spinal muscular atrophy symptoms between 3 weeks and 6 months, who had SMN1 homozygous gene deletion or mutation. Safety assessments included adverse events, physical and neurological examinations, vital signs, clinical laboratory tests, cerebrospinal fluid laboratory tests, and electrocardiographs. Clinical efficacy assessments included event free survival, and change from baseline of two assessments of motor function: the motor milestones portion of the Hammersmith Infant Neurological Exam-Part 2 (HINE-2) and the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) motor function test, and compound motor action potentials. Autopsy tissue was analysed for target engagement, drug concentrations, and pharmacological activity. HINE-2, CHOP-INTEND, and compound motor action potential were compared between baseline and last visit using the Wilcoxon signed-rank test. Age at death or permanent ventilation was compared with natural history using the log-rank test. The study is registered at ClinicalTrials.gov, number NCT01839656. 20 participants were enrolled between May 3, 2013, and July 9, 2014, and assessed through to an interim analysis done on Jan 26, 2016. All participants experienced adverse events, with 77 serious adverse events reported in 16 participants, all considered by study investigators not related or unlikely related to the study drug. In the 12 mg dose group, incremental achievements of motor milestones (p<0\u00b70001), improvements in CHOP-INTEND motor function scores (p=0\u00b70013), and increased compound muscle action potential amplitude of the ulnar nerve (p=0\u00b70103) and peroneal nerve (p<0\u00b70001), compared with baseline, were observed. Median age at death or permanent ventilation was not reached and the Kaplan-Meier survival curve diverged from a published natural history case series (p=0\u00b70014). Analysis of autopsy tissue from patients exposed to nusinersen showed drug uptake into motor neurons throughout the spinal cord and neurons and other cell types in the brainstem and other brain regions, exposure at therapeutic concentrations, and increased SMN2 mRNA exon 7 inclusion and SMN protein concentrations in the spinal cord. Administration of multiple intrathecal doses of nusinersen showed acceptable safety and tolerability, pharmacology consistent with its intended mechanism of action, and encouraging clinical efficacy. Results informed the design of an ongoing, sham-controlled, phase 3 clinical study of nusinersen in infantile-onset spinal muscular atrophy. Ionis Pharmaceuticals, Inc and Biogen.", "qas": [{"question": "Which disease is treated with Nusinersen?", "answers": ["Spinal Muscular Atrophy", "SMA"], "qid": "0ddc50b6e2eb4c54b88303df7172ac37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["treated", 17], ["with", 25], ["Nusinersen", 30], ["?", 40]], "detected_answers": [{"text": "Spinal Muscular Atrophy", "token_spans": [[120, 122], [99, 101], [15, 17], [546, 548], [51, 53]], "char_spans": [[702, 724], [581, 603], [100, 122], [3221, 3243], [310, 332]]}]}], "context_tokens": [["Nusinersen", 0], ["is", 11], ["a", 14], ["2'-O", 16], ["-", 20], ["methoxyethyl", 21], ["phosphorothioate", 34], ["-", 50], ["modified", 51], ["antisense", 60], ["drug", 70], ["being", 75], ["developed", 81], ["to", 91], ["treat", 94], ["spinal", 100], ["muscular", 107], ["atrophy", 116], [".", 123], ["Nusinersen", 125], ["is", 136], ["specifically", 139], ["designed", 152], ["to", 161], ["alter", 164], ["splicing", 170], ["of", 179], ["SMN2", 182], ["pre", 187], ["-", 190], ["mRNA", 191], ["and", 196], ["thus", 200], ["increase", 205], ["the", 214], ["amount", 218], ["of", 225], ["functional", 228], ["survival", 239], ["motor", 248], ["neuron", 254], ["(", 261], ["SMN", 262], [")", 265], ["protein", 267], ["that", 275], ["is", 280], ["deficient", 283], ["in", 293], ["patients", 296], ["with", 305], ["spinal", 310], ["muscular", 317], ["atrophy", 326], [".", 333], ["This", 335], ["open", 340], ["-", 344], ["label", 345], [",", 350], ["phase", 352], ["2", 358], [",", 359], ["escalating", 361], ["dose", 372], ["clinical", 377], ["study", 386], ["assessed", 392], ["the", 401], ["safety", 405], ["and", 412], ["tolerability", 416], [",", 428], ["pharmacokinetics", 430], [",", 446], ["and", 448], ["clinical", 452], ["efficacy", 461], ["of", 470], ["multiple", 473], ["intrathecal", 482], ["doses", 494], ["of", 500], ["nusinersen", 503], ["(", 514], ["6", 515], ["mg", 517], ["and", 520], ["12", 524], ["mg", 527], ["dose", 530], ["equivalents", 535], [")", 546], ["in", 548], ["patients", 551], ["with", 560], ["infantile", 565], ["-", 574], ["onset", 575], ["spinal", 581], ["muscular", 588], ["atrophy", 597], [".", 604], ["Eligible", 606], ["participants", 615], ["were", 628], ["of", 633], ["either", 636], ["gender", 643], ["aged", 650], ["between", 655], ["3", 663], ["weeks", 665], ["and", 671], ["7", 675], ["months", 677], ["old", 684], ["with", 688], ["onset", 693], ["of", 699], ["spinal", 702], ["muscular", 709], ["atrophy", 718], ["symptoms", 726], ["between", 735], ["3", 743], ["weeks", 745], ["and", 751], ["6", 755], ["months", 757], [",", 763], ["who", 765], ["had", 769], ["SMN1", 773], ["homozygous", 778], ["gene", 789], ["deletion", 794], ["or", 803], ["mutation", 806], [".", 814], ["Safety", 816], ["assessments", 823], ["included", 835], ["adverse", 844], ["events", 852], [",", 858], ["physical", 860], ["and", 869], ["neurological", 873], ["examinations", 886], [",", 898], ["vital", 900], ["signs", 906], [",", 911], ["clinical", 913], ["laboratory", 922], ["tests", 933], [",", 938], ["cerebrospinal", 940], ["fluid", 954], ["laboratory", 960], ["tests", 971], [",", 976], ["and", 978], ["electrocardiographs", 982], [".", 1001], ["Clinical", 1003], ["efficacy", 1012], ["assessments", 1021], ["included", 1033], ["event", 1042], ["free", 1048], ["survival", 1053], [",", 1061], ["and", 1063], ["change", 1067], ["from", 1074], ["baseline", 1079], ["of", 1088], ["two", 1091], ["assessments", 1095], ["of", 1107], ["motor", 1110], ["function", 1116], [":", 1124], ["the", 1126], ["motor", 1130], ["milestones", 1136], ["portion", 1147], ["of", 1155], ["the", 1158], ["Hammersmith", 1162], ["Infant", 1174], ["Neurological", 1181], ["Exam", 1194], ["-", 1198], ["Part", 1199], ["2", 1204], ["(", 1206], ["HINE-2", 1207], [")", 1213], ["and", 1215], ["the", 1219], ["Children", 1223], ["'s", 1231], ["Hospital", 1234], ["of", 1243], ["Philadelphia", 1246], ["Infant", 1259], ["Test", 1266], ["of", 1271], ["Neuromuscular", 1274], ["Disorders", 1288], ["(", 1298], ["CHOP", 1299], ["-", 1303], ["INTEND", 1304], [")", 1310], ["motor", 1312], ["function", 1318], ["test", 1327], [",", 1331], ["and", 1333], ["compound", 1337], ["motor", 1346], ["action", 1352], ["potentials", 1359], [".", 1369], ["Autopsy", 1371], ["tissue", 1379], ["was", 1386], ["analysed", 1390], ["for", 1399], ["target", 1403], ["engagement", 1410], [",", 1420], ["drug", 1422], ["concentrations", 1427], [",", 1441], ["and", 1443], ["pharmacological", 1447], ["activity", 1463], [".", 1471], ["HINE-2", 1473], [",", 1479], ["CHOP", 1481], ["-", 1485], ["INTEND", 1486], [",", 1492], ["and", 1494], ["compound", 1498], ["motor", 1507], ["action", 1513], ["potential", 1520], ["were", 1530], ["compared", 1535], ["between", 1544], ["baseline", 1552], ["and", 1561], ["last", 1565], ["visit", 1570], ["using", 1576], ["the", 1582], ["Wilcoxon", 1586], ["signed", 1595], ["-", 1601], ["rank", 1602], ["test", 1607], [".", 1611], ["Age", 1613], ["at", 1617], ["death", 1620], ["or", 1626], ["permanent", 1629], ["ventilation", 1639], ["was", 1651], ["compared", 1655], ["with", 1664], ["natural", 1669], ["history", 1677], ["using", 1685], ["the", 1691], ["log", 1695], ["-", 1698], ["rank", 1699], ["test", 1704], [".", 1708], ["The", 1710], ["study", 1714], ["is", 1720], ["registered", 1723], ["at", 1734], ["ClinicalTrials.gov", 1737], [",", 1755], ["number", 1757], ["NCT01839656", 1764], [".", 1775], ["20", 1777], ["participants", 1780], ["were", 1793], ["enrolled", 1798], ["between", 1807], ["May", 1815], ["3", 1819], [",", 1820], ["2013", 1822], [",", 1826], ["and", 1828], ["July", 1832], ["9", 1837], [",", 1838], ["2014", 1840], [",", 1844], ["and", 1846], ["assessed", 1850], ["through", 1859], ["to", 1867], ["an", 1870], ["interim", 1873], ["analysis", 1881], ["done", 1890], ["on", 1895], ["Jan", 1898], ["26", 1902], [",", 1904], ["2016", 1906], [".", 1910], ["All", 1912], ["participants", 1916], ["experienced", 1929], ["adverse", 1941], ["events", 1949], [",", 1955], ["with", 1957], ["77", 1962], ["serious", 1965], ["adverse", 1973], ["events", 1981], ["reported", 1988], ["in", 1997], ["16", 2000], ["participants", 2003], [",", 2015], ["all", 2017], ["considered", 2021], ["by", 2032], ["study", 2035], ["investigators", 2041], ["not", 2055], ["related", 2059], ["or", 2067], ["unlikely", 2070], ["related", 2079], ["to", 2087], ["the", 2090], ["study", 2094], ["drug", 2100], [".", 2104], ["In", 2106], ["the", 2109], ["12", 2113], ["mg", 2116], ["dose", 2119], ["group", 2124], [",", 2129], ["incremental", 2131], ["achievements", 2143], ["of", 2156], ["motor", 2159], ["milestones", 2165], ["(", 2176], ["p<0\u00b70001", 2177], [")", 2185], [",", 2186], ["improvements", 2188], ["in", 2201], ["CHOP", 2204], ["-", 2208], ["INTEND", 2209], ["motor", 2216], ["function", 2222], ["scores", 2231], ["(", 2238], ["p=0\u00b70013", 2239], [")", 2247], [",", 2248], ["and", 2250], ["increased", 2254], ["compound", 2264], ["muscle", 2273], ["action", 2280], ["potential", 2287], ["amplitude", 2297], ["of", 2307], ["the", 2310], ["ulnar", 2314], ["nerve", 2320], ["(", 2326], ["p=0\u00b70103", 2327], [")", 2335], ["and", 2337], ["peroneal", 2341], ["nerve", 2350], ["(", 2356], ["p<0\u00b70001", 2357], [")", 2365], [",", 2366], ["compared", 2368], ["with", 2377], ["baseline", 2382], [",", 2390], ["were", 2392], ["observed", 2397], [".", 2405], ["Median", 2407], ["age", 2414], ["at", 2418], ["death", 2421], ["or", 2427], ["permanent", 2430], ["ventilation", 2440], ["was", 2452], ["not", 2456], ["reached", 2460], ["and", 2468], ["the", 2472], ["Kaplan", 2476], ["-", 2482], ["Meier", 2483], ["survival", 2489], ["curve", 2498], ["diverged", 2504], ["from", 2513], ["a", 2518], ["published", 2520], ["natural", 2530], ["history", 2538], ["case", 2546], ["series", 2551], ["(", 2558], ["p=0\u00b70014", 2559], [")", 2567], [".", 2568], ["Analysis", 2570], ["of", 2579], ["autopsy", 2582], ["tissue", 2590], ["from", 2597], ["patients", 2602], ["exposed", 2611], ["to", 2619], ["nusinersen", 2622], ["showed", 2633], ["drug", 2640], ["uptake", 2645], ["into", 2652], ["motor", 2657], ["neurons", 2663], ["throughout", 2671], ["the", 2682], ["spinal", 2686], ["cord", 2693], ["and", 2698], ["neurons", 2702], ["and", 2710], ["other", 2714], ["cell", 2720], ["types", 2725], ["in", 2731], ["the", 2734], ["brainstem", 2738], ["and", 2748], ["other", 2752], ["brain", 2758], ["regions", 2764], [",", 2771], ["exposure", 2773], ["at", 2782], ["therapeutic", 2785], ["concentrations", 2797], [",", 2811], ["and", 2813], ["increased", 2817], ["SMN2", 2827], ["mRNA", 2832], ["exon", 2837], ["7", 2842], ["inclusion", 2844], ["and", 2854], ["SMN", 2858], ["protein", 2862], ["concentrations", 2870], ["in", 2885], ["the", 2888], ["spinal", 2892], ["cord", 2899], [".", 2903], ["Administration", 2905], ["of", 2920], ["multiple", 2923], ["intrathecal", 2932], ["doses", 2944], ["of", 2950], ["nusinersen", 2953], ["showed", 2964], ["acceptable", 2971], ["safety", 2982], ["and", 2989], ["tolerability", 2993], [",", 3005], ["pharmacology", 3007], ["consistent", 3020], ["with", 3031], ["its", 3036], ["intended", 3040], ["mechanism", 3049], ["of", 3059], ["action", 3062], [",", 3068], ["and", 3070], ["encouraging", 3074], ["clinical", 3086], ["efficacy", 3095], [".", 3103], ["Results", 3105], ["informed", 3113], ["the", 3122], ["design", 3126], ["of", 3133], ["an", 3136], ["ongoing", 3139], [",", 3146], ["sham", 3148], ["-", 3152], ["controlled", 3153], [",", 3163], ["phase", 3165], ["3", 3171], ["clinical", 3173], ["study", 3182], ["of", 3188], ["nusinersen", 3191], ["in", 3202], ["infantile", 3205], ["-", 3214], ["onset", 3215], ["spinal", 3221], ["muscular", 3228], ["atrophy", 3237], [".", 3244], ["Ionis", 3246], ["Pharmaceuticals", 3252], [",", 3267], ["Inc", 3269], ["and", 3273], ["Biogen", 3277], [".", 3283]]}
{"context": "Ca2+ is a ubiquitous intracellular messenger responsible for controlling numerous cellular processes including fertilization, mitosis, neuronal transmission, contraction and relaxation of muscles, gene transcription, and cell death. At rest, the cytoplasmic Ca2+ concentration [Ca2+]i is approximately 100 nM, but this level rises to 500-1,000 nM upon activation. In osteoblasts, the elevation of [Ca2+]i is a result of an increase in the release of Ca2+ from endoplasmic reticulum and/or extracellular Ca2+ influx through voltage gated Ca2+ channels. Many of the cellular effects of Ca2+ are mediated by the Ca2+ binding protein, calmodulin (CaM). Upon binding up to four calcium ions, CaM undergoes a conformational change, which enables it to bind to specific proteins eliciting a specific response. Calmodulin kinase II (CaMKII) is a major target of the Ca(2+)/CaM second messenger system. Once bound to Ca(2+)/CaM, the multimeric CaMKII is released from its autoinhibitory status and maximally activated, which then leads to an intraholoenzyme autophosphorylation reaction. Calcineurin (Cn) is another major target protein that is activated by Ca(2+)/CaM. Cn is a serine-threonine phosphatase that consists of a heterodimeric protein complex composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). Upon activation, Cn directly binds to, and dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors within the cytoplasm allowing them to translocate to the nucleus and participate in the regulation of gene expression. This review will examine the potential mechanisms by which calcium, CaM, CaMKII, and Cn/NFAT control osteoblast proliferation and differentiation.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "4739d60b47ce43b3a2834c15aa922cab", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[189, 189]], "char_spans": [[1079, 1089]]}]}], "context_tokens": [["Ca2", 0], ["+", 3], ["is", 5], ["a", 8], ["ubiquitous", 10], ["intracellular", 21], ["messenger", 35], ["responsible", 45], ["for", 57], ["controlling", 61], ["numerous", 73], ["cellular", 82], ["processes", 91], ["including", 101], ["fertilization", 111], [",", 124], ["mitosis", 126], [",", 133], ["neuronal", 135], ["transmission", 144], [",", 156], ["contraction", 158], ["and", 170], ["relaxation", 174], ["of", 185], ["muscles", 188], [",", 195], ["gene", 197], ["transcription", 202], [",", 215], ["and", 217], ["cell", 221], ["death", 226], [".", 231], ["At", 233], ["rest", 236], [",", 240], ["the", 242], ["cytoplasmic", 246], ["Ca2", 258], ["+", 261], ["concentration", 263], ["[", 277], ["Ca2+]i", 278], ["is", 285], ["approximately", 288], ["100", 302], ["nM", 306], [",", 308], ["but", 310], ["this", 314], ["level", 319], ["rises", 325], ["to", 331], ["500", 334], ["-", 337], ["1,000", 338], ["nM", 344], ["upon", 347], ["activation", 352], [".", 362], ["In", 364], ["osteoblasts", 367], [",", 378], ["the", 380], ["elevation", 384], ["of", 394], ["[", 397], ["Ca2+]i", 398], ["is", 405], ["a", 408], ["result", 410], ["of", 417], ["an", 420], ["increase", 423], ["in", 432], ["the", 435], ["release", 439], ["of", 447], ["Ca2", 450], ["+", 453], ["from", 455], ["endoplasmic", 460], ["reticulum", 472], ["and/or", 482], ["extracellular", 489], ["Ca2", 503], ["+", 506], ["influx", 508], ["through", 515], ["voltage", 523], ["gated", 531], ["Ca2", 537], ["+", 540], ["channels", 542], [".", 550], ["Many", 552], ["of", 557], ["the", 560], ["cellular", 564], ["effects", 573], ["of", 581], ["Ca2", 584], ["+", 587], ["are", 589], ["mediated", 593], ["by", 602], ["the", 605], ["Ca2", 609], ["+", 612], ["binding", 614], ["protein", 622], [",", 629], ["calmodulin", 631], ["(", 642], ["CaM", 643], [")", 646], [".", 647], ["Upon", 649], ["binding", 654], ["up", 662], ["to", 665], ["four", 668], ["calcium", 673], ["ions", 681], [",", 685], ["CaM", 687], ["undergoes", 691], ["a", 701], ["conformational", 703], ["change", 718], [",", 724], ["which", 726], ["enables", 732], ["it", 740], ["to", 743], ["bind", 746], ["to", 751], ["specific", 754], ["proteins", 763], ["eliciting", 772], ["a", 782], ["specific", 784], ["response", 793], [".", 801], ["Calmodulin", 803], ["kinase", 814], ["II", 821], ["(", 824], ["CaMKII", 825], [")", 831], ["is", 833], ["a", 836], ["major", 838], ["target", 844], ["of", 851], ["the", 854], ["Ca(2+)/CaM", 858], ["second", 869], ["messenger", 876], ["system", 886], [".", 892], ["Once", 894], ["bound", 899], ["to", 905], ["Ca(2+)/CaM", 908], [",", 918], ["the", 920], ["multimeric", 924], ["CaMKII", 935], ["is", 942], ["released", 945], ["from", 954], ["its", 959], ["autoinhibitory", 963], ["status", 978], ["and", 985], ["maximally", 989], ["activated", 999], [",", 1008], ["which", 1010], ["then", 1016], ["leads", 1021], ["to", 1027], ["an", 1030], ["intraholoenzyme", 1033], ["autophosphorylation", 1049], ["reaction", 1069], [".", 1077], ["Calcineurin", 1079], ["(", 1091], ["Cn", 1092], [")", 1094], ["is", 1096], ["another", 1099], ["major", 1107], ["target", 1113], ["protein", 1120], ["that", 1128], ["is", 1133], ["activated", 1136], ["by", 1146], ["Ca(2+)/CaM.", 1149], ["Cn", 1161], ["is", 1164], ["a", 1167], ["serine", 1169], ["-", 1175], ["threonine", 1176], ["phosphatase", 1186], ["that", 1198], ["consists", 1203], ["of", 1212], ["a", 1215], ["heterodimeric", 1217], ["protein", 1231], ["complex", 1239], ["composed", 1247], ["of", 1256], ["a", 1259], ["catalytic", 1261], ["subunit", 1271], ["(", 1279], ["CnA", 1280], [")", 1283], ["and", 1285], ["a", 1289], ["regulatory", 1291], ["subunit", 1302], ["(", 1310], ["CnB", 1311], [")", 1314], [".", 1315], ["Upon", 1317], ["activation", 1322], [",", 1332], ["Cn", 1334], ["directly", 1337], ["binds", 1346], ["to", 1352], [",", 1354], ["and", 1356], ["dephosphorylates", 1360], ["nuclear", 1377], ["factor", 1385], ["of", 1392], ["activated", 1395], ["T", 1405], ["cells", 1407], ["(", 1413], ["NFAT", 1414], [")", 1418], ["transcription", 1420], ["factors", 1434], ["within", 1442], ["the", 1449], ["cytoplasm", 1453], ["allowing", 1463], ["them", 1472], ["to", 1477], ["translocate", 1480], ["to", 1492], ["the", 1495], ["nucleus", 1499], ["and", 1507], ["participate", 1511], ["in", 1523], ["the", 1526], ["regulation", 1530], ["of", 1541], ["gene", 1544], ["expression", 1549], [".", 1559], ["This", 1561], ["review", 1566], ["will", 1573], ["examine", 1578], ["the", 1586], ["potential", 1590], ["mechanisms", 1600], ["by", 1611], ["which", 1614], ["calcium", 1620], [",", 1627], ["CaM", 1629], [",", 1632], ["CaMKII", 1634], [",", 1640], ["and", 1642], ["Cn", 1646], ["/", 1648], ["NFAT", 1649], ["control", 1654], ["osteoblast", 1662], ["proliferation", 1673], ["and", 1687], ["differentiation", 1691], [".", 1706]]}
{"context": "Viroids are plant subviral pathogens whose genomes are constituted by a single-stranded and covalently closed small RNA molecule that does not encode for any protein. Despite this genomic simplicity, they are able of inducing devastating symptoms in susceptible plants. Most of the 29 described viroid species fold into a rodlike or quasi-rodlike structure, whereas a few of them fold as branched structures. The shape of these RNA structures is perhaps one of the most characteristic properties of viroids and sometimes is considered their only phenotype. Here we use RNA thermodynamic secondary structure prediction algorithms to compare the mutational robustness of all viroid species. After characterizing the statistical properties of the distribution of mutational effects on structure stability and the wideness of neutral neighborhood for each viroid species, we show an evolutionary trend toward increased structural robustness during viroid radiation, giving support to the adaptive value of robustness. Differences in robustness among the 2 viroid families can be explained by the larger fragility of branched structures compared with the rodlike ones. We also show that genomic redundancy can contribute to the robustness of these simple RNA genomes.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "8eceba755842479382ec48217193b107", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[0, 0], [86, 86]], "char_spans": [[0, 6], [499, 505]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["plant", 12], ["subviral", 18], ["pathogens", 27], ["whose", 37], ["genomes", 43], ["are", 51], ["constituted", 55], ["by", 67], ["a", 70], ["single", 72], ["-", 78], ["stranded", 79], ["and", 88], ["covalently", 92], ["closed", 103], ["small", 110], ["RNA", 116], ["molecule", 120], ["that", 129], ["does", 134], ["not", 139], ["encode", 143], ["for", 150], ["any", 154], ["protein", 158], [".", 165], ["Despite", 167], ["this", 175], ["genomic", 180], ["simplicity", 188], [",", 198], ["they", 200], ["are", 205], ["able", 209], ["of", 214], ["inducing", 217], ["devastating", 226], ["symptoms", 238], ["in", 247], ["susceptible", 250], ["plants", 262], [".", 268], ["Most", 270], ["of", 275], ["the", 278], ["29", 282], ["described", 285], ["viroid", 295], ["species", 302], ["fold", 310], ["into", 315], ["a", 320], ["rodlike", 322], ["or", 330], ["quasi", 333], ["-", 338], ["rodlike", 339], ["structure", 347], [",", 356], ["whereas", 358], ["a", 366], ["few", 368], ["of", 372], ["them", 375], ["fold", 380], ["as", 385], ["branched", 388], ["structures", 397], [".", 407], ["The", 409], ["shape", 413], ["of", 419], ["these", 422], ["RNA", 428], ["structures", 432], ["is", 443], ["perhaps", 446], ["one", 454], ["of", 458], ["the", 461], ["most", 465], ["characteristic", 470], ["properties", 485], ["of", 496], ["viroids", 499], ["and", 507], ["sometimes", 511], ["is", 521], ["considered", 524], ["their", 535], ["only", 541], ["phenotype", 546], [".", 555], ["Here", 557], ["we", 562], ["use", 565], ["RNA", 569], ["thermodynamic", 573], ["secondary", 587], ["structure", 597], ["prediction", 607], ["algorithms", 618], ["to", 629], ["compare", 632], ["the", 640], ["mutational", 644], ["robustness", 655], ["of", 666], ["all", 669], ["viroid", 673], ["species", 680], [".", 687], ["After", 689], ["characterizing", 695], ["the", 710], ["statistical", 714], ["properties", 726], ["of", 737], ["the", 740], ["distribution", 744], ["of", 757], ["mutational", 760], ["effects", 771], ["on", 779], ["structure", 782], ["stability", 792], ["and", 802], ["the", 806], ["wideness", 810], ["of", 819], ["neutral", 822], ["neighborhood", 830], ["for", 843], ["each", 847], ["viroid", 852], ["species", 859], [",", 866], ["we", 868], ["show", 871], ["an", 876], ["evolutionary", 879], ["trend", 892], ["toward", 898], ["increased", 905], ["structural", 915], ["robustness", 926], ["during", 937], ["viroid", 944], ["radiation", 951], [",", 960], ["giving", 962], ["support", 969], ["to", 977], ["the", 980], ["adaptive", 984], ["value", 993], ["of", 999], ["robustness", 1002], [".", 1012], ["Differences", 1014], ["in", 1026], ["robustness", 1029], ["among", 1040], ["the", 1046], ["2", 1050], ["viroid", 1052], ["families", 1059], ["can", 1068], ["be", 1072], ["explained", 1075], ["by", 1085], ["the", 1088], ["larger", 1092], ["fragility", 1099], ["of", 1109], ["branched", 1112], ["structures", 1121], ["compared", 1132], ["with", 1141], ["the", 1146], ["rodlike", 1150], ["ones", 1158], [".", 1162], ["We", 1164], ["also", 1167], ["show", 1172], ["that", 1177], ["genomic", 1182], ["redundancy", 1190], ["can", 1201], ["contribute", 1205], ["to", 1216], ["the", 1219], ["robustness", 1223], ["of", 1234], ["these", 1237], ["simple", 1243], ["RNA", 1250], ["genomes", 1254], [".", 1261]]}
{"context": "CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "3aa0a515baa742df87b15ccd76e1ea2d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[49, 49], [22, 22]], "char_spans": [[269, 276], [120, 127]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["a", 11], ["cerebrovascular", 13], ["disease", 29], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["NOTCH3", 64], ["gene", 71], [".", 75], ["Most", 77], ["mutations", 82], ["result", 92], ["in", 99], ["a", 102], ["gain", 104], ["or", 109], ["loss", 112], ["of", 117], ["cysteine", 120], ["residue", 129], ["in", 137], ["one", 140], ["of", 144], ["the", 147], ["34", 151], ["epidermal", 154], ["growth", 164], ["factor", 171], ["-", 177], ["like", 178], ["repeats", 183], ["in", 191], ["the", 194], ["extracellular", 198], ["domain", 212], ["of", 219], ["the", 222], ["Notch3", 226], ["protein", 233], [",", 240], ["thus", 242], ["sparing", 247], ["the", 255], ["number", 259], ["of", 266], ["cysteine", 269], ["residues", 278], [".", 286], ["To", 288], ["date", 291], [",", 295], ["more", 297], ["than", 302], ["130", 307], ["different", 311], ["mutations", 321], ["in", 331], ["the", 334], ["NOTCH3", 338], ["gene", 345], ["have", 350], ["been", 355], ["reported", 360], ["in", 369], ["CADASIL", 372], ["patients", 380], [",", 388], ["of", 390], ["which", 393], ["95", 399], ["%", 401], ["are", 403], ["missense", 407], ["point", 416], ["mutations", 422], [".", 431], ["Many", 433], ["polymorphisms", 438], ["have", 452], ["also", 457], ["been", 462], ["identified", 467], ["in", 478], ["the", 481], ["NOTCH3", 485], ["coding", 492], ["sequence", 499], [",", 507], ["some", 509], ["of", 514], ["them", 517], ["leading", 522], ["to", 530], ["amino", 533], ["acid", 539], ["substitutions", 544], [".", 557], ["The", 559], ["aim", 563], ["of", 567], ["the", 570], ["present", 574], ["study", 582], ["was", 588], ["to", 592], ["analyze", 595], ["the", 603], ["NOTCH3", 607], ["gene", 614], ["in", 619], ["a", 622], ["large", 624], ["group", 630], ["of", 636], ["patients", 639], ["affected", 648], ["by", 657], ["leukoencephalopathy", 660], ["and", 680], ["to", 684], ["investigate", 687], ["the", 699], ["presence", 703], ["of", 712], ["genetic", 715], ["variants", 723], [".", 731], ["The", 733], ["molecular", 737], ["analysis", 747], ["revealed", 756], ["several", 765], ["nucleotide", 773], ["alterations", 784], [".", 795], ["In", 797], ["particular", 800], [",", 810], ["we", 812], ["identified", 815], ["20", 826], ["different", 829], ["mutations", 839], [",", 848], ["22", 850], ["polymorphisms", 853], [",", 866], ["and", 868], ["8", 872], ["genetic", 874], ["variants", 882], ["of", 891], ["unknown", 894], ["pathological", 902], ["significance", 915], ["never", 928], ["reported", 934], ["previously", 943], [".", 953], ["We", 955], ["hope", 958], ["that", 963], ["this", 968], ["NOTCH3", 973], ["gene", 980], ["mutational", 985], ["analysis", 996], [",", 1004], ["performed", 1006], ["in", 1016], ["such", 1019], ["a", 1024], ["significant", 1026], ["number", 1038], ["of", 1045], ["unrelated", 1048], ["and", 1058], ["related", 1062], ["patients", 1070], ["affected", 1079], ["by", 1088], ["leukoencephalopathy", 1091], [",", 1110], ["will", 1112], ["help", 1117], ["in", 1122], ["molecular", 1125], ["screening", 1135], ["for", 1145], ["the", 1149], ["NOTCH3", 1153], ["gene", 1160], [",", 1164], ["thus", 1166], ["contributing", 1171], ["to", 1184], ["enlargement", 1187], ["of", 1199], ["the", 1202], ["NOTCH3", 1206], ["gene", 1213], ["variation", 1218], ["database", 1228], [".", 1236]]}
{"context": "Restless legs syndrome/Willis Ekbom disease (RLS/WED) has been recognized as a significant medical disorder since the 17th century. It was studied mostly in the last 50 years in relation to increasing interest in sleep medicine and health-related quality of life. This led to recognition that the disease is not well characterized as restless feelings in the legs. These symptoms are reported in many situations, but the subjective experience of RLS/WED patients differs from that experienced by others. Thus a new name has been introduced that avoids problems of symptom definition of a disease by naming it after those who first characterized it, i.e. 'Willis Ekbom disease'. This article emphasizes the importance of RLS/WED for psychiatry. The disease carries significant increased risk for depression and anxiety disorders. Treatment requires consideration of these co-morbid disorders. RLS/WED can exacerbate or even engender psychiatric disease, so treatment of psychiatric disease should also include consideration of RLS/WED. The need for attention to RLS/WED is particularly significant for depression. Most anti-depressants exacerbate or can even engender RLS/WED. Thus this article seeks to introduce RLS/WED in relation to psychiatric practice. It presents the RLS/WED disease, its overlap with psychiatry and the current treatment options.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "289d6353e4064a62a58db9f9192b3eff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["has", 54], ["been", 58], ["recognized", 63], ["as", 74], ["a", 77], ["significant", 79], ["medical", 91], ["disorder", 99], ["since", 108], ["the", 114], ["17th", 118], ["century", 123], [".", 130], ["It", 132], ["was", 135], ["studied", 139], ["mostly", 147], ["in", 154], ["the", 157], ["last", 161], ["50", 166], ["years", 169], ["in", 175], ["relation", 178], ["to", 187], ["increasing", 190], ["interest", 201], ["in", 210], ["sleep", 213], ["medicine", 219], ["and", 228], ["health", 232], ["-", 238], ["related", 239], ["quality", 247], ["of", 255], ["life", 258], [".", 262], ["This", 264], ["led", 269], ["to", 273], ["recognition", 276], ["that", 288], ["the", 293], ["disease", 297], ["is", 305], ["not", 308], ["well", 312], ["characterized", 317], ["as", 331], ["restless", 334], ["feelings", 343], ["in", 352], ["the", 355], ["legs", 359], [".", 363], ["These", 365], ["symptoms", 371], ["are", 380], ["reported", 384], ["in", 393], ["many", 396], ["situations", 401], [",", 411], ["but", 413], ["the", 417], ["subjective", 421], ["experience", 432], ["of", 443], ["RLS", 446], ["/", 449], ["WED", 450], ["patients", 454], ["differs", 463], ["from", 471], ["that", 476], ["experienced", 481], ["by", 493], ["others", 496], [".", 502], ["Thus", 504], ["a", 509], ["new", 511], ["name", 515], ["has", 520], ["been", 524], ["introduced", 529], ["that", 540], ["avoids", 545], ["problems", 552], ["of", 561], ["symptom", 564], ["definition", 572], ["of", 583], ["a", 586], ["disease", 588], ["by", 596], ["naming", 599], ["it", 606], ["after", 609], ["those", 615], ["who", 621], ["first", 625], ["characterized", 631], ["it", 645], [",", 647], ["i.e.", 649], ["'", 654], ["Willis", 655], ["Ekbom", 662], ["disease", 668], ["'", 675], [".", 676], ["This", 678], ["article", 683], ["emphasizes", 691], ["the", 702], ["importance", 706], ["of", 717], ["RLS", 720], ["/", 723], ["WED", 724], ["for", 728], ["psychiatry", 732], [".", 742], ["The", 744], ["disease", 748], ["carries", 756], ["significant", 764], ["increased", 776], ["risk", 786], ["for", 791], ["depression", 795], ["and", 806], ["anxiety", 810], ["disorders", 818], [".", 827], ["Treatment", 829], ["requires", 839], ["consideration", 848], ["of", 862], ["these", 865], ["co", 871], ["-", 873], ["morbid", 874], ["disorders", 881], [".", 890], ["RLS", 892], ["/", 895], ["WED", 896], ["can", 900], ["exacerbate", 904], ["or", 915], ["even", 918], ["engender", 923], ["psychiatric", 932], ["disease", 944], [",", 951], ["so", 953], ["treatment", 956], ["of", 966], ["psychiatric", 969], ["disease", 981], ["should", 989], ["also", 996], ["include", 1001], ["consideration", 1009], ["of", 1023], ["RLS", 1026], ["/", 1029], ["WED", 1030], [".", 1033], ["The", 1035], ["need", 1039], ["for", 1044], ["attention", 1048], ["to", 1058], ["RLS", 1061], ["/", 1064], ["WED", 1065], ["is", 1069], ["particularly", 1072], ["significant", 1085], ["for", 1097], ["depression", 1101], [".", 1111], ["Most", 1113], ["anti", 1118], ["-", 1122], ["depressants", 1123], ["exacerbate", 1135], ["or", 1146], ["can", 1149], ["even", 1153], ["engender", 1158], ["RLS", 1167], ["/", 1170], ["WED", 1171], [".", 1174], ["Thus", 1176], ["this", 1181], ["article", 1186], ["seeks", 1194], ["to", 1200], ["introduce", 1203], ["RLS", 1213], ["/", 1216], ["WED", 1217], ["in", 1221], ["relation", 1224], ["to", 1233], ["psychiatric", 1236], ["practice", 1248], [".", 1256], ["It", 1258], ["presents", 1261], ["the", 1270], ["RLS", 1274], ["/", 1277], ["WED", 1278], ["disease", 1282], [",", 1289], ["its", 1291], ["overlap", 1295], ["with", 1303], ["psychiatry", 1308], ["and", 1319], ["the", 1323], ["current", 1327], ["treatment", 1335], ["options", 1345], [".", 1352]]}
{"context": "Many Prader-Willi syndrome (PWS) and Angelman syndrome (AS) patients have a cytogenetic deletion of 15q11q13. While AS and PWS share a similar cytogenetic anomaly, they have very different clinical phenotypes. DNAs from 4 AS patients were examined using 5 chromosome 15q11q13-specific cloned DNA segments. With the present level of resolution, the molecular deletions between AS and those previously reported for PWS did not appear to differ. However, in contrast to the paternal inheritance of the deleted chromosome 15 observed in the majority of PWS patients, maternal inheritance of the deleted chromosome 15 was demonstrated in the AS patients by restriction fragment length polymorphisms (RFLPs).", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "0886b5bfb37f4842a63d965014d3b9fa", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[1, 4]], "char_spans": [[5, 25]]}]}], "context_tokens": [["Many", 0], ["Prader", 5], ["-", 11], ["Willi", 12], ["syndrome", 18], ["(", 27], ["PWS", 28], [")", 31], ["and", 33], ["Angelman", 37], ["syndrome", 46], ["(", 55], ["AS", 56], [")", 58], ["patients", 60], ["have", 69], ["a", 74], ["cytogenetic", 76], ["deletion", 88], ["of", 97], ["15q11q13", 100], [".", 108], ["While", 110], ["AS", 116], ["and", 119], ["PWS", 123], ["share", 127], ["a", 133], ["similar", 135], ["cytogenetic", 143], ["anomaly", 155], [",", 162], ["they", 164], ["have", 169], ["very", 174], ["different", 179], ["clinical", 189], ["phenotypes", 198], [".", 208], ["DNAs", 210], ["from", 215], ["4", 220], ["AS", 222], ["patients", 225], ["were", 234], ["examined", 239], ["using", 248], ["5", 254], ["chromosome", 256], ["15q11q13-specific", 267], ["cloned", 285], ["DNA", 292], ["segments", 296], [".", 304], ["With", 306], ["the", 311], ["present", 315], ["level", 323], ["of", 329], ["resolution", 332], [",", 342], ["the", 344], ["molecular", 348], ["deletions", 358], ["between", 368], ["AS", 376], ["and", 379], ["those", 383], ["previously", 389], ["reported", 400], ["for", 409], ["PWS", 413], ["did", 417], ["not", 421], ["appear", 425], ["to", 432], ["differ", 435], [".", 441], ["However", 443], [",", 450], ["in", 452], ["contrast", 455], ["to", 464], ["the", 467], ["paternal", 471], ["inheritance", 480], ["of", 492], ["the", 495], ["deleted", 499], ["chromosome", 507], ["15", 518], ["observed", 521], ["in", 530], ["the", 533], ["majority", 537], ["of", 546], ["PWS", 549], ["patients", 553], [",", 561], ["maternal", 563], ["inheritance", 572], ["of", 584], ["the", 587], ["deleted", 591], ["chromosome", 599], ["15", 610], ["was", 613], ["demonstrated", 617], ["in", 630], ["the", 633], ["AS", 637], ["patients", 640], ["by", 649], ["restriction", 652], ["fragment", 664], ["length", 673], ["polymorphisms", 680], ["(", 694], ["RFLPs", 695], [")", 700], [".", 701]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "Extrapolating the figures from a previous study on FSHD in a province of The Netherlands to the entire Dutch population suggests that at present a nearly complete overview is obtained of all symptomatic kindred. In 139 families, dominant inheritance was observed in 97, a pattern compatible with germline mosaicism in 6, while sporadic cases were found in 36 families. A mutation frequency of 9.6% was calculated. Mental retardation and severe retinal vasculopathy were reported in low frequencies (1%). Early onset was seen more frequently in sporadic cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal-dominant families. The clinical pictures in the linked and nonlinked families were identical.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "4aa2254c611946849f987fbc7af289e2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[108, 110]], "char_spans": [[610, 627]]}]}], "context_tokens": [["Extrapolating", 0], ["the", 14], ["figures", 18], ["from", 26], ["a", 31], ["previous", 33], ["study", 42], ["on", 48], ["FSHD", 51], ["in", 56], ["a", 59], ["province", 61], ["of", 70], ["The", 73], ["Netherlands", 77], ["to", 89], ["the", 92], ["entire", 96], ["Dutch", 103], ["population", 109], ["suggests", 120], ["that", 129], ["at", 134], ["present", 137], ["a", 145], ["nearly", 147], ["complete", 154], ["overview", 163], ["is", 172], ["obtained", 175], ["of", 184], ["all", 187], ["symptomatic", 191], ["kindred", 203], [".", 210], ["In", 212], ["139", 215], ["families", 219], [",", 227], ["dominant", 229], ["inheritance", 238], ["was", 250], ["observed", 254], ["in", 263], ["97", 266], [",", 268], ["a", 270], ["pattern", 272], ["compatible", 280], ["with", 291], ["germline", 296], ["mosaicism", 305], ["in", 315], ["6", 318], [",", 319], ["while", 321], ["sporadic", 327], ["cases", 336], ["were", 342], ["found", 347], ["in", 353], ["36", 356], ["families", 359], [".", 367], ["A", 369], ["mutation", 371], ["frequency", 380], ["of", 390], ["9.6", 393], ["%", 396], ["was", 398], ["calculated", 402], [".", 412], ["Mental", 414], ["retardation", 421], ["and", 433], ["severe", 437], ["retinal", 444], ["vasculopathy", 452], ["were", 465], ["reported", 470], ["in", 479], ["low", 482], ["frequencies", 486], ["(", 498], ["1", 499], ["%", 500], [")", 501], [".", 502], ["Early", 504], ["onset", 510], ["was", 516], ["seen", 520], ["more", 525], ["frequently", 530], ["in", 541], ["sporadic", 544], ["cases", 553], [".", 558], ["Chromosome", 560], ["4", 571], ["linkage", 573], ["appeared", 581], ["excluded", 590], ["in", 599], ["3", 602], ["of", 604], ["22", 607], ["autosomal", 610], ["-", 619], ["dominant", 620], ["families", 629], [".", 637], ["The", 639], ["clinical", 643], ["pictures", 652], ["in", 661], ["the", 664], ["linked", 668], ["and", 675], ["nonlinked", 679], ["families", 689], ["were", 698], ["identical", 703], [".", 712]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "The serotonergic system is implicated in the pathophysiology of posttraumatic stress disorder (PTSD) and depression. The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD. PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale. Sixty-five male drug-free war veterans (48 with PTSD and 17 without PTSD) and 65 age- and sex-matched healthy controls were studied. Comorbid depression occurred in 54 and 31% of war veterans with PTSD and without PTSD, respectively. Platelet 5-HT concentration was similar in the groups of depressed and nondepressed war veterans with or without PTSD and healthy controls. Platelet 5-HT concentration was found to differ between war veterans with various degrees of appetite loss. A positive correlation was observed between platelet 5-HT concentration and severity of appetite loss in veterans with PTSD. There was no relationship between platelet 5-HT concentration and severity of other symptoms of PTSD or depression. War veterans included in the study were outpatients. War veterans with PTSD had a high incidence of comorbid depression, that was not related to platelet 5-HT concentration. The marked relationship between platelet 5-HT concentration and severity of appetite loss, suggested that 5-HT system is involved in the regulation of appetite, at least in depressed war veterans with PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "3a4f863ee8e149ab960b2f0eccb04cdd", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[80, 80], [13, 13], [173, 173], [42, 42], [134, 134], [189, 189], [205, 205], [84, 84], [40, 40], [255, 255], [50, 50], [113, 113], [110, 110]], "char_spans": [[477, 480], [95, 98], [1030, 1033], [260, 263], [776, 779], [1132, 1135], [1223, 1226], [497, 500], [254, 257], [1527, 1530], [324, 327], [643, 646], [626, 629]]}]}], "context_tokens": [["The", 0], ["serotonergic", 4], ["system", 17], ["is", 24], ["implicated", 27], ["in", 38], ["the", 41], ["pathophysiology", 45], ["of", 61], ["posttraumatic", 64], ["stress", 78], ["disorder", 85], ["(", 94], ["PTSD", 95], [")", 99], ["and", 101], ["depression", 105], [".", 115], ["The", 117], ["present", 121], ["study", 129], ["focused", 135], ["on", 143], ["platelet", 146], ["serotonin", 155], ["(", 165], ["5-HT", 166], [")", 170], ["concentration", 172], ["and", 186], ["symptoms", 190], ["of", 199], ["comorbid", 202], ["depression", 211], ["in", 222], ["war", 225], ["veterans", 229], ["with", 238], ["or", 243], ["without", 246], ["PTSD", 254], [".", 258], ["PTSD", 260], ["and", 265], ["depression", 269], ["were", 280], ["evaluated", 285], ["using", 295], ["Clinician", 301], ["Administered", 311], ["PTSD", 324], ["Scale", 329], [",", 334], ["Davidson", 336], ["Trauma", 345], ["Scale", 352], [",", 357], ["Montgomery", 359], ["-", 369], ["Asberg", 370], ["Depression", 377], ["Rating", 388], ["Scale", 395], ["and", 401], ["Hamilton", 405], ["Anxiety", 414], ["Scale", 422], [".", 427], ["Sixty", 429], ["-", 434], ["five", 435], ["male", 440], ["drug", 445], ["-", 449], ["free", 450], ["war", 455], ["veterans", 459], ["(", 468], ["48", 469], ["with", 472], ["PTSD", 477], ["and", 482], ["17", 486], ["without", 489], ["PTSD", 497], [")", 501], ["and", 503], ["65", 507], ["age-", 510], ["and", 515], ["sex", 519], ["-", 522], ["matched", 523], ["healthy", 531], ["controls", 539], ["were", 548], ["studied", 553], [".", 560], ["Comorbid", 562], ["depression", 571], ["occurred", 582], ["in", 591], ["54", 594], ["and", 597], ["31", 601], ["%", 603], ["of", 605], ["war", 608], ["veterans", 612], ["with", 621], ["PTSD", 626], ["and", 631], ["without", 635], ["PTSD", 643], [",", 647], ["respectively", 649], [".", 661], ["Platelet", 663], ["5-HT", 672], ["concentration", 677], ["was", 691], ["similar", 695], ["in", 703], ["the", 706], ["groups", 710], ["of", 717], ["depressed", 720], ["and", 730], ["nondepressed", 734], ["war", 747], ["veterans", 751], ["with", 760], ["or", 765], ["without", 768], ["PTSD", 776], ["and", 781], ["healthy", 785], ["controls", 793], [".", 801], ["Platelet", 803], ["5-HT", 812], ["concentration", 817], ["was", 831], ["found", 835], ["to", 841], ["differ", 844], ["between", 851], ["war", 859], ["veterans", 863], ["with", 872], ["various", 877], ["degrees", 885], ["of", 893], ["appetite", 896], ["loss", 905], [".", 909], ["A", 911], ["positive", 913], ["correlation", 922], ["was", 934], ["observed", 938], ["between", 947], ["platelet", 955], ["5-HT", 964], ["concentration", 969], ["and", 983], ["severity", 987], ["of", 996], ["appetite", 999], ["loss", 1008], ["in", 1013], ["veterans", 1016], ["with", 1025], ["PTSD", 1030], [".", 1034], ["There", 1036], ["was", 1042], ["no", 1046], ["relationship", 1049], ["between", 1062], ["platelet", 1070], ["5-HT", 1079], ["concentration", 1084], ["and", 1098], ["severity", 1102], ["of", 1111], ["other", 1114], ["symptoms", 1120], ["of", 1129], ["PTSD", 1132], ["or", 1137], ["depression", 1140], [".", 1150], ["War", 1152], ["veterans", 1156], ["included", 1165], ["in", 1174], ["the", 1177], ["study", 1181], ["were", 1187], ["outpatients", 1192], [".", 1203], ["War", 1205], ["veterans", 1209], ["with", 1218], ["PTSD", 1223], ["had", 1228], ["a", 1232], ["high", 1234], ["incidence", 1239], ["of", 1249], ["comorbid", 1252], ["depression", 1261], [",", 1271], ["that", 1273], ["was", 1278], ["not", 1282], ["related", 1286], ["to", 1294], ["platelet", 1297], ["5-HT", 1306], ["concentration", 1311], [".", 1324], ["The", 1326], ["marked", 1330], ["relationship", 1337], ["between", 1350], ["platelet", 1358], ["5-HT", 1367], ["concentration", 1372], ["and", 1386], ["severity", 1390], ["of", 1399], ["appetite", 1402], ["loss", 1411], [",", 1415], ["suggested", 1417], ["that", 1427], ["5-HT", 1432], ["system", 1437], ["is", 1444], ["involved", 1447], ["in", 1456], ["the", 1459], ["regulation", 1463], ["of", 1474], ["appetite", 1477], [",", 1485], ["at", 1487], ["least", 1490], ["in", 1496], ["depressed", 1499], ["war", 1509], ["veterans", 1513], ["with", 1522], ["PTSD", 1527], [".", 1531]]}
{"context": "Shprintzen-Goldberg syndrome (SGS) is a rare disorder characterized by a Marfan-like habitus, mental retardation and craniosynostosis. Cardiac abnormalities, such as aortic root dilation have also been noted as well as several skeletal abnormalities. Its nosological status is unclear as it is hard to delineate SGS from similar disorders, such as Furlong, Marfan type II, Camurati-Engelmann and Loeys-Dietz syndromes. It has been suggested that these conditions represent a phenotypical spectrum associated with aberrant TGF-beta signalling. In support of this notion, we found a novel TGFBR2 missense mutation in a patient with features of SGS.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "9038f03f7233434d94806443d485149a", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[22, 22]], "char_spans": [[117, 132]]}]}], "context_tokens": [["Shprintzen", 0], ["-", 10], ["Goldberg", 11], ["syndrome", 20], ["(", 29], ["SGS", 30], [")", 33], ["is", 35], ["a", 38], ["rare", 40], ["disorder", 45], ["characterized", 54], ["by", 68], ["a", 71], ["Marfan", 73], ["-", 79], ["like", 80], ["habitus", 85], [",", 92], ["mental", 94], ["retardation", 101], ["and", 113], ["craniosynostosis", 117], [".", 133], ["Cardiac", 135], ["abnormalities", 143], [",", 156], ["such", 158], ["as", 163], ["aortic", 166], ["root", 173], ["dilation", 178], ["have", 187], ["also", 192], ["been", 197], ["noted", 202], ["as", 208], ["well", 211], ["as", 216], ["several", 219], ["skeletal", 227], ["abnormalities", 236], [".", 249], ["Its", 251], ["nosological", 255], ["status", 267], ["is", 274], ["unclear", 277], ["as", 285], ["it", 288], ["is", 291], ["hard", 294], ["to", 299], ["delineate", 302], ["SGS", 312], ["from", 316], ["similar", 321], ["disorders", 329], [",", 338], ["such", 340], ["as", 345], ["Furlong", 348], [",", 355], ["Marfan", 357], ["type", 364], ["II", 369], [",", 371], ["Camurati", 373], ["-", 381], ["Engelmann", 382], ["and", 392], ["Loeys", 396], ["-", 401], ["Dietz", 402], ["syndromes", 408], [".", 417], ["It", 419], ["has", 422], ["been", 426], ["suggested", 431], ["that", 441], ["these", 446], ["conditions", 452], ["represent", 463], ["a", 473], ["phenotypical", 475], ["spectrum", 488], ["associated", 497], ["with", 508], ["aberrant", 513], ["TGF", 522], ["-", 525], ["beta", 526], ["signalling", 531], [".", 541], ["In", 543], ["support", 546], ["of", 554], ["this", 557], ["notion", 562], [",", 568], ["we", 570], ["found", 573], ["a", 579], ["novel", 581], ["TGFBR2", 587], ["missense", 594], ["mutation", 603], ["in", 612], ["a", 615], ["patient", 617], ["with", 625], ["features", 630], ["of", 639], ["SGS", 642], [".", 645]]}
{"context": "The inflammatory cytokine IL-1\u03b2 has an essential role in the innate immune response. High levels of IL-1\u03b2 have been implicated in the development of many diseases, including type 1 and 2 diabetes (T1D and T2D), rheumatoid arthritis (RA) and cardiovascular disease. XOMA is developing gevokizumab (XOMA-052), an IgG2 humanized mAb against human IL-1\u03b2, for the potential treatment of these diseases. Gevokizumab has a high affinity for IL-1\u03b2 and a long t1/2, which would allow for once-monthly dosing and offer a considerable advantage for patients over agents requiring more frequent dosing. Data from preclinical studies and clinical trials suggest that gevokizumab is a potentially effective and well-tolerated treatment for the indicated diseases. At the time of publication, phase II clinical trials were ongoing in patients with T1D, T2D and RA, with the T2D trials assessing key cardiovascular markers. Following promising data from a recent pilot trial, XOMA was also planning a phase I/II trial of gevokizumab for the potential treatment of uveitis in patients with the vasculitic inflammatory disorder Beh\u00e7et's disease and the autoinflammatory conditions familial cold autoinflammatory syndrome and Muckle-Wells syndrome.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "e156bae24ed442c581112e4b34e212a5", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[17, 17], [63, 63], [3, 3], [79, 79]], "char_spans": [[100, 104], [344, 348], [26, 30], [434, 438]]}]}], "context_tokens": [["The", 0], ["inflammatory", 4], ["cytokine", 17], ["IL-1\u03b2", 26], ["has", 32], ["an", 36], ["essential", 39], ["role", 49], ["in", 54], ["the", 57], ["innate", 61], ["immune", 68], ["response", 75], [".", 83], ["High", 85], ["levels", 90], ["of", 97], ["IL-1\u03b2", 100], ["have", 106], ["been", 111], ["implicated", 116], ["in", 127], ["the", 130], ["development", 134], ["of", 146], ["many", 149], ["diseases", 154], [",", 162], ["including", 164], ["type", 174], ["1", 179], ["and", 181], ["2", 185], ["diabetes", 187], ["(", 196], ["T1D", 197], ["and", 201], ["T2D", 205], [")", 208], [",", 209], ["rheumatoid", 211], ["arthritis", 222], ["(", 232], ["RA", 233], [")", 235], ["and", 237], ["cardiovascular", 241], ["disease", 256], [".", 263], ["XOMA", 265], ["is", 270], ["developing", 273], ["gevokizumab", 284], ["(", 296], ["XOMA-052", 297], [")", 305], [",", 306], ["an", 308], ["IgG2", 311], ["humanized", 316], ["mAb", 326], ["against", 330], ["human", 338], ["IL-1\u03b2", 344], [",", 349], ["for", 351], ["the", 355], ["potential", 359], ["treatment", 369], ["of", 379], ["these", 382], ["diseases", 388], [".", 396], ["Gevokizumab", 398], ["has", 410], ["a", 414], ["high", 416], ["affinity", 421], ["for", 430], ["IL-1\u03b2", 434], ["and", 440], ["a", 444], ["long", 446], ["t1/2", 451], [",", 455], ["which", 457], ["would", 463], ["allow", 469], ["for", 475], ["once", 479], ["-", 483], ["monthly", 484], ["dosing", 492], ["and", 499], ["offer", 503], ["a", 509], ["considerable", 511], ["advantage", 524], ["for", 534], ["patients", 538], ["over", 547], ["agents", 552], ["requiring", 559], ["more", 569], ["frequent", 574], ["dosing", 583], [".", 589], ["Data", 591], ["from", 596], ["preclinical", 601], ["studies", 613], ["and", 621], ["clinical", 625], ["trials", 634], ["suggest", 641], ["that", 649], ["gevokizumab", 654], ["is", 666], ["a", 669], ["potentially", 671], ["effective", 683], ["and", 693], ["well", 697], ["-", 701], ["tolerated", 702], ["treatment", 712], ["for", 722], ["the", 726], ["indicated", 730], ["diseases", 740], [".", 748], ["At", 750], ["the", 753], ["time", 757], ["of", 762], ["publication", 765], [",", 776], ["phase", 778], ["II", 784], ["clinical", 787], ["trials", 796], ["were", 803], ["ongoing", 808], ["in", 816], ["patients", 819], ["with", 828], ["T1D", 833], [",", 836], ["T2D", 838], ["and", 842], ["RA", 846], [",", 848], ["with", 850], ["the", 855], ["T2D", 859], ["trials", 863], ["assessing", 870], ["key", 880], ["cardiovascular", 884], ["markers", 899], [".", 906], ["Following", 908], ["promising", 918], ["data", 928], ["from", 933], ["a", 938], ["recent", 940], ["pilot", 947], ["trial", 953], [",", 958], ["XOMA", 960], ["was", 965], ["also", 969], ["planning", 974], ["a", 983], ["phase", 985], ["I", 991], ["/", 992], ["II", 993], ["trial", 996], ["of", 1002], ["gevokizumab", 1005], ["for", 1017], ["the", 1021], ["potential", 1025], ["treatment", 1035], ["of", 1045], ["uveitis", 1048], ["in", 1056], ["patients", 1059], ["with", 1068], ["the", 1073], ["vasculitic", 1077], ["inflammatory", 1088], ["disorder", 1101], ["Beh\u00e7et", 1110], ["'s", 1116], ["disease", 1119], ["and", 1127], ["the", 1131], ["autoinflammatory", 1135], ["conditions", 1152], ["familial", 1163], ["cold", 1172], ["autoinflammatory", 1177], ["syndrome", 1194], ["and", 1203], ["Muckle", 1207], ["-", 1213], ["Wells", 1214], ["syndrome", 1220], [".", 1228]]}
{"context": "Chronic myelogenous leukemia (CML) accounts for 15-20% of adult leukemias but is very rare in children (2%). Fewer than 10% of CML patients are younger than 20 years. CML is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome or the BCR-ABL fusion oncogene. The objective of this paper is to present the monitoring of imatinib therapy in two children with CML by the BCR-ABL fusion gene expression assessment from peripheral blood with quantitative real-time polymerase chain reaction (PCR) method. The 18 and six months follow-up of the patients included clinical examination, routine laboratory tests, bone marrow aspirate investigation including cytogenetic tests and the major BCR-ABL fusion gene expression measurement with qRT-PCR method from the peripheral blood. Patient No. 1 diagnosed with chronic phase CML showed excellent adherence to daily 400 mg imatinib treatment and achieved complete hematologic (CHR) and cytogenetic response (CCR) by three months and major molecular response (MMR) by 12 months, with lack of side effects due to imatinib. Patient No. 2 experienced severe hematologic toxicity, which necessitated temporary withdrawal of the drug. Transient non-compliance together with imatinib dose reduction has driven to treatment failure. In this case, mutational analysis is warranted. BCR-ABL fusion gene expression level measurement from peripheral blood with qRT-PCR method is an excellent tool in the follow-up of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee2bb6f12fef47d0a3ddeb7d9f328f4d", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[132, 134], [244, 246], [54, 56], [80, 82]], "char_spans": [[720, 726], [1350, 1356], [272, 278], [406, 412]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["accounts", 35], ["for", 44], ["15", 48], ["-", 50], ["20", 51], ["%", 53], ["of", 55], ["adult", 58], ["leukemias", 64], ["but", 74], ["is", 78], ["very", 81], ["rare", 86], ["in", 91], ["children", 94], ["(", 103], ["2", 104], ["%", 105], [")", 106], [".", 107], ["Fewer", 109], ["than", 115], ["10", 120], ["%", 122], ["of", 124], ["CML", 127], ["patients", 131], ["are", 140], ["younger", 144], ["than", 152], ["20", 157], ["years", 160], [".", 165], ["CML", 167], ["is", 171], ["a", 174], ["myeloproliferative", 176], ["disorder", 195], ["characterized", 204], ["by", 218], ["the", 221], ["presence", 225], ["of", 234], ["the", 237], ["Philadelphia", 241], ["chromosome", 254], ["or", 265], ["the", 268], ["BCR", 272], ["-", 275], ["ABL", 276], ["fusion", 280], ["oncogene", 287], [".", 295], ["The", 297], ["objective", 301], ["of", 311], ["this", 314], ["paper", 319], ["is", 325], ["to", 328], ["present", 331], ["the", 339], ["monitoring", 343], ["of", 354], ["imatinib", 357], ["therapy", 366], ["in", 374], ["two", 377], ["children", 381], ["with", 390], ["CML", 395], ["by", 399], ["the", 402], ["BCR", 406], ["-", 409], ["ABL", 410], ["fusion", 414], ["gene", 421], ["expression", 426], ["assessment", 437], ["from", 448], ["peripheral", 453], ["blood", 464], ["with", 470], ["quantitative", 475], ["real", 488], ["-", 492], ["time", 493], ["polymerase", 498], ["chain", 509], ["reaction", 515], ["(", 524], ["PCR", 525], [")", 528], ["method", 530], [".", 536], ["The", 538], ["18", 542], ["and", 545], ["six", 549], ["months", 553], ["follow", 560], ["-", 566], ["up", 567], ["of", 570], ["the", 573], ["patients", 577], ["included", 586], ["clinical", 595], ["examination", 604], [",", 615], ["routine", 617], ["laboratory", 625], ["tests", 636], [",", 641], ["bone", 643], ["marrow", 648], ["aspirate", 655], ["investigation", 664], ["including", 678], ["cytogenetic", 688], ["tests", 700], ["and", 706], ["the", 710], ["major", 714], ["BCR", 720], ["-", 723], ["ABL", 724], ["fusion", 728], ["gene", 735], ["expression", 740], ["measurement", 751], ["with", 763], ["qRT", 768], ["-", 771], ["PCR", 772], ["method", 776], ["from", 783], ["the", 788], ["peripheral", 792], ["blood", 803], [".", 808], ["Patient", 810], ["No", 818], [".", 820], ["1", 822], ["diagnosed", 824], ["with", 834], ["chronic", 839], ["phase", 847], ["CML", 853], ["showed", 857], ["excellent", 864], ["adherence", 874], ["to", 884], ["daily", 887], ["400", 893], ["mg", 897], ["imatinib", 900], ["treatment", 909], ["and", 919], ["achieved", 923], ["complete", 932], ["hematologic", 941], ["(", 953], ["CHR", 954], [")", 957], ["and", 959], ["cytogenetic", 963], ["response", 975], ["(", 984], ["CCR", 985], [")", 988], ["by", 990], ["three", 993], ["months", 999], ["and", 1006], ["major", 1010], ["molecular", 1016], ["response", 1026], ["(", 1035], ["MMR", 1036], [")", 1039], ["by", 1041], ["12", 1044], ["months", 1047], [",", 1053], ["with", 1055], ["lack", 1060], ["of", 1065], ["side", 1068], ["effects", 1073], ["due", 1081], ["to", 1085], ["imatinib", 1088], [".", 1096], ["Patient", 1098], ["No", 1106], [".", 1108], ["2", 1110], ["experienced", 1112], ["severe", 1124], ["hematologic", 1131], ["toxicity", 1143], [",", 1151], ["which", 1153], ["necessitated", 1159], ["temporary", 1172], ["withdrawal", 1182], ["of", 1193], ["the", 1196], ["drug", 1200], [".", 1204], ["Transient", 1206], ["non", 1216], ["-", 1219], ["compliance", 1220], ["together", 1231], ["with", 1240], ["imatinib", 1245], ["dose", 1254], ["reduction", 1259], ["has", 1269], ["driven", 1273], ["to", 1280], ["treatment", 1283], ["failure", 1293], [".", 1300], ["In", 1302], ["this", 1305], ["case", 1310], [",", 1314], ["mutational", 1316], ["analysis", 1327], ["is", 1336], ["warranted", 1339], [".", 1348], ["BCR", 1350], ["-", 1353], ["ABL", 1354], ["fusion", 1358], ["gene", 1365], ["expression", 1370], ["level", 1381], ["measurement", 1387], ["from", 1399], ["peripheral", 1404], ["blood", 1415], ["with", 1421], ["qRT", 1426], ["-", 1429], ["PCR", 1430], ["method", 1434], ["is", 1441], ["an", 1444], ["excellent", 1447], ["tool", 1457], ["in", 1462], ["the", 1465], ["follow", 1469], ["-", 1475], ["up", 1476], ["of", 1479], ["CML", 1482], ["patients", 1486], [".", 1494]]}
{"context": "Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are already available in many countries (dapagliflozin, canagliflozin, empagliflozin and ipragliflozin) and some others are in a late phase of development. The available SGLT2 inhibitors share similar pharmacokinetic characteristics, with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites, the absence of clinically relevant drug-drug interactions and a low renal elimination as parent drug. SGLT2 co-transporters are responsible for reabsorption of most (90\u00a0%) of the glucose filtered by the kidneys. The pharmacological inhibition of SGLT2 co-transporters reduces hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. The amount of glucose excreted in the urine depends on both the level of hyperglycaemia and the glomerular filtration rate. Results of numerous placebo-controlled randomised clinical trials of 12-104\u00a0weeks duration have shown significant reductions in glycated haemoglobin (HbA1c), resulting in a significant increase in the proportion of patients reaching HbA1c targets, and a significant lowering of fasting plasma glucose when SGLT2 inhibitors were administered as monotherapy or in addition to other glucose-lowering therapies including insulin in patients with T2DM. In head-to-head trials of up to 2\u00a0years, SGLT2 inhibitors exerted similar glucose-lowering activity to metformin, sulphonylureas or sitagliptin. The durability of the glucose-lowering effect of SGLT2 inhibitors appears to be better; however, this remains to be more extensively investigated. The risk of hypoglycaemia was much lower with SGLT2 inhibitors than with sulphonylureas and was similarly low as that reported with metformin, pioglitazone or sitagliptin. Increased renal glucose elimination also assists weight loss and could help to reduce blood pressure. Both effects were very consistent across the trials and they represent some advantages for SGLT2 inhibitors when compared with other oral glucose-lowering agents. The pharmacodynamic response to SGLT2 inhibitors declines with increasing severity of renal impairment, and prescribing information for each SGLT2 inhibitor should be consulted regarding dosage adjustments or restrictions in moderate to severe renal dysfunction. Caution is also recommended in the elderly population because of a higher risk of renal impairment, orthostatic hypotension and dehydration, even if the absence of hypoglycaemia represents an obvious advantage in this population. The overall effect of SGLT2 inhibitors on the risk of cardiovascular disease is unknown and will be evaluated in several ongoing prospective placebo-controlled trials with cardiovascular outcomes. The impact of SGLT2 inhibitors on renal function and their potential to influence the course of diabetic nephropathy also deserve more attention. SGLT2 inhibitors are generally well-tolerated. The most frequently reported adverse events are female genital mycotic infections, while urinary tract infections are less commonly observed and generally benign. In conclusion, with their unique mechanism of action that is independent of insulin secretion and action, SGLT2 inhibitors are a useful addition to the therapeutic options available for the management of T2DM at any stage in the natural history of the disease. Although SGLT2 inhibitors have already been extensively investigated, further studies should even better delineate the best place of these new glucose-lowering agents in the already rich armamentarium for the management of T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "32d5c9e48b75450989842a6e97cc6f21", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[288, 288], [229, 229], [141, 141], [11, 11], [115, 115], [61, 61], [362, 362], [378, 378], [499, 499], [313, 313], [393, 393], [577, 577], [549, 549], [264, 264], [450, 450], [479, 479]], "char_spans": [[1723, 1727], [1387, 1391], [824, 828], [52, 56], [680, 684], [335, 339], [2186, 2190], [2290, 2294], [3094, 3098], [1867, 1871], [2399, 2403], [3574, 3578], [3410, 3414], [1570, 1574], [2773, 2777], [2962, 2966]]}]}], "context_tokens": [["Inhibitors", 0], ["of", 11], ["sodium", 14], ["-", 20], ["glucose", 21], ["co", 29], ["-", 31], ["transporter", 32], ["type", 44], ["2", 49], ["(", 51], ["SGLT2", 52], [")", 57], ["are", 59], ["proposed", 63], ["as", 72], ["a", 75], ["novel", 77], ["approach", 83], ["for", 92], ["the", 96], ["management", 100], ["of", 111], ["type", 114], ["2", 119], ["diabetes", 121], ["mellitus", 130], ["(", 139], ["T2DM", 140], [")", 144], [".", 145], ["Several", 147], ["compounds", 155], ["are", 165], ["already", 169], ["available", 177], ["in", 187], ["many", 190], ["countries", 195], ["(", 205], ["dapagliflozin", 206], [",", 219], ["canagliflozin", 221], [",", 234], ["empagliflozin", 236], ["and", 250], ["ipragliflozin", 254], [")", 267], ["and", 269], ["some", 273], ["others", 278], ["are", 285], ["in", 289], ["a", 292], ["late", 294], ["phase", 299], ["of", 305], ["development", 308], [".", 319], ["The", 321], ["available", 325], ["SGLT2", 335], ["inhibitors", 341], ["share", 352], ["similar", 358], ["pharmacokinetic", 366], ["characteristics", 382], [",", 397], ["with", 399], ["a", 404], ["rapid", 406], ["oral", 412], ["absorption", 417], [",", 427], ["a", 429], ["long", 431], ["elimination", 436], ["half", 448], ["-", 452], ["life", 453], ["allowing", 458], ["once", 467], ["-", 471], ["daily", 472], ["administration", 478], [",", 492], ["an", 494], ["extensive", 497], ["hepatic", 507], ["metabolism", 515], ["mainly", 526], ["via", 533], ["glucuronidation", 537], ["to", 553], ["inactive", 556], ["metabolites", 565], [",", 576], ["the", 578], ["absence", 582], ["of", 590], ["clinically", 593], ["relevant", 604], ["drug", 613], ["-", 617], ["drug", 618], ["interactions", 623], ["and", 636], ["a", 640], ["low", 642], ["renal", 646], ["elimination", 652], ["as", 664], ["parent", 667], ["drug", 674], [".", 678], ["SGLT2", 680], ["co", 686], ["-", 688], ["transporters", 689], ["are", 702], ["responsible", 706], ["for", 718], ["reabsorption", 722], ["of", 735], ["most", 738], ["(", 743], ["90", 744], ["%", 747], [")", 748], ["of", 750], ["the", 753], ["glucose", 757], ["filtered", 765], ["by", 774], ["the", 777], ["kidneys", 781], [".", 788], ["The", 790], ["pharmacological", 794], ["inhibition", 810], ["of", 821], ["SGLT2", 824], ["co", 830], ["-", 832], ["transporters", 833], ["reduces", 846], ["hyperglycaemia", 854], ["by", 869], ["decreasing", 872], ["renal", 883], ["glucose", 889], ["threshold", 897], ["and", 907], ["thereby", 911], ["increasing", 919], ["urinary", 930], ["glucose", 938], ["excretion", 946], [".", 955], ["The", 957], ["amount", 961], ["of", 968], ["glucose", 971], ["excreted", 979], ["in", 988], ["the", 991], ["urine", 995], ["depends", 1001], ["on", 1009], ["both", 1012], ["the", 1017], ["level", 1021], ["of", 1027], ["hyperglycaemia", 1030], ["and", 1045], ["the", 1049], ["glomerular", 1053], ["filtration", 1064], ["rate", 1075], [".", 1079], ["Results", 1081], ["of", 1089], ["numerous", 1092], ["placebo", 1101], ["-", 1108], ["controlled", 1109], ["randomised", 1120], ["clinical", 1131], ["trials", 1140], ["of", 1147], ["12", 1150], ["-", 1152], ["104", 1153], ["weeks", 1157], ["duration", 1163], ["have", 1172], ["shown", 1177], ["significant", 1183], ["reductions", 1195], ["in", 1206], ["glycated", 1209], ["haemoglobin", 1218], ["(", 1230], ["HbA1c", 1231], [")", 1236], [",", 1237], ["resulting", 1239], ["in", 1249], ["a", 1252], ["significant", 1254], ["increase", 1266], ["in", 1275], ["the", 1278], ["proportion", 1282], ["of", 1293], ["patients", 1296], ["reaching", 1305], ["HbA1c", 1314], ["targets", 1320], [",", 1327], ["and", 1329], ["a", 1333], ["significant", 1335], ["lowering", 1347], ["of", 1356], ["fasting", 1359], ["plasma", 1367], ["glucose", 1374], ["when", 1382], ["SGLT2", 1387], ["inhibitors", 1393], ["were", 1404], ["administered", 1409], ["as", 1422], ["monotherapy", 1425], ["or", 1437], ["in", 1440], ["addition", 1443], ["to", 1452], ["other", 1455], ["glucose", 1461], ["-", 1468], ["lowering", 1469], ["therapies", 1478], ["including", 1488], ["insulin", 1498], ["in", 1506], ["patients", 1509], ["with", 1518], ["T2DM", 1523], [".", 1527], ["In", 1529], ["head", 1532], ["-", 1536], ["to", 1537], ["-", 1539], ["head", 1540], ["trials", 1545], ["of", 1552], ["up", 1555], ["to", 1558], ["2", 1561], ["years", 1563], [",", 1568], ["SGLT2", 1570], ["inhibitors", 1576], ["exerted", 1587], ["similar", 1595], ["glucose", 1603], ["-", 1610], ["lowering", 1611], ["activity", 1620], ["to", 1629], ["metformin", 1632], [",", 1641], ["sulphonylureas", 1643], ["or", 1658], ["sitagliptin", 1661], [".", 1672], ["The", 1674], ["durability", 1678], ["of", 1689], ["the", 1692], ["glucose", 1696], ["-", 1703], ["lowering", 1704], ["effect", 1713], ["of", 1720], ["SGLT2", 1723], ["inhibitors", 1729], ["appears", 1740], ["to", 1748], ["be", 1751], ["better", 1754], [";", 1760], ["however", 1762], [",", 1769], ["this", 1771], ["remains", 1776], ["to", 1784], ["be", 1787], ["more", 1790], ["extensively", 1795], ["investigated", 1807], [".", 1819], ["The", 1821], ["risk", 1825], ["of", 1830], ["hypoglycaemia", 1833], ["was", 1847], ["much", 1851], ["lower", 1856], ["with", 1862], ["SGLT2", 1867], ["inhibitors", 1873], ["than", 1884], ["with", 1889], ["sulphonylureas", 1894], ["and", 1909], ["was", 1913], ["similarly", 1917], ["low", 1927], ["as", 1931], ["that", 1934], ["reported", 1939], ["with", 1948], ["metformin", 1953], [",", 1962], ["pioglitazone", 1964], ["or", 1977], ["sitagliptin", 1980], [".", 1991], ["Increased", 1993], ["renal", 2003], ["glucose", 2009], ["elimination", 2017], ["also", 2029], ["assists", 2034], ["weight", 2042], ["loss", 2049], ["and", 2054], ["could", 2058], ["help", 2064], ["to", 2069], ["reduce", 2072], ["blood", 2079], ["pressure", 2085], [".", 2093], ["Both", 2095], ["effects", 2100], ["were", 2108], ["very", 2113], ["consistent", 2118], ["across", 2129], ["the", 2136], ["trials", 2140], ["and", 2147], ["they", 2151], ["represent", 2156], ["some", 2166], ["advantages", 2171], ["for", 2182], ["SGLT2", 2186], ["inhibitors", 2192], ["when", 2203], ["compared", 2208], ["with", 2217], ["other", 2222], ["oral", 2228], ["glucose", 2233], ["-", 2240], ["lowering", 2241], ["agents", 2250], [".", 2256], ["The", 2258], ["pharmacodynamic", 2262], ["response", 2278], ["to", 2287], ["SGLT2", 2290], ["inhibitors", 2296], ["declines", 2307], ["with", 2316], ["increasing", 2321], ["severity", 2332], ["of", 2341], ["renal", 2344], ["impairment", 2350], [",", 2360], ["and", 2362], ["prescribing", 2366], ["information", 2378], ["for", 2390], ["each", 2394], ["SGLT2", 2399], ["inhibitor", 2405], ["should", 2415], ["be", 2422], ["consulted", 2425], ["regarding", 2435], ["dosage", 2445], ["adjustments", 2452], ["or", 2464], ["restrictions", 2467], ["in", 2480], ["moderate", 2483], ["to", 2492], ["severe", 2495], ["renal", 2502], ["dysfunction", 2508], [".", 2519], ["Caution", 2521], ["is", 2529], ["also", 2532], ["recommended", 2537], ["in", 2549], ["the", 2552], ["elderly", 2556], ["population", 2564], ["because", 2575], ["of", 2583], ["a", 2586], ["higher", 2588], ["risk", 2595], ["of", 2600], ["renal", 2603], ["impairment", 2609], [",", 2619], ["orthostatic", 2621], ["hypotension", 2633], ["and", 2645], ["dehydration", 2649], [",", 2660], ["even", 2662], ["if", 2667], ["the", 2670], ["absence", 2674], ["of", 2682], ["hypoglycaemia", 2685], ["represents", 2699], ["an", 2710], ["obvious", 2713], ["advantage", 2721], ["in", 2731], ["this", 2734], ["population", 2739], [".", 2749], ["The", 2751], ["overall", 2755], ["effect", 2763], ["of", 2770], ["SGLT2", 2773], ["inhibitors", 2779], ["on", 2790], ["the", 2793], ["risk", 2797], ["of", 2802], ["cardiovascular", 2805], ["disease", 2820], ["is", 2828], ["unknown", 2831], ["and", 2839], ["will", 2843], ["be", 2848], ["evaluated", 2851], ["in", 2861], ["several", 2864], ["ongoing", 2872], ["prospective", 2880], ["placebo", 2892], ["-", 2899], ["controlled", 2900], ["trials", 2911], ["with", 2918], ["cardiovascular", 2923], ["outcomes", 2938], [".", 2946], ["The", 2948], ["impact", 2952], ["of", 2959], ["SGLT2", 2962], ["inhibitors", 2968], ["on", 2979], ["renal", 2982], ["function", 2988], ["and", 2997], ["their", 3001], ["potential", 3007], ["to", 3017], ["influence", 3020], ["the", 3030], ["course", 3034], ["of", 3041], ["diabetic", 3044], ["nephropathy", 3053], ["also", 3065], ["deserve", 3070], ["more", 3078], ["attention", 3083], [".", 3092], ["SGLT2", 3094], ["inhibitors", 3100], ["are", 3111], ["generally", 3115], ["well", 3125], ["-", 3129], ["tolerated", 3130], [".", 3139], ["The", 3141], ["most", 3145], ["frequently", 3150], ["reported", 3161], ["adverse", 3170], ["events", 3178], ["are", 3185], ["female", 3189], ["genital", 3196], ["mycotic", 3204], ["infections", 3212], [",", 3222], ["while", 3224], ["urinary", 3230], ["tract", 3238], ["infections", 3244], ["are", 3255], ["less", 3259], ["commonly", 3264], ["observed", 3273], ["and", 3282], ["generally", 3286], ["benign", 3296], [".", 3302], ["In", 3304], ["conclusion", 3307], [",", 3317], ["with", 3319], ["their", 3324], ["unique", 3330], ["mechanism", 3337], ["of", 3347], ["action", 3350], ["that", 3357], ["is", 3362], ["independent", 3365], ["of", 3377], ["insulin", 3380], ["secretion", 3388], ["and", 3398], ["action", 3402], [",", 3408], ["SGLT2", 3410], ["inhibitors", 3416], ["are", 3427], ["a", 3431], ["useful", 3433], ["addition", 3440], ["to", 3449], ["the", 3452], ["therapeutic", 3456], ["options", 3468], ["available", 3476], ["for", 3486], ["the", 3490], ["management", 3494], ["of", 3505], ["T2DM", 3508], ["at", 3513], ["any", 3516], ["stage", 3520], ["in", 3526], ["the", 3529], ["natural", 3533], ["history", 3541], ["of", 3549], ["the", 3552], ["disease", 3556], [".", 3563], ["Although", 3565], ["SGLT2", 3574], ["inhibitors", 3580], ["have", 3591], ["already", 3596], ["been", 3604], ["extensively", 3609], ["investigated", 3621], [",", 3633], ["further", 3635], ["studies", 3643], ["should", 3651], ["even", 3658], ["better", 3663], ["delineate", 3670], ["the", 3680], ["best", 3684], ["place", 3689], ["of", 3695], ["these", 3698], ["new", 3704], ["glucose", 3708], ["-", 3715], ["lowering", 3716], ["agents", 3725], ["in", 3732], ["the", 3735], ["already", 3739], ["rich", 3747], ["armamentarium", 3752], ["for", 3766], ["the", 3770], ["management", 3774], ["of", 3785], ["T2DM", 3788], [".", 3792]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose. From March 27, 2009, until Jan 31, 2011, children (age 5-17 months) and young infants (age 6-12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical malaria was analysed by negative binomial regression and against severe malaria by relative risk reduction. This trial is registered with ClinicalTrials.gov, number NCT00866619. 8922 children and 6537 young infants were included in the modified intention-to-treat analyses. Children were followed up for a median of 48 months (IQR 39-50) and young infants for 38 months (34-41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C group, 6616 episodes occurred in the R3R group (VE 36\u00b73%, 95% CI 31\u00b78-40\u00b75) and 7396 occurred in the R3C group (28\u00b73%, 23\u00b73-32\u00b79); compared with 171 children who experienced at least one episode of severe malaria in the C3C group, 116 children experienced at least one episode of severe malaria in the R3R group (32\u00b72%, 13\u00b77 to 46\u00b79) and 169 in the R3C group (1\u00b71%, -23\u00b70 to 20\u00b75). In young infants, compared with 6170 episodes of clinical malaria that met the primary case definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25\u00b79%, 95% CI 19\u00b79-31\u00b75) and 5444 occurred in the R3C group (18\u00b73%, 11\u00b77-24\u00b74); and compared with 116 infants who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced at least one episode of severe malaria in the R3R group (17\u00b73%, 95% CI -9\u00b74 to 37\u00b75) and 104 in the R3C group (10\u00b73%, -17\u00b79 to 31\u00b78). In children, 1774 cases of clinical malaria were averted per 1000 children (95% CI 1387-2186) in the R3R group and 1363 per 1000 children (995-1797) in the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592-1337) in the R3R group and 558 (158-926) in the R3C group. The frequency of SAEs overall was balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2\u00b72 per 1000 doses in young infants and 2\u00b75 per 1000 doses in children. RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e339e78113964de2b3b0f21b5a8d959d", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[261, 261], [419, 419], [358, 358], [547, 547], [739, 739], [789, 789], [196, 196], [12, 12], [231, 231], [434, 434], [532, 532], [585, 585], [280, 280], [472, 472], [270, 270]], "char_spans": [[1217, 1223], [2000, 2006], [1727, 1733], [2579, 2585], [3391, 3397], [3662, 3668], [857, 863], [52, 58], [1066, 1072], [2082, 2088], [2499, 2505], [2718, 2724], [1337, 1343], [2235, 2241], [1265, 1271]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["the", 27], ["RTS", 31], [",", 34], ["S", 35], ["/", 36], ["AS01", 37], ["candidate", 42], ["malaria", 52], ["vaccine", 60], ["during", 68], ["18", 75], ["months", 78], ["of", 85], ["follow", 88], ["-", 94], ["up", 95], ["have", 98], ["been", 103], ["published", 108], ["previously", 118], [".", 128], ["Herein", 130], [",", 136], ["we", 138], ["report", 141], ["the", 148], ["final", 152], ["results", 158], ["from", 166], ["the", 171], ["same", 175], ["trial", 180], [",", 185], ["including", 187], ["the", 197], ["efficacy", 201], ["of", 210], ["a", 213], ["booster", 215], ["dose", 223], [".", 227], ["From", 229], ["March", 234], ["27", 240], [",", 242], ["2009", 244], [",", 248], ["until", 250], ["Jan", 256], ["31", 260], [",", 262], ["2011", 264], [",", 268], ["children", 270], ["(", 279], ["age", 280], ["5", 284], ["-", 285], ["17", 286], ["months", 289], [")", 295], ["and", 297], ["young", 301], ["infants", 307], ["(", 315], ["age", 316], ["6", 320], ["-", 321], ["12", 322], ["weeks", 325], [")", 330], ["were", 332], ["enrolled", 337], ["at", 346], ["11", 349], ["centres", 352], ["in", 360], ["seven", 363], ["countries", 369], ["in", 379], ["sub", 382], ["-", 385], ["Saharan", 386], ["Africa", 394], [".", 400], ["Participants", 402], ["were", 415], ["randomly", 420], ["assigned", 429], ["(", 438], ["1:1:1", 439], [")", 444], ["at", 446], ["first", 449], ["vaccination", 455], ["by", 467], ["block", 470], ["randomisation", 476], ["with", 490], ["minimisation", 495], ["by", 508], ["centre", 511], ["to", 518], ["receive", 521], ["three", 529], ["doses", 535], ["of", 541], ["RTS", 544], [",", 547], ["S", 548], ["/", 549], ["AS01", 550], ["at", 555], ["months", 558], ["0", 565], [",", 566], ["1", 568], [",", 569], ["and", 571], ["2", 575], ["and", 577], ["a", 581], ["booster", 583], ["dose", 591], ["at", 596], ["month", 599], ["20", 605], ["(", 608], ["R3R", 609], ["group", 613], [")", 618], [";", 619], ["three", 621], ["doses", 627], ["of", 633], ["RTS", 636], [",", 639], ["S", 640], ["/", 641], ["AS01", 642], ["and", 647], ["a", 651], ["dose", 653], ["of", 658], ["comparator", 661], ["vaccine", 672], ["at", 680], ["month", 683], ["20", 689], ["(", 692], ["R3C", 693], ["group", 697], [")", 702], [";", 703], ["or", 705], ["a", 708], ["comparator", 710], ["vaccine", 721], ["at", 729], ["months", 732], ["0", 739], [",", 740], ["1", 742], [",", 743], ["2", 745], [",", 746], ["and", 748], ["20", 752], ["(", 755], ["C3C", 756], ["[", 760], ["control", 761], ["group", 769], ["]", 774], [")", 775], [".", 776], ["Participants", 778], ["were", 791], ["followed", 796], ["up", 805], ["until", 808], ["Jan", 814], ["31", 818], [",", 820], ["2014", 822], [".", 826], ["Cases", 828], ["of", 834], ["clinical", 837], ["and", 846], ["severe", 850], ["malaria", 857], ["were", 865], ["captured", 870], ["through", 879], ["passive", 887], ["case", 895], ["detection", 900], [".", 909], ["Serious", 911], ["adverse", 919], ["events", 927], ["(", 934], ["SAEs", 935], [")", 939], ["were", 941], ["recorded", 946], [".", 954], ["Analyses", 956], ["were", 965], ["by", 970], ["modified", 973], ["intention", 982], ["to", 992], ["treat", 995], ["and", 1001], ["per", 1005], ["protocol", 1009], [".", 1017], ["The", 1019], ["coprimary", 1023], ["endpoints", 1033], ["were", 1043], ["the", 1048], ["occurrence", 1052], ["of", 1063], ["malaria", 1066], ["over", 1074], ["12", 1079], ["months", 1082], ["after", 1089], ["dose", 1095], ["3", 1100], ["in", 1102], ["each", 1105], ["age", 1110], ["category", 1114], [".", 1122], ["In", 1124], ["this", 1127], ["final", 1132], ["analysis", 1138], [",", 1146], ["we", 1148], ["present", 1151], ["data", 1159], ["for", 1164], ["the", 1168], ["efficacy", 1172], ["of", 1181], ["the", 1184], ["booster", 1188], ["on", 1196], ["the", 1199], ["occurrence", 1203], ["of", 1214], ["malaria", 1217], [".", 1224], ["Vaccine", 1226], ["efficacy", 1234], ["(", 1243], ["VE", 1244], [")", 1246], ["against", 1248], ["clinical", 1256], ["malaria", 1265], ["was", 1273], ["analysed", 1277], ["by", 1286], ["negative", 1289], ["binomial", 1298], ["regression", 1307], ["and", 1318], ["against", 1322], ["severe", 1330], ["malaria", 1337], ["by", 1345], ["relative", 1348], ["risk", 1357], ["reduction", 1362], [".", 1371], ["This", 1373], ["trial", 1378], ["is", 1384], ["registered", 1387], ["with", 1398], ["ClinicalTrials.gov", 1403], [",", 1421], ["number", 1423], ["NCT00866619", 1430], [".", 1441], ["8922", 1443], ["children", 1448], ["and", 1457], ["6537", 1461], ["young", 1466], ["infants", 1472], ["were", 1480], ["included", 1485], ["in", 1494], ["the", 1497], ["modified", 1501], ["intention", 1510], ["-", 1519], ["to", 1520], ["-", 1522], ["treat", 1523], ["analyses", 1529], [".", 1537], ["Children", 1539], ["were", 1548], ["followed", 1553], ["up", 1562], ["for", 1565], ["a", 1569], ["median", 1571], ["of", 1578], ["48", 1581], ["months", 1584], ["(", 1591], ["IQR", 1592], ["39", 1596], ["-", 1598], ["50", 1599], [")", 1601], ["and", 1603], ["young", 1607], ["infants", 1613], ["for", 1621], ["38", 1625], ["months", 1628], ["(", 1635], ["34", 1636], ["-", 1638], ["41", 1639], [")", 1641], ["after", 1643], ["dose", 1649], ["1", 1654], [".", 1655], ["From", 1657], ["month", 1662], ["0", 1668], ["until", 1670], ["study", 1676], ["end", 1682], [",", 1685], ["compared", 1687], ["with", 1696], ["9585", 1701], ["episodes", 1706], ["of", 1715], ["clinical", 1718], ["malaria", 1727], ["that", 1735], ["met", 1740], ["the", 1744], ["primary", 1748], ["case", 1756], ["definition", 1761], ["in", 1772], ["children", 1775], ["in", 1784], ["the", 1787], ["C3C", 1791], ["group", 1795], [",", 1800], ["6616", 1802], ["episodes", 1807], ["occurred", 1816], ["in", 1825], ["the", 1828], ["R3R", 1832], ["group", 1836], ["(", 1842], ["VE", 1843], ["36\u00b73", 1846], ["%", 1850], [",", 1851], ["95", 1853], ["%", 1855], ["CI", 1857], ["31\u00b78", 1860], ["-", 1864], ["40\u00b75", 1865], [")", 1869], ["and", 1871], ["7396", 1875], ["occurred", 1880], ["in", 1889], ["the", 1892], ["R3C", 1896], ["group", 1900], ["(", 1906], ["28\u00b73", 1907], ["%", 1911], [",", 1912], ["23\u00b73", 1914], ["-", 1918], ["32\u00b79", 1919], [")", 1923], [";", 1924], ["compared", 1926], ["with", 1935], ["171", 1940], ["children", 1944], ["who", 1953], ["experienced", 1957], ["at", 1969], ["least", 1972], ["one", 1978], ["episode", 1982], ["of", 1990], ["severe", 1993], ["malaria", 2000], ["in", 2008], ["the", 2011], ["C3C", 2015], ["group", 2019], [",", 2024], ["116", 2026], ["children", 2030], ["experienced", 2039], ["at", 2051], ["least", 2054], ["one", 2060], ["episode", 2064], ["of", 2072], ["severe", 2075], ["malaria", 2082], ["in", 2090], ["the", 2093], ["R3R", 2097], ["group", 2101], ["(", 2107], ["32\u00b72", 2108], ["%", 2112], [",", 2113], ["13\u00b77", 2115], ["to", 2120], ["46\u00b79", 2123], [")", 2127], ["and", 2129], ["169", 2133], ["in", 2137], ["the", 2140], ["R3C", 2144], ["group", 2148], ["(", 2154], ["1\u00b71", 2155], ["%", 2158], [",", 2159], ["-23\u00b70", 2161], ["to", 2167], ["20\u00b75", 2170], [")", 2174], [".", 2175], ["In", 2177], ["young", 2180], ["infants", 2186], [",", 2193], ["compared", 2195], ["with", 2204], ["6170", 2209], ["episodes", 2214], ["of", 2223], ["clinical", 2226], ["malaria", 2235], ["that", 2243], ["met", 2248], ["the", 2252], ["primary", 2256], ["case", 2264], ["definition", 2269], ["in", 2280], ["the", 2283], ["C3C", 2287], ["group", 2291], [",", 2296], ["4993", 2298], ["episodes", 2303], ["occurred", 2312], ["in", 2321], ["the", 2324], ["R3R", 2328], ["group", 2332], ["(", 2338], ["VE", 2339], ["25\u00b79", 2342], ["%", 2346], [",", 2347], ["95", 2349], ["%", 2351], ["CI", 2353], ["19\u00b79", 2356], ["-", 2360], ["31\u00b75", 2361], [")", 2365], ["and", 2367], ["5444", 2371], ["occurred", 2376], ["in", 2385], ["the", 2388], ["R3C", 2392], ["group", 2396], ["(", 2402], ["18\u00b73", 2403], ["%", 2407], [",", 2408], ["11\u00b77", 2410], ["-", 2414], ["24\u00b74", 2415], [")", 2419], [";", 2420], ["and", 2422], ["compared", 2426], ["with", 2435], ["116", 2440], ["infants", 2444], ["who", 2452], ["experienced", 2456], ["at", 2468], ["least", 2471], ["one", 2477], ["episode", 2481], ["of", 2489], ["severe", 2492], ["malaria", 2499], ["in", 2507], ["the", 2510], ["C3C", 2514], ["group", 2518], [",", 2523], ["96", 2525], ["infants", 2528], ["experienced", 2536], ["at", 2548], ["least", 2551], ["one", 2557], ["episode", 2561], ["of", 2569], ["severe", 2572], ["malaria", 2579], ["in", 2587], ["the", 2590], ["R3R", 2594], ["group", 2598], ["(", 2604], ["17\u00b73", 2605], ["%", 2609], [",", 2610], ["95", 2612], ["%", 2614], ["CI", 2616], ["-9\u00b74", 2619], ["to", 2624], ["37\u00b75", 2627], [")", 2631], ["and", 2633], ["104", 2637], ["in", 2641], ["the", 2644], ["R3C", 2648], ["group", 2652], ["(", 2658], ["10\u00b73", 2659], ["%", 2663], [",", 2664], ["-17\u00b79", 2666], ["to", 2672], ["31\u00b78", 2675], [")", 2679], [".", 2680], ["In", 2682], ["children", 2685], [",", 2693], ["1774", 2695], ["cases", 2700], ["of", 2706], ["clinical", 2709], ["malaria", 2718], ["were", 2726], ["averted", 2731], ["per", 2739], ["1000", 2743], ["children", 2748], ["(", 2757], ["95", 2758], ["%", 2760], ["CI", 2762], ["1387", 2765], ["-", 2769], ["2186", 2770], [")", 2774], ["in", 2776], ["the", 2779], ["R3R", 2783], ["group", 2787], ["and", 2793], ["1363", 2797], ["per", 2802], ["1000", 2806], ["children", 2811], ["(", 2820], ["995", 2821], ["-", 2824], ["1797", 2825], [")", 2829], ["in", 2831], ["the", 2834], ["R3C", 2838], ["group", 2842], [".", 2847], ["The", 2849], ["numbers", 2853], ["of", 2861], ["cases", 2864], ["averted", 2870], ["per", 2878], ["1000", 2882], ["young", 2887], ["infants", 2893], ["were", 2901], ["983", 2906], ["(", 2910], ["95", 2911], ["%", 2913], ["CI", 2915], ["592", 2918], ["-", 2921], ["1337", 2922], [")", 2926], ["in", 2928], ["the", 2931], ["R3R", 2935], ["group", 2939], ["and", 2945], ["558", 2949], ["(", 2953], ["158", 2954], ["-", 2957], ["926", 2958], [")", 2961], ["in", 2963], ["the", 2966], ["R3C", 2970], ["group", 2974], [".", 2979], ["The", 2981], ["frequency", 2985], ["of", 2995], ["SAEs", 2998], ["overall", 3003], ["was", 3011], ["balanced", 3015], ["between", 3024], ["groups", 3032], [".", 3038], ["However", 3040], [",", 3047], ["meningitis", 3049], ["was", 3060], ["reported", 3064], ["as", 3073], ["a", 3076], ["SAE", 3078], ["in", 3082], ["22", 3085], ["children", 3088], [":", 3096], ["11", 3098], ["in", 3101], ["the", 3104], ["R3R", 3108], ["group", 3112], [",", 3117], ["ten", 3119], ["in", 3123], ["the", 3126], ["R3C", 3130], ["group", 3134], [",", 3139], ["and", 3141], ["one", 3145], ["in", 3149], ["the", 3152], ["C3C", 3156], ["group", 3160], [".", 3165], ["The", 3167], ["incidence", 3171], ["of", 3181], ["generalised", 3184], ["convulsive", 3196], ["seizures", 3207], ["within", 3216], ["7", 3223], ["days", 3225], ["of", 3230], ["RTS", 3233], [",", 3236], ["S", 3237], ["/", 3238], ["AS01", 3239], ["booster", 3244], ["was", 3252], ["2\u00b72", 3256], ["per", 3260], ["1000", 3264], ["doses", 3269], ["in", 3275], ["young", 3278], ["infants", 3284], ["and", 3292], ["2\u00b75", 3296], ["per", 3300], ["1000", 3304], ["doses", 3309], ["in", 3315], ["children", 3318], [".", 3326], ["RTS", 3328], [",", 3331], ["S", 3332], ["/", 3333], ["AS01", 3334], ["prevented", 3339], ["a", 3349], ["substantial", 3351], ["number", 3363], ["of", 3370], ["cases", 3373], ["of", 3379], ["clinical", 3382], ["malaria", 3391], ["over", 3399], ["a", 3404], ["3", 3406], ["-", 3407], ["4", 3408], ["year", 3410], ["period", 3415], ["in", 3422], ["young", 3425], ["infants", 3431], ["and", 3439], ["children", 3443], ["when", 3452], ["administered", 3457], ["with", 3470], ["or", 3475], ["without", 3478], ["a", 3486], ["booster", 3488], ["dose", 3496], [".", 3500], ["Efficacy", 3502], ["was", 3511], ["enhanced", 3515], ["by", 3524], ["the", 3527], ["administration", 3531], ["of", 3546], ["a", 3549], ["booster", 3551], ["dose", 3559], ["in", 3564], ["both", 3567], ["age", 3572], ["categories", 3576], [".", 3586], ["Thus", 3588], [",", 3592], ["the", 3594], ["vaccine", 3598], ["has", 3606], ["the", 3610], ["potential", 3614], ["to", 3624], ["make", 3627], ["a", 3632], ["substantial", 3634], ["contribution", 3646], ["to", 3659], ["malaria", 3662], ["control", 3670], ["when", 3678], ["used", 3683], ["in", 3688], ["combination", 3691], ["with", 3703], ["other", 3708], ["effective", 3714], ["control", 3724], ["measures", 3732]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0c2e363266584674a6c79cd1c7d3e1eb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[34, 36]], "char_spans": [[203, 209]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["presence", 55], ["of", 64], ["the", 67], ["Philadelphia", 71], ["chromosome", 84], [",", 94], ["which", 96], ["is", 102], ["associated", 105], ["with", 116], ["a", 121], ["balanced", 123], ["translocation", 132], ["involving", 146], ["chromosomes", 156], ["9", 168], ["and", 170], ["22", 174], ["to", 177], ["produce", 180], ["a", 188], ["fusion", 190], ["gene", 197], ["(", 202], ["bcr", 203], ["-", 206], ["abl", 207], [")", 210], ["that", 212], ["gives", 217], ["rise", 223], ["to", 228], ["a", 231], ["constitutively", 233], ["activated", 248], ["Abl", 258], ["tyrosine", 262], ["kinase", 271], [".", 277], ["This", 279], ["kinase", 284], ["led", 291], ["to", 295], ["the", 298], ["discovery", 302], ["of", 312], ["several", 315], ["small", 323], ["-", 328], ["molecule", 329], ["inhibitors", 338], [",", 348], ["imatinib", 350], ["being", 359], ["the", 365], ["first", 369], ["and", 375], ["most", 379], ["successful", 384], ["of", 395], ["these", 398], [".", 403], ["Resistance", 405], ["to", 416], ["imatinib", 419], ["results", 428], ["in", 436], ["some", 439], ["patients", 444], ["from", 453], ["Abl", 458], ["kinase", 462], ["point", 469], ["mutations", 475], [".", 484], ["Overcoming", 486], ["imatinib", 497], ["resistance", 506], ["represents", 517], ["one", 528], ["of", 532], ["the", 535], ["biggest", 539], ["challenges", 547], ["facing", 558], ["clinicians", 565], ["in", 576], ["the", 579], ["modern", 583], ["management", 590], ["of", 601], ["CML", 604], [".", 607], ["In", 609], ["this", 612], ["review", 617], [",", 623], ["we", 625], ["discuss", 628], ["the", 636], ["current", 640], ["understanding", 648], ["of", 662], ["CML", 665], ["pathophysiology", 669], ["and", 685], ["mechanisms", 689], ["of", 700], ["imatinib", 703], ["resistance", 712], ["and", 723], ["how", 727], ["advancing", 731], ["this", 741], ["knowledge", 746], ["has", 756], ["led", 760], ["to", 764], ["the", 767], ["design", 771], ["of", 778], ["novel", 781], ["therapies", 787], ["in", 797], ["the", 800], ["area", 804], ["of", 809], ["blastic", 812], ["phase", 820], ["CML", 826], ["and", 830], ["Philadelphia", 834], ["chromosome", 847], ["-", 857], ["positive", 858], ["acute", 867], ["lymphoblastic", 873], ["leukemia", 887], ["with", 896], ["previous", 901], ["imatinib", 910], ["failure", 919], [".", 926]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor disorder that can result in considerable sleep disruption. This narrative review provides an overview of RLS diagnosis and reports epidemiologic evidence for an association between RLS and mood disorders. Possible links between RLS, sleep disturbances, and mood disorders are considered, and theoretical pathophysiologic pathways are discussed. Finally, pharmacologic therapies for RLS are summarized. A PubMed search was performed using the search term restless legs syndrome in combination with affective/anxiety, antidepressants, anxiety/anxiety disorder, attention deficit hyperactivity disorder, depression/depressive disorder, mood/mood disorder, neuropsychiatric, panic/panic disorder, psychiatric disorder, and psychosis. English-language articles published between January 1993 and May 2013 were retrieved. Additional studies were identified from the reference lists of relevant publications. 173 publications were retrieved. Articles related to the association between idiopathic RLS and depression, anxiety, and mood disorders were reviewed. In total, 32 epidemiologic studies were identified. These studies were reviewed in detail and ranked according to quality. Data were extracted on the basis of relevance to the topic. Epidemiologic studies were assessed using 3 parameters: methodology, data quality, and generalizability of the results. Each factor was scored from 1 (high quality) to 4 (low quality), giving a total score of between 3 and 12 for each study. RLS and mood disorders are frequently comorbid. Recognition and appropriate treatment of comorbid RLS are particularly important in patients with psychiatric disorders, as RLS is a common medical reason for insomnia, and antidepressant use may exacerbate sensory symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "f69aed865e4f4461b59e86ff393595b6", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2], [88, 90]], "char_spans": [[0, 21], [538, 559]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensorimotor", 71], ["disorder", 84], ["that", 93], ["can", 98], ["result", 102], ["in", 109], ["considerable", 112], ["sleep", 125], ["disruption", 131], [".", 141], ["This", 143], ["narrative", 148], ["review", 158], ["provides", 165], ["an", 174], ["overview", 177], ["of", 186], ["RLS", 189], ["diagnosis", 193], ["and", 203], ["reports", 207], ["epidemiologic", 215], ["evidence", 229], ["for", 238], ["an", 242], ["association", 245], ["between", 257], ["RLS", 265], ["and", 269], ["mood", 273], ["disorders", 278], [".", 287], ["Possible", 289], ["links", 298], ["between", 304], ["RLS", 312], [",", 315], ["sleep", 317], ["disturbances", 323], [",", 335], ["and", 337], ["mood", 341], ["disorders", 346], ["are", 356], ["considered", 360], [",", 370], ["and", 372], ["theoretical", 376], ["pathophysiologic", 388], ["pathways", 405], ["are", 414], ["discussed", 418], [".", 427], ["Finally", 429], [",", 436], ["pharmacologic", 438], ["therapies", 452], ["for", 462], ["RLS", 466], ["are", 470], ["summarized", 474], [".", 484], ["A", 486], ["PubMed", 488], ["search", 495], ["was", 502], ["performed", 506], ["using", 516], ["the", 522], ["search", 526], ["term", 533], ["restless", 538], ["legs", 547], ["syndrome", 552], ["in", 561], ["combination", 564], ["with", 576], ["affective", 581], ["/", 590], ["anxiety", 591], [",", 598], ["antidepressants", 600], [",", 615], ["anxiety", 617], ["/", 624], ["anxiety", 625], ["disorder", 633], [",", 641], ["attention", 643], ["deficit", 653], ["hyperactivity", 661], ["disorder", 675], [",", 683], ["depression", 685], ["/", 695], ["depressive", 696], ["disorder", 707], [",", 715], ["mood", 717], ["/", 721], ["mood", 722], ["disorder", 727], [",", 735], ["neuropsychiatric", 737], [",", 753], ["panic", 755], ["/", 760], ["panic", 761], ["disorder", 767], [",", 775], ["psychiatric", 777], ["disorder", 789], [",", 797], ["and", 799], ["psychosis", 803], [".", 812], ["English", 814], ["-", 821], ["language", 822], ["articles", 831], ["published", 840], ["between", 850], ["January", 858], ["1993", 866], ["and", 871], ["May", 875], ["2013", 879], ["were", 884], ["retrieved", 889], [".", 898], ["Additional", 900], ["studies", 911], ["were", 919], ["identified", 924], ["from", 935], ["the", 940], ["reference", 944], ["lists", 954], ["of", 960], ["relevant", 963], ["publications", 972], [".", 984], ["173", 986], ["publications", 990], ["were", 1003], ["retrieved", 1008], [".", 1017], ["Articles", 1019], ["related", 1028], ["to", 1036], ["the", 1039], ["association", 1043], ["between", 1055], ["idiopathic", 1063], ["RLS", 1074], ["and", 1078], ["depression", 1082], [",", 1092], ["anxiety", 1094], [",", 1101], ["and", 1103], ["mood", 1107], ["disorders", 1112], ["were", 1122], ["reviewed", 1127], [".", 1135], ["In", 1137], ["total", 1140], [",", 1145], ["32", 1147], ["epidemiologic", 1150], ["studies", 1164], ["were", 1172], ["identified", 1177], [".", 1187], ["These", 1189], ["studies", 1195], ["were", 1203], ["reviewed", 1208], ["in", 1217], ["detail", 1220], ["and", 1227], ["ranked", 1231], ["according", 1238], ["to", 1248], ["quality", 1251], [".", 1258], ["Data", 1260], ["were", 1265], ["extracted", 1270], ["on", 1280], ["the", 1283], ["basis", 1287], ["of", 1293], ["relevance", 1296], ["to", 1306], ["the", 1309], ["topic", 1313], [".", 1318], ["Epidemiologic", 1320], ["studies", 1334], ["were", 1342], ["assessed", 1347], ["using", 1356], ["3", 1362], ["parameters", 1364], [":", 1374], ["methodology", 1376], [",", 1387], ["data", 1389], ["quality", 1394], [",", 1401], ["and", 1403], ["generalizability", 1407], ["of", 1424], ["the", 1427], ["results", 1431], [".", 1438], ["Each", 1440], ["factor", 1445], ["was", 1452], ["scored", 1456], ["from", 1463], ["1", 1468], ["(", 1470], ["high", 1471], ["quality", 1476], [")", 1483], ["to", 1485], ["4", 1488], ["(", 1490], ["low", 1491], ["quality", 1495], [")", 1502], [",", 1503], ["giving", 1505], ["a", 1512], ["total", 1514], ["score", 1520], ["of", 1526], ["between", 1529], ["3", 1537], ["and", 1539], ["12", 1543], ["for", 1546], ["each", 1550], ["study", 1555], [".", 1560], ["RLS", 1562], ["and", 1566], ["mood", 1570], ["disorders", 1575], ["are", 1585], ["frequently", 1589], ["comorbid", 1600], [".", 1608], ["Recognition", 1610], ["and", 1622], ["appropriate", 1626], ["treatment", 1638], ["of", 1648], ["comorbid", 1651], ["RLS", 1660], ["are", 1664], ["particularly", 1668], ["important", 1681], ["in", 1691], ["patients", 1694], ["with", 1703], ["psychiatric", 1708], ["disorders", 1720], [",", 1729], ["as", 1731], ["RLS", 1734], ["is", 1738], ["a", 1741], ["common", 1743], ["medical", 1750], ["reason", 1758], ["for", 1765], ["insomnia", 1769], [",", 1777], ["and", 1779], ["antidepressant", 1783], ["use", 1798], ["may", 1802], ["exacerbate", 1806], ["sensory", 1817], ["symptoms", 1825], [".", 1833]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been shown to function as second messenger molecules. To date, seven members of this family have been reported, including Nox1-5 and Duox1 and -2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and it requires two cytosolic regulators, NoxO1 and NoxA1, as well as the binding of Rac1 GTPase, for its activity. In this study, we investigate the role of the tyrosine kinase c-Src in the regulation of ROS formation by Nox1. We show that c-Src induces Nox1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechanism. Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1. This is associated with decreased Src-mediated phosphorylation and activation of the Rac1-guanine nucleotide exchange factor Vav2. Consistent with this, Vav2 siRNA that specifically reduces endogenous Vav2 protein is able to dramatically decrease Nox1-dependent ROS generation and abolish c-Src-induced Nox1 activity. Together, these results establish c-Src as an important regulator of Nox1 activity, and they may provide insight into the mechanisms of tumor formation in colon cancers.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "fdc8771a13204b6eb28d48a0e3f1d6c5", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[259, 259], [125, 125], [243, 243], [71, 71], [46, 46]], "char_spans": [[1353, 1356], [615, 618], [1269, 1272], [354, 357], [239, 242]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["shown", 122], ["to", 128], ["function", 131], ["as", 140], ["second", 143], ["messenger", 150], ["molecules", 160], [".", 169], ["To", 171], ["date", 174], [",", 178], ["seven", 180], ["members", 186], ["of", 194], ["this", 197], ["family", 202], ["have", 209], ["been", 214], ["reported", 219], [",", 227], ["including", 229], ["Nox1", 239], ["-", 243], ["5", 244], ["and", 246], ["Duox1", 250], ["and", 256], ["-2", 260], [".", 262], ["With", 264], ["the", 269], ["exception", 273], ["of", 283], ["Nox2", 286], [",", 290], ["the", 292], ["regulation", 296], ["of", 307], ["the", 310], ["Nox", 314], ["enzymes", 318], ["is", 326], ["still", 329], ["poorly", 335], ["understood", 342], [".", 352], ["Nox1", 354], ["is", 359], ["highly", 362], ["expressed", 369], ["in", 379], ["the", 382], ["colon", 386], [",", 391], ["and", 393], ["it", 397], ["requires", 400], ["two", 409], ["cytosolic", 413], ["regulators", 423], [",", 433], ["NoxO1", 435], ["and", 441], ["NoxA1", 445], [",", 450], ["as", 452], ["well", 455], ["as", 460], ["the", 463], ["binding", 467], ["of", 475], ["Rac1", 478], ["GTPase", 483], [",", 489], ["for", 491], ["its", 495], ["activity", 499], [".", 507], ["In", 509], ["this", 512], ["study", 517], [",", 522], ["we", 524], ["investigate", 527], ["the", 539], ["role", 543], ["of", 548], ["the", 551], ["tyrosine", 555], ["kinase", 564], ["c", 571], ["-", 572], ["Src", 573], ["in", 577], ["the", 580], ["regulation", 584], ["of", 595], ["ROS", 598], ["formation", 602], ["by", 612], ["Nox1", 615], [".", 619], ["We", 621], ["show", 624], ["that", 629], ["c", 634], ["-", 635], ["Src", 636], ["induces", 640], ["Nox1-mediated", 648], ["ROS", 662], ["generation", 666], ["in", 677], ["the", 680], ["HT29", 684], ["human", 689], ["colon", 695], ["carcinoma", 701], ["cell", 711], ["line", 716], ["through", 721], ["a", 729], ["Rac", 731], ["-", 734], ["dependent", 735], ["mechanism", 745], [".", 754], ["Treatment", 756], ["of", 766], ["HT29", 769], ["cells", 774], ["with", 780], ["the", 785], ["Src", 789], ["inhibitor", 793], ["PP2", 803], [",", 806], ["expression", 808], ["of", 819], ["a", 822], ["kinase", 824], ["-", 830], ["inactive", 831], ["form", 840], ["of", 845], ["c", 848], ["-", 849], ["Src", 850], [",", 853], ["and", 855], ["c", 859], ["-", 860], ["Src", 861], ["depletion", 865], ["by", 875], ["small", 878], ["interfering", 884], ["RNA", 896], ["(", 900], ["siRNA", 901], [")", 906], ["reduce", 908], ["both", 915], ["ROS", 920], ["generation", 924], ["and", 935], ["the", 939], ["levels", 943], ["of", 950], ["active", 953], ["Rac1", 960], [".", 964], ["This", 966], ["is", 971], ["associated", 974], ["with", 985], ["decreased", 990], ["Src", 1000], ["-", 1003], ["mediated", 1004], ["phosphorylation", 1013], ["and", 1029], ["activation", 1033], ["of", 1044], ["the", 1047], ["Rac1-guanine", 1051], ["nucleotide", 1064], ["exchange", 1075], ["factor", 1084], ["Vav2", 1091], [".", 1095], ["Consistent", 1097], ["with", 1108], ["this", 1113], [",", 1117], ["Vav2", 1119], ["siRNA", 1124], ["that", 1130], ["specifically", 1135], ["reduces", 1148], ["endogenous", 1156], ["Vav2", 1167], ["protein", 1172], ["is", 1180], ["able", 1183], ["to", 1188], ["dramatically", 1191], ["decrease", 1204], ["Nox1-dependent", 1213], ["ROS", 1228], ["generation", 1232], ["and", 1243], ["abolish", 1247], ["c", 1255], ["-", 1256], ["Src", 1257], ["-", 1260], ["induced", 1261], ["Nox1", 1269], ["activity", 1274], [".", 1282], ["Together", 1284], [",", 1292], ["these", 1294], ["results", 1300], ["establish", 1308], ["c", 1318], ["-", 1319], ["Src", 1320], ["as", 1324], ["an", 1327], ["important", 1330], ["regulator", 1340], ["of", 1350], ["Nox1", 1353], ["activity", 1358], [",", 1366], ["and", 1368], ["they", 1372], ["may", 1377], ["provide", 1381], ["insight", 1389], ["into", 1397], ["the", 1402], ["mechanisms", 1406], ["of", 1417], ["tumor", 1420], ["formation", 1426], ["in", 1436], ["colon", 1439], ["cancers", 1445], [".", 1452]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The sodium-calcium exchanger (NCX) is one of the transporters contributing to the control of intracellular calcium (Ca(2+)) concentration by normally mediating net Ca(2+) efflux. However, the reverse mode of the NCX can cause intracellular Ca(2+) concentration overload, which exacerbates the myocardial tissue injury resulting from ischemia. Although the NCX inhibitor SEA0400 has been shown to therapeutically reduce myocardial injury, no in vivo technique exists to monitor intracellular Ca(2+) fluctuations produced by this drug. Cardiac manganese-enhanced MRI (MEMRI) may indirectly assess Ca(2+) efflux by estimating changes in manganese (Mn(2+)) content in vivo, since Mn(2+) has been suggested as a surrogate marker for Ca(2+). This study used the MEMRI technique to examine the temporal features of cardiac Mn(2+) efflux by implementing a T(1)-mapping method and inhibiting the NCX with SEA0400. The change in (1)H(2)O longitudinal relaxation rate, Delta R(1), in the left ventricular free wall, was calculated at different time points following infusion of 190 nmol/g manganese chloride (MnCl(2)) in healthy adult male mice. The results showed 50% MEMRI signal attenuation at 3.4 +/- 0.6 h post-MnCl(2) infusion without drug intervention. Furthermore, treatment with 50 +/- 0.2 mg/kg of SEA0400 significantly reduced the rate of decrease in Delta R(1). At 4.9-5.9 h post-MnCl(2) infusion, the average Delta R(1) values for the two groups treated with SEA0400 were 2.46 +/- 0.29 and 1.72 +/- 0.24 s(-1) for 50 and 20 mg/kg doses, respectively, as compared to the value of 1.27 +/- 0.28 s(-1) for the control group. When this in vivo data were compared to ex vivo absolute manganese content data, the MEMRI T(1)-mapping technique was shown to effectively quantify Mn(2+) efflux rates in the myocardium. Therefore, combining an NCX inhibitor with MEMRI may be a useful technique for assessing Mn(2+) transport mechanisms and rates in vivo, which may reflect changes in Ca(2+) transport.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "f0923f0865c044f8998e18a6c175e105", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[64, 64], [163, 163], [42, 42], [6, 6], [360, 360]], "char_spans": [[356, 358], [887, 889], [212, 214], [30, 32], [1835, 1837]]}]}], "context_tokens": [["The", 0], ["sodium", 4], ["-", 10], ["calcium", 11], ["exchanger", 19], ["(", 29], ["NCX", 30], [")", 33], ["is", 35], ["one", 38], ["of", 42], ["the", 45], ["transporters", 49], ["contributing", 62], ["to", 75], ["the", 78], ["control", 82], ["of", 90], ["intracellular", 93], ["calcium", 107], ["(", 115], ["Ca(2", 116], ["+", 120], [")", 121], [")", 122], ["concentration", 124], ["by", 138], ["normally", 141], ["mediating", 150], ["net", 160], ["Ca(2", 164], ["+", 168], [")", 169], ["efflux", 171], [".", 177], ["However", 179], [",", 186], ["the", 188], ["reverse", 192], ["mode", 200], ["of", 205], ["the", 208], ["NCX", 212], ["can", 216], ["cause", 220], ["intracellular", 226], ["Ca(2", 240], ["+", 244], [")", 245], ["concentration", 247], ["overload", 261], [",", 269], ["which", 271], ["exacerbates", 277], ["the", 289], ["myocardial", 293], ["tissue", 304], ["injury", 311], ["resulting", 318], ["from", 328], ["ischemia", 333], [".", 341], ["Although", 343], ["the", 352], ["NCX", 356], ["inhibitor", 360], ["SEA0400", 370], ["has", 378], ["been", 382], ["shown", 387], ["to", 393], ["therapeutically", 396], ["reduce", 412], ["myocardial", 419], ["injury", 430], [",", 436], ["no", 438], ["in", 441], ["vivo", 444], ["technique", 449], ["exists", 459], ["to", 466], ["monitor", 469], ["intracellular", 477], ["Ca(2", 491], ["+", 495], [")", 496], ["fluctuations", 498], ["produced", 511], ["by", 520], ["this", 523], ["drug", 528], [".", 532], ["Cardiac", 534], ["manganese", 542], ["-", 551], ["enhanced", 552], ["MRI", 561], ["(", 565], ["MEMRI", 566], [")", 571], ["may", 573], ["indirectly", 577], ["assess", 588], ["Ca(2", 595], ["+", 599], [")", 600], ["efflux", 602], ["by", 609], ["estimating", 612], ["changes", 623], ["in", 631], ["manganese", 634], ["(", 644], ["Mn(2", 645], ["+", 649], [")", 650], [")", 651], ["content", 653], ["in", 661], ["vivo", 664], [",", 668], ["since", 670], ["Mn(2", 676], ["+", 680], [")", 681], ["has", 683], ["been", 687], ["suggested", 692], ["as", 702], ["a", 705], ["surrogate", 707], ["marker", 717], ["for", 724], ["Ca(2", 728], ["+", 732], [")", 733], [".", 734], ["This", 736], ["study", 741], ["used", 747], ["the", 752], ["MEMRI", 756], ["technique", 762], ["to", 772], ["examine", 775], ["the", 783], ["temporal", 787], ["features", 796], ["of", 805], ["cardiac", 808], ["Mn(2", 816], ["+", 820], [")", 821], ["efflux", 823], ["by", 830], ["implementing", 833], ["a", 846], ["T(1)-mapping", 848], ["method", 861], ["and", 868], ["inhibiting", 872], ["the", 883], ["NCX", 887], ["with", 891], ["SEA0400", 896], [".", 903], ["The", 905], ["change", 909], ["in", 916], ["(", 919], ["1)H(2)O", 920], ["longitudinal", 928], ["relaxation", 941], ["rate", 952], [",", 956], ["Delta", 958], ["R(1", 964], [")", 967], [",", 968], ["in", 970], ["the", 973], ["left", 977], ["ventricular", 982], ["free", 994], ["wall", 999], [",", 1003], ["was", 1005], ["calculated", 1009], ["at", 1020], ["different", 1023], ["time", 1033], ["points", 1038], ["following", 1045], ["infusion", 1055], ["of", 1064], ["190", 1067], ["nmol", 1071], ["/", 1075], ["g", 1076], ["manganese", 1078], ["chloride", 1088], ["(", 1097], ["MnCl(2", 1098], [")", 1104], [")", 1105], ["in", 1107], ["healthy", 1110], ["adult", 1118], ["male", 1124], ["mice", 1129], [".", 1133], ["The", 1135], ["results", 1139], ["showed", 1147], ["50", 1154], ["%", 1156], ["MEMRI", 1158], ["signal", 1164], ["attenuation", 1171], ["at", 1183], ["3.4", 1186], ["+", 1190], ["/-", 1191], ["0.6", 1194], ["h", 1198], ["post", 1200], ["-", 1204], ["MnCl(2", 1205], [")", 1211], ["infusion", 1213], ["without", 1222], ["drug", 1230], ["intervention", 1235], [".", 1247], ["Furthermore", 1249], [",", 1260], ["treatment", 1262], ["with", 1272], ["50", 1277], ["+", 1280], ["/-", 1281], ["0.2", 1284], ["mg", 1288], ["/", 1290], ["kg", 1291], ["of", 1294], ["SEA0400", 1297], ["significantly", 1305], ["reduced", 1319], ["the", 1327], ["rate", 1331], ["of", 1336], ["decrease", 1339], ["in", 1348], ["Delta", 1351], ["R(1", 1357], [")", 1360], [".", 1361], ["At", 1363], ["4.9", 1366], ["-", 1369], ["5.9", 1370], ["h", 1374], ["post", 1376], ["-", 1380], ["MnCl(2", 1381], [")", 1387], ["infusion", 1389], [",", 1397], ["the", 1399], ["average", 1403], ["Delta", 1411], ["R(1", 1417], [")", 1420], ["values", 1422], ["for", 1429], ["the", 1433], ["two", 1437], ["groups", 1441], ["treated", 1448], ["with", 1456], ["SEA0400", 1461], ["were", 1469], ["2.46", 1474], ["+", 1479], ["/-", 1480], ["0.29", 1483], ["and", 1488], ["1.72", 1492], ["+", 1497], ["/-", 1498], ["0.24", 1501], ["s(-1", 1506], [")", 1510], ["for", 1512], ["50", 1516], ["and", 1519], ["20", 1523], ["mg", 1526], ["/", 1528], ["kg", 1529], ["doses", 1532], [",", 1537], ["respectively", 1539], [",", 1551], ["as", 1553], ["compared", 1556], ["to", 1565], ["the", 1568], ["value", 1572], ["of", 1578], ["1.27", 1581], ["+", 1586], ["/-", 1587], ["0.28", 1590], ["s(-1", 1595], [")", 1599], ["for", 1601], ["the", 1605], ["control", 1609], ["group", 1617], [".", 1622], ["When", 1624], ["this", 1629], ["in", 1634], ["vivo", 1637], ["data", 1642], ["were", 1647], ["compared", 1652], ["to", 1661], ["ex", 1664], ["vivo", 1667], ["absolute", 1672], ["manganese", 1681], ["content", 1691], ["data", 1699], [",", 1703], ["the", 1705], ["MEMRI", 1709], ["T(1)-mapping", 1715], ["technique", 1728], ["was", 1738], ["shown", 1742], ["to", 1748], ["effectively", 1751], ["quantify", 1763], ["Mn(2", 1772], ["+", 1776], [")", 1777], ["efflux", 1779], ["rates", 1786], ["in", 1792], ["the", 1795], ["myocardium", 1799], [".", 1809], ["Therefore", 1811], [",", 1820], ["combining", 1822], ["an", 1832], ["NCX", 1835], ["inhibitor", 1839], ["with", 1849], ["MEMRI", 1854], ["may", 1860], ["be", 1864], ["a", 1867], ["useful", 1869], ["technique", 1876], ["for", 1886], ["assessing", 1890], ["Mn(2", 1900], ["+", 1904], [")", 1905], ["transport", 1907], ["mechanisms", 1917], ["and", 1928], ["rates", 1932], ["in", 1938], ["vivo", 1941], [",", 1945], ["which", 1947], ["may", 1953], ["reflect", 1957], ["changes", 1965], ["in", 1973], ["Ca(2", 1976], ["+", 1980], [")", 1981], ["transport", 1983], [".", 1992]]}
{"context": "Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K\u03b4-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "1eb2d0fe88414c37812859c1e4d6e1b5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[161, 161]], "char_spans": [[917, 925]]}]}], "context_tokens": [["Protein", 0], ["kinases", 8], ["(", 16], ["PKs", 17], [")", 20], ["and", 22], ["lipid", 26], ["kinases", 32], ["(", 40], ["LKs", 41], [")", 44], ["are", 46], ["good", 50], ["choices", 55], ["for", 63], ["targets", 67], ["of", 75], ["signal", 78], ["transduction", 85], ["therapy", 98], ["as", 106], ["these", 109], ["enzymes", 115], ["are", 123], ["involved", 127], ["in", 136], ["signaling", 139], ["pathways", 149], [",", 157], ["and", 159], ["are", 163], ["often", 167], ["related", 173], ["to", 181], ["the", 184], ["pathogenesis", 188], ["of", 201], ["lymphoid", 204], ["malignancies", 213], [".", 225], ["The", 227], ["attractiveness", 231], ["of", 246], ["PKs", 249], ["and", 253], ["LKs", 257], ["as", 261], ["drug", 264], ["able", 269], ["targets", 274], ["is", 282], ["enhanced", 285], ["by", 294], ["the", 297], ["fact", 301], ["that", 306], ["they", 311], ["are", 316], ["enzymes", 320], ["whose", 328], ["biological", 334], ["activity", 345], ["can", 354], ["be", 358], ["turned", 361], ["off", 368], ["by", 372], ["drugs", 375], ["that", 381], ["block", 386], ["their", 392], ["catalytic", 398], ["site", 408], [".", 412], ["In", 414], ["the", 417], ["last", 421], ["few", 426], ["years", 430], ["small", 436], ["molecular", 442], ["kinase", 452], ["inhibitors", 459], ["(", 470], ["KIs", 471], [")", 474], ["have", 476], ["been", 481], ["synthesized", 486], ["and", 498], ["become", 502], ["available", 509], ["for", 519], ["preclinical", 523], ["studies", 535], ["and", 543], ["clinical", 547], ["trials", 556], [".", 562], ["The", 564], ["first", 568], ["KI", 574], [",", 576], ["introduced", 578], ["into", 589], ["clinical", 594], ["practice", 603], ["in", 612], ["1998", 615], [",", 619], ["was", 621], ["imatinib", 625], ["mesylate", 634], [",", 642], ["which", 644], ["became", 650], ["the", 657], ["first", 661], ["choice", 667], ["drug", 674], ["in", 679], ["chronic", 682], ["myeloid", 690], ["leukemia", 698], [".", 706], ["More", 708], ["recently", 713], [",", 721], ["several", 723], ["KIs", 731], ["have", 735], ["been", 740], ["developed", 745], ["to", 755], ["target", 758], ["the", 765], ["proximal", 769], ["B", 778], ["-", 779], ["cell", 780], ["receptor", 785], ["(", 794], ["BCR", 795], [")", 798], ["signaling", 800], ["pathway", 810], ["including", 818], ["spleen", 828], ["tyrosine", 835], ["kinase", 844], ["inhibitor", 851], ["(", 861], ["Fostamatinib", 862], [")", 874], ["and", 876], ["Bruton", 880], ["'s", 886], ["tyrosine", 889], ["kinase", 898], ["inhibitors", 905], ["(", 916], ["Ibrutinib", 917], [",", 926], ["AVL-263", 928], [")", 935], [".", 936], ["These", 938], ["agents", 944], ["are", 951], ["currently", 955], ["evaluated", 965], ["in", 975], ["early", 978], ["clinical", 984], ["trials", 993], ["in", 1000], ["chronic", 1003], ["lymphocytic", 1011], ["leukemia", 1023], ["(", 1032], ["CLL", 1033], [")", 1036], ["and", 1038], ["other", 1042], ["diseases", 1048], [".", 1056], ["Cyclin", 1058], ["-", 1064], ["dependent", 1065], ["kinase", 1075], ["(", 1082], ["Cdk", 1083], [")", 1086], ["inhibitors", 1088], [",", 1098], ["flavopiridol", 1100], ["(", 1113], ["alvocidib", 1114], [")", 1123], [",", 1124], ["BMS-387032", 1126], ["(", 1137], ["SNS-032", 1138], [")", 1145], [",", 1146], ["sunitinib", 1148], ["and", 1158], ["sorafenib", 1162], ["are", 1172], ["currently", 1176], ["under", 1186], ["evaluation", 1192], ["in", 1203], ["clinical", 1206], ["trials", 1215], ["for", 1222], ["relapsed", 1226], ["/", 1234], ["refractory", 1235], ["CLL", 1246], [".", 1249], ["Multi", 1251], ["-", 1256], ["tyrosine", 1257], ["kinase", 1266], ["inhibitors", 1273], ["including", 1284], ["vandetanib", 1294], ["(", 1305], ["ZD6474", 1306], [")", 1312], ["bosutinib", 1314], ["(", 1324], ["SKI-606", 1325], [")", 1332], [",", 1333], ["TKI258", 1335], ["(", 1342], ["CHIR-258", 1343], [")", 1351], [",", 1352], ["pazopanib", 1354], ["(", 1364], ["GW786034", 1365], [")", 1373], ["and", 1375], ["axitinib", 1379], ["(", 1388], ["AG013736", 1389], [")", 1397], ["have", 1399], ["been", 1404], ["also", 1409], ["developed", 1414], ["for", 1424], ["the", 1428], ["treatment", 1432], ["of", 1442], ["lymphoid", 1445], ["malignancies", 1454], [".", 1466], ["Phosphatidylinositol", 1468], ["3-kinases", 1489], ["(", 1499], ["PI3", 1500], ["K", 1503], [")", 1505], ["are", 1507], ["a", 1511], ["family", 1513], ["of", 1520], ["lipid", 1523], ["kinases", 1529], ["that", 1537], ["mediate", 1542], ["signals", 1550], ["from", 1558], ["cell", 1563], ["surface", 1568], ["receptors", 1576], [".", 1585], ["CAL-101", 1587], ["(", 1595], ["GS-1101", 1596], [")", 1603], ["is", 1605], ["an", 1608], ["oral", 1611], ["PI3K\u03b4", 1616], ["-", 1621], ["specific", 1622], ["inhibitor", 1631], ["which", 1641], ["has", 1647], ["shown", 1651], ["preclinical", 1657], ["and", 1669], ["clinical", 1673], ["activity", 1682], ["against", 1691], ["CLL", 1699], [".", 1702], ["This", 1704], ["article", 1709], ["summarizes", 1717], ["recent", 1728], ["achievements", 1735], ["in", 1748], ["the", 1751], ["mechanism", 1755], ["of", 1765], ["action", 1768], [",", 1774], ["pharmacological", 1776], ["properties", 1792], ["and", 1803], ["clinical", 1807], ["activity", 1816], ["and", 1825], ["toxicity", 1829], ["of", 1838], ["PK", 1841], ["and", 1844], ["LK", 1848], ["inhibitors", 1851], ["in", 1862], ["CLL", 1865], [".", 1868]]}
{"context": "Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD). Recent evidence suggests that impairment of lysosomal pathways (i.e. autophagy) involved in alpha-synuclein clearance might play an important role. For this reason, we sought to examine the expression levels of members of the autophagy pathway in brains of patients with DLB and Alzheimer's Disease (AD) and in alpha-synuclein transgenic mice. By immunoblot analysis, compared to controls and AD, in DLB cases levels of mTor were elevated and Atg7 were reduced. Levels of other components of the autophagy pathway such as Atg5, Atg10, Atg12 and Beclin-1 were not different in DLB compared to controls. In DLB brains, mTor was more abundant in neurons displaying alpha-synuclein accumulation. These neurons also showed abnormal expression of lysosomal markers such as LC3, and ultrastructural analysis revealed the presence of abundant and abnormal autophagosomes. Similar alterations were observed in the brains of alpha-synuclein transgenic mice. Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations. This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and alpha-synuclein transgenic models and supports the possibility that modulators of the autophagy pathway might have potential therapeutic effects.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "2fa17a29be5d4cdb8b61ce90ede60e4a", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[26, 30]], "char_spans": [[170, 192]]}]}], "context_tokens": [["Lewy", 0], ["body", 5], ["disease", 10], ["is", 18], ["a", 21], ["heterogeneous", 23], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["disorders", 64], ["characterized", 74], ["by", 88], ["alpha", 91], ["-", 96], ["synuclein", 97], ["accumulation", 107], ["that", 120], ["includes", 125], ["dementia", 134], ["with", 143], ["Lewy", 148], ["bodies", 153], ["(", 160], ["DLB", 161], [")", 164], ["and", 166], ["Parkinson", 170], ["'s", 179], ["Disease", 182], ["(", 190], ["PD", 191], [")", 193], [".", 194], ["Recent", 196], ["evidence", 203], ["suggests", 212], ["that", 221], ["impairment", 226], ["of", 237], ["lysosomal", 240], ["pathways", 250], ["(", 259], ["i.e.", 260], ["autophagy", 265], [")", 274], ["involved", 276], ["in", 285], ["alpha", 288], ["-", 293], ["synuclein", 294], ["clearance", 304], ["might", 314], ["play", 320], ["an", 325], ["important", 328], ["role", 338], [".", 342], ["For", 344], ["this", 348], ["reason", 353], [",", 359], ["we", 361], ["sought", 364], ["to", 371], ["examine", 374], ["the", 382], ["expression", 386], ["levels", 397], ["of", 404], ["members", 407], ["of", 415], ["the", 418], ["autophagy", 422], ["pathway", 432], ["in", 440], ["brains", 443], ["of", 450], ["patients", 453], ["with", 462], ["DLB", 467], ["and", 471], ["Alzheimer", 475], ["'s", 484], ["Disease", 487], ["(", 495], ["AD", 496], [")", 498], ["and", 500], ["in", 504], ["alpha", 507], ["-", 512], ["synuclein", 513], ["transgenic", 523], ["mice", 534], [".", 538], ["By", 540], ["immunoblot", 543], ["analysis", 554], [",", 562], ["compared", 564], ["to", 573], ["controls", 576], ["and", 585], ["AD", 589], [",", 591], ["in", 593], ["DLB", 596], ["cases", 600], ["levels", 606], ["of", 613], ["mTor", 616], ["were", 621], ["elevated", 626], ["and", 635], ["Atg7", 639], ["were", 644], ["reduced", 649], [".", 656], ["Levels", 658], ["of", 665], ["other", 668], ["components", 674], ["of", 685], ["the", 688], ["autophagy", 692], ["pathway", 702], ["such", 710], ["as", 715], ["Atg5", 718], [",", 722], ["Atg10", 724], [",", 729], ["Atg12", 731], ["and", 737], ["Beclin-1", 741], ["were", 750], ["not", 755], ["different", 759], ["in", 769], ["DLB", 772], ["compared", 776], ["to", 785], ["controls", 788], [".", 796], ["In", 798], ["DLB", 801], ["brains", 805], [",", 811], ["mTor", 813], ["was", 818], ["more", 822], ["abundant", 827], ["in", 836], ["neurons", 839], ["displaying", 847], ["alpha", 858], ["-", 863], ["synuclein", 864], ["accumulation", 874], [".", 886], ["These", 888], ["neurons", 894], ["also", 902], ["showed", 907], ["abnormal", 914], ["expression", 923], ["of", 934], ["lysosomal", 937], ["markers", 947], ["such", 955], ["as", 960], ["LC3", 963], [",", 966], ["and", 968], ["ultrastructural", 972], ["analysis", 988], ["revealed", 997], ["the", 1006], ["presence", 1010], ["of", 1019], ["abundant", 1022], ["and", 1031], ["abnormal", 1035], ["autophagosomes", 1044], [".", 1058], ["Similar", 1060], ["alterations", 1068], ["were", 1080], ["observed", 1085], ["in", 1094], ["the", 1097], ["brains", 1101], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["transgenic", 1127], ["mice", 1138], [".", 1142], ["Intra", 1144], ["-", 1149], ["cerebral", 1150], ["infusion", 1159], ["of", 1168], ["rapamycin", 1171], [",", 1180], ["an", 1182], ["inhibitor", 1185], ["of", 1195], ["mTor", 1198], [",", 1202], ["or", 1204], ["injection", 1207], ["of", 1217], ["a", 1220], ["lentiviral", 1222], ["vector", 1233], ["expressing", 1240], ["Atg7", 1251], ["resulted", 1256], ["in", 1265], ["reduced", 1268], ["accumulation", 1276], ["of", 1289], ["alpha", 1292], ["-", 1297], ["synuclein", 1298], ["in", 1308], ["transgenic", 1311], ["mice", 1322], ["and", 1327], ["amelioration", 1331], ["of", 1344], ["associated", 1347], ["neurodegenerative", 1358], ["alterations", 1376], [".", 1387], ["This", 1389], ["study", 1394], ["supports", 1400], ["the", 1409], ["notion", 1413], ["that", 1420], ["defects", 1425], ["in", 1433], ["the", 1436], ["autophagy", 1440], ["pathway", 1450], ["and", 1458], ["more", 1462], ["specifically", 1467], ["in", 1480], ["mTor", 1483], ["and", 1488], ["Atg7", 1492], ["are", 1497], ["associated", 1501], ["with", 1512], ["neurodegeneration", 1517], ["in", 1535], ["DLB", 1538], ["cases", 1542], ["and", 1548], ["alpha", 1552], ["-", 1557], ["synuclein", 1558], ["transgenic", 1568], ["models", 1579], ["and", 1586], ["supports", 1590], ["the", 1599], ["possibility", 1603], ["that", 1615], ["modulators", 1620], ["of", 1631], ["the", 1634], ["autophagy", 1638], ["pathway", 1648], ["might", 1656], ["have", 1662], ["potential", 1667], ["therapeutic", 1677], ["effects", 1689], [".", 1696]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "Epidemiology of Clostridium difficile is characterized by worldwide increase of C. difficile infections (CDI) and the emergence of new epidemic outbreak strains with the capacity for global spreading. Long-term local surveillance at the University of Saarland Medical Center between 2000 and 2013 shows that the incidence rate of laboratory-confirmed CDI was influenced by local epidemiology as well as by testing strategies. Since 2008, molecular typing of C. difficile was regularly performed for symptomatic hospitalized patients by surface-layer protein A sequence typing (slpAST), which is an established highly standardized technique for genotyping of C. difficile. The results were assigned to known ribotypes for better comparison to international data. It could be demonstrated that distribution of genotypes was different between age groups. Older patients were predominantly infected with ribotype 001 and 027, whereas ribotype 027 was not detected in the pediatric population. Molecular typing of German isolates sent to the advisory laboratory between 2011 and 2013 revealed that ribotype 027 is present with high percentages in most German regions except for the very North. In conclusion, optimized testing of all hospitalized patients with diarrhea should be generally implemented to avoid under-diagnosis of C. difficile infection. Ribotype 027 is highly prevalent in Germany, but its infections are restricted to older patients, while absent in children. Molecular typing of suspected hospital outbreaks and of patients with severe or recurrent disease may help to better understand virulence and epidemic spreading of C. difficile.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "e08396e636f94ad19455f09fad2df0c8", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[149, 150], [175, 176], [217, 218]], "char_spans": [[930, 941], [1093, 1104], [1349, 1360]]}]}], "context_tokens": [["Epidemiology", 0], ["of", 13], ["Clostridium", 16], ["difficile", 28], ["is", 38], ["characterized", 41], ["by", 55], ["worldwide", 58], ["increase", 68], ["of", 77], ["C.", 80], ["difficile", 83], ["infections", 93], ["(", 104], ["CDI", 105], [")", 108], ["and", 110], ["the", 114], ["emergence", 118], ["of", 128], ["new", 131], ["epidemic", 135], ["outbreak", 144], ["strains", 153], ["with", 161], ["the", 166], ["capacity", 170], ["for", 179], ["global", 183], ["spreading", 190], [".", 199], ["Long", 201], ["-", 205], ["term", 206], ["local", 211], ["surveillance", 217], ["at", 230], ["the", 233], ["University", 237], ["of", 248], ["Saarland", 251], ["Medical", 260], ["Center", 268], ["between", 275], ["2000", 283], ["and", 288], ["2013", 292], ["shows", 297], ["that", 303], ["the", 308], ["incidence", 312], ["rate", 322], ["of", 327], ["laboratory", 330], ["-", 340], ["confirmed", 341], ["CDI", 351], ["was", 355], ["influenced", 359], ["by", 370], ["local", 373], ["epidemiology", 379], ["as", 392], ["well", 395], ["as", 400], ["by", 403], ["testing", 406], ["strategies", 414], [".", 424], ["Since", 426], ["2008", 432], [",", 436], ["molecular", 438], ["typing", 448], ["of", 455], ["C.", 458], ["difficile", 461], ["was", 471], ["regularly", 475], ["performed", 485], ["for", 495], ["symptomatic", 499], ["hospitalized", 511], ["patients", 524], ["by", 533], ["surface", 536], ["-", 543], ["layer", 544], ["protein", 550], ["A", 558], ["sequence", 560], ["typing", 569], ["(", 576], ["slpAST", 577], [")", 583], [",", 584], ["which", 586], ["is", 592], ["an", 595], ["established", 598], ["highly", 610], ["standardized", 617], ["technique", 630], ["for", 640], ["genotyping", 644], ["of", 655], ["C.", 658], ["difficile", 661], [".", 670], ["The", 672], ["results", 676], ["were", 684], ["assigned", 689], ["to", 698], ["known", 701], ["ribotypes", 707], ["for", 717], ["better", 721], ["comparison", 728], ["to", 739], ["international", 742], ["data", 756], [".", 760], ["It", 762], ["could", 765], ["be", 771], ["demonstrated", 774], ["that", 787], ["distribution", 792], ["of", 805], ["genotypes", 808], ["was", 818], ["different", 822], ["between", 832], ["age", 840], ["groups", 844], [".", 850], ["Older", 852], ["patients", 858], ["were", 867], ["predominantly", 872], ["infected", 886], ["with", 895], ["ribotype", 900], ["001", 909], ["and", 913], ["027", 917], [",", 920], ["whereas", 922], ["ribotype", 930], ["027", 939], ["was", 943], ["not", 947], ["detected", 951], ["in", 960], ["the", 963], ["pediatric", 967], ["population", 977], [".", 987], ["Molecular", 989], ["typing", 999], ["of", 1006], ["German", 1009], ["isolates", 1016], ["sent", 1025], ["to", 1030], ["the", 1033], ["advisory", 1037], ["laboratory", 1046], ["between", 1057], ["2011", 1065], ["and", 1070], ["2013", 1074], ["revealed", 1079], ["that", 1088], ["ribotype", 1093], ["027", 1102], ["is", 1106], ["present", 1109], ["with", 1117], ["high", 1122], ["percentages", 1127], ["in", 1139], ["most", 1142], ["German", 1147], ["regions", 1154], ["except", 1162], ["for", 1169], ["the", 1173], ["very", 1177], ["North", 1182], [".", 1187], ["In", 1189], ["conclusion", 1192], [",", 1202], ["optimized", 1204], ["testing", 1214], ["of", 1222], ["all", 1225], ["hospitalized", 1229], ["patients", 1242], ["with", 1251], ["diarrhea", 1256], ["should", 1265], ["be", 1272], ["generally", 1275], ["implemented", 1285], ["to", 1297], ["avoid", 1300], ["under", 1306], ["-", 1311], ["diagnosis", 1312], ["of", 1322], ["C.", 1325], ["difficile", 1328], ["infection", 1338], [".", 1347], ["Ribotype", 1349], ["027", 1358], ["is", 1362], ["highly", 1365], ["prevalent", 1372], ["in", 1382], ["Germany", 1385], [",", 1392], ["but", 1394], ["its", 1398], ["infections", 1402], ["are", 1413], ["restricted", 1417], ["to", 1428], ["older", 1431], ["patients", 1437], [",", 1445], ["while", 1447], ["absent", 1453], ["in", 1460], ["children", 1463], [".", 1471], ["Molecular", 1473], ["typing", 1483], ["of", 1490], ["suspected", 1493], ["hospital", 1503], ["outbreaks", 1512], ["and", 1522], ["of", 1526], ["patients", 1529], ["with", 1538], ["severe", 1543], ["or", 1550], ["recurrent", 1553], ["disease", 1563], ["may", 1571], ["help", 1575], ["to", 1580], ["better", 1583], ["understand", 1590], ["virulence", 1601], ["and", 1611], ["epidemic", 1615], ["spreading", 1624], ["of", 1634], ["C.", 1637], ["difficile", 1640], [".", 1649]]}
{"context": "Anterograde amnesia, possibly accompanied by acute brain syndrome, is a potential side-effect of certain benzodiazepines, particularly triazolam. Flumazenil is a benzodiazepine antagonist that is highly effective in reversing the central nervous system effects of benzodiazepine overdose. We report a case of triazolam overdose resulting in anterograde amnesia after flumazenil administration had restored clear consciousness. The defect in memory may have been due to too little flumazenil being given or failure of memory consolidation affected by the character of triazolam during the induced lucent period. We feel that physicians should be aware of the potential occurrence of acute brain syndrome in patients with benzodiazepine overdose despite treatment with flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6d6de0afbd534ae696a092a6416d4001", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[116, 116], [55, 55], [23, 23], [73, 73]], "char_spans": [[767, 776], [367, 376], [146, 155], [480, 489]]}]}], "context_tokens": [["Anterograde", 0], ["amnesia", 12], [",", 19], ["possibly", 21], ["accompanied", 30], ["by", 42], ["acute", 45], ["brain", 51], ["syndrome", 57], [",", 65], ["is", 67], ["a", 70], ["potential", 72], ["side", 82], ["-", 86], ["effect", 87], ["of", 94], ["certain", 97], ["benzodiazepines", 105], [",", 120], ["particularly", 122], ["triazolam", 135], [".", 144], ["Flumazenil", 146], ["is", 157], ["a", 160], ["benzodiazepine", 162], ["antagonist", 177], ["that", 188], ["is", 193], ["highly", 196], ["effective", 203], ["in", 213], ["reversing", 216], ["the", 226], ["central", 230], ["nervous", 238], ["system", 246], ["effects", 253], ["of", 261], ["benzodiazepine", 264], ["overdose", 279], [".", 287], ["We", 289], ["report", 292], ["a", 299], ["case", 301], ["of", 306], ["triazolam", 309], ["overdose", 319], ["resulting", 328], ["in", 338], ["anterograde", 341], ["amnesia", 353], ["after", 361], ["flumazenil", 367], ["administration", 378], ["had", 393], ["restored", 397], ["clear", 406], ["consciousness", 412], [".", 425], ["The", 427], ["defect", 431], ["in", 438], ["memory", 441], ["may", 448], ["have", 452], ["been", 457], ["due", 462], ["to", 466], ["too", 469], ["little", 473], ["flumazenil", 480], ["being", 491], ["given", 497], ["or", 503], ["failure", 506], ["of", 514], ["memory", 517], ["consolidation", 524], ["affected", 538], ["by", 547], ["the", 550], ["character", 554], ["of", 564], ["triazolam", 567], ["during", 577], ["the", 584], ["induced", 588], ["lucent", 596], ["period", 603], [".", 609], ["We", 611], ["feel", 614], ["that", 619], ["physicians", 624], ["should", 635], ["be", 642], ["aware", 645], ["of", 651], ["the", 654], ["potential", 658], ["occurrence", 668], ["of", 679], ["acute", 682], ["brain", 688], ["syndrome", 694], ["in", 703], ["patients", 706], ["with", 715], ["benzodiazepine", 720], ["overdose", 735], ["despite", 744], ["treatment", 752], ["with", 762], ["flumazenil", 767], [".", 777]]}
{"context": "To elucidate the phenotype, genotype, and MRI findings of Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mutation carriers. The authors studied 40 members of nine unrelated Korean CADASIL families. After genetic analysis of Notch3, clinical and MRI findings were correlated in 27 mutation carriers. Notch3 mutation sites were C174R (one family, n = 3), R133C (one family, n = 3), R587C (one family, n = 1), R544C (two families, n = 5), and R75P (four families, n = 15). The clinical features were typical of CADASIL, but the frequency of migraine in the Korean population appears low. MRI abnormalities were found in 54% of the mutant carriers, the most common being white matter hyperintensities. The prevalence of lacunes and microbleeds increased with patient age. Anterior temporal areas were less often involved in subjects with R75P mutations than in those where mutations occurred in other sites (p = 0.02). Gradient echo imaging identified microbleedings in 33% of mutation carriers (64% of those with abnormal MRI), whereas diffusion-weighted MRI showed abnormal findings in only one patient. Neurologic disability was related to the number of lacunar infarcts and the lesion volume of white matter hyperintensities (p < 0.001) whereas MMSE score was related to the number of lacunar infarcts (p < 0.005). Although Korean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutation carriers show similar clinical and MRI findings, these abnormalities appear less frequently than in other populations. Relatively frequent microbleedings on gradient echo imaging suggest that treatment should be individualized according to MRI findings. The novel mutation of R75P, not involving a cysteine residue, is related to less frequent involvement of the anterior temporal area, thus broadening the spectrum of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "ea472668bef643f08d9793d914e6370d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[326, 326]], "char_spans": [[1818, 1825]]}]}], "context_tokens": [["To", 0], ["elucidate", 3], ["the", 13], ["phenotype", 17], [",", 26], ["genotype", 28], [",", 36], ["and", 38], ["MRI", 42], ["findings", 46], ["of", 55], ["Korean", 58], ["patients", 65], ["with", 74], ["cerebral", 79], ["autosomal", 88], ["dominant", 98], ["arteriopathy", 107], ["with", 120], ["subcortical", 125], ["infarcts", 137], ["and", 146], ["leukoencephalopathy", 150], ["(", 170], ["CADASIL", 171], [")", 178], ["and", 180], ["mutation", 184], ["carriers", 193], [".", 201], ["The", 203], ["authors", 207], ["studied", 215], ["40", 223], ["members", 226], ["of", 234], ["nine", 237], ["unrelated", 242], ["Korean", 252], ["CADASIL", 259], ["families", 267], [".", 275], ["After", 277], ["genetic", 283], ["analysis", 291], ["of", 300], ["Notch3", 303], [",", 309], ["clinical", 311], ["and", 320], ["MRI", 324], ["findings", 328], ["were", 337], ["correlated", 342], ["in", 353], ["27", 356], ["mutation", 359], ["carriers", 368], [".", 376], ["Notch3", 378], ["mutation", 385], ["sites", 394], ["were", 400], ["C174R", 405], ["(", 411], ["one", 412], ["family", 416], [",", 422], ["n", 424], ["=", 426], ["3", 428], [")", 429], [",", 430], ["R133C", 432], ["(", 438], ["one", 439], ["family", 443], [",", 449], ["n", 451], ["=", 453], ["3", 455], [")", 456], [",", 457], ["R587C", 459], ["(", 465], ["one", 466], ["family", 470], [",", 476], ["n", 478], ["=", 480], ["1", 482], [")", 483], [",", 484], ["R544C", 486], ["(", 492], ["two", 493], ["families", 497], [",", 505], ["n", 507], ["=", 509], ["5", 511], [")", 512], [",", 513], ["and", 515], ["R75P", 519], ["(", 524], ["four", 525], ["families", 530], [",", 538], ["n", 540], ["=", 542], ["15", 544], [")", 546], [".", 547], ["The", 549], ["clinical", 553], ["features", 562], ["were", 571], ["typical", 576], ["of", 584], ["CADASIL", 587], [",", 594], ["but", 596], ["the", 600], ["frequency", 604], ["of", 614], ["migraine", 617], ["in", 626], ["the", 629], ["Korean", 633], ["population", 640], ["appears", 651], ["low", 659], [".", 662], ["MRI", 664], ["abnormalities", 668], ["were", 682], ["found", 687], ["in", 693], ["54", 696], ["%", 698], ["of", 700], ["the", 703], ["mutant", 707], ["carriers", 714], [",", 722], ["the", 724], ["most", 728], ["common", 733], ["being", 740], ["white", 746], ["matter", 752], ["hyperintensities", 759], [".", 775], ["The", 777], ["prevalence", 781], ["of", 792], ["lacunes", 795], ["and", 803], ["microbleeds", 807], ["increased", 819], ["with", 829], ["patient", 834], ["age", 842], [".", 845], ["Anterior", 847], ["temporal", 856], ["areas", 865], ["were", 871], ["less", 876], ["often", 881], ["involved", 887], ["in", 896], ["subjects", 899], ["with", 908], ["R75P", 913], ["mutations", 918], ["than", 928], ["in", 933], ["those", 936], ["where", 942], ["mutations", 948], ["occurred", 958], ["in", 967], ["other", 970], ["sites", 976], ["(", 982], ["p", 983], ["=", 985], ["0.02", 987], [")", 991], [".", 992], ["Gradient", 994], ["echo", 1003], ["imaging", 1008], ["identified", 1016], ["microbleedings", 1027], ["in", 1042], ["33", 1045], ["%", 1047], ["of", 1049], ["mutation", 1052], ["carriers", 1061], ["(", 1070], ["64", 1071], ["%", 1073], ["of", 1075], ["those", 1078], ["with", 1084], ["abnormal", 1089], ["MRI", 1098], [")", 1101], [",", 1102], ["whereas", 1104], ["diffusion", 1112], ["-", 1121], ["weighted", 1122], ["MRI", 1131], ["showed", 1135], ["abnormal", 1142], ["findings", 1151], ["in", 1160], ["only", 1163], ["one", 1168], ["patient", 1172], [".", 1179], ["Neurologic", 1181], ["disability", 1192], ["was", 1203], ["related", 1207], ["to", 1215], ["the", 1218], ["number", 1222], ["of", 1229], ["lacunar", 1232], ["infarcts", 1240], ["and", 1249], ["the", 1253], ["lesion", 1257], ["volume", 1264], ["of", 1271], ["white", 1274], ["matter", 1280], ["hyperintensities", 1287], ["(", 1304], ["p", 1305], ["<", 1307], ["0.001", 1309], [")", 1314], ["whereas", 1316], ["MMSE", 1324], ["score", 1329], ["was", 1335], ["related", 1339], ["to", 1347], ["the", 1350], ["number", 1354], ["of", 1361], ["lacunar", 1364], ["infarcts", 1372], ["(", 1381], ["p", 1382], ["<", 1384], ["0.005", 1386], [")", 1391], [".", 1392], ["Although", 1394], ["Korean", 1403], ["cerebral", 1410], ["autosomal", 1419], ["dominant", 1429], ["arteriopathy", 1438], ["with", 1451], ["subcortical", 1456], ["infarcts", 1468], ["and", 1477], ["leukoencephalopathy", 1481], ["(", 1501], ["CADASIL", 1502], [")", 1509], ["mutation", 1511], ["carriers", 1520], ["show", 1529], ["similar", 1534], ["clinical", 1542], ["and", 1551], ["MRI", 1555], ["findings", 1559], [",", 1567], ["these", 1569], ["abnormalities", 1575], ["appear", 1589], ["less", 1596], ["frequently", 1601], ["than", 1612], ["in", 1617], ["other", 1620], ["populations", 1626], [".", 1637], ["Relatively", 1639], ["frequent", 1650], ["microbleedings", 1659], ["on", 1674], ["gradient", 1677], ["echo", 1686], ["imaging", 1691], ["suggest", 1699], ["that", 1707], ["treatment", 1712], ["should", 1722], ["be", 1729], ["individualized", 1732], ["according", 1747], ["to", 1757], ["MRI", 1760], ["findings", 1764], [".", 1772], ["The", 1774], ["novel", 1778], ["mutation", 1784], ["of", 1793], ["R75P", 1796], [",", 1800], ["not", 1802], ["involving", 1806], ["a", 1816], ["cysteine", 1818], ["residue", 1827], [",", 1834], ["is", 1836], ["related", 1839], ["to", 1847], ["less", 1850], ["frequent", 1855], ["involvement", 1864], ["of", 1876], ["the", 1879], ["anterior", 1883], ["temporal", 1892], ["area", 1901], [",", 1905], ["thus", 1907], ["broadening", 1912], ["the", 1923], ["spectrum", 1927], ["of", 1936], ["CADASIL", 1939], [".", 1946]]}
{"context": "MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that act by direct base pairing to target sites within untranslated regions of messenger RNAs. Recently, miRNA activity has been shown to be affected by the presence of miRNA sponge transcripts, the so-called competing endogenous RNA in humans and target mimicry in plants. We previously identified a highly expressed circular RNA (circRNA) in human and mouse brain. Here we show that this circRNA acts as a miR-7 sponge; we term this circular transcript ciRS-7 (circular RNA sponge for miR-7). ciRS-7 contains more than 70 selectively conserved miRNA target sites, and it is highly and widely associated with Argonaute (AGO) proteins in a miR-7-dependent manner. Although the circRNA is completely resistant to miRNA-mediated target destabilization, it strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. In the mouse brain, we observe overlapping co-expression of ciRS-7 and miR-7, particularly in neocortical and hippocampal neurons, suggesting a high degree of endogenous interaction. We further show that the testis-specific circRNA, sex-determining region Y (Sry), serves as a miR-138 sponge, suggesting that miRNA sponge effects achieved by circRNA formation are a general phenomenon. This study serves as the first, to our knowledge, functional analysis of a naturally expressed circRNA.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "aac69dde3c754b6ab56366207d37f1f7", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[214, 214]], "char_spans": [[1199, 1205]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["important", 23], ["post", 33], ["-", 37], ["transcriptional", 38], ["regulators", 54], ["of", 65], ["gene", 68], ["expression", 73], ["that", 84], ["act", 89], ["by", 93], ["direct", 96], ["base", 103], ["pairing", 108], ["to", 116], ["target", 119], ["sites", 126], ["within", 132], ["untranslated", 139], ["regions", 152], ["of", 160], ["messenger", 163], ["RNAs", 173], [".", 177], ["Recently", 179], [",", 187], ["miRNA", 189], ["activity", 195], ["has", 204], ["been", 208], ["shown", 213], ["to", 219], ["be", 222], ["affected", 225], ["by", 234], ["the", 237], ["presence", 241], ["of", 250], ["miRNA", 253], ["sponge", 259], ["transcripts", 266], [",", 277], ["the", 279], ["so", 283], ["-", 285], ["called", 286], ["competing", 293], ["endogenous", 303], ["RNA", 314], ["in", 318], ["humans", 321], ["and", 328], ["target", 332], ["mimicry", 339], ["in", 347], ["plants", 350], [".", 356], ["We", 358], ["previously", 361], ["identified", 372], ["a", 383], ["highly", 385], ["expressed", 392], ["circular", 402], ["RNA", 411], ["(", 415], ["circRNA", 416], [")", 423], ["in", 425], ["human", 428], ["and", 434], ["mouse", 438], ["brain", 444], [".", 449], ["Here", 451], ["we", 456], ["show", 459], ["that", 464], ["this", 469], ["circRNA", 474], ["acts", 482], ["as", 487], ["a", 490], ["miR-7", 492], ["sponge", 498], [";", 504], ["we", 506], ["term", 509], ["this", 514], ["circular", 519], ["transcript", 528], ["ciRS-7", 539], ["(", 546], ["circular", 547], ["RNA", 556], ["sponge", 560], ["for", 567], ["miR-7", 571], [")", 576], [".", 577], ["ciRS-7", 579], ["contains", 586], ["more", 595], ["than", 600], ["70", 605], ["selectively", 608], ["conserved", 620], ["miRNA", 630], ["target", 636], ["sites", 643], [",", 648], ["and", 650], ["it", 654], ["is", 657], ["highly", 660], ["and", 667], ["widely", 671], ["associated", 678], ["with", 689], ["Argonaute", 694], ["(", 704], ["AGO", 705], [")", 708], ["proteins", 710], ["in", 719], ["a", 722], ["miR-7-dependent", 724], ["manner", 740], [".", 746], ["Although", 748], ["the", 757], ["circRNA", 761], ["is", 769], ["completely", 772], ["resistant", 783], ["to", 793], ["miRNA", 796], ["-", 801], ["mediated", 802], ["target", 811], ["destabilization", 818], [",", 833], ["it", 835], ["strongly", 838], ["suppresses", 847], ["miR-7", 858], ["activity", 864], [",", 872], ["resulting", 874], ["in", 884], ["increased", 887], ["levels", 897], ["of", 904], ["miR-7", 907], ["targets", 913], [".", 920], ["In", 922], ["the", 925], ["mouse", 929], ["brain", 935], [",", 940], ["we", 942], ["observe", 945], ["overlapping", 953], ["co", 965], ["-", 967], ["expression", 968], ["of", 979], ["ciRS-7", 982], ["and", 989], ["miR-7", 993], [",", 998], ["particularly", 1000], ["in", 1013], ["neocortical", 1016], ["and", 1028], ["hippocampal", 1032], ["neurons", 1044], [",", 1051], ["suggesting", 1053], ["a", 1064], ["high", 1066], ["degree", 1071], ["of", 1078], ["endogenous", 1081], ["interaction", 1092], [".", 1103], ["We", 1105], ["further", 1108], ["show", 1116], ["that", 1121], ["the", 1126], ["testis", 1130], ["-", 1136], ["specific", 1137], ["circRNA", 1146], [",", 1153], ["sex", 1155], ["-", 1158], ["determining", 1159], ["region", 1171], ["Y", 1178], ["(", 1180], ["Sry", 1181], [")", 1184], [",", 1185], ["serves", 1187], ["as", 1194], ["a", 1197], ["miR-138", 1199], ["sponge", 1207], [",", 1213], ["suggesting", 1215], ["that", 1226], ["miRNA", 1231], ["sponge", 1237], ["effects", 1244], ["achieved", 1252], ["by", 1261], ["circRNA", 1264], ["formation", 1272], ["are", 1282], ["a", 1286], ["general", 1288], ["phenomenon", 1296], [".", 1306], ["This", 1308], ["study", 1313], ["serves", 1319], ["as", 1326], ["the", 1329], ["first", 1333], [",", 1338], ["to", 1340], ["our", 1343], ["knowledge", 1347], [",", 1356], ["functional", 1358], ["analysis", 1369], ["of", 1378], ["a", 1381], ["naturally", 1383], ["expressed", 1393], ["circRNA", 1403], [".", 1410]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "U.K ambulance services assess patients with suspected stroke using the Face Arm Speech Test (FAST). The Recognition Of Stroke In the Emergency Room (ROSIER) tool has been shown superior to the FAST in identifying strokes in emergency departments but has not previously been tested in the ambulance setting. We investigated whether ROSIER use by ambulance clinicians can improve stroke recognition. Ambulance clinicians used the ROSIER in place of the FAST to assess patients with suspected stroke. As the ROSIER includes all FAST elements, we calculated a FAST score from the ROSIER to enable comparisons between the two tools. Ambulance clinicians' provisional stroke diagnoses using the ROSIER and calculated FAST were compared with stroke consultants' diagnosis. We used stepwise logistic regression to compare the contribution of individual ROSIER and FAST items and patient demographics to the prediction of consultants' diagnoses. Sixty-four percent of strokes and 78% of nonstrokes identified by ambulance clinicians using the ROSIER were subsequently confirmed by a stroke consultant. There was no difference in the proportion of strokes correctly detected by the ROSIER or FAST with both displaying excellent levels of sensitivity. The ROSIER detected marginally more nonstroke cases than the FAST, but both demonstrated poor specificity. Facial weakness, arm weakness, seizure activity, age, and sex predicted consultants' diagnosis of stroke. The ROSIER was not better than the FAST for prehospital recognition of stroke. A revised version of the FAST incorporating assessment of seizure activity may improve stroke identification and decision making by ambulance clinicians.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "14137672ed6a4876bd365f25ca43ab63", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [64, 64], [21, 21], [123, 123], [253, 253], [268, 268], [7, 7], [82, 82], [239, 239], [177, 177]], "char_spans": [[662, 667], [378, 383], [119, 124], [735, 740], [1525, 1530], [1620, 1625], [54, 59], [490, 495], [1446, 1451], [1074, 1079]]}]}], "context_tokens": [["U.K", 0], ["ambulance", 4], ["services", 14], ["assess", 23], ["patients", 30], ["with", 39], ["suspected", 44], ["stroke", 54], ["using", 61], ["the", 67], ["Face", 71], ["Arm", 76], ["Speech", 80], ["Test", 87], ["(", 92], ["FAST", 93], [")", 97], [".", 98], ["The", 100], ["Recognition", 104], ["Of", 116], ["Stroke", 119], ["In", 126], ["the", 129], ["Emergency", 133], ["Room", 143], ["(", 148], ["ROSIER", 149], [")", 155], ["tool", 157], ["has", 162], ["been", 166], ["shown", 171], ["superior", 177], ["to", 186], ["the", 189], ["FAST", 193], ["in", 198], ["identifying", 201], ["strokes", 213], ["in", 221], ["emergency", 224], ["departments", 234], ["but", 246], ["has", 250], ["not", 254], ["previously", 258], ["been", 269], ["tested", 274], ["in", 281], ["the", 284], ["ambulance", 288], ["setting", 298], [".", 305], ["We", 307], ["investigated", 310], ["whether", 323], ["ROSIER", 331], ["use", 338], ["by", 342], ["ambulance", 345], ["clinicians", 355], ["can", 366], ["improve", 370], ["stroke", 378], ["recognition", 385], [".", 396], ["Ambulance", 398], ["clinicians", 408], ["used", 419], ["the", 424], ["ROSIER", 428], ["in", 435], ["place", 438], ["of", 444], ["the", 447], ["FAST", 451], ["to", 456], ["assess", 459], ["patients", 466], ["with", 475], ["suspected", 480], ["stroke", 490], [".", 496], ["As", 498], ["the", 501], ["ROSIER", 505], ["includes", 512], ["all", 521], ["FAST", 525], ["elements", 530], [",", 538], ["we", 540], ["calculated", 543], ["a", 554], ["FAST", 556], ["score", 561], ["from", 567], ["the", 572], ["ROSIER", 576], ["to", 583], ["enable", 586], ["comparisons", 593], ["between", 605], ["the", 613], ["two", 617], ["tools", 621], [".", 626], ["Ambulance", 628], ["clinicians", 638], ["'", 648], ["provisional", 650], ["stroke", 662], ["diagnoses", 669], ["using", 679], ["the", 685], ["ROSIER", 689], ["and", 696], ["calculated", 700], ["FAST", 711], ["were", 716], ["compared", 721], ["with", 730], ["stroke", 735], ["consultants", 742], ["'", 753], ["diagnosis", 755], [".", 764], ["We", 766], ["used", 769], ["stepwise", 774], ["logistic", 783], ["regression", 792], ["to", 803], ["compare", 806], ["the", 814], ["contribution", 818], ["of", 831], ["individual", 834], ["ROSIER", 845], ["and", 852], ["FAST", 856], ["items", 861], ["and", 867], ["patient", 871], ["demographics", 879], ["to", 892], ["the", 895], ["prediction", 899], ["of", 910], ["consultants", 913], ["'", 924], ["diagnoses", 926], [".", 935], ["Sixty", 937], ["-", 942], ["four", 943], ["percent", 948], ["of", 956], ["strokes", 959], ["and", 967], ["78", 971], ["%", 973], ["of", 975], ["nonstrokes", 978], ["identified", 989], ["by", 1000], ["ambulance", 1003], ["clinicians", 1013], ["using", 1024], ["the", 1030], ["ROSIER", 1034], ["were", 1041], ["subsequently", 1046], ["confirmed", 1059], ["by", 1069], ["a", 1072], ["stroke", 1074], ["consultant", 1081], [".", 1091], ["There", 1093], ["was", 1099], ["no", 1103], ["difference", 1106], ["in", 1117], ["the", 1120], ["proportion", 1124], ["of", 1135], ["strokes", 1138], ["correctly", 1146], ["detected", 1156], ["by", 1165], ["the", 1168], ["ROSIER", 1172], ["or", 1179], ["FAST", 1182], ["with", 1187], ["both", 1192], ["displaying", 1197], ["excellent", 1208], ["levels", 1218], ["of", 1225], ["sensitivity", 1228], [".", 1239], ["The", 1241], ["ROSIER", 1245], ["detected", 1252], ["marginally", 1261], ["more", 1272], ["nonstroke", 1277], ["cases", 1287], ["than", 1293], ["the", 1298], ["FAST", 1302], [",", 1306], ["but", 1308], ["both", 1312], ["demonstrated", 1317], ["poor", 1330], ["specificity", 1335], [".", 1346], ["Facial", 1348], ["weakness", 1355], [",", 1363], ["arm", 1365], ["weakness", 1369], [",", 1377], ["seizure", 1379], ["activity", 1387], [",", 1395], ["age", 1397], [",", 1400], ["and", 1402], ["sex", 1406], ["predicted", 1410], ["consultants", 1420], ["'", 1431], ["diagnosis", 1433], ["of", 1443], ["stroke", 1446], [".", 1452], ["The", 1454], ["ROSIER", 1458], ["was", 1465], ["not", 1469], ["better", 1473], ["than", 1480], ["the", 1485], ["FAST", 1489], ["for", 1494], ["prehospital", 1498], ["recognition", 1510], ["of", 1522], ["stroke", 1525], [".", 1531], ["A", 1533], ["revised", 1535], ["version", 1543], ["of", 1551], ["the", 1554], ["FAST", 1558], ["incorporating", 1563], ["assessment", 1577], ["of", 1588], ["seizure", 1591], ["activity", 1599], ["may", 1608], ["improve", 1612], ["stroke", 1620], ["identification", 1627], ["and", 1642], ["decision", 1646], ["making", 1655], ["by", 1662], ["ambulance", 1665], ["clinicians", 1675], [".", 1685]]}
{"context": "To evaluate the usefulness of the periportal free air (PPFA) sign on computed tomography (CT) to distinguish upper from lower gastrointestinal (GI) tract perforation. During a 30-month period, we retrospectively analyzed abdominal CT images of 53 consecutive patients with surgically proven GI tract perforation. We divided the patients into two groups, i.e. upper and lower GI tract perforation groups. According to the distribution of free air, we divided the peritoneal cavity into supramesocolic compartment and inframesocolic compartment. We observed the presence or absence of free air in each compartment in each group. When there was free air in the periportal area, it was defined as periportal free air (PPFA) and the sign was positive. To evaluate the usefulness of the PPFA sign, we compared the PPFA sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known CT signs of pneumoperitoneum. Statistical analyses were performed with univariate and multivariate analyses using SPSS version 11.5 for significant findings among the CT signs. Free air was seen in supramesocolic compartment in 29 of 30 (97%) patients in the upper GI perforation group and in 17 of 23 (74%) in the lower GI perforation group. Free air in inframesocolic compartment did not show significant difference in either group (p=.16). The PPFA sign was seen in 28 of 30 (93%) patients with upper GI tract perforation, but in only 8 of 23 (35%) patients with lower GI tract perforation (p<.0001). The falciform ligament sign was seen in 24 of 30 (80%) patients with upper GI tract perforation and in 10 of 23 (43%) patients with lower GI tract perforation (p=.020). The ligamentum teres sign was seen in 16 of 30 (53%) patients with upper GI tract perforation and in 2 of 23 (8%) patients with lower GI tract perforation (p=.008). Multivariate logistic regression analysis showed that the PPFA sign was the only variable, which adjusted odds ratio of 15.5 (p=.002). The PPFA sign is a useful finding which can help to distinguish upper from lower GI tract perforation. When this sign is present, upper GI tract perforation is strongly suggested.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "7b02cb46d87c4b849e37b82396d1c3b0", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[167, 167]], "char_spans": [[923, 938]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["usefulness", 16], ["of", 27], ["the", 30], ["periportal", 34], ["free", 45], ["air", 50], ["(", 54], ["PPFA", 55], [")", 59], ["sign", 61], ["on", 66], ["computed", 69], ["tomography", 78], ["(", 89], ["CT", 90], [")", 92], ["to", 94], ["distinguish", 97], ["upper", 109], ["from", 115], ["lower", 120], ["gastrointestinal", 126], ["(", 143], ["GI", 144], [")", 146], ["tract", 148], ["perforation", 154], [".", 165], ["During", 167], ["a", 174], ["30-month", 176], ["period", 185], [",", 191], ["we", 193], ["retrospectively", 196], ["analyzed", 212], ["abdominal", 221], ["CT", 231], ["images", 234], ["of", 241], ["53", 244], ["consecutive", 247], ["patients", 259], ["with", 268], ["surgically", 273], ["proven", 284], ["GI", 291], ["tract", 294], ["perforation", 300], [".", 311], ["We", 313], ["divided", 316], ["the", 324], ["patients", 328], ["into", 337], ["two", 342], ["groups", 346], [",", 352], ["i.e.", 354], ["upper", 359], ["and", 365], ["lower", 369], ["GI", 375], ["tract", 378], ["perforation", 384], ["groups", 396], [".", 402], ["According", 404], ["to", 414], ["the", 417], ["distribution", 421], ["of", 434], ["free", 437], ["air", 442], [",", 445], ["we", 447], ["divided", 450], ["the", 458], ["peritoneal", 462], ["cavity", 473], ["into", 480], ["supramesocolic", 485], ["compartment", 500], ["and", 512], ["inframesocolic", 516], ["compartment", 531], [".", 542], ["We", 544], ["observed", 547], ["the", 556], ["presence", 560], ["or", 569], ["absence", 572], ["of", 580], ["free", 583], ["air", 588], ["in", 592], ["each", 595], ["compartment", 600], ["in", 612], ["each", 615], ["group", 620], [".", 625], ["When", 627], ["there", 632], ["was", 638], ["free", 642], ["air", 647], ["in", 651], ["the", 654], ["periportal", 658], ["area", 669], [",", 673], ["it", 675], ["was", 678], ["defined", 682], ["as", 690], ["periportal", 693], ["free", 704], ["air", 709], ["(", 713], ["PPFA", 714], [")", 718], ["and", 720], ["the", 724], ["sign", 728], ["was", 733], ["positive", 737], [".", 745], ["To", 747], ["evaluate", 750], ["the", 759], ["usefulness", 763], ["of", 774], ["the", 777], ["PPFA", 781], ["sign", 786], [",", 790], ["we", 792], ["compared", 795], ["the", 804], ["PPFA", 808], ["sign", 813], ["with", 818], ["the", 823], ["falciform", 827], ["ligament", 837], ["sign", 846], ["and", 851], ["the", 855], ["ligamentum", 859], ["teres", 870], ["sign", 876], [",", 880], ["both", 882], ["of", 887], ["which", 890], ["are", 896], ["well", 900], ["-", 904], ["known", 905], ["CT", 911], ["signs", 914], ["of", 920], ["pneumoperitoneum", 923], [".", 939], ["Statistical", 941], ["analyses", 953], ["were", 962], ["performed", 967], ["with", 977], ["univariate", 982], ["and", 993], ["multivariate", 997], ["analyses", 1010], ["using", 1019], ["SPSS", 1025], ["version", 1030], ["11.5", 1038], ["for", 1043], ["significant", 1047], ["findings", 1059], ["among", 1068], ["the", 1074], ["CT", 1078], ["signs", 1081], [".", 1086], ["Free", 1088], ["air", 1093], ["was", 1097], ["seen", 1101], ["in", 1106], ["supramesocolic", 1109], ["compartment", 1124], ["in", 1136], ["29", 1139], ["of", 1142], ["30", 1145], ["(", 1148], ["97", 1149], ["%", 1151], [")", 1152], ["patients", 1154], ["in", 1163], ["the", 1166], ["upper", 1170], ["GI", 1176], ["perforation", 1179], ["group", 1191], ["and", 1197], ["in", 1201], ["17", 1204], ["of", 1207], ["23", 1210], ["(", 1213], ["74", 1214], ["%", 1216], [")", 1217], ["in", 1219], ["the", 1222], ["lower", 1226], ["GI", 1232], ["perforation", 1235], ["group", 1247], [".", 1252], ["Free", 1254], ["air", 1259], ["in", 1263], ["inframesocolic", 1266], ["compartment", 1281], ["did", 1293], ["not", 1297], ["show", 1301], ["significant", 1306], ["difference", 1318], ["in", 1329], ["either", 1332], ["group", 1339], ["(", 1345], ["p=.16", 1346], [")", 1351], [".", 1352], ["The", 1354], ["PPFA", 1358], ["sign", 1363], ["was", 1368], ["seen", 1372], ["in", 1377], ["28", 1380], ["of", 1383], ["30", 1386], ["(", 1389], ["93", 1390], ["%", 1392], [")", 1393], ["patients", 1395], ["with", 1404], ["upper", 1409], ["GI", 1415], ["tract", 1418], ["perforation", 1424], [",", 1435], ["but", 1437], ["in", 1441], ["only", 1444], ["8", 1449], ["of", 1451], ["23", 1454], ["(", 1457], ["35", 1458], ["%", 1460], [")", 1461], ["patients", 1463], ["with", 1472], ["lower", 1477], ["GI", 1483], ["tract", 1486], ["perforation", 1492], ["(", 1504], ["p<.0001", 1505], [")", 1512], [".", 1513], ["The", 1515], ["falciform", 1519], ["ligament", 1529], ["sign", 1538], ["was", 1543], ["seen", 1547], ["in", 1552], ["24", 1555], ["of", 1558], ["30", 1561], ["(", 1564], ["80", 1565], ["%", 1567], [")", 1568], ["patients", 1570], ["with", 1579], ["upper", 1584], ["GI", 1590], ["tract", 1593], ["perforation", 1599], ["and", 1611], ["in", 1615], ["10", 1618], ["of", 1621], ["23", 1624], ["(", 1627], ["43", 1628], ["%", 1630], [")", 1631], ["patients", 1633], ["with", 1642], ["lower", 1647], ["GI", 1653], ["tract", 1656], ["perforation", 1662], ["(", 1674], ["p=.020", 1675], [")", 1681], [".", 1682], ["The", 1684], ["ligamentum", 1688], ["teres", 1699], ["sign", 1705], ["was", 1710], ["seen", 1714], ["in", 1719], ["16", 1722], ["of", 1725], ["30", 1728], ["(", 1731], ["53", 1732], ["%", 1734], [")", 1735], ["patients", 1737], ["with", 1746], ["upper", 1751], ["GI", 1757], ["tract", 1760], ["perforation", 1766], ["and", 1778], ["in", 1782], ["2", 1785], ["of", 1787], ["23", 1790], ["(", 1793], ["8", 1794], ["%", 1795], [")", 1796], ["patients", 1798], ["with", 1807], ["lower", 1812], ["GI", 1818], ["tract", 1821], ["perforation", 1827], ["(", 1839], ["p=.008", 1840], [")", 1846], [".", 1847], ["Multivariate", 1849], ["logistic", 1862], ["regression", 1871], ["analysis", 1882], ["showed", 1891], ["that", 1898], ["the", 1903], ["PPFA", 1907], ["sign", 1912], ["was", 1917], ["the", 1921], ["only", 1925], ["variable", 1930], [",", 1938], ["which", 1940], ["adjusted", 1946], ["odds", 1955], ["ratio", 1960], ["of", 1966], ["15.5", 1969], ["(", 1974], ["p=.002", 1975], [")", 1981], [".", 1982], ["The", 1984], ["PPFA", 1988], ["sign", 1993], ["is", 1998], ["a", 2001], ["useful", 2003], ["finding", 2010], ["which", 2018], ["can", 2024], ["help", 2028], ["to", 2033], ["distinguish", 2036], ["upper", 2048], ["from", 2054], ["lower", 2059], ["GI", 2065], ["tract", 2068], ["perforation", 2074], [".", 2085], ["When", 2087], ["this", 2092], ["sign", 2097], ["is", 2102], ["present", 2105], [",", 2112], ["upper", 2114], ["GI", 2120], ["tract", 2123], ["perforation", 2129], ["is", 2141], ["strongly", 2144], ["suggested", 2153], [".", 2162]]}
{"context": "Transcription factors belonging to the nuclear factor of activated T cells (NFAT) family regulate the expression of cytokine genes and other inducible genes during the immune response. The functions of NFAT proteins are directly controlled by the calcium- and calmodulin-dependent phosphatase calcineurin. Here we show that the binding of calcineurin to NFAT is substantially increased when calcineurin is activated with calmodulin and calcium. FK506.FKBP12 drug-immunophilin complexes inhibited the interaction of NFAT with activated calcineurin much more effectively than they inhibited the interaction with inactive calcineurin, suggesting that part of the interaction with activated calcineurin involved the enzyme active site. We have previously shown that NFAT is targeted to inactive calcineurin at a region distinct from the calcineurin active site (Aramburu, J., Garcia-Cozar, F. J., Raghavan, A., Okamura, H., Rao, A., and Hogan, P. G. (1998) Mol. Cell 1, 627-637); this region is also involved in NFAT binding to activated calcineurin, since binding is inhibited by an NFAT peptide spanning the calcineurin docking site on NFAT. The interacting surfaces are located on the catalytic domain of the calcineurin A chain and on an 86-amino acid fragment of the NFAT regulatory domain. NFAT binding to the calcineurin catalytic domain was inhibited by the calcineurin autoinhibitory domain and the RII substrate peptide, which bind in the calcineurin active site, as well as by the NFAT docking site peptide, which binds to a region of calcineurin distinct from the active site. We propose that, in resting cells, NFAT is targeted to a region of the calcineurin catalytic domain that does not overlap the calcineurin active site. Upon cell activation, displacement of the autoinhibitory domain by calmodulin binding allows NFAT to bind additionally to the calcineurin active site, thus positioning NFAT for immediate dephosphorylation at functional phosphoserine residues.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "95cd880240a7419293999192f422b60e", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[194, 194], [293, 293], [93, 93], [211, 211], [82, 82], [46, 46], [182, 182], [230, 230], [237, 237], [250, 250], [55, 55], [103, 103], [324, 324], [270, 270], [120, 120], [62, 62], [301, 301], [127, 127]], "char_spans": [[1106, 1116], [1656, 1666], [619, 629], [1208, 1218], [535, 545], [293, 303], [1034, 1044], [1312, 1322], [1362, 1372], [1445, 1455], [339, 349], [687, 697], [1862, 1872], [1542, 1552], [791, 801], [391, 401], [1711, 1721], [833, 843]]}]}], "context_tokens": [["Transcription", 0], ["factors", 14], ["belonging", 22], ["to", 32], ["the", 35], ["nuclear", 39], ["factor", 47], ["of", 54], ["activated", 57], ["T", 67], ["cells", 69], ["(", 75], ["NFAT", 76], [")", 80], ["family", 82], ["regulate", 89], ["the", 98], ["expression", 102], ["of", 113], ["cytokine", 116], ["genes", 125], ["and", 131], ["other", 135], ["inducible", 141], ["genes", 151], ["during", 157], ["the", 164], ["immune", 168], ["response", 175], [".", 183], ["The", 185], ["functions", 189], ["of", 199], ["NFAT", 202], ["proteins", 207], ["are", 216], ["directly", 220], ["controlled", 229], ["by", 240], ["the", 243], ["calcium-", 247], ["and", 256], ["calmodulin", 260], ["-", 270], ["dependent", 271], ["phosphatase", 281], ["calcineurin", 293], [".", 304], ["Here", 306], ["we", 311], ["show", 314], ["that", 319], ["the", 324], ["binding", 328], ["of", 336], ["calcineurin", 339], ["to", 351], ["NFAT", 354], ["is", 359], ["substantially", 362], ["increased", 376], ["when", 386], ["calcineurin", 391], ["is", 403], ["activated", 406], ["with", 416], ["calmodulin", 421], ["and", 432], ["calcium", 436], [".", 443], ["FK506.FKBP12", 445], ["drug", 458], ["-", 462], ["immunophilin", 463], ["complexes", 476], ["inhibited", 486], ["the", 496], ["interaction", 500], ["of", 512], ["NFAT", 515], ["with", 520], ["activated", 525], ["calcineurin", 535], ["much", 547], ["more", 552], ["effectively", 557], ["than", 569], ["they", 574], ["inhibited", 579], ["the", 589], ["interaction", 593], ["with", 605], ["inactive", 610], ["calcineurin", 619], [",", 630], ["suggesting", 632], ["that", 643], ["part", 648], ["of", 653], ["the", 656], ["interaction", 660], ["with", 672], ["activated", 677], ["calcineurin", 687], ["involved", 699], ["the", 708], ["enzyme", 712], ["active", 719], ["site", 726], [".", 730], ["We", 732], ["have", 735], ["previously", 740], ["shown", 751], ["that", 757], ["NFAT", 762], ["is", 767], ["targeted", 770], ["to", 779], ["inactive", 782], ["calcineurin", 791], ["at", 803], ["a", 806], ["region", 808], ["distinct", 815], ["from", 824], ["the", 829], ["calcineurin", 833], ["active", 845], ["site", 852], ["(", 857], ["Aramburu", 858], [",", 866], ["J.", 868], [",", 870], ["Garcia", 872], ["-", 878], ["Cozar", 879], [",", 884], ["F.", 886], ["J.", 889], [",", 891], ["Raghavan", 893], [",", 901], ["A.", 903], [",", 905], ["Okamura", 907], [",", 914], ["H.", 916], [",", 918], ["Rao", 920], [",", 923], ["A.", 925], [",", 927], ["and", 929], ["Hogan", 933], [",", 938], ["P.", 940], ["G.", 943], ["(", 946], ["1998", 947], [")", 951], ["Mol", 953], [".", 956], ["Cell", 958], ["1", 963], [",", 964], ["627", 966], ["-", 969], ["637", 970], [")", 973], [";", 974], ["this", 976], ["region", 981], ["is", 988], ["also", 991], ["involved", 996], ["in", 1005], ["NFAT", 1008], ["binding", 1013], ["to", 1021], ["activated", 1024], ["calcineurin", 1034], [",", 1045], ["since", 1047], ["binding", 1053], ["is", 1061], ["inhibited", 1064], ["by", 1074], ["an", 1077], ["NFAT", 1080], ["peptide", 1085], ["spanning", 1093], ["the", 1102], ["calcineurin", 1106], ["docking", 1118], ["site", 1126], ["on", 1131], ["NFAT", 1134], [".", 1138], ["The", 1140], ["interacting", 1144], ["surfaces", 1156], ["are", 1165], ["located", 1169], ["on", 1177], ["the", 1180], ["catalytic", 1184], ["domain", 1194], ["of", 1201], ["the", 1204], ["calcineurin", 1208], ["A", 1220], ["chain", 1222], ["and", 1228], ["on", 1232], ["an", 1235], ["86-amino", 1238], ["acid", 1247], ["fragment", 1252], ["of", 1261], ["the", 1264], ["NFAT", 1268], ["regulatory", 1273], ["domain", 1284], [".", 1290], ["NFAT", 1292], ["binding", 1297], ["to", 1305], ["the", 1308], ["calcineurin", 1312], ["catalytic", 1324], ["domain", 1334], ["was", 1341], ["inhibited", 1345], ["by", 1355], ["the", 1358], ["calcineurin", 1362], ["autoinhibitory", 1374], ["domain", 1389], ["and", 1396], ["the", 1400], ["RII", 1404], ["substrate", 1408], ["peptide", 1418], [",", 1425], ["which", 1427], ["bind", 1433], ["in", 1438], ["the", 1441], ["calcineurin", 1445], ["active", 1457], ["site", 1464], [",", 1468], ["as", 1470], ["well", 1473], ["as", 1478], ["by", 1481], ["the", 1484], ["NFAT", 1488], ["docking", 1493], ["site", 1501], ["peptide", 1506], [",", 1513], ["which", 1515], ["binds", 1521], ["to", 1527], ["a", 1530], ["region", 1532], ["of", 1539], ["calcineurin", 1542], ["distinct", 1554], ["from", 1563], ["the", 1568], ["active", 1572], ["site", 1579], [".", 1583], ["We", 1585], ["propose", 1588], ["that", 1596], [",", 1600], ["in", 1602], ["resting", 1605], ["cells", 1613], [",", 1618], ["NFAT", 1620], ["is", 1625], ["targeted", 1628], ["to", 1637], ["a", 1640], ["region", 1642], ["of", 1649], ["the", 1652], ["calcineurin", 1656], ["catalytic", 1668], ["domain", 1678], ["that", 1685], ["does", 1690], ["not", 1695], ["overlap", 1699], ["the", 1707], ["calcineurin", 1711], ["active", 1723], ["site", 1730], [".", 1734], ["Upon", 1736], ["cell", 1741], ["activation", 1746], [",", 1756], ["displacement", 1758], ["of", 1771], ["the", 1774], ["autoinhibitory", 1778], ["domain", 1793], ["by", 1800], ["calmodulin", 1803], ["binding", 1814], ["allows", 1822], ["NFAT", 1829], ["to", 1834], ["bind", 1837], ["additionally", 1842], ["to", 1855], ["the", 1858], ["calcineurin", 1862], ["active", 1874], ["site", 1881], [",", 1885], ["thus", 1887], ["positioning", 1892], ["NFAT", 1904], ["for", 1909], ["immediate", 1913], ["dephosphorylation", 1923], ["at", 1941], ["functional", 1944], ["phosphoserine", 1955], ["residues", 1969], [".", 1977]]}
{"context": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information. First, it includes a genome browser which interrogates 1260 genomic sequence scaffolds and features gene, transcript and CDS annotation tracks. Second, we annotated gene models with gene ontology (GO) terms and InterPro domains which are directly accessible in the browser with links to their entries in the GO (http://www.geneontology.org/) and InterPro (http://www.ebi.ac.uk/interpro/) databases, and we provide transcript and peptide links for sequence downloads. Third, we introduce the transcriptomics of a comprehensive set of developmental stages of O. dioica at high resolution and provide downloadable gene expression data for all developmental stages. Fourth, we incorporate a BLAST tool to identify homologs of genes and proteins. Finally, we include a tutorial that describes how to use OikoBase as well as a link to detailed methods, explaining the data generation and analysis pipeline. OikoBase will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism.", "qas": [{"question": "Mention the only available genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "answers": ["OikoBase"], "qid": "6fc08188d45a419184053b7f1897cddc", "question_tokens": [["Mention", 0], ["the", 8], ["only", 12], ["available", 17], ["genomics", 27], ["and", 36], ["developmental", 40], ["transcriptomics", 54], ["resource", 70], ["for", 79], ["the", 83], ["urochordate", 87], ["Oikopleura", 99], ["dioica", 110]], "detected_answers": [{"text": "OikoBase", "token_spans": [[36, 36], [180, 180], [5, 5], [198, 198]], "char_spans": [[234, 241], [1120, 1127], [29, 36], [1222, 1229]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["development", 14], ["of", 26], ["OikoBase", 29], ["(", 38], ["http://oikoarrays.biology.uiowa.edu/Oiko/", 39], [")", 80], [",", 81], ["a", 83], ["tiling", 85], ["array", 92], ["-", 97], ["based", 98], ["genome", 104], ["browser", 111], ["resource", 119], ["for", 128], ["Oikopleura", 132], ["dioica", 143], [",", 149], ["a", 151], ["metazoan", 153], ["belonging", 162], ["to", 172], ["the", 175], ["urochordates", 179], [",", 191], ["the", 193], ["closest", 197], ["extant", 205], ["group", 212], ["to", 218], ["vertebrates", 221], [".", 232], ["OikoBase", 234], ["facilitates", 243], ["retrieval", 255], ["and", 265], ["mining", 269], ["of", 276], ["a", 279], ["variety", 281], ["of", 289], ["useful", 292], ["genomics", 299], ["information", 308], [".", 319], ["First", 321], [",", 326], ["it", 328], ["includes", 331], ["a", 340], ["genome", 342], ["browser", 349], ["which", 357], ["interrogates", 363], ["1260", 376], ["genomic", 381], ["sequence", 389], ["scaffolds", 398], ["and", 408], ["features", 412], ["gene", 421], [",", 425], ["transcript", 427], ["and", 438], ["CDS", 442], ["annotation", 446], ["tracks", 457], [".", 463], ["Second", 465], [",", 471], ["we", 473], ["annotated", 476], ["gene", 486], ["models", 491], ["with", 498], ["gene", 503], ["ontology", 508], ["(", 517], ["GO", 518], [")", 520], ["terms", 522], ["and", 528], ["InterPro", 532], ["domains", 541], ["which", 549], ["are", 555], ["directly", 559], ["accessible", 568], ["in", 579], ["the", 582], ["browser", 586], ["with", 594], ["links", 599], ["to", 605], ["their", 608], ["entries", 614], ["in", 622], ["the", 625], ["GO", 629], ["(", 632], ["http://www.geneontology.org/", 633], [")", 661], ["and", 663], ["InterPro", 667], ["(", 676], ["http://www.ebi.ac.uk/interpro/", 677], [")", 707], ["databases", 709], [",", 718], ["and", 720], ["we", 724], ["provide", 727], ["transcript", 735], ["and", 746], ["peptide", 750], ["links", 758], ["for", 764], ["sequence", 768], ["downloads", 777], [".", 786], ["Third", 788], [",", 793], ["we", 795], ["introduce", 798], ["the", 808], ["transcriptomics", 812], ["of", 828], ["a", 831], ["comprehensive", 833], ["set", 847], ["of", 851], ["developmental", 854], ["stages", 868], ["of", 875], ["O.", 878], ["dioica", 881], ["at", 888], ["high", 891], ["resolution", 896], ["and", 907], ["provide", 911], ["downloadable", 919], ["gene", 932], ["expression", 937], ["data", 948], ["for", 953], ["all", 957], ["developmental", 961], ["stages", 975], [".", 981], ["Fourth", 983], [",", 989], ["we", 991], ["incorporate", 994], ["a", 1006], ["BLAST", 1008], ["tool", 1014], ["to", 1019], ["identify", 1022], ["homologs", 1031], ["of", 1040], ["genes", 1043], ["and", 1049], ["proteins", 1053], [".", 1061], ["Finally", 1063], [",", 1070], ["we", 1072], ["include", 1075], ["a", 1083], ["tutorial", 1085], ["that", 1094], ["describes", 1099], ["how", 1109], ["to", 1113], ["use", 1116], ["OikoBase", 1120], ["as", 1129], ["well", 1132], ["as", 1137], ["a", 1140], ["link", 1142], ["to", 1147], ["detailed", 1150], ["methods", 1159], [",", 1166], ["explaining", 1168], ["the", 1179], ["data", 1183], ["generation", 1188], ["and", 1199], ["analysis", 1203], ["pipeline", 1212], [".", 1220], ["OikoBase", 1222], ["will", 1231], ["provide", 1236], ["a", 1244], ["valuable", 1246], ["resource", 1255], ["for", 1264], ["research", 1268], ["in", 1277], ["chordate", 1280], ["development", 1289], [",", 1300], ["genome", 1302], ["evolution", 1309], ["and", 1319], ["plasticity", 1323], ["and", 1334], ["the", 1338], ["molecular", 1342], ["ecology", 1352], ["of", 1360], ["this", 1363], ["important", 1368], ["marine", 1378], ["planktonic", 1385], ["organism", 1396], [".", 1404]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a common movement disorder characterised by an uncontrollable urge to move because of uncomfortable, sometimes painful sensations in the legs with a diurnal variation and a release with movement. The pathophysiology is only partially known and a genetic component together with dopaminergic and brain iron dysregulation plays an important role. Secondary causes for RLS need to be excluded. Treatment depends on the severity and frequency of RLS symptoms, comprises non-pharmacological (eg lifestyle changes) and pharmacological interventions (eg dopaminergic medication, alpha-2-delta calcium channel ligands, opioids) and relieves symptoms only. Augmentation is the main complication of long-term dopaminergic treatment of RLS. This article will provide a clinically useful overview of RLS with provision of diagnostic criteria, differential diagnoses, possible investigations and different treatment strategies with their associated complications.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "ee27b6a18fa848d0a07f50eae299fa52", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["common", 77], ["movement", 84], ["disorder", 93], ["characterised", 102], ["by", 116], ["an", 119], ["uncontrollable", 122], ["urge", 137], ["to", 142], ["move", 145], ["because", 150], ["of", 158], ["uncomfortable", 161], [",", 174], ["sometimes", 176], ["painful", 186], ["sensations", 194], ["in", 205], ["the", 208], ["legs", 212], ["with", 217], ["a", 222], ["diurnal", 224], ["variation", 232], ["and", 242], ["a", 246], ["release", 248], ["with", 256], ["movement", 261], [".", 269], ["The", 271], ["pathophysiology", 275], ["is", 291], ["only", 294], ["partially", 299], ["known", 309], ["and", 315], ["a", 319], ["genetic", 321], ["component", 329], ["together", 339], ["with", 348], ["dopaminergic", 353], ["and", 366], ["brain", 370], ["iron", 376], ["dysregulation", 381], ["plays", 395], ["an", 401], ["important", 404], ["role", 414], [".", 418], ["Secondary", 420], ["causes", 430], ["for", 437], ["RLS", 441], ["need", 445], ["to", 450], ["be", 453], ["excluded", 456], [".", 464], ["Treatment", 466], ["depends", 476], ["on", 484], ["the", 487], ["severity", 491], ["and", 500], ["frequency", 504], ["of", 514], ["RLS", 517], ["symptoms", 521], [",", 529], ["comprises", 531], ["non", 541], ["-", 544], ["pharmacological", 545], ["(", 561], ["eg", 562], ["lifestyle", 565], ["changes", 575], [")", 582], ["and", 584], ["pharmacological", 588], ["interventions", 604], ["(", 618], ["eg", 619], ["dopaminergic", 622], ["medication", 635], [",", 645], ["alpha-2-delta", 647], ["calcium", 661], ["channel", 669], ["ligands", 677], [",", 684], ["opioids", 686], [")", 693], ["and", 695], ["relieves", 699], ["symptoms", 708], ["only", 717], [".", 721], ["Augmentation", 723], ["is", 736], ["the", 739], ["main", 743], ["complication", 748], ["of", 761], ["long", 764], ["-", 768], ["term", 769], ["dopaminergic", 774], ["treatment", 787], ["of", 797], ["RLS", 800], [".", 803], ["This", 805], ["article", 810], ["will", 818], ["provide", 823], ["a", 831], ["clinically", 833], ["useful", 844], ["overview", 851], ["of", 860], ["RLS", 863], ["with", 867], ["provision", 872], ["of", 882], ["diagnostic", 885], ["criteria", 896], [",", 904], ["differential", 906], ["diagnoses", 919], [",", 928], ["possible", 930], ["investigations", 939], ["and", 954], ["different", 958], ["treatment", 968], ["strategies", 978], ["with", 989], ["their", 994], ["associated", 1000], ["complications", 1011], [".", 1024]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Among the movement disorders associated with acanthocytosis, McLeod syndrome (McKusick 314850) is the one that is best characterized on the molecular level. Its defining feature is low reactivity of Kell erythrocyte antigens. This is due to absence of membrane protein KX that forms a complex with the Kell protein. KX is coded for by the XK gene on the X-chromosome. We present six males (aged 29 to 60 years), with proven XK mutations, to discuss the chorea associated with McLeod syndrome. The movement disorder commonly develops in the fifth decade and is progressive. It affects the limbs, the trunk and the face. In addition to facial grimacing, involuntary vocalization can be present. In early stages there may only be some restlessness or slight involuntary distal movements of ankles and fingers. Lip-biting and facial tics seem more common in autosomal recessive choreoacanthocytosis linked to chromosome 9. This, together with the absence of dysphagia in McLeod syndrome, may help in differential diagnosis. Recent findings suggest a role for the endothelin system of the striatum in the pathogenesis of McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "7188c1bd11be428bab87e000b19fdf3b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[83, 83], [61, 61]], "char_spans": [[424, 425], [339, 340]]}]}], "context_tokens": [["Among", 0], ["the", 6], ["movement", 10], ["disorders", 19], ["associated", 29], ["with", 40], ["acanthocytosis", 45], [",", 59], ["McLeod", 61], ["syndrome", 68], ["(", 77], ["McKusick", 78], ["314850", 87], [")", 93], ["is", 95], ["the", 98], ["one", 102], ["that", 106], ["is", 111], ["best", 114], ["characterized", 119], ["on", 133], ["the", 136], ["molecular", 140], ["level", 150], [".", 155], ["Its", 157], ["defining", 161], ["feature", 170], ["is", 178], ["low", 181], ["reactivity", 185], ["of", 196], ["Kell", 199], ["erythrocyte", 204], ["antigens", 216], [".", 224], ["This", 226], ["is", 231], ["due", 234], ["to", 238], ["absence", 241], ["of", 249], ["membrane", 252], ["protein", 261], ["KX", 269], ["that", 272], ["forms", 277], ["a", 283], ["complex", 285], ["with", 293], ["the", 298], ["Kell", 302], ["protein", 307], [".", 314], ["KX", 316], ["is", 319], ["coded", 322], ["for", 328], ["by", 332], ["the", 335], ["XK", 339], ["gene", 342], ["on", 347], ["the", 350], ["X", 354], ["-", 355], ["chromosome", 356], [".", 366], ["We", 368], ["present", 371], ["six", 379], ["males", 383], ["(", 389], ["aged", 390], ["29", 395], ["to", 398], ["60", 401], ["years", 404], [")", 409], [",", 410], ["with", 412], ["proven", 417], ["XK", 424], ["mutations", 427], [",", 436], ["to", 438], ["discuss", 441], ["the", 449], ["chorea", 453], ["associated", 460], ["with", 471], ["McLeod", 476], ["syndrome", 483], [".", 491], ["The", 493], ["movement", 497], ["disorder", 506], ["commonly", 515], ["develops", 524], ["in", 533], ["the", 536], ["fifth", 540], ["decade", 546], ["and", 553], ["is", 557], ["progressive", 560], [".", 571], ["It", 573], ["affects", 576], ["the", 584], ["limbs", 588], [",", 593], ["the", 595], ["trunk", 599], ["and", 605], ["the", 609], ["face", 613], [".", 617], ["In", 619], ["addition", 622], ["to", 631], ["facial", 634], ["grimacing", 641], [",", 650], ["involuntary", 652], ["vocalization", 664], ["can", 677], ["be", 681], ["present", 684], [".", 691], ["In", 693], ["early", 696], ["stages", 702], ["there", 709], ["may", 715], ["only", 719], ["be", 724], ["some", 727], ["restlessness", 732], ["or", 745], ["slight", 748], ["involuntary", 755], ["distal", 767], ["movements", 774], ["of", 784], ["ankles", 787], ["and", 794], ["fingers", 798], [".", 805], ["Lip", 807], ["-", 810], ["biting", 811], ["and", 818], ["facial", 822], ["tics", 829], ["seem", 834], ["more", 839], ["common", 844], ["in", 851], ["autosomal", 854], ["recessive", 864], ["choreoacanthocytosis", 874], ["linked", 895], ["to", 902], ["chromosome", 905], ["9", 916], [".", 917], ["This", 919], [",", 923], ["together", 925], ["with", 934], ["the", 939], ["absence", 943], ["of", 951], ["dysphagia", 954], ["in", 964], ["McLeod", 967], ["syndrome", 974], [",", 982], ["may", 984], ["help", 988], ["in", 993], ["differential", 996], ["diagnosis", 1009], [".", 1018], ["Recent", 1020], ["findings", 1027], ["suggest", 1036], ["a", 1044], ["role", 1046], ["for", 1051], ["the", 1055], ["endothelin", 1059], ["system", 1070], ["of", 1077], ["the", 1080], ["striatum", 1084], ["in", 1093], ["the", 1096], ["pathogenesis", 1100], ["of", 1113], ["McLeod", 1116], ["syndrome", 1123], [".", 1131]]}
{"context": "Nox activator 1 (NoxA1) is a homologue of p67(phox) that acts in conjunction with Nox organizer 1 (NoxO1) to regulate reactive oxygen species (ROS) production by the NADPH oxidase Nox1. The phosphorylation of cytosolic regulatory components by multiple kinases plays important roles in assembly and activity of the phagocyte NADPH oxidase (Nox2) system, but little is known about regulation by phosphorylation in the Nox1 system. Here we identify Ser(172) and Ser(461) of NoxA1 as phosphorylation sites for protein kinase A (PKA). A consequence of this phosphorylation was the enhancement of NoxA1 complex formation with 14-3-3 proteins. Using both a transfected human embryonic kidney 293 cell Nox1 model system and endogenous Nox1 in colon cell lines, we showed that the elevation of cAMP inhibits, whereas the inhibition of PKA enhances, Nox1-dependent ROS production through effects on NoxA1. Inhibition of Nox1 activity was intensified by the availability of 14-3-3zeta protein, and this regulatory interaction was dependent on PKA-phosphorylatable sites at Ser(172) and Ser(461) in NoxA1. We showed that phosphorylation and 14-3-3 binding induce the dissociation of NoxA1 from the Nox1 complex at the plasma membrane, suggesting a mechanism for the inhibitory effect on Nox1 activity. Our data establish that PKA-phosphorylated NoxA1 is a new binding partner of 14-3-3 protein(s) and that this forms the basis of a novel mechanism regulating the formation of ROS by Nox1 and, potentially, other NoxA1-regulated Nox family members.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d136608f31e4ac89782b0aa4082ddf6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[272, 272], [74, 74], [164, 164], [36, 36], [132, 132], [217, 217], [232, 232], [127, 127]], "char_spans": [[1472, 1475], [417, 420], [911, 914], [180, 183], [728, 731], [1187, 1190], [1276, 1279], [695, 698]]}]}], "context_tokens": [["Nox", 0], ["activator", 4], ["1", 14], ["(", 16], ["NoxA1", 17], [")", 22], ["is", 24], ["a", 27], ["homologue", 29], ["of", 39], ["p67(phox", 42], [")", 50], ["that", 52], ["acts", 57], ["in", 62], ["conjunction", 65], ["with", 77], ["Nox", 82], ["organizer", 86], ["1", 96], ["(", 98], ["NoxO1", 99], [")", 104], ["to", 106], ["regulate", 109], ["reactive", 118], ["oxygen", 127], ["species", 134], ["(", 142], ["ROS", 143], [")", 146], ["production", 148], ["by", 159], ["the", 162], ["NADPH", 166], ["oxidase", 172], ["Nox1", 180], [".", 184], ["The", 186], ["phosphorylation", 190], ["of", 206], ["cytosolic", 209], ["regulatory", 219], ["components", 230], ["by", 241], ["multiple", 244], ["kinases", 253], ["plays", 261], ["important", 267], ["roles", 277], ["in", 283], ["assembly", 286], ["and", 295], ["activity", 299], ["of", 308], ["the", 311], ["phagocyte", 315], ["NADPH", 325], ["oxidase", 331], ["(", 339], ["Nox2", 340], [")", 344], ["system", 346], [",", 352], ["but", 354], ["little", 358], ["is", 365], ["known", 368], ["about", 374], ["regulation", 380], ["by", 391], ["phosphorylation", 394], ["in", 410], ["the", 413], ["Nox1", 417], ["system", 422], [".", 428], ["Here", 430], ["we", 435], ["identify", 438], ["Ser(172", 447], [")", 454], ["and", 456], ["Ser(461", 460], [")", 467], ["of", 469], ["NoxA1", 472], ["as", 478], ["phosphorylation", 481], ["sites", 497], ["for", 503], ["protein", 507], ["kinase", 515], ["A", 522], ["(", 524], ["PKA", 525], [")", 528], [".", 529], ["A", 531], ["consequence", 533], ["of", 545], ["this", 548], ["phosphorylation", 553], ["was", 569], ["the", 573], ["enhancement", 577], ["of", 589], ["NoxA1", 592], ["complex", 598], ["formation", 606], ["with", 616], ["14", 621], ["-", 623], ["3", 624], ["-", 625], ["3", 626], ["proteins", 628], [".", 636], ["Using", 638], ["both", 644], ["a", 649], ["transfected", 651], ["human", 663], ["embryonic", 669], ["kidney", 679], ["293", 686], ["cell", 690], ["Nox1", 695], ["model", 700], ["system", 706], ["and", 713], ["endogenous", 717], ["Nox1", 728], ["in", 733], ["colon", 736], ["cell", 742], ["lines", 747], [",", 752], ["we", 754], ["showed", 757], ["that", 764], ["the", 769], ["elevation", 773], ["of", 783], ["cAMP", 786], ["inhibits", 791], [",", 799], ["whereas", 801], ["the", 809], ["inhibition", 813], ["of", 824], ["PKA", 827], ["enhances", 831], [",", 839], ["Nox1-dependent", 841], ["ROS", 856], ["production", 860], ["through", 871], ["effects", 879], ["on", 887], ["NoxA1", 890], [".", 895], ["Inhibition", 897], ["of", 908], ["Nox1", 911], ["activity", 916], ["was", 925], ["intensified", 929], ["by", 941], ["the", 944], ["availability", 948], ["of", 961], ["14", 964], ["-", 966], ["3", 967], ["-", 968], ["3zeta", 969], ["protein", 975], [",", 982], ["and", 984], ["this", 988], ["regulatory", 993], ["interaction", 1004], ["was", 1016], ["dependent", 1020], ["on", 1030], ["PKA", 1033], ["-", 1036], ["phosphorylatable", 1037], ["sites", 1054], ["at", 1060], ["Ser(172", 1063], [")", 1070], ["and", 1072], ["Ser(461", 1076], [")", 1083], ["in", 1085], ["NoxA1", 1088], [".", 1093], ["We", 1095], ["showed", 1098], ["that", 1105], ["phosphorylation", 1110], ["and", 1126], ["14", 1130], ["-", 1132], ["3", 1133], ["-", 1134], ["3", 1135], ["binding", 1137], ["induce", 1145], ["the", 1152], ["dissociation", 1156], ["of", 1169], ["NoxA1", 1172], ["from", 1178], ["the", 1183], ["Nox1", 1187], ["complex", 1192], ["at", 1200], ["the", 1203], ["plasma", 1207], ["membrane", 1214], [",", 1222], ["suggesting", 1224], ["a", 1235], ["mechanism", 1237], ["for", 1247], ["the", 1251], ["inhibitory", 1255], ["effect", 1266], ["on", 1273], ["Nox1", 1276], ["activity", 1281], [".", 1289], ["Our", 1291], ["data", 1295], ["establish", 1300], ["that", 1310], ["PKA", 1315], ["-", 1318], ["phosphorylated", 1319], ["NoxA1", 1334], ["is", 1340], ["a", 1343], ["new", 1345], ["binding", 1349], ["partner", 1357], ["of", 1365], ["14", 1368], ["-", 1370], ["3", 1371], ["-", 1372], ["3", 1373], ["protein(s", 1375], [")", 1384], ["and", 1386], ["that", 1390], ["this", 1395], ["forms", 1400], ["the", 1406], ["basis", 1410], ["of", 1416], ["a", 1419], ["novel", 1421], ["mechanism", 1427], ["regulating", 1437], ["the", 1448], ["formation", 1452], ["of", 1462], ["ROS", 1465], ["by", 1469], ["Nox1", 1472], ["and", 1477], [",", 1480], ["potentially", 1482], [",", 1493], ["other", 1495], ["NoxA1-regulated", 1501], ["Nox", 1517], ["family", 1521], ["members", 1528], [".", 1535]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "To study the impact of genetic and lifestyle factors on protein biomarkers and develop personally normalized plasma protein profiles (PNPPP) controlling for non-disease-related variance. Proximity extension assays were used to measure 145 proteins in 632 controls and 344 cases with non-communicable diseases. Genetic and lifestyle factors explained 20-88% of the variation in healthy controls. Adjusting for these factors reduced the number of candidate biomarkers by 63%. PNPPP efficiently controls for non-disease-related variance, allowing both for efficient discovery of novel biomarkers and for covariate-independent linear cut-offs suitable for clinical use.", "qas": [{"question": "What is PNPPP?", "answers": ["personally normalized plasma protein profiles"], "qid": "fd51aa90ceb147e78cd27c4328ac7962", "question_tokens": [["What", 0], ["is", 5], ["PNPPP", 8], ["?", 13]], "detected_answers": [{"text": "personally normalized plasma protein profiles", "token_spans": [[14, 18]], "char_spans": [[87, 131]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["impact", 13], ["of", 20], ["genetic", 23], ["and", 31], ["lifestyle", 35], ["factors", 45], ["on", 53], ["protein", 56], ["biomarkers", 64], ["and", 75], ["develop", 79], ["personally", 87], ["normalized", 98], ["plasma", 109], ["protein", 116], ["profiles", 124], ["(", 133], ["PNPPP", 134], [")", 139], ["controlling", 141], ["for", 153], ["non", 157], ["-", 160], ["disease", 161], ["-", 168], ["related", 169], ["variance", 177], [".", 185], ["Proximity", 187], ["extension", 197], ["assays", 207], ["were", 214], ["used", 219], ["to", 224], ["measure", 227], ["145", 235], ["proteins", 239], ["in", 248], ["632", 251], ["controls", 255], ["and", 264], ["344", 268], ["cases", 272], ["with", 278], ["non", 283], ["-", 286], ["communicable", 287], ["diseases", 300], [".", 308], ["Genetic", 310], ["and", 318], ["lifestyle", 322], ["factors", 332], ["explained", 340], ["20", 350], ["-", 352], ["88", 353], ["%", 355], ["of", 357], ["the", 360], ["variation", 364], ["in", 374], ["healthy", 377], ["controls", 385], [".", 393], ["Adjusting", 395], ["for", 405], ["these", 409], ["factors", 415], ["reduced", 423], ["the", 431], ["number", 435], ["of", 442], ["candidate", 445], ["biomarkers", 455], ["by", 466], ["63", 469], ["%", 471], [".", 472], ["PNPPP", 474], ["efficiently", 480], ["controls", 492], ["for", 501], ["non", 505], ["-", 508], ["disease", 509], ["-", 516], ["related", 517], ["variance", 525], [",", 533], ["allowing", 535], ["both", 544], ["for", 549], ["efficient", 553], ["discovery", 563], ["of", 573], ["novel", 576], ["biomarkers", 582], ["and", 593], ["for", 597], ["covariate", 601], ["-", 610], ["independent", 611], ["linear", 623], ["cut", 630], ["-", 633], ["offs", 634], ["suitable", 639], ["for", 648], ["clinical", 652], ["use", 661], [".", 664]]}
{"context": "The ubiquitously expressed iron storage protein ferritin plays a central role in maintaining cellular iron homeostasis. Cytosolic ferritins are composed of heavy (H) and light (L) subunits that co-assemble into a hollow spherical shell with an internal cavity where iron is stored. The ferroxidase activity of the ferritin H chain is critical to store iron in its Fe3+ oxidation state, while the L chain shows iron nucleation properties. We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). We show that L chain ferritin is undetectable in primary fibroblasts from the patient, and thus ferritin consists only of H chains. Increased iron incorporation into the FtH homopolymer leads to reduced cellular iron availability, diminished levels of cytosolic catalase, SOD1 protein levels, enhanced ROS production and higher levels of oxidized proteins. Importantly, key phenotypic features observed in fibroblasts are also mirrored in reprogrammed neurons from the patient's fibroblasts. Our results demonstrate for the first time the pathophysiological consequences of L-ferritin deficiency in a human and help to define the concept for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f7f92b936c074e0eb3a943162c19c19b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[14, 14], [144, 144], [75, 75], [3, 3], [46, 46], [154, 154], [62, 62]], "char_spans": [[102, 105], [786, 789], [410, 413], [27, 30], [266, 269], [856, 859], [352, 355]]}]}], "context_tokens": [["The", 0], ["ubiquitously", 4], ["expressed", 17], ["iron", 27], ["storage", 32], ["protein", 40], ["ferritin", 48], ["plays", 57], ["a", 63], ["central", 65], ["role", 73], ["in", 78], ["maintaining", 81], ["cellular", 93], ["iron", 102], ["homeostasis", 107], [".", 118], ["Cytosolic", 120], ["ferritins", 130], ["are", 140], ["composed", 144], ["of", 153], ["heavy", 156], ["(", 162], ["H", 163], [")", 164], ["and", 166], ["light", 170], ["(", 176], ["L", 177], [")", 178], ["subunits", 180], ["that", 189], ["co", 194], ["-", 196], ["assemble", 197], ["into", 206], ["a", 211], ["hollow", 213], ["spherical", 220], ["shell", 230], ["with", 236], ["an", 241], ["internal", 244], ["cavity", 253], ["where", 260], ["iron", 266], ["is", 271], ["stored", 274], [".", 280], ["The", 282], ["ferroxidase", 286], ["activity", 298], ["of", 307], ["the", 310], ["ferritin", 314], ["H", 323], ["chain", 325], ["is", 331], ["critical", 334], ["to", 343], ["store", 346], ["iron", 352], ["in", 357], ["its", 360], ["Fe3", 364], ["+", 367], ["oxidation", 369], ["state", 379], [",", 384], ["while", 386], ["the", 392], ["L", 396], ["chain", 398], ["shows", 404], ["iron", 410], ["nucleation", 415], ["properties", 426], [".", 436], ["We", 438], ["describe", 441], ["a", 450], ["unique", 452], ["case", 459], ["of", 464], ["a", 467], ["23-yr", 469], ["-", 474], ["old", 475], ["female", 479], ["patient", 486], ["affected", 494], ["by", 503], ["a", 506], ["homozygous", 508], ["loss", 519], ["of", 524], ["function", 527], ["mutation", 536], ["in", 545], ["the", 548], ["L", 552], ["-", 553], ["ferritin", 554], ["gene", 563], [",", 567], ["idiopathic", 569], ["generalized", 580], ["seizures", 592], [",", 600], ["and", 602], ["atypical", 606], ["restless", 615], ["leg", 624], ["syndrome", 628], ["(", 637], ["RLS", 638], [")", 641], [".", 642], ["We", 644], ["show", 647], ["that", 652], ["L", 657], ["chain", 659], ["ferritin", 665], ["is", 674], ["undetectable", 677], ["in", 690], ["primary", 693], ["fibroblasts", 701], ["from", 713], ["the", 718], ["patient", 722], [",", 729], ["and", 731], ["thus", 735], ["ferritin", 740], ["consists", 749], ["only", 758], ["of", 763], ["H", 766], ["chains", 768], [".", 774], ["Increased", 776], ["iron", 786], ["incorporation", 791], ["into", 805], ["the", 810], ["FtH", 814], ["homopolymer", 818], ["leads", 830], ["to", 836], ["reduced", 839], ["cellular", 847], ["iron", 856], ["availability", 861], [",", 873], ["diminished", 875], ["levels", 886], ["of", 893], ["cytosolic", 896], ["catalase", 906], [",", 914], ["SOD1", 916], ["protein", 921], ["levels", 929], [",", 935], ["enhanced", 937], ["ROS", 946], ["production", 950], ["and", 961], ["higher", 965], ["levels", 972], ["of", 979], ["oxidized", 982], ["proteins", 991], [".", 999], ["Importantly", 1001], [",", 1012], ["key", 1014], ["phenotypic", 1018], ["features", 1029], ["observed", 1038], ["in", 1047], ["fibroblasts", 1050], ["are", 1062], ["also", 1066], ["mirrored", 1071], ["in", 1080], ["reprogrammed", 1083], ["neurons", 1096], ["from", 1104], ["the", 1109], ["patient", 1113], ["'s", 1120], ["fibroblasts", 1123], [".", 1134], ["Our", 1136], ["results", 1140], ["demonstrate", 1148], ["for", 1160], ["the", 1164], ["first", 1168], ["time", 1174], ["the", 1179], ["pathophysiological", 1183], ["consequences", 1202], ["of", 1215], ["L", 1218], ["-", 1219], ["ferritin", 1220], ["deficiency", 1229], ["in", 1240], ["a", 1243], ["human", 1245], ["and", 1251], ["help", 1255], ["to", 1260], ["define", 1263], ["the", 1270], ["concept", 1274], ["for", 1282], ["a", 1286], ["new", 1288], ["disease", 1292], ["entity", 1300], ["hallmarked", 1307], ["by", 1318], ["idiopathic", 1321], ["generalized", 1332], ["seizure", 1344], ["and", 1352], ["atypical", 1356], ["RLS", 1365], [".", 1368]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "Although peak finding in next-generation sequencing (NGS) datasets has been addressed extensively, there is no consensus on how to analyze and process biological replicates. Furthermore, most peak finders do not focus on accurate determination of enrichment site widths and are not widely applicable to different types of datasets. We developed JAMM (Joint Analysis of NGS replicates via Mixture Model clustering): a peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM is among the best performing peak finders in terms of site detection accuracy and in terms of accurate determination of enrichment sites widths. In addition, JAMM's replicate integration improves peak spatial resolution, sorting and peak finding accuracy. JAMM is available for free and can run on Linux machines through the command line: http://code.google.com/p/jamm-peak-finder.", "qas": [{"question": "Which peak calling algorithm employs mixture model clustering under the hood?", "answers": ["JAMM"], "qid": "34f812a7bd0645b481c7269f56ee725d", "question_tokens": [["Which", 0], ["peak", 6], ["calling", 11], ["algorithm", 19], ["employs", 29], ["mixture", 37], ["model", 45], ["clustering", 51], ["under", 62], ["the", 68], ["hood", 72], ["?", 76]], "detected_answers": [{"text": "JAMM", "token_spans": [[139, 139], [93, 93], [154, 154], [58, 58], [111, 111]], "char_spans": [[829, 832], [570, 573], [927, 930], [345, 348], [666, 669]]}]}], "context_tokens": [["Although", 0], ["peak", 9], ["finding", 14], ["in", 22], ["next", 25], ["-", 29], ["generation", 30], ["sequencing", 41], ["(", 52], ["NGS", 53], [")", 56], ["datasets", 58], ["has", 67], ["been", 71], ["addressed", 76], ["extensively", 86], [",", 97], ["there", 99], ["is", 105], ["no", 108], ["consensus", 111], ["on", 121], ["how", 124], ["to", 128], ["analyze", 131], ["and", 139], ["process", 143], ["biological", 151], ["replicates", 162], [".", 172], ["Furthermore", 174], [",", 185], ["most", 187], ["peak", 192], ["finders", 197], ["do", 205], ["not", 208], ["focus", 212], ["on", 218], ["accurate", 221], ["determination", 230], ["of", 244], ["enrichment", 247], ["site", 258], ["widths", 263], ["and", 270], ["are", 274], ["not", 278], ["widely", 282], ["applicable", 289], ["to", 300], ["different", 303], ["types", 313], ["of", 319], ["datasets", 322], [".", 330], ["We", 332], ["developed", 335], ["JAMM", 345], ["(", 350], ["Joint", 351], ["Analysis", 357], ["of", 366], ["NGS", 369], ["replicates", 373], ["via", 384], ["Mixture", 388], ["Model", 396], ["clustering", 402], [")", 412], [":", 413], ["a", 415], ["peak", 417], ["finder", 422], ["that", 429], ["can", 434], ["integrate", 438], ["information", 448], ["from", 460], ["biological", 465], ["replicates", 476], [",", 486], ["determine", 488], ["enrichment", 498], ["site", 509], ["widths", 514], ["accurately", 521], ["and", 532], ["resolve", 536], ["neighboring", 544], ["narrow", 556], ["peaks", 563], [".", 568], ["JAMM", 570], ["is", 575], ["a", 578], ["universal", 580], ["peak", 590], ["finder", 595], ["that", 602], ["is", 607], ["applicable", 610], ["to", 621], ["different", 624], ["types", 634], ["of", 640], ["datasets", 643], [".", 651], ["We", 653], ["show", 656], ["that", 661], ["JAMM", 666], ["is", 671], ["among", 674], ["the", 680], ["best", 684], ["performing", 689], ["peak", 700], ["finders", 705], ["in", 713], ["terms", 716], ["of", 722], ["site", 725], ["detection", 730], ["accuracy", 740], ["and", 749], ["in", 753], ["terms", 756], ["of", 762], ["accurate", 765], ["determination", 774], ["of", 788], ["enrichment", 791], ["sites", 802], ["widths", 808], [".", 814], ["In", 816], ["addition", 819], [",", 827], ["JAMM", 829], ["'s", 833], ["replicate", 836], ["integration", 846], ["improves", 858], ["peak", 867], ["spatial", 872], ["resolution", 880], [",", 890], ["sorting", 892], ["and", 900], ["peak", 904], ["finding", 909], ["accuracy", 917], [".", 925], ["JAMM", 927], ["is", 932], ["available", 935], ["for", 945], ["free", 949], ["and", 954], ["can", 958], ["run", 962], ["on", 966], ["Linux", 969], ["machines", 975], ["through", 984], ["the", 992], ["command", 996], ["line", 1004], [":", 1008], ["http://code.google.com/p/jamm-peak-finder", 1010], [".", 1051]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "The rash in infectious mononucleosis is usually diffusely macular. A 15-year-old boy presented to us with high grade fever, sore throat, malaise, body aches, and polyarthralgia. He developed annular, erythematous, and non-scaly eruptions on chest and right arm. Blanching erythema was noted on his trunk. He had bilateral tender cervical lymph nodes, severe pharyngeal congestion, petechiae on soft palate, uvular edema, infraorbital edema, and marginal tender hepatomegaly. Investigations revealed lymphocytosis and activated atypical lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient. To our knowledge, this atypical case is the third reported case of annular lesions in infectious mononucleosis. Dermatologists and other clinicians should be alerted to this special presentation of primary EBV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "2fa6c155febe4bc2bb8a93675adab78c", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[118, 121]], "char_spans": [[682, 699]]}]}], "context_tokens": [["The", 0], ["rash", 4], ["in", 9], ["infectious", 12], ["mononucleosis", 23], ["is", 37], ["usually", 40], ["diffusely", 48], ["macular", 58], [".", 65], ["A", 67], ["15-year", 69], ["-", 76], ["old", 77], ["boy", 81], ["presented", 85], ["to", 95], ["us", 98], ["with", 101], ["high", 106], ["grade", 111], ["fever", 117], [",", 122], ["sore", 124], ["throat", 129], [",", 135], ["malaise", 137], [",", 144], ["body", 146], ["aches", 151], [",", 156], ["and", 158], ["polyarthralgia", 162], [".", 176], ["He", 178], ["developed", 181], ["annular", 191], [",", 198], ["erythematous", 200], [",", 212], ["and", 214], ["non", 218], ["-", 221], ["scaly", 222], ["eruptions", 228], ["on", 238], ["chest", 241], ["and", 247], ["right", 251], ["arm", 257], [".", 260], ["Blanching", 262], ["erythema", 272], ["was", 281], ["noted", 285], ["on", 291], ["his", 294], ["trunk", 298], [".", 303], ["He", 305], ["had", 308], ["bilateral", 312], ["tender", 322], ["cervical", 329], ["lymph", 338], ["nodes", 344], [",", 349], ["severe", 351], ["pharyngeal", 358], ["congestion", 369], [",", 379], ["petechiae", 381], ["on", 391], ["soft", 394], ["palate", 399], [",", 405], ["uvular", 407], ["edema", 414], [",", 419], ["infraorbital", 421], ["edema", 434], [",", 439], ["and", 441], ["marginal", 445], ["tender", 454], ["hepatomegaly", 461], [".", 473], ["Investigations", 475], ["revealed", 490], ["lymphocytosis", 499], ["and", 513], ["activated", 517], ["atypical", 527], ["lymphocytes", 536], ["in", 548], ["the", 551], ["peripheral", 555], ["smear", 566], [",", 571], ["and", 573], ["positive", 577], ["monospot", 586], ["test", 595], [".", 599], ["The", 601], ["boy", 605], ["subsequently", 609], ["recovered", 622], ["in", 632], ["one", 635], ["week", 639], ["with", 644], ["total", 649], ["disappearance", 655], ["of", 669], ["his", 672], ["rash", 676], [".", 680], ["Epstein", 682], ["-", 689], ["Barr", 690], ["virus", 695], ["-", 700], ["related", 701], ["infectious", 709], ["mononucleosis", 720], ["was", 734], ["considered", 738], ["the", 749], ["most", 753], ["likely", 758], ["diagnosis", 765], ["for", 775], ["our", 779], ["patient", 783], [".", 790], ["To", 792], ["our", 795], ["knowledge", 799], [",", 808], ["this", 810], ["atypical", 815], ["case", 824], ["is", 829], ["the", 832], ["third", 836], ["reported", 842], ["case", 851], ["of", 856], ["annular", 859], ["lesions", 867], ["in", 875], ["infectious", 878], ["mononucleosis", 889], [".", 902], ["Dermatologists", 904], ["and", 919], ["other", 923], ["clinicians", 929], ["should", 940], ["be", 947], ["alerted", 950], ["to", 958], ["this", 961], ["special", 966], ["presentation", 974], ["of", 987], ["primary", 990], ["EBV", 998], ["infection", 1002], [".", 1011]]}
{"context": "Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5900db93e2d94cedaf489326063c2ede", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[258, 260], [10, 12], [275, 277]], "char_spans": [[1284, 1290], [55, 61], [1358, 1364]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["Glivec", 19], [")", 25], ["is", 27], ["a", 30], ["selective", 32], ["inhibitor", 42], ["of", 52], ["bcr", 55], ["-", 58], ["abl", 59], ["tyrosine", 63], ["kinase", 72], [",", 78], ["the", 80], ["product", 84], ["of", 92], ["the", 95], ["Philadelphia", 99], ["chromosome", 112], [",", 122], ["which", 124], ["is", 130], ["the", 133], ["hallmark", 137], ["of", 146], ["chronic", 149], ["myeloid", 157], ["leukaemia", 165], ["(", 175], ["CML", 176], [")", 179], [".", 180], ["With", 182], ["imatinib", 187], [",", 195], ["complete", 197], ["cytogenetic", 206], ["response", 218], ["(", 227], ["CCR", 228], [")", 231], ["can", 233], ["be", 237], ["achieved", 240], ["in", 249], ["over", 252], ["70", 257], ["%", 259], ["of", 261], ["newly", 264], ["diagnosed", 270], ["patients", 280], ["with", 289], ["CML", 294], [".", 297], ["However", 299], [",", 306], ["the", 308], ["optimal", 312], ["long", 320], ["-", 324], ["term", 325], ["management", 330], ["of", 341], ["patients", 344], ["who", 353], ["achieve", 357], ["CCR", 365], ["after", 369], ["imatinib", 375], ["is", 384], ["unknown", 387], [".", 394], ["With", 396], ["longer", 401], ["follow", 408], ["-", 414], ["up", 415], [",", 417], ["it", 419], ["is", 422], ["anticipated", 425], ["that", 437], ["some", 442], ["patients", 447], ["are", 456], ["likely", 460], ["to", 467], ["progress", 470], ["and", 479], ["become", 483], ["candidates", 490], ["for", 501], ["autologous", 505], ["transplantation", 516], [".", 531], ["We", 533], ["studied", 536], ["filgrastim", 544], ["(", 555], ["r", 556], ["-", 557], ["metHuG", 558], ["-", 564], ["CSF", 565], [")", 568], ["mobilisation", 570], ["of", 583], ["peripheral", 586], ["blood", 597], ["stem", 603], ["cells", 608], ["(", 614], ["PBSC", 615], [")", 619], ["in", 621], ["32", 624], ["patients", 627], ["who", 636], ["have", 640], ["achieved", 645], ["CCR", 654], ["with", 658], ["imatinib", 663], [".", 671], ["Our", 673], ["data", 677], ["demonstrate", 682], ["that", 694], ["(", 699], ["1", 700], [")", 701], ["the", 703], ["target", 707], ["CD34(+", 714], [")", 720], ["cell", 722], ["yields", 727], ["of", 734], [">", 737], ["/=2.0", 738], ["x", 744], ["10(6)/kg", 746], ["were", 755], ["attained", 760], ["with", 769], ["filgrastim", 774], ["10", 785], ["microg", 788], ["/", 794], ["kg", 795], ["/", 797], ["day", 798], [",", 801], ["in", 803], ["9/18", 806], ["(", 811], ["50", 812], ["%", 814], [")", 815], ["of", 817], ["patients", 820], ["during", 829], ["uninterrupted", 836], ["imatinib", 850], ["therapy", 859], [",", 866], ["and", 868], ["in", 872], ["10/14", 875], ["(", 881], ["70", 882], ["%", 884], [")", 885], ["when", 887], ["imatinib", 892], ["was", 901], ["temporarily", 905], ["withheld", 917], [".", 925], ["The", 927], ["median", 931], ["CD34(+", 938], [")", 944], ["cell", 946], ["yield", 951], ["per", 957], ["aphaeresis", 961], ["was", 972], ["0.70", 976], ["x", 981], ["10(6)/kg", 983], ["(", 992], ["range", 993], ["0.14", 999], ["-", 1003], ["2.18", 1004], [")", 1008], ["and", 1010], ["2.90", 1014], ["x", 1019], ["10(6)/kg", 1021], ["(", 1030], ["range", 1031], ["0.15", 1037], ["-", 1041], ["8.71", 1042], [")", 1046], ["in", 1048], ["the", 1051], ["two", 1055], ["groups", 1059], [",", 1065], ["respectively", 1067], ["(", 1080], ["P&<0.005", 1081], [")", 1089], [".", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["The", 1096], ["cell", 1100], ["yields", 1105], ["did", 1112], ["not", 1116], ["correlate", 1120], ["with", 1130], ["the", 1135], ["duration", 1139], ["of", 1148], ["imatinib", 1151], ["administration", 1160], [".", 1174], ["(", 1176], ["3", 1177], [")", 1178], ["There", 1180], ["was", 1186], ["no", 1190], ["impact", 1193], ["of", 1200], ["the", 1203], ["mobilisation", 1207], ["procedure", 1220], ["on", 1230], ["the", 1233], ["level", 1237], ["of", 1243], ["leukaemia", 1246], ["as", 1256], ["measured", 1259], ["by", 1268], ["serial", 1271], ["blood", 1278], ["bcr", 1284], ["-", 1287], ["abl", 1288], ["levels", 1292], ["using", 1299], ["real", 1305], ["-", 1309], ["time", 1310], ["quantitative", 1315], ["PCR", 1328], ["with", 1332], ["either", 1337], ["protocol", 1344], [".", 1352], ["(", 1354], ["4", 1355], [")", 1356], ["bcr", 1358], ["-", 1361], ["abl", 1362], ["remained", 1366], ["detectable", 1375], ["at", 1386], ["low", 1389], ["levels", 1393], ["in", 1400], ["the", 1403], ["harvests", 1407], ["in", 1416], ["most", 1419], ["but", 1424], ["not", 1428], ["all", 1432], ["patients", 1436], [".", 1444], ["In", 1446], ["conclusion", 1449], [",", 1459], ["filgrastim", 1461], ["can", 1472], ["safely", 1476], ["be", 1483], ["used", 1486], ["to", 1491], ["mobilise", 1494], ["PBSC", 1503], ["in", 1508], ["patients", 1511], ["who", 1520], ["have", 1524], ["achieved", 1529], ["CCR", 1538], ["with", 1542], ["imatinib", 1547], [",", 1555], ["but", 1557], ["CD34(+", 1561], [")", 1567], ["cell", 1569], ["yields", 1574], ["are", 1581], ["significantly", 1585], ["improved", 1599], ["when", 1608], ["imatinib", 1613], ["is", 1622], ["temporarily", 1625], ["withheld", 1637], [".", 1645]]}
{"context": "The proliferation and migration of vascular smooth muscle cells (VSMCs) in the intima of an artery, known as intimal hyperplasia, is an important component of cardiovascular diseases. This is seen most clearly in the case of in-stent restenosis, where drug eluting stents are used to deliver agents that prevent VSMC proliferation and migration. One class of agents that are highly effective in the prevention of in-stent restenosis is the mammalian Target of Rapamycin (mTOR) inhibitors. Inhibition of mTOR blocks protein synthesis, cell cycle progression, and cell migration. Key to the effects on cell cycle progression and cell migration is the inhibition of mTOR-mediated degradation of p27Kip1 protein. p27Kip1 is a cyclin dependent kinase inhibitor that is elevated in quiescent VSMCs and inhibits the G1 to S phase transition and cell migration. Under normal conditions, vascular injury promotes degradation of p27Kip1 protein in an mTOR dependent manner. Recent reports from our lab suggest that in the presence of diabetes mellitus, elevation of extracellular signal response kinase activity may promote decreased p27Kip1 mRNA and produce a relative resistance to mTOR inhibition. Here we review these findings and their relevance to designing treatments for cardiovascular disease in the presence of diabetes mellitus.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "4512014da03b487ba5925f69cc357394", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[80, 83]], "char_spans": [[440, 468]]}]}], "context_tokens": [["The", 0], ["proliferation", 4], ["and", 18], ["migration", 22], ["of", 32], ["vascular", 35], ["smooth", 44], ["muscle", 51], ["cells", 58], ["(", 64], ["VSMCs", 65], [")", 70], ["in", 72], ["the", 75], ["intima", 79], ["of", 86], ["an", 89], ["artery", 92], [",", 98], ["known", 100], ["as", 106], ["intimal", 109], ["hyperplasia", 117], [",", 128], ["is", 130], ["an", 133], ["important", 136], ["component", 146], ["of", 156], ["cardiovascular", 159], ["diseases", 174], [".", 182], ["This", 184], ["is", 189], ["seen", 192], ["most", 197], ["clearly", 202], ["in", 210], ["the", 213], ["case", 217], ["of", 222], ["in", 225], ["-", 227], ["stent", 228], ["restenosis", 234], [",", 244], ["where", 246], ["drug", 252], ["eluting", 257], ["stents", 265], ["are", 272], ["used", 276], ["to", 281], ["deliver", 284], ["agents", 292], ["that", 299], ["prevent", 304], ["VSMC", 312], ["proliferation", 317], ["and", 331], ["migration", 335], [".", 344], ["One", 346], ["class", 350], ["of", 356], ["agents", 359], ["that", 366], ["are", 371], ["highly", 375], ["effective", 382], ["in", 392], ["the", 395], ["prevention", 399], ["of", 410], ["in", 413], ["-", 415], ["stent", 416], ["restenosis", 422], ["is", 433], ["the", 436], ["mammalian", 440], ["Target", 450], ["of", 457], ["Rapamycin", 460], ["(", 470], ["mTOR", 471], [")", 475], ["inhibitors", 477], [".", 487], ["Inhibition", 489], ["of", 500], ["mTOR", 503], ["blocks", 508], ["protein", 515], ["synthesis", 523], [",", 532], ["cell", 534], ["cycle", 539], ["progression", 545], [",", 556], ["and", 558], ["cell", 562], ["migration", 567], [".", 576], ["Key", 578], ["to", 582], ["the", 585], ["effects", 589], ["on", 597], ["cell", 600], ["cycle", 605], ["progression", 611], ["and", 623], ["cell", 627], ["migration", 632], ["is", 642], ["the", 645], ["inhibition", 649], ["of", 660], ["mTOR", 663], ["-", 667], ["mediated", 668], ["degradation", 677], ["of", 689], ["p27Kip1", 692], ["protein", 700], [".", 707], ["p27Kip1", 709], ["is", 717], ["a", 720], ["cyclin", 722], ["dependent", 729], ["kinase", 739], ["inhibitor", 746], ["that", 756], ["is", 761], ["elevated", 764], ["in", 773], ["quiescent", 776], ["VSMCs", 786], ["and", 792], ["inhibits", 796], ["the", 805], ["G1", 809], ["to", 812], ["S", 815], ["phase", 817], ["transition", 823], ["and", 834], ["cell", 838], ["migration", 843], [".", 852], ["Under", 854], ["normal", 860], ["conditions", 867], [",", 877], ["vascular", 879], ["injury", 888], ["promotes", 895], ["degradation", 904], ["of", 916], ["p27Kip1", 919], ["protein", 927], ["in", 935], ["an", 938], ["mTOR", 941], ["dependent", 946], ["manner", 956], [".", 962], ["Recent", 964], ["reports", 971], ["from", 979], ["our", 984], ["lab", 988], ["suggest", 992], ["that", 1000], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["diabetes", 1024], ["mellitus", 1033], [",", 1041], ["elevation", 1043], ["of", 1053], ["extracellular", 1056], ["signal", 1070], ["response", 1077], ["kinase", 1086], ["activity", 1093], ["may", 1102], ["promote", 1106], ["decreased", 1114], ["p27Kip1", 1124], ["mRNA", 1132], ["and", 1137], ["produce", 1141], ["a", 1149], ["relative", 1151], ["resistance", 1160], ["to", 1171], ["mTOR", 1174], ["inhibition", 1179], [".", 1189], ["Here", 1191], ["we", 1196], ["review", 1199], ["these", 1206], ["findings", 1212], ["and", 1221], ["their", 1225], ["relevance", 1231], ["to", 1241], ["designing", 1244], ["treatments", 1254], ["for", 1265], ["cardiovascular", 1269], ["disease", 1284], ["in", 1292], ["the", 1295], ["presence", 1299], ["of", 1308], ["diabetes", 1311], ["mellitus", 1320], [".", 1328]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "Nox3, a member of the superoxide-producing NADPH oxidase (Nox) family, participates in otoconia formation in mouse inner ears, which is required for perception of balance and gravity. The activity of other Nox enzymes such as gp91(phox)/Nox2 and Nox1 is known to absolutely require both an organizer protein (p47(phox) or Noxo1) andanactivatorprotein (p67(phox) or Noxa1); for the p47(phox)-dependent activation of these oxidases, treatment of cells with stimulants such as phorbol 12-myristate 13-acetate is also indispensable. Here we show that ectopic expression of Nox3 in various types of cells leads to phorbol 12-myristate 13-acetate-independent constitutive production of a substantial amount of superoxide under the conditions where gp91(phox) and Nox1 fail to generate superoxide, i.e. in the absence of the oxidase organizers and activators. Nox3 likely forms a functional complex with p22(phox); Nox3 physically interacts with and stabilizes p22(phox), and the Nox3-dependent superoxide production is totally dependent on p22(phox). The organizers p47(phox) and Noxo1 are capable of enhancing the superoxide production by Nox3 in the absence of the activators, and the enhancement requires the interaction of the organizers with p22(phox), further indicating a link between Nox3 and p22(phox). The p47(phox)-enhanced Nox3 activity is further facilitated by p67(phox) or Noxa1, whereas the activators cancel the Noxo1-induced enhancement. On the other hand, the small GTPase Rac, essential for the gp91(phox) activity, is likely dispensable to the Nox3 system. Thus Nox3 functions together with p22(phox) as an enzyme constitutively producing superoxide, which can be distinctly regulated by combinatorial use of the organizers and activators.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "e662d0daac3047e6bbb879f08d0a56eb", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[45, 45], [126, 126]], "char_spans": [[246, 249], [757, 760]]}]}], "context_tokens": [["Nox3", 0], [",", 4], ["a", 6], ["member", 8], ["of", 15], ["the", 18], ["superoxide", 22], ["-", 32], ["producing", 33], ["NADPH", 43], ["oxidase", 49], ["(", 57], ["Nox", 58], [")", 61], ["family", 63], [",", 69], ["participates", 71], ["in", 84], ["otoconia", 87], ["formation", 96], ["in", 106], ["mouse", 109], ["inner", 115], ["ears", 121], [",", 125], ["which", 127], ["is", 133], ["required", 136], ["for", 145], ["perception", 149], ["of", 160], ["balance", 163], ["and", 171], ["gravity", 175], [".", 182], ["The", 184], ["activity", 188], ["of", 197], ["other", 200], ["Nox", 206], ["enzymes", 210], ["such", 218], ["as", 223], ["gp91(phox)/Nox2", 226], ["and", 242], ["Nox1", 246], ["is", 251], ["known", 254], ["to", 260], ["absolutely", 263], ["require", 274], ["both", 282], ["an", 287], ["organizer", 290], ["protein", 300], ["(", 308], ["p47(phox", 309], [")", 317], ["or", 319], ["Noxo1", 322], [")", 327], ["andanactivatorprotein", 329], ["(", 351], ["p67(phox", 352], [")", 360], ["or", 362], ["Noxa1", 365], [")", 370], [";", 371], ["for", 373], ["the", 377], ["p47(phox)-dependent", 381], ["activation", 401], ["of", 412], ["these", 415], ["oxidases", 421], [",", 429], ["treatment", 431], ["of", 441], ["cells", 444], ["with", 450], ["stimulants", 455], ["such", 466], ["as", 471], ["phorbol", 474], ["12-myristate", 482], ["13-acetate", 495], ["is", 506], ["also", 509], ["indispensable", 514], [".", 527], ["Here", 529], ["we", 534], ["show", 537], ["that", 542], ["ectopic", 547], ["expression", 555], ["of", 566], ["Nox3", 569], ["in", 574], ["various", 577], ["types", 585], ["of", 591], ["cells", 594], ["leads", 600], ["to", 606], ["phorbol", 609], ["12-myristate", 617], ["13-acetate", 630], ["-", 640], ["independent", 641], ["constitutive", 653], ["production", 666], ["of", 677], ["a", 680], ["substantial", 682], ["amount", 694], ["of", 701], ["superoxide", 704], ["under", 715], ["the", 721], ["conditions", 725], ["where", 736], ["gp91(phox", 742], [")", 751], ["and", 753], ["Nox1", 757], ["fail", 762], ["to", 767], ["generate", 770], ["superoxide", 779], [",", 789], ["i.e.", 791], ["in", 796], ["the", 799], ["absence", 803], ["of", 811], ["the", 814], ["oxidase", 818], ["organizers", 826], ["and", 837], ["activators", 841], [".", 851], ["Nox3", 853], ["likely", 858], ["forms", 865], ["a", 871], ["functional", 873], ["complex", 884], ["with", 892], ["p22(phox", 897], [")", 905], [";", 906], ["Nox3", 908], ["physically", 913], ["interacts", 924], ["with", 934], ["and", 939], ["stabilizes", 943], ["p22(phox", 954], [")", 962], [",", 963], ["and", 965], ["the", 969], ["Nox3-dependent", 973], ["superoxide", 988], ["production", 999], ["is", 1010], ["totally", 1013], ["dependent", 1021], ["on", 1031], ["p22(phox", 1034], [")", 1042], [".", 1043], ["The", 1045], ["organizers", 1049], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["Noxo1", 1074], ["are", 1080], ["capable", 1084], ["of", 1092], ["enhancing", 1095], ["the", 1105], ["superoxide", 1109], ["production", 1120], ["by", 1131], ["Nox3", 1134], ["in", 1139], ["the", 1142], ["absence", 1146], ["of", 1154], ["the", 1157], ["activators", 1161], [",", 1171], ["and", 1173], ["the", 1177], ["enhancement", 1181], ["requires", 1193], ["the", 1202], ["interaction", 1206], ["of", 1218], ["the", 1221], ["organizers", 1225], ["with", 1236], ["p22(phox", 1241], [")", 1249], [",", 1250], ["further", 1252], ["indicating", 1260], ["a", 1271], ["link", 1273], ["between", 1278], ["Nox3", 1286], ["and", 1291], ["p22(phox", 1295], [")", 1303], [".", 1304], ["The", 1306], ["p47(phox)-enhanced", 1310], ["Nox3", 1329], ["activity", 1334], ["is", 1343], ["further", 1346], ["facilitated", 1354], ["by", 1366], ["p67(phox", 1369], [")", 1377], ["or", 1379], ["Noxa1", 1382], [",", 1387], ["whereas", 1389], ["the", 1397], ["activators", 1401], ["cancel", 1412], ["the", 1419], ["Noxo1-induced", 1423], ["enhancement", 1437], [".", 1448], ["On", 1450], ["the", 1453], ["other", 1457], ["hand", 1463], [",", 1467], ["the", 1469], ["small", 1473], ["GTPase", 1479], ["Rac", 1486], [",", 1489], ["essential", 1491], ["for", 1501], ["the", 1505], ["gp91(phox", 1509], [")", 1518], ["activity", 1520], [",", 1528], ["is", 1530], ["likely", 1533], ["dispensable", 1540], ["to", 1552], ["the", 1555], ["Nox3", 1559], ["system", 1564], [".", 1570], ["Thus", 1572], ["Nox3", 1577], ["functions", 1582], ["together", 1592], ["with", 1601], ["p22(phox", 1606], [")", 1614], ["as", 1616], ["an", 1619], ["enzyme", 1622], ["constitutively", 1629], ["producing", 1644], ["superoxide", 1654], [",", 1664], ["which", 1666], ["can", 1672], ["be", 1676], ["distinctly", 1679], ["regulated", 1690], ["by", 1700], ["combinatorial", 1703], ["use", 1717], ["of", 1721], ["the", 1724], ["organizers", 1728], ["and", 1739], ["activators", 1743], [".", 1753]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/d) is only one third of its maximum tolerated dose, whereas the dose of erlotinib (150 mg/d) is at its maximum tolerated dose. In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC. To study the inhibitory concentrations of gefitinib and erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255, PC-9, and H1975) to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI. Gefitinib and erlotinib generated similar inhibitory curves across our panel of EGFR-mutated NSCLC cell lines with overlapping mean 50% inhibitory concentration 95% confidence intervals for HCC827, PC-9, and H1975. Both drugs also displayed a high degree of correlation in mean 50% inhibitory concentration (Pearson's r = 0.99, p = 0.0417). Of the seven patients, five patients (71.5%) had partial responses to erlotinib 25 mg/d. Median progression-free survival was 17 months (95% confidence interval, 6-35 months). Toxicities were minimal, with only two (28.5%) patients having a rash and none experiencing (0%) diarrhea. In NSCLC cell lines, gefitinib and erlotinib have similar inhibitory profiles. In patients with NSCLC and EGFR-activating mutations, a dose of erlotinib 25 mg/d (equivalent to gefitinib 250 mg/d) leads to impressive response rates and progression-free survival similar to the growing experience with the approved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d). Identifying prospectively the lowest and clinically active dose ranges of erlotinib and gefitinib will help further to personalize care for patients with tumors harboring EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "2e559521de4543c0bcd36ddc1c47fc44", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[23, 30]], "char_spans": [[121, 164]]}]}], "context_tokens": [["The", 0], ["tyrosine", 4], ["kinase", 13], ["inhibitors", 20], ["(", 31], ["TKIs", 32], [")", 36], ["gefitinib", 38], ["and", 48], ["erlotinib", 52], ["are", 62], ["effective", 66], ["in", 76], ["non", 79], ["-", 82], ["small", 83], ["cell", 89], ["lung", 94], ["cancers", 99], ["(", 107], ["NSCLCs", 108], [")", 114], ["with", 116], ["epidermal", 121], ["growth", 131], ["factor", 138], ["receptor", 145], ["(", 154], ["EGFR", 155], [")", 159], ["gene", 161], ["mutations", 166], [".", 175], ["The", 177], ["usual", 181], ["clinical", 187], ["dose", 196], ["of", 201], ["gefitinib", 204], ["(", 214], ["250", 215], ["mg", 219], ["/", 221], ["d", 222], [")", 223], ["is", 225], ["only", 228], ["one", 233], ["third", 237], ["of", 243], ["its", 246], ["maximum", 250], ["tolerated", 258], ["dose", 268], [",", 272], ["whereas", 274], ["the", 282], ["dose", 286], ["of", 291], ["erlotinib", 294], ["(", 304], ["150", 305], ["mg", 309], ["/", 311], ["d", 312], [")", 313], ["is", 315], ["at", 318], ["its", 321], ["maximum", 325], ["tolerated", 333], ["dose", 343], [".", 347], ["In", 349], ["NSCLC", 352], ["cell", 358], ["lines", 363], [",", 368], ["both", 370], ["TKIs", 375], ["have", 380], ["similar", 385], ["micromolar", 393], ["inhibitory", 404], ["concentrations", 415], [".", 429], ["We", 431], ["explored", 434], ["whether", 443], ["erlotinib", 451], ["at", 461], ["25", 464], ["mg", 467], ["/", 469], ["d", 470], ["(", 472], ["trough", 473], ["serum", 480], ["concentration", 486], ["similar", 500], ["to", 508], ["gefitinib", 511], ["250", 521], ["mg", 525], ["/", 527], ["d", 528], [")", 529], ["would", 531], ["be", 537], ["efficacious", 540], ["in", 552], ["EGFR", 555], ["-", 559], ["mutated", 560], ["NSCLC", 568], [".", 573], ["To", 575], ["study", 578], ["the", 584], ["inhibitory", 588], ["concentrations", 599], ["of", 614], ["gefitinib", 617], ["and", 627], ["erlotinib", 631], [",", 640], ["we", 642], ["exposed", 645], ["EGFR", 653], ["-", 657], ["mutated", 658], ["cell", 666], ["lines", 671], ["(", 677], ["HCC827", 678], [",", 684], ["H3255", 686], [",", 691], ["PC-9", 693], [",", 697], ["and", 699], ["H1975", 703], [")", 708], ["to", 710], ["increasing", 713], ["concentrations", 724], ["of", 739], ["these", 742], ["TKIs", 748], [".", 752], ["Further", 754], ["on", 762], [",", 764], ["we", 766], ["performed", 769], ["a", 779], ["retrospective", 781], ["evaluation", 795], ["of", 806], ["seven", 809], ["patients", 815], ["with", 824], ["advanced", 829], ["EGFR", 838], ["-", 842], ["mutated", 843], ["(", 851], ["exon", 852], ["19", 857], ["deletions", 860], ["and", 870], ["L858R", 874], [")", 879], ["NSCLC", 881], ["that", 887], ["were", 892], ["given", 897], ["erlotinib", 903], ["at", 913], ["25", 916], ["mg", 919], ["/", 921], ["d", 922], ["as", 924], ["their", 927], ["first", 933], ["EGFR", 939], ["TKI", 944], [".", 947], ["Gefitinib", 949], ["and", 959], ["erlotinib", 963], ["generated", 973], ["similar", 983], ["inhibitory", 991], ["curves", 1002], ["across", 1009], ["our", 1016], ["panel", 1020], ["of", 1026], ["EGFR", 1029], ["-", 1033], ["mutated", 1034], ["NSCLC", 1042], ["cell", 1048], ["lines", 1053], ["with", 1059], ["overlapping", 1064], ["mean", 1076], ["50", 1081], ["%", 1083], ["inhibitory", 1085], ["concentration", 1096], ["95", 1110], ["%", 1112], ["confidence", 1114], ["intervals", 1125], ["for", 1135], ["HCC827", 1139], [",", 1145], ["PC-9", 1147], [",", 1151], ["and", 1153], ["H1975", 1157], [".", 1162], ["Both", 1164], ["drugs", 1169], ["also", 1175], ["displayed", 1180], ["a", 1190], ["high", 1192], ["degree", 1197], ["of", 1204], ["correlation", 1207], ["in", 1219], ["mean", 1222], ["50", 1227], ["%", 1229], ["inhibitory", 1231], ["concentration", 1242], ["(", 1256], ["Pearson", 1257], ["'s", 1264], ["r", 1267], ["=", 1269], ["0.99", 1271], [",", 1275], ["p", 1277], ["=", 1279], ["0.0417", 1281], [")", 1287], [".", 1288], ["Of", 1290], ["the", 1293], ["seven", 1297], ["patients", 1303], [",", 1311], ["five", 1313], ["patients", 1318], ["(", 1327], ["71.5", 1328], ["%", 1332], [")", 1333], ["had", 1335], ["partial", 1339], ["responses", 1347], ["to", 1357], ["erlotinib", 1360], ["25", 1370], ["mg", 1373], ["/", 1375], ["d", 1376], [".", 1377], ["Median", 1379], ["progression", 1386], ["-", 1397], ["free", 1398], ["survival", 1403], ["was", 1412], ["17", 1416], ["months", 1419], ["(", 1426], ["95", 1427], ["%", 1429], ["confidence", 1431], ["interval", 1442], [",", 1450], ["6", 1452], ["-", 1453], ["35", 1454], ["months", 1457], [")", 1463], [".", 1464], ["Toxicities", 1466], ["were", 1477], ["minimal", 1482], [",", 1489], ["with", 1491], ["only", 1496], ["two", 1501], ["(", 1505], ["28.5", 1506], ["%", 1510], [")", 1511], ["patients", 1513], ["having", 1522], ["a", 1529], ["rash", 1531], ["and", 1536], ["none", 1540], ["experiencing", 1545], ["(", 1558], ["0", 1559], ["%", 1560], [")", 1561], ["diarrhea", 1563], [".", 1571], ["In", 1573], ["NSCLC", 1576], ["cell", 1582], ["lines", 1587], [",", 1592], ["gefitinib", 1594], ["and", 1604], ["erlotinib", 1608], ["have", 1618], ["similar", 1623], ["inhibitory", 1631], ["profiles", 1642], [".", 1650], ["In", 1652], ["patients", 1655], ["with", 1664], ["NSCLC", 1669], ["and", 1675], ["EGFR", 1679], ["-", 1683], ["activating", 1684], ["mutations", 1695], [",", 1704], ["a", 1706], ["dose", 1708], ["of", 1713], ["erlotinib", 1716], ["25", 1726], ["mg", 1729], ["/", 1731], ["d", 1732], ["(", 1734], ["equivalent", 1735], ["to", 1746], ["gefitinib", 1749], ["250", 1759], ["mg", 1763], ["/", 1765], ["d", 1766], [")", 1767], ["leads", 1769], ["to", 1775], ["impressive", 1778], ["response", 1789], ["rates", 1798], ["and", 1804], ["progression", 1808], ["-", 1819], ["free", 1820], ["survival", 1825], ["similar", 1834], ["to", 1842], ["the", 1845], ["growing", 1849], ["experience", 1857], ["with", 1868], ["the", 1873], ["approved", 1877], ["doses", 1886], ["of", 1892], ["gefitinib", 1895], ["(", 1905], ["250", 1906], ["mg", 1910], ["/", 1912], ["d", 1913], [")", 1914], ["and", 1916], ["erlotinib", 1920], ["(", 1930], ["150", 1931], ["mg", 1935], ["/", 1937], ["d", 1938], [")", 1939], [".", 1940], ["Identifying", 1942], ["prospectively", 1954], ["the", 1968], ["lowest", 1972], ["and", 1979], ["clinically", 1983], ["active", 1994], ["dose", 2001], ["ranges", 2006], ["of", 2013], ["erlotinib", 2016], ["and", 2026], ["gefitinib", 2030], ["will", 2040], ["help", 2045], ["further", 2050], ["to", 2058], ["personalize", 2061], ["care", 2073], ["for", 2078], ["patients", 2082], ["with", 2091], ["tumors", 2096], ["harboring", 2103], ["EGFR", 2113], ["mutations", 2118], [".", 2127]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "Opioid overdose is rarely the primary cause of altered mental status in cancer patients receiving opioid therapy. The inappropriate administration of naloxone to reverse an abnormal mental status can cause severe withdrawal symptoms and pain. To illustrate this problem, we report the case of a patient inappropriately treated with naloxone and the results of a retrospective review of the medical records of 15 consecutive patients with cancer treated with naloxone in the emergency department over a 5-month period. We offer guidelines for a more thoughtful approach to the management of patients with cancer who present with encephalopathy.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bbac40c6eb3c41cd806dbc42ad8f54dc", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[52, 52], [72, 72], [22, 22]], "char_spans": [[332, 339], [458, 465], [150, 157]]}]}], "context_tokens": [["Opioid", 0], ["overdose", 7], ["is", 16], ["rarely", 19], ["the", 26], ["primary", 30], ["cause", 38], ["of", 44], ["altered", 47], ["mental", 55], ["status", 62], ["in", 69], ["cancer", 72], ["patients", 79], ["receiving", 88], ["opioid", 98], ["therapy", 105], [".", 112], ["The", 114], ["inappropriate", 118], ["administration", 132], ["of", 147], ["naloxone", 150], ["to", 159], ["reverse", 162], ["an", 170], ["abnormal", 173], ["mental", 182], ["status", 189], ["can", 196], ["cause", 200], ["severe", 206], ["withdrawal", 213], ["symptoms", 224], ["and", 233], ["pain", 237], [".", 241], ["To", 243], ["illustrate", 246], ["this", 257], ["problem", 262], [",", 269], ["we", 271], ["report", 274], ["the", 281], ["case", 285], ["of", 290], ["a", 293], ["patient", 295], ["inappropriately", 303], ["treated", 319], ["with", 327], ["naloxone", 332], ["and", 341], ["the", 345], ["results", 349], ["of", 357], ["a", 360], ["retrospective", 362], ["review", 376], ["of", 383], ["the", 386], ["medical", 390], ["records", 398], ["of", 406], ["15", 409], ["consecutive", 412], ["patients", 424], ["with", 433], ["cancer", 438], ["treated", 445], ["with", 453], ["naloxone", 458], ["in", 467], ["the", 470], ["emergency", 474], ["department", 484], ["over", 495], ["a", 500], ["5-month", 502], ["period", 510], [".", 516], ["We", 518], ["offer", 521], ["guidelines", 527], ["for", 538], ["a", 542], ["more", 544], ["thoughtful", 549], ["approach", 560], ["to", 569], ["the", 572], ["management", 576], ["of", 587], ["patients", 590], ["with", 599], ["cancer", 604], ["who", 611], ["present", 615], ["with", 623], ["encephalopathy", 628], [".", 642]]}
{"context": "Nucleotide excision repair (NER) is a multistep process capable to remove a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires more than 30 proteins to perform the different steps, i.e. recognition of DNA damage, single strand incisions and excision of the lesion-containing DNA fragment and DNA repair synthesis/ligation. NER can operate via two subpathways: global genome repair (GGR) and a specialized pathway coupled to active transcription (transcription-coupled repair, TCR) and directed to DNA lesions in the transcribed strand of active genes. Both in vivo as well as in cultured cells the fast removal of transcription blocking lesions by TCR is crucial to escape from lethal effects of inhibited transcription inhibition The most delicate step in NER is the recognition of the DNA lesions in their different chromatin context and the mechanism of damage recognition in GGR and TCR is principally different and requires specific proteins. In GGR, the XPC-HR23B is essential for the formation of the incision complex. In TCR the Cockayne syndrome (CS) gene products are key players in the recognition of a stalled RNA polymerase the presumed signaling structure for repair of transcribed strands. In this study, we show that the extent of recovery of UV-inhibited transcription and TCR strictly depends on the amount of CSB protein as well as the amount of DNA damage present in the cell. This indicates that the ratio between DNA damage frequency and CSB protein concentration in the cell is rather critical for acute cellular response, i.e. recovery of inhibited transcription upon DNA damage infliction, and hence cellular survival.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "dfc374abfd1246c8bd30686662c51d05", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[582, 599]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["multistep", 38], ["process", 48], ["capable", 56], ["to", 64], ["remove", 67], ["a", 74], ["variety", 76], ["of", 84], ["DNA", 87], ["distorting", 91], ["lesions", 102], ["from", 110], ["prokaryotic", 115], ["and", 127], ["eukaryotic", 131], ["genomes", 142], [".", 149], ["In", 151], ["eukaryotic", 154], ["cells", 165], [",", 170], ["the", 172], ["process", 176], ["requires", 184], ["more", 193], ["than", 198], ["30", 203], ["proteins", 206], ["to", 215], ["perform", 218], ["the", 226], ["different", 230], ["steps", 240], [",", 245], ["i.e.", 247], ["recognition", 252], ["of", 264], ["DNA", 267], ["damage", 271], [",", 277], ["single", 279], ["strand", 286], ["incisions", 293], ["and", 303], ["excision", 307], ["of", 316], ["the", 319], ["lesion", 323], ["-", 329], ["containing", 330], ["DNA", 341], ["fragment", 345], ["and", 354], ["DNA", 358], ["repair", 362], ["synthesis", 369], ["/", 378], ["ligation", 379], [".", 387], ["NER", 389], ["can", 393], ["operate", 397], ["via", 405], ["two", 409], ["subpathways", 413], [":", 424], ["global", 426], ["genome", 433], ["repair", 440], ["(", 447], ["GGR", 448], [")", 451], ["and", 453], ["a", 457], ["specialized", 459], ["pathway", 471], ["coupled", 479], ["to", 487], ["active", 490], ["transcription", 497], ["(", 511], ["transcription", 512], ["-", 525], ["coupled", 526], ["repair", 534], [",", 540], ["TCR", 542], [")", 545], ["and", 547], ["directed", 551], ["to", 560], ["DNA", 563], ["lesions", 567], ["in", 575], ["the", 578], ["transcribed", 582], ["strand", 594], ["of", 601], ["active", 604], ["genes", 611], [".", 616], ["Both", 618], ["in", 623], ["vivo", 626], ["as", 631], ["well", 634], ["as", 639], ["in", 642], ["cultured", 645], ["cells", 654], ["the", 660], ["fast", 664], ["removal", 669], ["of", 677], ["transcription", 680], ["blocking", 694], ["lesions", 703], ["by", 711], ["TCR", 714], ["is", 718], ["crucial", 721], ["to", 729], ["escape", 732], ["from", 739], ["lethal", 744], ["effects", 751], ["of", 759], ["inhibited", 762], ["transcription", 772], ["inhibition", 786], ["The", 797], ["most", 801], ["delicate", 806], ["step", 815], ["in", 820], ["NER", 823], ["is", 827], ["the", 830], ["recognition", 834], ["of", 846], ["the", 849], ["DNA", 853], ["lesions", 857], ["in", 865], ["their", 868], ["different", 874], ["chromatin", 884], ["context", 894], ["and", 902], ["the", 906], ["mechanism", 910], ["of", 920], ["damage", 923], ["recognition", 930], ["in", 942], ["GGR", 945], ["and", 949], ["TCR", 953], ["is", 957], ["principally", 960], ["different", 972], ["and", 982], ["requires", 986], ["specific", 995], ["proteins", 1004], [".", 1012], ["In", 1014], ["GGR", 1017], [",", 1020], ["the", 1022], ["XPC", 1026], ["-", 1029], ["HR23B", 1030], ["is", 1036], ["essential", 1039], ["for", 1049], ["the", 1053], ["formation", 1057], ["of", 1067], ["the", 1070], ["incision", 1074], ["complex", 1083], [".", 1090], ["In", 1092], ["TCR", 1095], ["the", 1099], ["Cockayne", 1103], ["syndrome", 1112], ["(", 1121], ["CS", 1122], [")", 1124], ["gene", 1126], ["products", 1131], ["are", 1140], ["key", 1144], ["players", 1148], ["in", 1156], ["the", 1159], ["recognition", 1163], ["of", 1175], ["a", 1178], ["stalled", 1180], ["RNA", 1188], ["polymerase", 1192], ["the", 1203], ["presumed", 1207], ["signaling", 1216], ["structure", 1226], ["for", 1236], ["repair", 1240], ["of", 1247], ["transcribed", 1250], ["strands", 1262], [".", 1269], ["In", 1271], ["this", 1274], ["study", 1279], [",", 1284], ["we", 1286], ["show", 1289], ["that", 1294], ["the", 1299], ["extent", 1303], ["of", 1310], ["recovery", 1313], ["of", 1322], ["UV", 1325], ["-", 1327], ["inhibited", 1328], ["transcription", 1338], ["and", 1352], ["TCR", 1356], ["strictly", 1360], ["depends", 1369], ["on", 1377], ["the", 1380], ["amount", 1384], ["of", 1391], ["CSB", 1394], ["protein", 1398], ["as", 1406], ["well", 1409], ["as", 1414], ["the", 1417], ["amount", 1421], ["of", 1428], ["DNA", 1431], ["damage", 1435], ["present", 1442], ["in", 1450], ["the", 1453], ["cell", 1457], [".", 1461], ["This", 1463], ["indicates", 1468], ["that", 1478], ["the", 1483], ["ratio", 1487], ["between", 1493], ["DNA", 1501], ["damage", 1505], ["frequency", 1512], ["and", 1522], ["CSB", 1526], ["protein", 1530], ["concentration", 1538], ["in", 1552], ["the", 1555], ["cell", 1559], ["is", 1564], ["rather", 1567], ["critical", 1574], ["for", 1583], ["acute", 1587], ["cellular", 1593], ["response", 1602], [",", 1610], ["i.e.", 1612], ["recovery", 1617], ["of", 1626], ["inhibited", 1629], ["transcription", 1639], ["upon", 1653], ["DNA", 1658], ["damage", 1662], ["infliction", 1669], [",", 1679], ["and", 1681], ["hence", 1685], ["cellular", 1691], ["survival", 1700], [".", 1708]]}
{"context": "Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300 mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300 mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "412a49803a00424099cd84a75d92bd63", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[295, 297], [36, 38], [101, 103], [69, 71], [10, 12], [277, 279], [259, 261]], "char_spans": [[1409, 1415], [172, 178], [515, 521], [362, 368], [48, 54], [1320, 1326], [1221, 1227]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["caused", 34], ["by", 41], ["the", 44], ["BCR", 48], ["-", 51], ["ABL", 52], ["oncogene", 56], [".", 64], ["The", 66], ["Philadelphia", 70], ["chromosome", 83], ["(", 94], ["Ph", 95], [")", 97], ["from", 99], ["a", 104], ["reciprocal", 106], ["translocation", 117], [",", 130], ["t(9;22", 132], [")", 138], ["(", 140], ["q34;q11", 141], [")", 148], ["causes", 150], ["a", 157], ["fusion", 159], ["gene", 166], [",", 170], ["BCR", 172], ["-", 175], ["ABL", 176], [",", 179], ["that", 181], ["encodes", 186], ["a", 194], ["constitutively", 196], ["active", 211], ["tyrosine", 218], ["kinase", 227], [".", 233], ["Treatment", 235], ["of", 245], ["CML", 248], ["by", 252], ["imatinib", 255], ["is", 264], ["effective", 267], ["to", 277], ["control", 280], ["the", 288], ["tyrosyl", 292], ["phosphorylation", 300], ["of", 316], ["the", 319], ["protein", 323], ["related", 331], ["to", 339], ["the", 342], ["cell", 346], ["signaling", 351], [".", 360], ["BCR", 362], ["-", 365], ["ABL", 366], ["mRNA", 370], ["is", 375], ["overexpressed", 378], ["in", 392], ["the", 395], ["minimal", 399], ["residual", 407], ["disease", 416], ["(", 424], ["MRD", 425], [")", 428], [",", 429], ["known", 431], ["as", 437], ["an", 440], ["early", 443], ["sign", 449], ["of", 454], ["relapse", 457], [".", 464], ["Between", 466], ["December", 474], ["2005", 483], ["and", 488], ["June", 492], ["2008", 497], [",", 501], ["we", 503], ["measured", 506], ["BCR", 515], ["-", 518], ["ABL", 519], ["mRNA", 523], ["levels", 528], ["in", 535], ["the", 538], ["bone", 542], ["marrow", 547], ["(", 554], ["BM", 555], [")", 557], ["from", 559], ["patients", 564], ["by", 573], ["quantitative", 576], ["real", 589], ["-", 593], ["time", 594], ["polymerase", 599], ["chain", 610], ["reaction", 616], ["(", 625], ["RQ", 626], ["-", 628], ["PCR", 629], [")", 632], ["in", 634], ["Aomori", 637], ["Prefectural", 644], ["Central", 656], ["Hospital", 664], [".", 672], ["Eighty", 674], ["-", 680], ["six", 681], ["samples", 685], ["from", 693], ["26", 698], ["patients", 701], ["were", 710], ["collected", 715], [".", 724], ["Among", 726], ["the", 732], ["26", 736], ["CML", 739], ["patients", 743], [",", 751], ["11", 753], ["patients", 756], ["(", 765], ["42", 766], ["%", 768], [")", 769], ["were", 771], ["in", 776], ["the", 779], ["pretreatment", 783], ["group", 796], [".", 801], ["Seven", 803], ["(", 809], ["64", 810], ["%", 812], [")", 813], ["of", 815], ["the", 818], ["11", 822], ["patients", 825], ["achieved", 834], ["complete", 843], ["molecular", 852], ["response", 862], ["(", 871], ["CMR", 872], [")", 875], [".", 876], ["In", 878], ["the", 881], ["post", 885], ["-", 889], ["treatment", 890], ["group", 900], ["consisting", 906], ["of", 917], ["the", 920], ["remaining", 924], ["15", 934], ["patients", 937], [",", 945], ["9", 947], ["(", 949], ["60", 950], ["%", 952], [")", 953], ["patients", 955], ["achieved", 964], ["CMR", 973], [".", 976], ["The", 978], ["patients", 982], ["receiving", 991], ["imatinib", 1001], ["at", 1010], ["a", 1013], ["dose", 1015], ["over", 1020], ["300", 1025], ["mg", 1029], ["per", 1032], ["day", 1036], ["required", 1040], ["13", 1049], ["(", 1052], ["6", 1053], ["-", 1054], ["77", 1055], [")", 1057], ["months", 1059], ["[", 1066], ["median", 1067], ["(", 1074], ["range", 1075], [")", 1080], ["]", 1081], ["to", 1083], ["achieve", 1086], ["CMR", 1094], [".", 1097], ["On", 1099], ["the", 1102], ["other", 1106], ["hand", 1112], [",", 1116], ["the", 1118], ["patients", 1122], ["receiving", 1131], ["a", 1141], ["dose", 1143], ["below", 1148], ["300", 1154], ["mg", 1158], ["per", 1161], ["day", 1165], ["required", 1169], ["29.5", 1178], ["(", 1183], ["11", 1184], ["-", 1186], ["84", 1187], [")", 1189], ["months", 1191], ["[", 1198], ["median", 1199], ["(", 1206], ["range)].", 1207], ["When", 1216], ["BCR", 1221], ["-", 1224], ["ABL", 1225], ["mRNA", 1229], ["was", 1234], ["detected", 1238], ["during", 1247], ["the", 1254], ["treatment", 1258], ["course", 1268], ["of", 1275], ["patients", 1278], ["with", 1287], ["CMR", 1292], [",", 1295], ["careful", 1297], ["observation", 1305], ["of", 1317], ["BCR", 1320], ["-", 1323], ["ABL", 1324], ["mRNA", 1328], ["was", 1333], ["useful", 1337], ["for", 1344], ["tracking", 1348], ["the", 1357], ["clinical", 1361], ["course", 1370], ["of", 1377], ["patients", 1380], [".", 1388], ["In", 1390], ["conclusion", 1393], [",", 1403], ["the", 1405], ["BCR", 1409], ["-", 1412], ["ABL", 1413], ["mRNA", 1417], ["level", 1422], ["was", 1428], ["useful", 1432], ["for", 1439], ["monitoring", 1443], ["the", 1454], ["clinical", 1458], ["course", 1467], ["in", 1474], ["26", 1477], ["patients", 1480], ["with", 1489], ["CML", 1494], [".", 1497]]}
{"context": "Spleen tyrosine kinase (Syk) is a cytoplasmic tyrosine kinase involved in signalling in many of the cells that drive immune inflammation. The development of small molecules that inhibit Syk kinase may change the way we treat disorders such as rheumatoid arthritis (RA), as well as a range of other inflammatory diseases. Fostamatinib (R-788) is an orally bioavailable small molecule. It is the prodrug of R406, which is a potent Syk inhibitor. Fostamatinib was developed because it has more favourable physiochemical properties. It is rapidly converted to R406 by intestinal enterocytes. It has been evaluated in experimental models of RA, such as collagen-induced arthritis. In these models, fostamatinib suppressed clinical arthritis, bone erosions, pannus formation and synovitis. A phase II programme with fostamatinib has largely been completed. Three key trials have been published, lasting 12-26 weeks and each enrolling 189-457 patients (875 in total). All these trials involved placebo therapy and patients continued to receive methotrexate in addition to active treatment with fostamatinib. The first dose-ranging trial evaluated three treatment doses in RA patients who had not fully responded to methotrexate therapy. The second trial compared two treatment doses in patients who had not responded to methotrexate therapy. The third trial compared a single treatment dose with placebo in patients who had not responded to biological therapy. The primary outcome measure was the number of patients achieving American College of Rheumatology (ACR) 20% (ACR20) responses. Placebo ACR20 response rates in all three trials were similar (35-38%). All three trials involved one treatment arm receiving fostamatinib 100 mg twice daily; ACR20 responses with this active treatment ranged from 38% to 67%. A meta-analysis of ACR responses in these trials, using responses to the highest dose in each trial for comparisons with placebo therapy in a random effects model, showed a borderline benefit with ACR20 responses. There were more significant differences with ACR50 and ACR70 responses. The reason that this meta-analysis was not more strongly positive is that the third trial, which evaluated patients who had failed to respond to biological treatments, gave negative results. Individual ACR response components, such as changes in swollen joint counts, showed significant differences in the first two trials, but there were no definite treatment benefits in the third trial. Overall, the differences were significant in a meta-analysis of all three trials. The most important adverse reactions were diarrhoea, neutropenia and raised ALT levels, which all showed significant excesses with active treatment compared with placebo. Too few patients have been studied for a definitive safety profile to be known. Overall, the results of the phase II trials were sufficiently encouraging for a phase III programme to be initiated. It will be some years before their definitive results are available.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "cdffae7e17c6461b9d318dade835ff28", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["is", 29], ["a", 32], ["cytoplasmic", 34], ["tyrosine", 46], ["kinase", 55], ["involved", 62], ["in", 71], ["signalling", 74], ["in", 85], ["many", 88], ["of", 93], ["the", 96], ["cells", 100], ["that", 106], ["drive", 111], ["immune", 117], ["inflammation", 124], [".", 136], ["The", 138], ["development", 142], ["of", 154], ["small", 157], ["molecules", 163], ["that", 173], ["inhibit", 178], ["Syk", 186], ["kinase", 190], ["may", 197], ["change", 201], ["the", 208], ["way", 212], ["we", 216], ["treat", 219], ["disorders", 225], ["such", 235], ["as", 240], ["rheumatoid", 243], ["arthritis", 254], ["(", 264], ["RA", 265], [")", 267], [",", 268], ["as", 270], ["well", 273], ["as", 278], ["a", 281], ["range", 283], ["of", 289], ["other", 292], ["inflammatory", 298], ["diseases", 311], [".", 319], ["Fostamatinib", 321], ["(", 334], ["R-788", 335], [")", 340], ["is", 342], ["an", 345], ["orally", 348], ["bioavailable", 355], ["small", 368], ["molecule", 374], [".", 382], ["It", 384], ["is", 387], ["the", 390], ["prodrug", 394], ["of", 402], ["R406", 405], [",", 409], ["which", 411], ["is", 417], ["a", 420], ["potent", 422], ["Syk", 429], ["inhibitor", 433], [".", 442], ["Fostamatinib", 444], ["was", 457], ["developed", 461], ["because", 471], ["it", 479], ["has", 482], ["more", 486], ["favourable", 491], ["physiochemical", 502], ["properties", 517], [".", 527], ["It", 529], ["is", 532], ["rapidly", 535], ["converted", 543], ["to", 553], ["R406", 556], ["by", 561], ["intestinal", 564], ["enterocytes", 575], [".", 586], ["It", 588], ["has", 591], ["been", 595], ["evaluated", 600], ["in", 610], ["experimental", 613], ["models", 626], ["of", 633], ["RA", 636], [",", 638], ["such", 640], ["as", 645], ["collagen", 648], ["-", 656], ["induced", 657], ["arthritis", 665], [".", 674], ["In", 676], ["these", 679], ["models", 685], [",", 691], ["fostamatinib", 693], ["suppressed", 706], ["clinical", 717], ["arthritis", 726], [",", 735], ["bone", 737], ["erosions", 742], [",", 750], ["pannus", 752], ["formation", 759], ["and", 769], ["synovitis", 773], [".", 782], ["A", 784], ["phase", 786], ["II", 792], ["programme", 795], ["with", 805], ["fostamatinib", 810], ["has", 823], ["largely", 827], ["been", 835], ["completed", 840], [".", 849], ["Three", 851], ["key", 857], ["trials", 861], ["have", 868], ["been", 873], ["published", 878], [",", 887], ["lasting", 889], ["12", 897], ["-", 899], ["26", 900], ["weeks", 903], ["and", 909], ["each", 913], ["enrolling", 918], ["189", 928], ["-", 931], ["457", 932], ["patients", 936], ["(", 945], ["875", 946], ["in", 950], ["total", 953], [")", 958], [".", 959], ["All", 961], ["these", 965], ["trials", 971], ["involved", 978], ["placebo", 987], ["therapy", 995], ["and", 1003], ["patients", 1007], ["continued", 1016], ["to", 1026], ["receive", 1029], ["methotrexate", 1037], ["in", 1050], ["addition", 1053], ["to", 1062], ["active", 1065], ["treatment", 1072], ["with", 1082], ["fostamatinib", 1087], [".", 1099], ["The", 1101], ["first", 1105], ["dose", 1111], ["-", 1115], ["ranging", 1116], ["trial", 1124], ["evaluated", 1130], ["three", 1140], ["treatment", 1146], ["doses", 1156], ["in", 1162], ["RA", 1165], ["patients", 1168], ["who", 1177], ["had", 1181], ["not", 1185], ["fully", 1189], ["responded", 1195], ["to", 1205], ["methotrexate", 1208], ["therapy", 1221], [".", 1228], ["The", 1230], ["second", 1234], ["trial", 1241], ["compared", 1247], ["two", 1256], ["treatment", 1260], ["doses", 1270], ["in", 1276], ["patients", 1279], ["who", 1288], ["had", 1292], ["not", 1296], ["responded", 1300], ["to", 1310], ["methotrexate", 1313], ["therapy", 1326], [".", 1333], ["The", 1335], ["third", 1339], ["trial", 1345], ["compared", 1351], ["a", 1360], ["single", 1362], ["treatment", 1369], ["dose", 1379], ["with", 1384], ["placebo", 1389], ["in", 1397], ["patients", 1400], ["who", 1409], ["had", 1413], ["not", 1417], ["responded", 1421], ["to", 1431], ["biological", 1434], ["therapy", 1445], [".", 1452], ["The", 1454], ["primary", 1458], ["outcome", 1466], ["measure", 1474], ["was", 1482], ["the", 1486], ["number", 1490], ["of", 1497], ["patients", 1500], ["achieving", 1509], ["American", 1519], ["College", 1528], ["of", 1536], ["Rheumatology", 1539], ["(", 1552], ["ACR", 1553], [")", 1556], ["20", 1558], ["%", 1560], ["(", 1562], ["ACR20", 1563], [")", 1568], ["responses", 1570], [".", 1579], ["Placebo", 1581], ["ACR20", 1589], ["response", 1595], ["rates", 1604], ["in", 1610], ["all", 1613], ["three", 1617], ["trials", 1623], ["were", 1630], ["similar", 1635], ["(", 1643], ["35", 1644], ["-", 1646], ["38", 1647], ["%", 1649], [")", 1650], [".", 1651], ["All", 1653], ["three", 1657], ["trials", 1663], ["involved", 1670], ["one", 1679], ["treatment", 1683], ["arm", 1693], ["receiving", 1697], ["fostamatinib", 1707], ["100", 1720], ["mg", 1724], ["twice", 1727], ["daily", 1733], [";", 1738], ["ACR20", 1740], ["responses", 1746], ["with", 1756], ["this", 1761], ["active", 1766], ["treatment", 1773], ["ranged", 1783], ["from", 1790], ["38", 1795], ["%", 1797], ["to", 1799], ["67", 1802], ["%", 1804], [".", 1805], ["A", 1807], ["meta", 1809], ["-", 1813], ["analysis", 1814], ["of", 1823], ["ACR", 1826], ["responses", 1830], ["in", 1840], ["these", 1843], ["trials", 1849], [",", 1855], ["using", 1857], ["responses", 1863], ["to", 1873], ["the", 1876], ["highest", 1880], ["dose", 1888], ["in", 1893], ["each", 1896], ["trial", 1901], ["for", 1907], ["comparisons", 1911], ["with", 1923], ["placebo", 1928], ["therapy", 1936], ["in", 1944], ["a", 1947], ["random", 1949], ["effects", 1956], ["model", 1964], [",", 1969], ["showed", 1971], ["a", 1978], ["borderline", 1980], ["benefit", 1991], ["with", 1999], ["ACR20", 2004], ["responses", 2010], [".", 2019], ["There", 2021], ["were", 2027], ["more", 2032], ["significant", 2037], ["differences", 2049], ["with", 2061], ["ACR50", 2066], ["and", 2072], ["ACR70", 2076], ["responses", 2082], [".", 2091], ["The", 2093], ["reason", 2097], ["that", 2104], ["this", 2109], ["meta", 2114], ["-", 2118], ["analysis", 2119], ["was", 2128], ["not", 2132], ["more", 2136], ["strongly", 2141], ["positive", 2150], ["is", 2159], ["that", 2162], ["the", 2167], ["third", 2171], ["trial", 2177], [",", 2182], ["which", 2184], ["evaluated", 2190], ["patients", 2200], ["who", 2209], ["had", 2213], ["failed", 2217], ["to", 2224], ["respond", 2227], ["to", 2235], ["biological", 2238], ["treatments", 2249], [",", 2259], ["gave", 2261], ["negative", 2266], ["results", 2275], [".", 2282], ["Individual", 2284], ["ACR", 2295], ["response", 2299], ["components", 2308], [",", 2318], ["such", 2320], ["as", 2325], ["changes", 2328], ["in", 2336], ["swollen", 2339], ["joint", 2347], ["counts", 2353], [",", 2359], ["showed", 2361], ["significant", 2368], ["differences", 2380], ["in", 2392], ["the", 2395], ["first", 2399], ["two", 2405], ["trials", 2409], [",", 2415], ["but", 2417], ["there", 2421], ["were", 2427], ["no", 2432], ["definite", 2435], ["treatment", 2444], ["benefits", 2454], ["in", 2463], ["the", 2466], ["third", 2470], ["trial", 2476], [".", 2481], ["Overall", 2483], [",", 2490], ["the", 2492], ["differences", 2496], ["were", 2508], ["significant", 2513], ["in", 2525], ["a", 2528], ["meta", 2530], ["-", 2534], ["analysis", 2535], ["of", 2544], ["all", 2547], ["three", 2551], ["trials", 2557], [".", 2563], ["The", 2565], ["most", 2569], ["important", 2574], ["adverse", 2584], ["reactions", 2592], ["were", 2602], ["diarrhoea", 2607], [",", 2616], ["neutropenia", 2618], ["and", 2630], ["raised", 2634], ["ALT", 2641], ["levels", 2645], [",", 2651], ["which", 2653], ["all", 2659], ["showed", 2663], ["significant", 2670], ["excesses", 2682], ["with", 2691], ["active", 2696], ["treatment", 2703], ["compared", 2713], ["with", 2722], ["placebo", 2727], [".", 2734], ["Too", 2736], ["few", 2740], ["patients", 2744], ["have", 2753], ["been", 2758], ["studied", 2763], ["for", 2771], ["a", 2775], ["definitive", 2777], ["safety", 2788], ["profile", 2795], ["to", 2803], ["be", 2806], ["known", 2809], [".", 2814], ["Overall", 2816], [",", 2823], ["the", 2825], ["results", 2829], ["of", 2837], ["the", 2840], ["phase", 2844], ["II", 2850], ["trials", 2853], ["were", 2860], ["sufficiently", 2865], ["encouraging", 2878], ["for", 2890], ["a", 2894], ["phase", 2896], ["III", 2902], ["programme", 2906], ["to", 2916], ["be", 2919], ["initiated", 2922], [".", 2931], ["It", 2933], ["will", 2936], ["be", 2941], ["some", 2944], ["years", 2949], ["before", 2955], ["their", 2962], ["definitive", 2968], ["results", 2979], ["are", 2987], ["available", 2991], [".", 3000]]}
{"context": "Chronic pain arising from various pathological conditions such as osteoarthritis, low back or spinal injuries, cancer, and urological chronic pelvic pain syndromes presents significant challenges in diagnosis and treatment. Specifically, since the underlying cause of these pain syndromes is unknown or heterogeneous, physicians diagnose and treat patients based on the symptoms presented. Nerve growth factor (NGF) has been recognized as an important mediator of chronic pain in many pathological conditions, and has been shown to be upregulated in a subset of individuals suffering from such pain syndromes. These findings have led to the development of anti-NGF monoclonal antibodies such as tanezumab as potentially effective therapeutics for chronic pain. Although tanezumab has reached Phase II and III clinical trials, the trials of anti-NGF antibodies were halted due to safety concerns. Some of these trials of anti-NGF treatment have had statistically significant decreases in pain, while others have yielded inconclusive results. These findings are suggestive of, though do not prove, target (NGF) neutralization in chronic pain syndromes. A biomarker-driven anti-NGF clinical study layout is proposed that incorporates NGF measurements in the relevant samples before and after treatment, in addition to collecting the pain scores. This approach might not only confirm the mechanism of tanezumab's action in these chronic pain patients, but should establish NGF levels as a predictive biomarker for patients who can benefit from anti-NGF treatment, thereby creating a personalized approach to pain treatment.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "325680c55d7146c69a2cdebde92b66df", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[59, 61]], "char_spans": [[390, 408]]}, {"text": "NGF", "token_spans": [[154, 154], [138, 138], [198, 198], [246, 246], [108, 108], [260, 260], [184, 184], [206, 206], [63, 63]], "char_spans": [[925, 927], [845, 847], [1175, 1177], [1469, 1471], [661, 663], [1545, 1547], [1104, 1106], [1231, 1233], [411, 413]]}]}], "context_tokens": [["Chronic", 0], ["pain", 8], ["arising", 13], ["from", 21], ["various", 26], ["pathological", 34], ["conditions", 47], ["such", 58], ["as", 63], ["osteoarthritis", 66], [",", 80], ["low", 82], ["back", 86], ["or", 91], ["spinal", 94], ["injuries", 101], [",", 109], ["cancer", 111], [",", 117], ["and", 119], ["urological", 123], ["chronic", 134], ["pelvic", 142], ["pain", 149], ["syndromes", 154], ["presents", 164], ["significant", 173], ["challenges", 185], ["in", 196], ["diagnosis", 199], ["and", 209], ["treatment", 213], [".", 222], ["Specifically", 224], [",", 236], ["since", 238], ["the", 244], ["underlying", 248], ["cause", 259], ["of", 265], ["these", 268], ["pain", 274], ["syndromes", 279], ["is", 289], ["unknown", 292], ["or", 300], ["heterogeneous", 303], [",", 316], ["physicians", 318], ["diagnose", 329], ["and", 338], ["treat", 342], ["patients", 348], ["based", 357], ["on", 363], ["the", 366], ["symptoms", 370], ["presented", 379], [".", 388], ["Nerve", 390], ["growth", 396], ["factor", 403], ["(", 410], ["NGF", 411], [")", 414], ["has", 416], ["been", 420], ["recognized", 425], ["as", 436], ["an", 439], ["important", 442], ["mediator", 452], ["of", 461], ["chronic", 464], ["pain", 472], ["in", 477], ["many", 480], ["pathological", 485], ["conditions", 498], [",", 508], ["and", 510], ["has", 514], ["been", 518], ["shown", 523], ["to", 529], ["be", 532], ["upregulated", 535], ["in", 547], ["a", 550], ["subset", 552], ["of", 559], ["individuals", 562], ["suffering", 574], ["from", 584], ["such", 589], ["pain", 594], ["syndromes", 599], [".", 608], ["These", 610], ["findings", 616], ["have", 625], ["led", 630], ["to", 634], ["the", 637], ["development", 641], ["of", 653], ["anti", 656], ["-", 660], ["NGF", 661], ["monoclonal", 665], ["antibodies", 676], ["such", 687], ["as", 692], ["tanezumab", 695], ["as", 705], ["potentially", 708], ["effective", 720], ["therapeutics", 730], ["for", 743], ["chronic", 747], ["pain", 755], [".", 759], ["Although", 761], ["tanezumab", 770], ["has", 780], ["reached", 784], ["Phase", 792], ["II", 798], ["and", 801], ["III", 805], ["clinical", 809], ["trials", 818], [",", 824], ["the", 826], ["trials", 830], ["of", 837], ["anti", 840], ["-", 844], ["NGF", 845], ["antibodies", 849], ["were", 860], ["halted", 865], ["due", 872], ["to", 876], ["safety", 879], ["concerns", 886], [".", 894], ["Some", 896], ["of", 901], ["these", 904], ["trials", 910], ["of", 917], ["anti", 920], ["-", 924], ["NGF", 925], ["treatment", 929], ["have", 939], ["had", 944], ["statistically", 948], ["significant", 962], ["decreases", 974], ["in", 984], ["pain", 987], [",", 991], ["while", 993], ["others", 999], ["have", 1006], ["yielded", 1011], ["inconclusive", 1019], ["results", 1032], [".", 1039], ["These", 1041], ["findings", 1047], ["are", 1056], ["suggestive", 1060], ["of", 1071], [",", 1073], ["though", 1075], ["do", 1082], ["not", 1085], ["prove", 1089], [",", 1094], ["target", 1096], ["(", 1103], ["NGF", 1104], [")", 1107], ["neutralization", 1109], ["in", 1124], ["chronic", 1127], ["pain", 1135], ["syndromes", 1140], [".", 1149], ["A", 1151], ["biomarker", 1153], ["-", 1162], ["driven", 1163], ["anti", 1170], ["-", 1174], ["NGF", 1175], ["clinical", 1179], ["study", 1188], ["layout", 1194], ["is", 1201], ["proposed", 1204], ["that", 1213], ["incorporates", 1218], ["NGF", 1231], ["measurements", 1235], ["in", 1248], ["the", 1251], ["relevant", 1255], ["samples", 1264], ["before", 1272], ["and", 1279], ["after", 1283], ["treatment", 1289], [",", 1298], ["in", 1300], ["addition", 1303], ["to", 1312], ["collecting", 1315], ["the", 1326], ["pain", 1330], ["scores", 1335], [".", 1341], ["This", 1343], ["approach", 1348], ["might", 1357], ["not", 1363], ["only", 1367], ["confirm", 1372], ["the", 1380], ["mechanism", 1384], ["of", 1394], ["tanezumab", 1397], ["'s", 1406], ["action", 1409], ["in", 1416], ["these", 1419], ["chronic", 1425], ["pain", 1433], ["patients", 1438], [",", 1446], ["but", 1448], ["should", 1452], ["establish", 1459], ["NGF", 1469], ["levels", 1473], ["as", 1480], ["a", 1483], ["predictive", 1485], ["biomarker", 1496], ["for", 1506], ["patients", 1510], ["who", 1519], ["can", 1523], ["benefit", 1527], ["from", 1535], ["anti", 1540], ["-", 1544], ["NGF", 1545], ["treatment", 1549], [",", 1558], ["thereby", 1560], ["creating", 1568], ["a", 1577], ["personalized", 1579], ["approach", 1592], ["to", 1601], ["pain", 1604], ["treatment", 1609], [".", 1618]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "Respirasomes are macromolecular assemblies of the respiratory chain complexes I, III and IV in the inner mitochondrial membrane. We determined the structure of supercomplex I", "qas": [{"question": "Where is the respirasome located?", "answers": ["In the inner mitochondrial membrane"], "qid": "33ef66d3e9fc40e58b68c9f3044a109b", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["respirasome", 13], ["located", 25], ["?", 32]], "detected_answers": [{"text": "In the inner mitochondrial membrane", "token_spans": [[14, 18]], "char_spans": [[92, 126]]}]}], "context_tokens": [["Respirasomes", 0], ["are", 13], ["macromolecular", 17], ["assemblies", 32], ["of", 43], ["the", 46], ["respiratory", 50], ["chain", 62], ["complexes", 68], ["I", 78], [",", 79], ["III", 81], ["and", 85], ["IV", 89], ["in", 92], ["the", 95], ["inner", 99], ["mitochondrial", 105], ["membrane", 119], [".", 127], ["We", 129], ["determined", 132], ["the", 143], ["structure", 147], ["of", 157], ["supercomplex", 160], ["I", 173]]}
{"context": "In a double-blind placebo-controlled prospective clinical trial we studied the efficacy and safety of the benzodiazepine antagonist, flumazenil. In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01). In the remaining 7 patients, needing two series of injections of flumazenil (up to 2.0 mg), GCS did not rise significantly and coma was related to intoxications with nonbenzodiazepine sedatives, flunitrazepam and in one patient, encephalitis. In the 10 patients receiving placebo, the GCS did not change. A significant increase in the GCS from 5.5 to 10.8 (p less than 0.001) was, however, observed when flumazenil (up to 1.0 mg) was given after placebo. In patients with EEG monitoring the changes in waveform pattern paralleled the clinical response. Effects could be detected within 1-2 min after flumazenil injection and lasted up to 45 min. There were no adverse reactions or benzodiazepine withdrawal symptoms. We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose. The use of flumazenil is of diagnostic value in mixed-drug intoxications or coma of unknown origin and is of therapeutic importance for reversal of benzodiazepine intoxications.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "59303c35c98b49d191c1a3ae65d248b9", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[107, 107], [285, 285], [22, 22], [246, 246], [44, 44], [268, 268], [209, 209], [62, 62], [143, 143]], "char_spans": [[564, 573], [1497, 1506], [133, 142], [1266, 1275], [263, 272], [1400, 1409], [1070, 1079], [335, 344], [731, 740]]}]}], "context_tokens": [["In", 0], ["a", 3], ["double", 5], ["-", 11], ["blind", 12], ["placebo", 18], ["-", 25], ["controlled", 26], ["prospective", 37], ["clinical", 49], ["trial", 58], ["we", 64], ["studied", 67], ["the", 75], ["efficacy", 79], ["and", 88], ["safety", 92], ["of", 99], ["the", 102], ["benzodiazepine", 106], ["antagonist", 121], [",", 131], ["flumazenil", 133], [".", 143], ["In", 145], ["23", 148], ["patients", 151], ["admitted", 160], ["to", 169], ["the", 172], ["Intensive", 176], ["Care", 186], ["Unit", 191], ["with", 196], ["coma", 201], ["due", 206], ["to", 210], ["overdose", 213], ["with", 222], ["benzodiazepines", 227], ["or", 243], ["other", 246], ["sedatives", 252], [",", 261], ["flumazenil", 263], ["i.v", 274], [".", 277], ["(", 279], ["up", 280], ["to", 283], ["2", 286], ["mg", 288], ["or", 291], ["placebo", 294], [")", 301], ["was", 303], ["given", 307], [".", 312], ["In", 314], ["13", 317], ["patients", 320], ["given", 329], ["flumazenil", 335], ["the", 346], ["Glasgow", 350], ["Coma", 358], ["Scale", 363], ["(", 369], ["GCS", 370], [")", 373], ["increased", 375], ["significantly", 385], ["from", 399], ["4.9", 404], ["to", 408], ["7.8", 411], ["(", 415], ["p", 416], ["less", 418], ["than", 423], ["0.05", 428], [")", 432], [".", 433], ["Six", 435], ["of", 439], ["these", 442], ["13", 448], ["patients", 451], [",", 459], ["including", 461], ["mainly", 471], ["benzodiazepine", 478], ["mono", 493], ["-", 497], ["intoxications", 498], [",", 511], ["needed", 513], ["only", 520], ["one", 525], ["series", 529], ["of", 536], ["injections", 539], ["(", 550], ["up", 551], ["to", 554], ["1.0", 557], ["mg", 561], ["flumazenil", 564], [")", 574], [";", 575], ["the", 577], ["GCS", 581], ["increased", 585], ["thereby", 595], ["from", 603], ["4.5", 608], ["to", 612], ["10.7", 615], ["within", 620], ["a", 627], ["maximum", 629], ["of", 637], ["5", 640], ["min", 642], ["(", 646], ["p", 647], ["less", 649], ["than", 654], ["0.01", 659], [")", 663], [".", 664], ["In", 666], ["the", 669], ["remaining", 673], ["7", 683], ["patients", 685], [",", 693], ["needing", 695], ["two", 703], ["series", 707], ["of", 714], ["injections", 717], ["of", 728], ["flumazenil", 731], ["(", 742], ["up", 743], ["to", 746], ["2.0", 749], ["mg", 753], [")", 755], [",", 756], ["GCS", 758], ["did", 762], ["not", 766], ["rise", 770], ["significantly", 775], ["and", 789], ["coma", 793], ["was", 798], ["related", 802], ["to", 810], ["intoxications", 813], ["with", 827], ["nonbenzodiazepine", 832], ["sedatives", 850], [",", 859], ["flunitrazepam", 861], ["and", 875], ["in", 879], ["one", 882], ["patient", 886], [",", 893], ["encephalitis", 895], [".", 907], ["In", 909], ["the", 912], ["10", 916], ["patients", 919], ["receiving", 928], ["placebo", 938], [",", 945], ["the", 947], ["GCS", 951], ["did", 955], ["not", 959], ["change", 963], [".", 969], ["A", 971], ["significant", 973], ["increase", 985], ["in", 994], ["the", 997], ["GCS", 1001], ["from", 1005], ["5.5", 1010], ["to", 1014], ["10.8", 1017], ["(", 1022], ["p", 1023], ["less", 1025], ["than", 1030], ["0.001", 1035], [")", 1040], ["was", 1042], [",", 1045], ["however", 1047], [",", 1054], ["observed", 1056], ["when", 1065], ["flumazenil", 1070], ["(", 1081], ["up", 1082], ["to", 1085], ["1.0", 1088], ["mg", 1092], [")", 1094], ["was", 1096], ["given", 1100], ["after", 1106], ["placebo", 1112], [".", 1119], ["In", 1121], ["patients", 1124], ["with", 1133], ["EEG", 1138], ["monitoring", 1142], ["the", 1153], ["changes", 1157], ["in", 1165], ["waveform", 1168], ["pattern", 1177], ["paralleled", 1185], ["the", 1196], ["clinical", 1200], ["response", 1209], [".", 1217], ["Effects", 1219], ["could", 1227], ["be", 1233], ["detected", 1236], ["within", 1245], ["1", 1252], ["-", 1253], ["2", 1254], ["min", 1256], ["after", 1260], ["flumazenil", 1266], ["injection", 1277], ["and", 1287], ["lasted", 1291], ["up", 1298], ["to", 1301], ["45", 1304], ["min", 1307], [".", 1310], ["There", 1312], ["were", 1318], ["no", 1323], ["adverse", 1326], ["reactions", 1334], ["or", 1344], ["benzodiazepine", 1347], ["withdrawal", 1362], ["symptoms", 1373], [".", 1381], ["We", 1383], ["conclude", 1386], ["that", 1395], ["flumazenil", 1400], ["is", 1411], ["an", 1414], ["effective", 1417], ["and", 1427], ["safe", 1431], ["drug", 1436], ["in", 1441], ["the", 1444], ["treatment", 1448], ["of", 1458], ["benzodiazepine", 1461], ["overdose", 1476], [".", 1484], ["The", 1486], ["use", 1490], ["of", 1494], ["flumazenil", 1497], ["is", 1508], ["of", 1511], ["diagnostic", 1514], ["value", 1525], ["in", 1531], ["mixed", 1534], ["-", 1539], ["drug", 1540], ["intoxications", 1545], ["or", 1559], ["coma", 1562], ["of", 1567], ["unknown", 1570], ["origin", 1578], ["and", 1585], ["is", 1589], ["of", 1592], ["therapeutic", 1595], ["importance", 1607], ["for", 1618], ["reversal", 1622], ["of", 1631], ["benzodiazepine", 1634], ["intoxications", 1649], [".", 1662]]}
{"context": "Recurrent syncope, malignant ventricular arrhythmias, and sudden death are complications of the long QT syndrome (LQTS). Two well-known syndromes with long QT intervals are known. The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. In the present study assessment was performed of the diagnostic importance of the ventricular derepolarization parameters, clinical features, and prevalence of JLNS among 132 children with congenital hearing loss (CHL). In the CHL group the mean QT, QTc, JT, and JTc intervals and the dispersion values (QT-d, JT-d, QTc-d, and JTc-d) were significantly longer than those of control subjects (n = 96) (P < 0.05). Patients with CHL and JLNS (n = 5) had significantly longer mean values of QT, QTc, JT, and JTc intervals and dispersion values than those of CHL without JLNS (n = 127) and control subjects (P < 0.05). The results suggest that assessment of ventricular derepolarization parameters in children with CHL will be helpful in the early detection of JLNS because infants with CHL cannot accurately describe the symptoms of syncope.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "e5d58ee5c70045e09f9863cc375814b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[74, 76]], "char_spans": [[400, 417]]}]}], "context_tokens": [["Recurrent", 0], ["syncope", 10], [",", 17], ["malignant", 19], ["ventricular", 29], ["arrhythmias", 41], [",", 52], ["and", 54], ["sudden", 58], ["death", 65], ["are", 71], ["complications", 75], ["of", 89], ["the", 92], ["long", 96], ["QT", 101], ["syndrome", 104], ["(", 113], ["LQTS", 114], [")", 118], [".", 119], ["Two", 121], ["well", 125], ["-", 129], ["known", 130], ["syndromes", 136], ["with", 146], ["long", 151], ["QT", 156], ["intervals", 159], ["are", 169], ["known", 173], [".", 178], ["The", 180], ["Jervell", 184], ["and", 192], ["Lange", 196], ["-", 201], ["Nielsen", 202], ["syndrome", 210], ["(", 219], ["JLNS", 220], [")", 224], ["is", 226], ["characterized", 229], ["by", 243], ["prolongation", 246], ["of", 259], ["the", 262], ["QT", 266], ["interval", 269], [",", 277], ["deafness", 279], [",", 287], ["and", 289], ["autosomal", 293], ["-", 302], ["recessive", 303], ["inheritance", 313], [",", 324], ["and", 326], ["the", 330], ["Romano", 334], ["-", 340], ["Ward", 341], ["syndrome", 346], ["is", 355], ["characterized", 358], ["by", 372], ["a", 375], ["prolonged", 377], ["QT", 387], ["interval", 390], [",", 398], ["autosomal", 400], ["-", 409], ["dominant", 410], ["inheritance", 419], [",", 430], ["and", 432], ["no", 436], ["deafness", 439], [".", 447], ["In", 449], ["the", 452], ["present", 456], ["study", 464], ["assessment", 470], ["was", 481], ["performed", 485], ["of", 495], ["the", 498], ["diagnostic", 502], ["importance", 513], ["of", 524], ["the", 527], ["ventricular", 531], ["derepolarization", 543], ["parameters", 560], [",", 570], ["clinical", 572], ["features", 581], [",", 589], ["and", 591], ["prevalence", 595], ["of", 606], ["JLNS", 609], ["among", 614], ["132", 620], ["children", 624], ["with", 633], ["congenital", 638], ["hearing", 649], ["loss", 657], ["(", 662], ["CHL", 663], [")", 666], [".", 667], ["In", 669], ["the", 672], ["CHL", 676], ["group", 680], ["the", 686], ["mean", 690], ["QT", 695], [",", 697], ["QTc", 699], [",", 702], ["JT", 704], [",", 706], ["and", 708], ["JTc", 712], ["intervals", 716], ["and", 726], ["the", 730], ["dispersion", 734], ["values", 745], ["(", 752], ["QT", 753], ["-", 755], ["d", 756], [",", 757], ["JT", 759], ["-", 761], ["d", 762], [",", 763], ["QTc", 765], ["-", 768], ["d", 769], [",", 770], ["and", 772], ["JTc", 776], ["-", 779], ["d", 780], [")", 781], ["were", 783], ["significantly", 788], ["longer", 802], ["than", 809], ["those", 814], ["of", 820], ["control", 823], ["subjects", 831], ["(", 840], ["n", 841], ["=", 843], ["96", 845], [")", 847], ["(", 849], ["P", 850], ["<", 852], ["0.05", 854], [")", 858], [".", 859], ["Patients", 861], ["with", 870], ["CHL", 875], ["and", 879], ["JLNS", 883], ["(", 888], ["n", 889], ["=", 891], ["5", 893], [")", 894], ["had", 896], ["significantly", 900], ["longer", 914], ["mean", 921], ["values", 926], ["of", 933], ["QT", 936], [",", 938], ["QTc", 940], [",", 943], ["JT", 945], [",", 947], ["and", 949], ["JTc", 953], ["intervals", 957], ["and", 967], ["dispersion", 971], ["values", 982], ["than", 989], ["those", 994], ["of", 1000], ["CHL", 1003], ["without", 1007], ["JLNS", 1015], ["(", 1020], ["n", 1021], ["=", 1023], ["127", 1025], [")", 1028], ["and", 1030], ["control", 1034], ["subjects", 1042], ["(", 1051], ["P", 1052], ["<", 1054], ["0.05", 1056], [")", 1060], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["assessment", 1088], ["of", 1099], ["ventricular", 1102], ["derepolarization", 1114], ["parameters", 1131], ["in", 1142], ["children", 1145], ["with", 1154], ["CHL", 1159], ["will", 1163], ["be", 1168], ["helpful", 1171], ["in", 1179], ["the", 1182], ["early", 1186], ["detection", 1192], ["of", 1202], ["JLNS", 1205], ["because", 1210], ["infants", 1218], ["with", 1226], ["CHL", 1231], ["can", 1235], ["not", 1238], ["accurately", 1242], ["describe", 1253], ["the", 1262], ["symptoms", 1266], ["of", 1275], ["syncope", 1278], [".", 1285]]}
{"context": "The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "19279b71c3f24df98e4583f3b5b1ad1e", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[109, 112], [1, 4]], "char_spans": [[650, 677], [4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["is", 33], ["involved", 36], ["in", 45], ["intracellular", 48], ["protein", 62], ["turnover", 70], [",", 78], ["and", 80], ["its", 84], ["function", 88], ["is", 97], ["crucial", 100], ["to", 108], ["cellular", 111], ["homeostasis", 120], [".", 131], ["First", 133], ["synthesized", 139], ["as", 151], ["probes", 154], ["of", 161], ["proteolytic", 164], ["processes", 176], [",", 185], ["proteasome", 187], ["inhibitors", 198], ["began", 209], ["to", 215], ["be", 218], ["thought", 221], ["of", 229], ["as", 232], ["potential", 235], ["drug", 245], ["candidates", 250], ["when", 261], ["they", 266], ["were", 271], ["found", 276], ["to", 282], ["induce", 285], ["programmed", 292], ["cell", 303], ["death", 308], ["preferentially", 314], ["in", 329], ["transformed", 332], ["cells", 344], [".", 349], ["They", 351], ["made", 356], ["their", 361], ["first", 367], ["leap", 373], ["into", 378], ["the", 383], ["clinic", 387], ["to", 394], ["be", 397], ["tested", 400], ["as", 407], ["therapeutic", 410], ["agents", 422], ["10", 429], ["years", 432], ["ago", 438], [",", 441], ["and", 443], ["since", 447], ["then", 453], [",", 457], ["great", 459], ["strides", 465], ["have", 473], ["been", 478], ["made", 483], ["in", 488], ["defining", 491], ["their", 500], ["mechanisms", 506], ["of", 517], ["action", 520], [",", 526], ["their", 528], ["clinical", 534], ["efficacy", 543], ["and", 552], ["toxicity", 556], [",", 564], ["and", 566], ["some", 570], ["of", 575], ["their", 578], ["limitations", 584], ["in", 596], ["the", 599], ["form", 603], ["of", 608], ["resistance", 611], ["pathways", 622], [".", 630], ["Validation", 632], ["of", 643], ["the", 646], ["ubiquitin", 650], ["-", 659], ["proteasome", 660], ["pathway", 671], ["as", 679], ["a", 682], ["target", 684], ["for", 691], ["cancer", 695], ["therapy", 702], ["has", 710], ["come", 714], ["in", 719], ["the", 722], ["form", 726], ["of", 731], ["approvals", 734], ["of", 744], ["the", 747], ["first", 751], ["such", 757], ["inhibitor", 762], [",", 771], ["bortezomib", 773], [",", 783], ["for", 785], ["relapsed", 789], ["/", 797], ["refractory", 798], ["multiple", 809], ["myeloma", 818], ["and", 826], ["mantle", 830], ["cell", 837], ["lymphoma", 842], [",", 850], ["for", 852], ["which", 856], ["this", 862], ["agent", 867], ["has", 873], ["become", 877], ["a", 884], ["standard", 886], ["of", 895], ["care", 898], [".", 902], ["Lessons", 904], ["learned", 912], ["from", 920], ["this", 925], ["first", 930], ["-", 935], ["in", 936], ["-", 938], ["class", 939], ["agent", 945], ["are", 951], ["now", 955], ["being", 959], ["applied", 965], ["to", 973], ["the", 976], ["development", 980], ["of", 992], ["a", 995], ["new", 997], ["generation", 1001], ["of", 1012], ["proteasome", 1015], ["inhibitors", 1026], ["that", 1037], ["hold", 1042], ["the", 1047], ["promise", 1051], ["of", 1059], ["efficacy", 1062], ["in", 1071], ["bortezomib", 1074], ["-", 1084], ["resistant", 1085], ["disease", 1095], ["and", 1103], ["possibly", 1107], ["in", 1116], ["a", 1119], ["broader", 1121], ["spectrum", 1129], ["of", 1138], ["diseases", 1141], [".", 1149], ["This", 1151], ["saga", 1156], ["provides", 1161], ["a", 1170], ["salient", 1172], ["example", 1180], ["of", 1188], ["the", 1191], ["promise", 1195], ["of", 1203], ["translational", 1206], ["medicine", 1220], ["and", 1229], ["a", 1233], ["paradigm", 1235], ["by", 1244], ["which", 1247], ["other", 1253], ["agents", 1259], ["may", 1266], ["be", 1270], ["successfully", 1273], ["brought", 1286], ["from", 1294], ["the", 1299], ["bench", 1303], ["to", 1309], ["the", 1312], ["bedside", 1316], [".", 1323]]}
{"context": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue. Affected patients are at risk of arterial, bowel and uterine rupture during pregnancy. Generally, this syndrome remains undiagnosed until a sudden, acute presentation with organ rupture, and results in premature death, even if the patients survive the first and second major complications. An early diagnosis with genetic assays can help to plan the best treatment, which is often challenging due to the frailty of the arterial tissue. We report on a 28-year-old lady who presented with spontaneous rupture of a pseudoaneurysm of the posterior tibial artery.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "1a2e7aaf9e9148c98bfc8b68db1ea274", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[22, 23]], "char_spans": [[104, 120]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["type", 23], ["4", 28], [",", 29], ["the", 31], ["vascular", 35], ["type", 44], [",", 48], ["is", 50], ["a", 53], ["rare", 55], [",", 59], ["life", 61], ["-", 65], ["threatening", 66], ["inherited", 78], ["disorder", 88], ["of", 97], ["the", 100], ["connective", 104], ["tissue", 115], [".", 121], ["Affected", 123], ["patients", 132], ["are", 141], ["at", 145], ["risk", 148], ["of", 153], ["arterial", 156], [",", 164], ["bowel", 166], ["and", 172], ["uterine", 176], ["rupture", 184], ["during", 192], ["pregnancy", 199], [".", 208], ["Generally", 210], [",", 219], ["this", 221], ["syndrome", 226], ["remains", 235], ["undiagnosed", 243], ["until", 255], ["a", 261], ["sudden", 263], [",", 269], ["acute", 271], ["presentation", 277], ["with", 290], ["organ", 295], ["rupture", 301], [",", 308], ["and", 310], ["results", 314], ["in", 322], ["premature", 325], ["death", 335], [",", 340], ["even", 342], ["if", 347], ["the", 350], ["patients", 354], ["survive", 363], ["the", 371], ["first", 375], ["and", 381], ["second", 385], ["major", 392], ["complications", 398], [".", 411], ["An", 413], ["early", 416], ["diagnosis", 422], ["with", 432], ["genetic", 437], ["assays", 445], ["can", 452], ["help", 456], ["to", 461], ["plan", 464], ["the", 469], ["best", 473], ["treatment", 478], [",", 487], ["which", 489], ["is", 495], ["often", 498], ["challenging", 504], ["due", 516], ["to", 520], ["the", 523], ["frailty", 527], ["of", 535], ["the", 538], ["arterial", 542], ["tissue", 551], [".", 557], ["We", 559], ["report", 562], ["on", 569], ["a", 572], ["28-year", 574], ["-", 581], ["old", 582], ["lady", 586], ["who", 591], ["presented", 595], ["with", 605], ["spontaneous", 610], ["rupture", 622], ["of", 630], ["a", 633], ["pseudoaneurysm", 635], ["of", 650], ["the", 653], ["posterior", 657], ["tibial", 667], ["artery", 674], [".", 680]]}
{"context": "Mutations in the gene that encodes Fibroblast Growth Factor Receptor 3 (FGFR3) are associated with Achondroplasia (MIM 100800), Hypochondroplasia (MIM 146000), Muenke Syndrome (MIM 602849), Thanatophoric Dysplasia (MIM 187600, MIM 187601) and Lacrimo-Auriculo-Dento-Digital Syndrome (MIM 149730).Here we report a clinical and molecular study in a large cohort of 125 Portuguese patients with these skeletal disorders. The identification of the P250R mutation allowed the confirmation of the Muenke Syndrome in 9 out of the 52 cases referred. Two known mutations were found in the Thanatophoric Dysplasia referred cases. No mutations were identified in the LADD syndrome patient. In Achondroplasia and Hypochondroplasia, genetic heterogeneity was present amongst the 70 clinically diagnosed patients with 5 different mutations identified. As in other studies, complex phenotypic heterogeneity amongst patients carrying the same gene defect was observed. In several cases, the new amino acids encoded, as a consequence of mutations, were related to the severity of patients' phenotype. The presence of 10 misdiagnosed cases emphasizes the importance of performing mutation analysis of the hotspot regions responsible for both dysplasias (Ach and Hch). For patients with an unquestionable clinical diagnosis, lacking the most common mutations, a complete screening of FGFR3 is necessary.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "761f9e814759455eb96445c42ae4b986", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[6, 12]], "char_spans": [[35, 76]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["gene", 17], ["that", 22], ["encodes", 27], ["Fibroblast", 35], ["Growth", 46], ["Factor", 53], ["Receptor", 60], ["3", 69], ["(", 71], ["FGFR3", 72], [")", 77], ["are", 79], ["associated", 83], ["with", 94], ["Achondroplasia", 99], ["(", 114], ["MIM", 115], ["100800", 119], [")", 125], [",", 126], ["Hypochondroplasia", 128], ["(", 146], ["MIM", 147], ["146000", 151], [")", 157], [",", 158], ["Muenke", 160], ["Syndrome", 167], ["(", 176], ["MIM", 177], ["602849", 181], [")", 187], [",", 188], ["Thanatophoric", 190], ["Dysplasia", 204], ["(", 214], ["MIM", 215], ["187600", 219], [",", 225], ["MIM", 227], ["187601", 231], [")", 237], ["and", 239], ["Lacrimo", 243], ["-", 250], ["Auriculo", 251], ["-", 259], ["Dento", 260], ["-", 265], ["Digital", 266], ["Syndrome", 274], ["(", 283], ["MIM", 284], ["149730).Here", 288], ["we", 301], ["report", 304], ["a", 311], ["clinical", 313], ["and", 322], ["molecular", 326], ["study", 336], ["in", 342], ["a", 345], ["large", 347], ["cohort", 353], ["of", 360], ["125", 363], ["Portuguese", 367], ["patients", 378], ["with", 387], ["these", 392], ["skeletal", 398], ["disorders", 407], [".", 416], ["The", 418], ["identification", 422], ["of", 437], ["the", 440], ["P250R", 444], ["mutation", 450], ["allowed", 459], ["the", 467], ["confirmation", 471], ["of", 484], ["the", 487], ["Muenke", 491], ["Syndrome", 498], ["in", 507], ["9", 510], ["out", 512], ["of", 516], ["the", 519], ["52", 523], ["cases", 526], ["referred", 532], [".", 540], ["Two", 542], ["known", 546], ["mutations", 552], ["were", 562], ["found", 567], ["in", 573], ["the", 576], ["Thanatophoric", 580], ["Dysplasia", 594], ["referred", 604], ["cases", 613], [".", 618], ["No", 620], ["mutations", 623], ["were", 633], ["identified", 638], ["in", 649], ["the", 652], ["LADD", 656], ["syndrome", 661], ["patient", 670], [".", 677], ["In", 679], ["Achondroplasia", 682], ["and", 697], ["Hypochondroplasia", 701], [",", 718], ["genetic", 720], ["heterogeneity", 728], ["was", 742], ["present", 746], ["amongst", 754], ["the", 762], ["70", 766], ["clinically", 769], ["diagnosed", 780], ["patients", 790], ["with", 799], ["5", 804], ["different", 806], ["mutations", 816], ["identified", 826], [".", 836], ["As", 838], ["in", 841], ["other", 844], ["studies", 850], [",", 857], ["complex", 859], ["phenotypic", 867], ["heterogeneity", 878], ["amongst", 892], ["patients", 900], ["carrying", 909], ["the", 918], ["same", 922], ["gene", 927], ["defect", 932], ["was", 939], ["observed", 943], [".", 951], ["In", 953], ["several", 956], ["cases", 964], [",", 969], ["the", 971], ["new", 975], ["amino", 979], ["acids", 985], ["encoded", 991], [",", 998], ["as", 1000], ["a", 1003], ["consequence", 1005], ["of", 1017], ["mutations", 1020], [",", 1029], ["were", 1031], ["related", 1036], ["to", 1044], ["the", 1047], ["severity", 1051], ["of", 1060], ["patients", 1063], ["'", 1071], ["phenotype", 1073], [".", 1082], ["The", 1084], ["presence", 1088], ["of", 1097], ["10", 1100], ["misdiagnosed", 1103], ["cases", 1116], ["emphasizes", 1122], ["the", 1133], ["importance", 1137], ["of", 1148], ["performing", 1151], ["mutation", 1162], ["analysis", 1171], ["of", 1180], ["the", 1183], ["hotspot", 1187], ["regions", 1195], ["responsible", 1203], ["for", 1215], ["both", 1219], ["dysplasias", 1224], ["(", 1235], ["Ach", 1236], ["and", 1240], ["Hch", 1244], [")", 1247], [".", 1248], ["For", 1250], ["patients", 1254], ["with", 1263], ["an", 1268], ["unquestionable", 1271], ["clinical", 1286], ["diagnosis", 1295], [",", 1304], ["lacking", 1306], ["the", 1314], ["most", 1318], ["common", 1323], ["mutations", 1330], [",", 1339], ["a", 1341], ["complete", 1343], ["screening", 1352], ["of", 1362], ["FGFR3", 1365], ["is", 1371], ["necessary", 1374], [".", 1383]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "Chediak-Higashi syndrome, a rare autosomal recessive disorder, was described over 50 years ago. Patients show hypopigmentation, recurrent infections, mild coagulation defects and varying neurologic problems. Treatment is bone marrow transplant, which is effective in treating the hematologic and immune defects, however the neurologic problems persist. The CHS1/LYST gene was identified over 10 years ago and homologous CHS1/LYST genes are present in all eukaryotes. This review will discuss the advances made in understanding the clinical aspects of the syndrome and the function of CHS1/LYST/Beige. Clinical reports of Chediak-Higashi syndrome have identified mutations throughout the CHS1/LYST gene. The nature of the mutation can be a predictor of the severity of the disease. Over the past decade the CHS1/LYST family of proteins has been analyzed using model organisms, two-hybrid analysis, overexpression phenotypes and dominant negatives. These studies suggest that the CHS1/LYST protein is involved in either vesicle fusion or fission. Although CHS is a rare disease, the Chediak-like family of proteins is providing insight into the regulation of vesicle trafficking. Understanding the basic mechanisms that govern vesicle trafficking will provide essential information regarding how loss of CHS1/LYST affects hematologic, immunologic and neurologic processes.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "8283a8628bfe440b908b5fe0ef0625ea", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3], [101, 104]], "char_spans": [[0, 23], [621, 644]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], [",", 24], ["a", 26], ["rare", 28], ["autosomal", 33], ["recessive", 43], ["disorder", 53], [",", 61], ["was", 63], ["described", 67], ["over", 77], ["50", 82], ["years", 85], ["ago", 91], [".", 94], ["Patients", 96], ["show", 105], ["hypopigmentation", 110], [",", 126], ["recurrent", 128], ["infections", 138], [",", 148], ["mild", 150], ["coagulation", 155], ["defects", 167], ["and", 175], ["varying", 179], ["neurologic", 187], ["problems", 198], [".", 206], ["Treatment", 208], ["is", 218], ["bone", 221], ["marrow", 226], ["transplant", 233], [",", 243], ["which", 245], ["is", 251], ["effective", 254], ["in", 264], ["treating", 267], ["the", 276], ["hematologic", 280], ["and", 292], ["immune", 296], ["defects", 303], [",", 310], ["however", 312], ["the", 320], ["neurologic", 324], ["problems", 335], ["persist", 344], [".", 351], ["The", 353], ["CHS1/LYST", 357], ["gene", 367], ["was", 372], ["identified", 376], ["over", 387], ["10", 392], ["years", 395], ["ago", 401], ["and", 405], ["homologous", 409], ["CHS1/LYST", 420], ["genes", 430], ["are", 436], ["present", 440], ["in", 448], ["all", 451], ["eukaryotes", 455], [".", 465], ["This", 467], ["review", 472], ["will", 479], ["discuss", 484], ["the", 492], ["advances", 496], ["made", 505], ["in", 510], ["understanding", 513], ["the", 527], ["clinical", 531], ["aspects", 540], ["of", 548], ["the", 551], ["syndrome", 555], ["and", 564], ["the", 568], ["function", 572], ["of", 581], ["CHS1/LYST", 584], ["/", 593], ["Beige", 594], [".", 599], ["Clinical", 601], ["reports", 610], ["of", 618], ["Chediak", 621], ["-", 628], ["Higashi", 629], ["syndrome", 637], ["have", 646], ["identified", 651], ["mutations", 662], ["throughout", 672], ["the", 683], ["CHS1/LYST", 687], ["gene", 697], [".", 701], ["The", 703], ["nature", 707], ["of", 714], ["the", 717], ["mutation", 721], ["can", 730], ["be", 734], ["a", 737], ["predictor", 739], ["of", 749], ["the", 752], ["severity", 756], ["of", 765], ["the", 768], ["disease", 772], [".", 779], ["Over", 781], ["the", 786], ["past", 790], ["decade", 795], ["the", 802], ["CHS1/LYST", 806], ["family", 816], ["of", 823], ["proteins", 826], ["has", 835], ["been", 839], ["analyzed", 844], ["using", 853], ["model", 859], ["organisms", 865], [",", 874], ["two", 876], ["-", 879], ["hybrid", 880], ["analysis", 887], [",", 895], ["overexpression", 897], ["phenotypes", 912], ["and", 923], ["dominant", 927], ["negatives", 936], [".", 945], ["These", 947], ["studies", 953], ["suggest", 961], ["that", 969], ["the", 974], ["CHS1/LYST", 978], ["protein", 988], ["is", 996], ["involved", 999], ["in", 1008], ["either", 1011], ["vesicle", 1018], ["fusion", 1026], ["or", 1033], ["fission", 1036], [".", 1043], ["Although", 1045], ["CHS", 1054], ["is", 1058], ["a", 1061], ["rare", 1063], ["disease", 1068], [",", 1075], ["the", 1077], ["Chediak", 1081], ["-", 1088], ["like", 1089], ["family", 1094], ["of", 1101], ["proteins", 1104], ["is", 1113], ["providing", 1116], ["insight", 1126], ["into", 1134], ["the", 1139], ["regulation", 1143], ["of", 1154], ["vesicle", 1157], ["trafficking", 1165], [".", 1176], ["Understanding", 1178], ["the", 1192], ["basic", 1196], ["mechanisms", 1202], ["that", 1213], ["govern", 1218], ["vesicle", 1225], ["trafficking", 1233], ["will", 1245], ["provide", 1250], ["essential", 1258], ["information", 1268], ["regarding", 1280], ["how", 1290], ["loss", 1294], ["of", 1299], ["CHS1/LYST", 1302], ["affects", 1312], ["hematologic", 1320], [",", 1331], ["immunologic", 1333], ["and", 1345], ["neurologic", 1349], ["processes", 1360], [".", 1369]]}
{"context": "The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. Most studies of this protein are performed in dilute solution, but its biologically relevant role is performed in the crowded environment inside cells. We addressed the effects of macromolecular crowding on alpha-synuclein by combining NMR data acquired in living Escherichia coli with in vitro NMR data. The crowded environment in the E.coli periplasm prevents a conformational change that is detected at 35 degrees C in dilute solution. This change is associated with an increase in hydrodynamic radius and the formation of secondary structure in the N-terminal 100 amino acid residues. By preventing this temperature-induced conformational change, crowding in the E.coli periplasm stabilizes the disordered monomer. We obtain the same stabilization in vitro upon crowding alpha-synuclein with 300 g/l of bovine serum albumin, indicating that crowding alone is sufficient to stabilize the disordered, monomeric protein. Two disease-associated variants (A30P and A53T) behave in the same way in both dilute solution and in the E.coli periplasm. These data reveal the importance of approaching the effects of macromolecular crowding on a case-by-case basis. Additionally, our work shows that discrete structured protein conformations may not be achieved by alpha-synuclein inside cells, implicating the commonly overlooked aspect of macromolecular crowding as a possible factor in the etiology of Parkinson's disease.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ef3220cd0654492584edc7a94fda2c33", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[150, 152], [56, 58], [4, 6], [239, 241]], "char_spans": [[910, 924], [342, 356], [32, 46], [1392, 1406]]}]}], "context_tokens": [["The", 0], ["natively", 4], ["disordered", 13], ["protein", 24], ["alpha", 32], ["-", 37], ["synuclein", 38], ["is", 48], ["the", 51], ["primary", 55], ["component", 63], ["of", 73], ["Lewy", 76], ["bodies", 81], [",", 87], ["the", 89], ["cellular", 93], ["hallmark", 102], ["of", 111], ["Parkinson", 114], ["'s", 123], ["disease", 126], [".", 133], ["Most", 135], ["studies", 140], ["of", 148], ["this", 151], ["protein", 156], ["are", 164], ["performed", 168], ["in", 178], ["dilute", 181], ["solution", 188], [",", 196], ["but", 198], ["its", 202], ["biologically", 206], ["relevant", 219], ["role", 228], ["is", 233], ["performed", 236], ["in", 246], ["the", 249], ["crowded", 253], ["environment", 261], ["inside", 273], ["cells", 280], [".", 285], ["We", 287], ["addressed", 290], ["the", 300], ["effects", 304], ["of", 312], ["macromolecular", 315], ["crowding", 330], ["on", 339], ["alpha", 342], ["-", 347], ["synuclein", 348], ["by", 358], ["combining", 361], ["NMR", 371], ["data", 375], ["acquired", 380], ["in", 389], ["living", 392], ["Escherichia", 399], ["coli", 411], ["with", 416], ["in", 421], ["vitro", 424], ["NMR", 430], ["data", 434], [".", 438], ["The", 440], ["crowded", 444], ["environment", 452], ["in", 464], ["the", 467], ["E.coli", 471], ["periplasm", 478], ["prevents", 488], ["a", 497], ["conformational", 499], ["change", 514], ["that", 521], ["is", 526], ["detected", 529], ["at", 538], ["35", 541], ["degrees", 544], ["C", 552], ["in", 554], ["dilute", 557], ["solution", 564], [".", 572], ["This", 574], ["change", 579], ["is", 586], ["associated", 589], ["with", 600], ["an", 605], ["increase", 608], ["in", 617], ["hydrodynamic", 620], ["radius", 633], ["and", 640], ["the", 644], ["formation", 648], ["of", 658], ["secondary", 661], ["structure", 671], ["in", 681], ["the", 684], ["N", 688], ["-", 689], ["terminal", 690], ["100", 699], ["amino", 703], ["acid", 709], ["residues", 714], [".", 722], ["By", 724], ["preventing", 727], ["this", 738], ["temperature", 743], ["-", 754], ["induced", 755], ["conformational", 763], ["change", 778], [",", 784], ["crowding", 786], ["in", 795], ["the", 798], ["E.coli", 802], ["periplasm", 809], ["stabilizes", 819], ["the", 830], ["disordered", 834], ["monomer", 845], [".", 852], ["We", 854], ["obtain", 857], ["the", 864], ["same", 868], ["stabilization", 873], ["in", 887], ["vitro", 890], ["upon", 896], ["crowding", 901], ["alpha", 910], ["-", 915], ["synuclein", 916], ["with", 926], ["300", 931], ["g", 935], ["/", 936], ["l", 937], ["of", 939], ["bovine", 942], ["serum", 949], ["albumin", 955], [",", 962], ["indicating", 964], ["that", 975], ["crowding", 980], ["alone", 989], ["is", 995], ["sufficient", 998], ["to", 1009], ["stabilize", 1012], ["the", 1022], ["disordered", 1026], [",", 1036], ["monomeric", 1038], ["protein", 1048], [".", 1055], ["Two", 1057], ["disease", 1061], ["-", 1068], ["associated", 1069], ["variants", 1080], ["(", 1089], ["A30P", 1090], ["and", 1095], ["A53", 1099], ["T", 1102], [")", 1103], ["behave", 1105], ["in", 1112], ["the", 1115], ["same", 1119], ["way", 1124], ["in", 1128], ["both", 1131], ["dilute", 1136], ["solution", 1143], ["and", 1152], ["in", 1156], ["the", 1159], ["E.coli", 1163], ["periplasm", 1170], [".", 1179], ["These", 1181], ["data", 1187], ["reveal", 1192], ["the", 1199], ["importance", 1203], ["of", 1214], ["approaching", 1217], ["the", 1229], ["effects", 1233], ["of", 1241], ["macromolecular", 1244], ["crowding", 1259], ["on", 1268], ["a", 1271], ["case", 1273], ["-", 1277], ["by", 1278], ["-", 1280], ["case", 1281], ["basis", 1286], [".", 1291], ["Additionally", 1293], [",", 1305], ["our", 1307], ["work", 1311], ["shows", 1316], ["that", 1322], ["discrete", 1327], ["structured", 1336], ["protein", 1347], ["conformations", 1355], ["may", 1369], ["not", 1373], ["be", 1377], ["achieved", 1380], ["by", 1389], ["alpha", 1392], ["-", 1397], ["synuclein", 1398], ["inside", 1408], ["cells", 1415], [",", 1420], ["implicating", 1422], ["the", 1434], ["commonly", 1438], ["overlooked", 1447], ["aspect", 1458], ["of", 1465], ["macromolecular", 1468], ["crowding", 1483], ["as", 1492], ["a", 1495], ["possible", 1497], ["factor", 1506], ["in", 1513], ["the", 1516], ["etiology", 1520], ["of", 1529], ["Parkinson", 1532], ["'s", 1541], ["disease", 1544], [".", 1551]]}
{"context": "The X-linked McLeod neuroacanthocytosis syndrome is a multisystem disorder with hematologic, neuromuscular, and central nervous system (CNS) manifestations. All carriers of the McLeod blood group phenotype examined so far had at least subclinical signs of systemic involvement. Evaluation of two brothers carrying the McLeod phenotype with neurologic examination, immunohematology, RBC membrane protein Western blotting, analysis of XK DNA sequence and RNA levels, muscle histology including XK/Kell immunohistochemistry, cerebral magnetic resonance imaging (MRI), and quantified positron emission tomography (PET). Immunohematology and Western blotting confirmed presence of the McLeod blood group phenotype. No acanthocytosis or other hematologic anomalies were found. XK gene sequence analysis revealed a missense mutation in exon 3 (E327K). WBC XK RNA levels were not decreased. There were no neuromuscular and CNS signs or symptoms. In addition, no subclinical involvement was discovered on the basis of normal muscle histology with a physiologic pattern of XK and Kell immunohistochemistry, normal cerebral MRI, and quantified PET. Known disease-causing XK gene mutations comprised deletions, nonsense, or splice-site mutations predicting absent or truncated XK protein devoid of the Kell-protein binding site. Although the E327K missense mutation was associated with the immunohematologic characteristics of McLeod syndrome, the mutated XK protein seemed to be largely functional. These findings contribute to the understanding of the physiology of XK and Kell proteins, and the pathogenetic mechanisms of acanthocytosis, myopathy, and striatal neurodegeneration in McLeod syndrome.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "9019bb534c7b4632b5c84114049ce836", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [256, 256], [67, 67], [77, 77], [138, 138], [121, 121], [209, 209], [238, 238], [175, 175]], "char_spans": [[1160, 1161], [1556, 1557], [433, 434], [492, 493], [849, 850], [771, 772], [1265, 1266], [1444, 1445], [1063, 1064]]}]}], "context_tokens": [["The", 0], ["X", 4], ["-", 5], ["linked", 6], ["McLeod", 13], ["neuroacanthocytosis", 20], ["syndrome", 40], ["is", 49], ["a", 52], ["multisystem", 54], ["disorder", 66], ["with", 75], ["hematologic", 80], [",", 91], ["neuromuscular", 93], [",", 106], ["and", 108], ["central", 112], ["nervous", 120], ["system", 128], ["(", 135], ["CNS", 136], [")", 139], ["manifestations", 141], [".", 155], ["All", 157], ["carriers", 161], ["of", 170], ["the", 173], ["McLeod", 177], ["blood", 184], ["group", 190], ["phenotype", 196], ["examined", 206], ["so", 215], ["far", 218], ["had", 222], ["at", 226], ["least", 229], ["subclinical", 235], ["signs", 247], ["of", 253], ["systemic", 256], ["involvement", 265], [".", 276], ["Evaluation", 278], ["of", 289], ["two", 292], ["brothers", 296], ["carrying", 305], ["the", 314], ["McLeod", 318], ["phenotype", 325], ["with", 335], ["neurologic", 340], ["examination", 351], [",", 362], ["immunohematology", 364], [",", 380], ["RBC", 382], ["membrane", 386], ["protein", 395], ["Western", 403], ["blotting", 411], [",", 419], ["analysis", 421], ["of", 430], ["XK", 433], ["DNA", 436], ["sequence", 440], ["and", 449], ["RNA", 453], ["levels", 457], [",", 463], ["muscle", 465], ["histology", 472], ["including", 482], ["XK", 492], ["/", 494], ["Kell", 495], ["immunohistochemistry", 500], [",", 520], ["cerebral", 522], ["magnetic", 531], ["resonance", 540], ["imaging", 550], ["(", 558], ["MRI", 559], [")", 562], [",", 563], ["and", 565], ["quantified", 569], ["positron", 580], ["emission", 589], ["tomography", 598], ["(", 609], ["PET", 610], [")", 613], [".", 614], ["Immunohematology", 616], ["and", 633], ["Western", 637], ["blotting", 645], ["confirmed", 654], ["presence", 664], ["of", 673], ["the", 676], ["McLeod", 680], ["blood", 687], ["group", 693], ["phenotype", 699], [".", 708], ["No", 710], ["acanthocytosis", 713], ["or", 728], ["other", 731], ["hematologic", 737], ["anomalies", 749], ["were", 759], ["found", 764], [".", 769], ["XK", 771], ["gene", 774], ["sequence", 779], ["analysis", 788], ["revealed", 797], ["a", 806], ["missense", 808], ["mutation", 817], ["in", 826], ["exon", 829], ["3", 834], ["(", 836], ["E327", 837], ["K", 841], [")", 842], [".", 843], ["WBC", 845], ["XK", 849], ["RNA", 852], ["levels", 856], ["were", 863], ["not", 868], ["decreased", 872], [".", 881], ["There", 883], ["were", 889], ["no", 894], ["neuromuscular", 897], ["and", 911], ["CNS", 915], ["signs", 919], ["or", 925], ["symptoms", 928], [".", 936], ["In", 938], ["addition", 941], [",", 949], ["no", 951], ["subclinical", 954], ["involvement", 966], ["was", 978], ["discovered", 982], ["on", 993], ["the", 996], ["basis", 1000], ["of", 1006], ["normal", 1009], ["muscle", 1016], ["histology", 1023], ["with", 1033], ["a", 1038], ["physiologic", 1040], ["pattern", 1052], ["of", 1060], ["XK", 1063], ["and", 1066], ["Kell", 1070], ["immunohistochemistry", 1075], [",", 1095], ["normal", 1097], ["cerebral", 1104], ["MRI", 1113], [",", 1116], ["and", 1118], ["quantified", 1122], ["PET", 1133], [".", 1136], ["Known", 1138], ["disease", 1144], ["-", 1151], ["causing", 1152], ["XK", 1160], ["gene", 1163], ["mutations", 1168], ["comprised", 1178], ["deletions", 1188], [",", 1197], ["nonsense", 1199], [",", 1207], ["or", 1209], ["splice", 1212], ["-", 1218], ["site", 1219], ["mutations", 1224], ["predicting", 1234], ["absent", 1245], ["or", 1252], ["truncated", 1255], ["XK", 1265], ["protein", 1268], ["devoid", 1276], ["of", 1283], ["the", 1286], ["Kell", 1290], ["-", 1294], ["protein", 1295], ["binding", 1303], ["site", 1311], [".", 1315], ["Although", 1317], ["the", 1326], ["E327", 1330], ["K", 1334], ["missense", 1336], ["mutation", 1345], ["was", 1354], ["associated", 1358], ["with", 1369], ["the", 1374], ["immunohematologic", 1378], ["characteristics", 1396], ["of", 1412], ["McLeod", 1415], ["syndrome", 1422], [",", 1430], ["the", 1432], ["mutated", 1436], ["XK", 1444], ["protein", 1447], ["seemed", 1455], ["to", 1462], ["be", 1465], ["largely", 1468], ["functional", 1476], [".", 1486], ["These", 1488], ["findings", 1494], ["contribute", 1503], ["to", 1514], ["the", 1517], ["understanding", 1521], ["of", 1535], ["the", 1538], ["physiology", 1542], ["of", 1553], ["XK", 1556], ["and", 1559], ["Kell", 1563], ["proteins", 1568], [",", 1576], ["and", 1578], ["the", 1582], ["pathogenetic", 1586], ["mechanisms", 1599], ["of", 1610], ["acanthocytosis", 1613], [",", 1627], ["myopathy", 1629], [",", 1637], ["and", 1639], ["striatal", 1643], ["neurodegeneration", 1652], ["in", 1670], ["McLeod", 1673], ["syndrome", 1680], [".", 1688]]}
{"context": "Loss of consciousness in childhood may be due to cardiovascular causes, and the Long Q-T syndromes can present with seizures. The Romano-Ward syndrome is of autosomal dominant inheritance, and the Jervell and Lange-Nielson syndrome, with associated deafness, of autosomal recessive inheritance. The diagnosis is often delayed, but a careful history can avoid this. The syndromes can appear to be due to an imbalance in the sympathetic nerve to the ventricular myocardium, and precipitating causes such as stress suggest a CNS influence on this. The electrocardiogram can confirm the prolonged Q-T interval, but this is not always present, at least without an exercise test. Treatment with beta-blockers is often successful. If a wrong diagnosis of epilepsy is made a chance may be missed of avoiding sudden death, quite apart from all the medical, and social consequences that can result from such a diagnosis.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "8f255d79fc124b75bbeb22b7b675d5cd", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[31, 32]], "char_spans": [[157, 174]]}]}], "context_tokens": [["Loss", 0], ["of", 5], ["consciousness", 8], ["in", 22], ["childhood", 25], ["may", 35], ["be", 39], ["due", 42], ["to", 46], ["cardiovascular", 49], ["causes", 64], [",", 70], ["and", 72], ["the", 76], ["Long", 80], ["Q", 85], ["-", 86], ["T", 87], ["syndromes", 89], ["can", 99], ["present", 103], ["with", 111], ["seizures", 116], [".", 124], ["The", 126], ["Romano", 130], ["-", 136], ["Ward", 137], ["syndrome", 142], ["is", 151], ["of", 154], ["autosomal", 157], ["dominant", 167], ["inheritance", 176], [",", 187], ["and", 189], ["the", 193], ["Jervell", 197], ["and", 205], ["Lange", 209], ["-", 214], ["Nielson", 215], ["syndrome", 223], [",", 231], ["with", 233], ["associated", 238], ["deafness", 249], [",", 257], ["of", 259], ["autosomal", 262], ["recessive", 272], ["inheritance", 282], [".", 293], ["The", 295], ["diagnosis", 299], ["is", 309], ["often", 312], ["delayed", 318], [",", 325], ["but", 327], ["a", 331], ["careful", 333], ["history", 341], ["can", 349], ["avoid", 353], ["this", 359], [".", 363], ["The", 365], ["syndromes", 369], ["can", 379], ["appear", 383], ["to", 390], ["be", 393], ["due", 396], ["to", 400], ["an", 403], ["imbalance", 406], ["in", 416], ["the", 419], ["sympathetic", 423], ["nerve", 435], ["to", 441], ["the", 444], ["ventricular", 448], ["myocardium", 460], [",", 470], ["and", 472], ["precipitating", 476], ["causes", 490], ["such", 497], ["as", 502], ["stress", 505], ["suggest", 512], ["a", 520], ["CNS", 522], ["influence", 526], ["on", 536], ["this", 539], [".", 543], ["The", 545], ["electrocardiogram", 549], ["can", 567], ["confirm", 571], ["the", 579], ["prolonged", 583], ["Q", 593], ["-", 594], ["T", 595], ["interval", 597], [",", 605], ["but", 607], ["this", 611], ["is", 616], ["not", 619], ["always", 623], ["present", 630], [",", 637], ["at", 639], ["least", 642], ["without", 648], ["an", 656], ["exercise", 659], ["test", 668], [".", 672], ["Treatment", 674], ["with", 684], ["beta", 689], ["-", 693], ["blockers", 694], ["is", 703], ["often", 706], ["successful", 712], [".", 722], ["If", 724], ["a", 727], ["wrong", 729], ["diagnosis", 735], ["of", 745], ["epilepsy", 748], ["is", 757], ["made", 760], ["a", 765], ["chance", 767], ["may", 774], ["be", 778], ["missed", 781], ["of", 788], ["avoiding", 791], ["sudden", 800], ["death", 807], [",", 812], ["quite", 814], ["apart", 820], ["from", 826], ["all", 831], ["the", 835], ["medical", 839], [",", 846], ["and", 848], ["social", 852], ["consequences", 859], ["that", 872], ["can", 877], ["result", 881], ["from", 888], ["such", 893], ["a", 898], ["diagnosis", 900], [".", 909]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "301b11ff9a5742d3b24508da29ebffcd", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[229, 229], [5, 5], [74, 74], [124, 124], [281, 281], [158, 158], [255, 255]], "char_spans": [[1325, 1328], [26, 29], [459, 462], [712, 715], [1670, 1673], [930, 933], [1485, 1488]]}]}], "context_tokens": [["GATA-1", 0], ["and", 7], ["the", 11], ["ets", 15], ["factor", 19], ["PU.1", 26], ["have", 31], ["been", 36], ["reported", 41], ["to", 50], ["functionally", 53], ["antagonize", 66], ["one", 77], ["another", 81], ["in", 89], ["the", 92], ["regulation", 96], ["of", 107], ["erythroid", 110], ["versus", 120], ["myeloid", 127], ["gene", 135], ["transcription", 140], ["and", 154], ["development", 158], [".", 169], ["The", 171], ["CCAAT", 175], ["enhancer", 181], ["binding", 190], ["protein", 198], ["epsilon", 206], ["(", 214], ["C", 215], ["/", 216], ["EBPepsilon", 217], [")", 227], ["is", 229], ["expressed", 232], ["as", 242], ["multiple", 245], ["isoforms", 254], ["and", 263], ["has", 267], ["been", 271], ["shown", 276], ["to", 282], ["be", 285], ["essential", 288], ["to", 298], ["myeloid", 301], ["(", 309], ["granulocyte", 310], [")", 321], ["terminal", 323], ["differentiation", 332], [".", 347], ["We", 349], ["have", 352], ["defined", 357], ["a", 365], ["novel", 367], ["synergistic", 373], [",", 384], ["as", 386], ["opposed", 389], ["to", 397], ["antagonistic", 400], [",", 412], ["combinatorial", 414], ["interaction", 428], ["between", 440], ["GATA-1", 448], ["and", 455], ["PU.1", 459], [",", 463], ["and", 465], ["a", 469], ["unique", 471], ["repressor", 478], ["role", 488], ["for", 493], ["certain", 497], ["C", 505], ["/", 506], ["EBPepsilon", 507], ["isoforms", 518], ["in", 527], ["the", 530], ["transcriptional", 534], ["regulation", 550], ["of", 561], ["a", 564], ["model", 566], ["eosinophil", 572], ["granulocyte", 583], ["gene", 595], [",", 599], ["the", 601], ["major", 605], ["basic", 611], ["protein", 617], ["(", 625], ["MBP", 626], [")", 629], [".", 630], ["The", 632], ["eosinophil", 636], ["-", 646], ["specific", 647], ["P2", 656], ["promoter", 659], ["of", 668], ["the", 671], ["MBP", 675], ["gene", 679], ["contains", 684], ["GATA-1", 693], [",", 699], ["C", 701], ["/", 702], ["EBP", 703], [",", 706], ["and", 708], ["PU.1", 712], ["consensus", 717], ["sites", 727], ["that", 733], ["bind", 738], ["these", 743], ["factors", 749], ["in", 757], ["nuclear", 760], ["extracts", 768], ["of", 777], ["the", 780], ["eosinophil", 784], ["myelocyte", 795], ["cell", 805], ["line", 810], [",", 814], ["AML14.3D10", 816], [".", 826], ["The", 828], ["promoter", 832], ["is", 841], ["transactivated", 844], ["by", 859], ["GATA-1", 862], ["alone", 869], ["but", 875], ["is", 879], ["synergistically", 882], ["transactivated", 898], ["by", 913], ["low", 916], ["levels", 920], ["of", 927], ["PU.1", 930], ["in", 935], ["the", 938], ["context", 942], ["of", 950], ["optimal", 953], ["levels", 961], ["of", 968], ["GATA-1", 971], [".", 977], ["The", 979], ["C", 983], ["/", 984], ["EBPepsilon(27", 985], [")", 998], ["isoform", 1000], ["strongly", 1008], ["represses", 1017], ["GATA-1", 1027], ["activity", 1034], ["and", 1043], ["completely", 1047], ["blocks", 1058], ["GATA-1/PU.1", 1065], ["synergy", 1077], [".", 1084], ["In", 1086], ["vitro", 1089], ["mutational", 1095], ["analyses", 1106], ["of", 1115], ["the", 1118], ["MBP", 1122], ["-", 1125], ["P2", 1126], ["promoter", 1129], ["showed", 1138], ["that", 1145], ["both", 1150], ["the", 1155], ["GATA-1/PU.1", 1159], ["synergy", 1171], [",", 1178], ["and", 1180], ["repressor", 1184], ["activity", 1194], ["of", 1203], ["C", 1206], ["/", 1207], ["EBPepsilon(27", 1208], [")", 1221], ["are", 1223], ["mediated", 1227], ["via", 1236], ["protein", 1240], ["-", 1247], ["protein", 1248], ["interactions", 1256], ["through", 1269], ["the", 1277], ["C", 1281], ["/", 1282], ["EBP", 1283], ["and/or", 1287], ["GATA", 1294], ["-", 1298], ["binding", 1299], ["sites", 1307], ["but", 1313], ["not", 1317], ["the", 1321], ["PU.1", 1325], ["sites", 1330], [".", 1335], ["Co", 1337], ["-", 1339], ["immunoprecipitations", 1340], ["using", 1361], ["lysates", 1367], ["of", 1375], ["AML14.3D10", 1378], ["eosinophils", 1389], ["show", 1401], ["that", 1406], ["both", 1411], ["C", 1416], ["/", 1417], ["EBPepsilon(32/30", 1418], [")", 1434], ["and", 1436], ["epsilon(27", 1440], [")", 1450], ["physically", 1452], ["interact", 1463], ["in", 1472], ["vivo", 1475], ["with", 1480], ["PU.1", 1485], ["and", 1490], ["GATA-1", 1494], [",", 1500], ["demonstrating", 1502], ["functional", 1516], ["interactions", 1527], ["among", 1540], ["these", 1546], ["factors", 1552], ["in", 1560], ["eosinophil", 1563], ["progenitors", 1574], [".", 1585], ["Our", 1587], ["findings", 1591], ["identify", 1600], ["novel", 1609], ["combinatorial", 1615], ["protein", 1629], ["-", 1636], ["protein", 1637], ["interactions", 1645], ["for", 1658], ["GATA-1", 1662], [",", 1668], ["PU.1", 1670], [",", 1674], ["and", 1676], ["C", 1680], ["/", 1681], ["EBPepsilon", 1682], ["isoforms", 1693], ["in", 1702], ["eosinophil", 1705], ["gene", 1716], ["transcription", 1721], ["that", 1735], ["include", 1740], ["GATA-1/PU.1", 1748], ["synergy", 1760], ["and", 1768], ["repressor", 1772], ["activity", 1782], ["for", 1791], ["C", 1795], ["/", 1796], ["EBPepsilon(27", 1797], [")", 1810], [".", 1811]]}
{"context": "To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides. A solvent casting method was used to manufacture the films. Solid phase solubility was used to identify potential polymers for use in the film formulation. Physical and chemical properties (such as water content, puncture strength and in vitro release) and product stability were determined. The bioactivity of the film products against HIV was assessed using the TZM-bl assay and a cervical explant model. Polymers identified from the solid phase solubility study maintained tenofovir and maraviroc in an amorphous state and prevented drug crystallization. Three combination film products were developed using cellulose polymers and polyvinyl alcohol. The residual water content in all films was <10% (w/w). All films delivered the active agents with release of >50% of film drug content within 30 min. Stability testing confirmed that the combination film products were stable for 12 months at ambient temperature and 6 months under stressed conditions. Antiviral activity was confirmed in TZM-bl and cervical explant models. Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "387330c38e704509996ffc03774c1391", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[82, 82], [10, 10]], "char_spans": [[505, 507], [64, 66]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["polymeric", 11], ["films", 21], ["containing", 27], ["dual", 38], ["combinations", 43], ["of", 56], ["anti", 59], ["-", 63], ["HIV", 64], ["drug", 68], ["candidate", 73], ["tenofovir", 83], [",", 92], ["maraviroc", 94], ["and", 104], ["dapivirine", 108], ["for", 119], ["vaginal", 123], ["application", 131], ["as", 143], ["topical", 146], ["microbicides", 154], [".", 166], ["A", 168], ["solvent", 170], ["casting", 178], ["method", 186], ["was", 193], ["used", 197], ["to", 202], ["manufacture", 205], ["the", 217], ["films", 221], [".", 226], ["Solid", 228], ["phase", 234], ["solubility", 240], ["was", 251], ["used", 255], ["to", 260], ["identify", 263], ["potential", 272], ["polymers", 282], ["for", 291], ["use", 295], ["in", 299], ["the", 302], ["film", 306], ["formulation", 311], [".", 322], ["Physical", 324], ["and", 333], ["chemical", 337], ["properties", 346], ["(", 357], ["such", 358], ["as", 363], ["water", 366], ["content", 372], [",", 379], ["puncture", 381], ["strength", 390], ["and", 399], ["in", 403], ["vitro", 406], ["release", 412], [")", 419], ["and", 421], ["product", 425], ["stability", 433], ["were", 443], ["determined", 448], [".", 458], ["The", 460], ["bioactivity", 464], ["of", 476], ["the", 479], ["film", 483], ["products", 488], ["against", 497], ["HIV", 505], ["was", 509], ["assessed", 513], ["using", 522], ["the", 528], ["TZM", 532], ["-", 535], ["bl", 536], ["assay", 539], ["and", 545], ["a", 549], ["cervical", 551], ["explant", 560], ["model", 568], [".", 573], ["Polymers", 575], ["identified", 584], ["from", 595], ["the", 600], ["solid", 604], ["phase", 610], ["solubility", 616], ["study", 627], ["maintained", 633], ["tenofovir", 644], ["and", 654], ["maraviroc", 658], ["in", 668], ["an", 671], ["amorphous", 674], ["state", 684], ["and", 690], ["prevented", 694], ["drug", 704], ["crystallization", 709], [".", 724], ["Three", 726], ["combination", 732], ["film", 744], ["products", 749], ["were", 758], ["developed", 763], ["using", 773], ["cellulose", 779], ["polymers", 789], ["and", 798], ["polyvinyl", 802], ["alcohol", 812], [".", 819], ["The", 821], ["residual", 825], ["water", 834], ["content", 840], ["in", 848], ["all", 851], ["films", 855], ["was", 861], ["<", 865], ["10", 866], ["%", 868], ["(", 870], ["w", 871], ["/", 872], ["w", 873], [")", 874], [".", 875], ["All", 877], ["films", 881], ["delivered", 887], ["the", 897], ["active", 901], ["agents", 908], ["with", 915], ["release", 920], ["of", 928], [">", 931], ["50", 932], ["%", 934], ["of", 936], ["film", 939], ["drug", 944], ["content", 949], ["within", 957], ["30", 964], ["min", 967], [".", 970], ["Stability", 972], ["testing", 982], ["confirmed", 990], ["that", 1000], ["the", 1005], ["combination", 1009], ["film", 1021], ["products", 1026], ["were", 1035], ["stable", 1040], ["for", 1047], ["12", 1051], ["months", 1054], ["at", 1061], ["ambient", 1064], ["temperature", 1072], ["and", 1084], ["6", 1088], ["months", 1090], ["under", 1097], ["stressed", 1103], ["conditions", 1112], [".", 1122], ["Antiviral", 1124], ["activity", 1134], ["was", 1143], ["confirmed", 1147], ["in", 1157], ["TZM", 1160], ["-", 1163], ["bl", 1164], ["and", 1167], ["cervical", 1171], ["explant", 1180], ["models", 1188], [".", 1194], ["Polymeric", 1196], ["films", 1206], ["can", 1212], ["be", 1216], ["used", 1219], ["as", 1224], ["a", 1227], ["stable", 1229], ["dosage", 1236], ["form", 1243], ["for", 1248], ["the", 1252], ["delivery", 1256], ["of", 1265], ["antiretroviral", 1268], ["combinations", 1283], ["as", 1296], ["microbicides", 1299], [".", 1311]]}
{"context": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria. Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses. The aim of the study was to determine the prevalence of the etiologic agents of superficial mycoses and the frequency of Corynebacterium minutissimum in interdigital foot infections. All the samples obtained from the 121 patients with interdigital foot infections were examined directly with the use of 20% potassium hydroxide mounts and Gram stain under the microscope and cultured on Sabouraud's dextrose agar plates. In identification of superficial mycoses, the rate was found to be 14% with the cultural method and 14% with direct microscopic examination. Using a combination of direct microscopic examination and culture, a 33.8% ratio was achieved. In the culture of these samples, the most isolated factor was Trichophyton rubrum (33.7%). In 24 of the patients (19.8%) Corynebacterium minutissimum was detected by Gram staining, in 6 of these patients Trichophyton rubrum was found, Trichophyton mentagrophytes was found in 2 and Trichosporon spp. was found in 1. The examination of interdigital foot lesions in the laboratory, the coexistence of erythrasma with dermatophytes and yeast should be considered.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f20fb69656624faba286b877bd7b0c35", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[20, 21], [50, 51], [167, 168]], "char_spans": [[136, 163], [328, 355], [984, 1011]]}]}], "context_tokens": [["Interdigital", 0], ["foot", 13], ["infections", 18], ["are", 29], ["mostly", 33], ["caused", 40], ["initially", 47], ["by", 57], ["dermatophytes", 60], [",", 73], ["yeasts", 75], ["and", 82], ["less", 86], ["frequently", 91], ["by", 102], ["bacteria", 105], [".", 113], ["Erythrasma", 115], ["caused", 126], ["by", 133], ["Corynebacterium", 136], ["minutissimum", 152], ["can", 165], ["be", 169], ["confused", 172], ["with", 181], ["superficial", 186], ["mycoses", 198], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["the", 218], ["study", 222], ["was", 228], ["to", 232], ["determine", 235], ["the", 245], ["prevalence", 249], ["of", 260], ["the", 263], ["etiologic", 267], ["agents", 277], ["of", 284], ["superficial", 287], ["mycoses", 299], ["and", 307], ["the", 311], ["frequency", 315], ["of", 325], ["Corynebacterium", 328], ["minutissimum", 344], ["in", 357], ["interdigital", 360], ["foot", 373], ["infections", 378], [".", 388], ["All", 390], ["the", 394], ["samples", 398], ["obtained", 406], ["from", 415], ["the", 420], ["121", 424], ["patients", 428], ["with", 437], ["interdigital", 442], ["foot", 455], ["infections", 460], ["were", 471], ["examined", 476], ["directly", 485], ["with", 494], ["the", 499], ["use", 503], ["of", 507], ["20", 510], ["%", 512], ["potassium", 514], ["hydroxide", 524], ["mounts", 534], ["and", 541], ["Gram", 545], ["stain", 550], ["under", 556], ["the", 562], ["microscope", 566], ["and", 577], ["cultured", 581], ["on", 590], ["Sabouraud", 593], ["'s", 602], ["dextrose", 605], ["agar", 614], ["plates", 619], [".", 625], ["In", 627], ["identification", 630], ["of", 645], ["superficial", 648], ["mycoses", 660], [",", 667], ["the", 669], ["rate", 673], ["was", 678], ["found", 682], ["to", 688], ["be", 691], ["14", 694], ["%", 696], ["with", 698], ["the", 703], ["cultural", 707], ["method", 716], ["and", 723], ["14", 727], ["%", 729], ["with", 731], ["direct", 736], ["microscopic", 743], ["examination", 755], [".", 766], ["Using", 768], ["a", 774], ["combination", 776], ["of", 788], ["direct", 791], ["microscopic", 798], ["examination", 810], ["and", 822], ["culture", 826], [",", 833], ["a", 835], ["33.8", 837], ["%", 841], ["ratio", 843], ["was", 849], ["achieved", 853], [".", 861], ["In", 863], ["the", 866], ["culture", 870], ["of", 878], ["these", 881], ["samples", 887], [",", 894], ["the", 896], ["most", 900], ["isolated", 905], ["factor", 914], ["was", 921], ["Trichophyton", 925], ["rubrum", 938], ["(", 945], ["33.7", 946], ["%", 950], [")", 951], [".", 952], ["In", 954], ["24", 957], ["of", 960], ["the", 963], ["patients", 967], ["(", 976], ["19.8", 977], ["%", 981], [")", 982], ["Corynebacterium", 984], ["minutissimum", 1000], ["was", 1013], ["detected", 1017], ["by", 1026], ["Gram", 1029], ["staining", 1034], [",", 1042], ["in", 1044], ["6", 1047], ["of", 1049], ["these", 1052], ["patients", 1058], ["Trichophyton", 1067], ["rubrum", 1080], ["was", 1087], ["found", 1091], [",", 1096], ["Trichophyton", 1098], ["mentagrophytes", 1111], ["was", 1126], ["found", 1130], ["in", 1136], ["2", 1139], ["and", 1141], ["Trichosporon", 1145], ["spp", 1158], [".", 1161], ["was", 1163], ["found", 1167], ["in", 1173], ["1", 1176], [".", 1177], ["The", 1179], ["examination", 1183], ["of", 1195], ["interdigital", 1198], ["foot", 1211], ["lesions", 1216], ["in", 1224], ["the", 1227], ["laboratory", 1231], [",", 1241], ["the", 1243], ["coexistence", 1247], ["of", 1259], ["erythrasma", 1262], ["with", 1273], ["dermatophytes", 1278], ["and", 1292], ["yeast", 1296], ["should", 1302], ["be", 1309], ["considered", 1312], [".", 1322]]}
{"context": "The worldwide expansion in the use of benzodiazepines has led to their frequent, and often inappropriate, use and to increase in their involvement in self-induced poisoning and iatrogenic overdosing. Flumazenil is a specific and competitive antagonist at the central benzodiazepine receptor, reversing all effects of benzodiazepine agonists without tranquillising or anticonvulsant actions. Incremental intravenous bolus injections of flumazenil 0.1 to 0.3 mg are the most effective and well tolerated in the diagnosis and treatment of pure benzodiazepine overdose; additional boluses or an infusion (0.3 to 0.5 mg/h) can be given to prevent patients from relapsing into coma. Intravenous flumazenil 10 to 20 micrograms/kg is effective in neonates and small children. Intramuscular, oral (20 to 25 mg 3 times daily or as required) and rectal administration may be used as alternatives in long term regimens. Patients with mixed-drug overdose require higher doses (up to 2 mg bolus, approximately equal to 1 mg/h infusion) to regain consciousness. Children and the elderly, chronically ill patients, and pregnant women and their fetuses all respond satisfactorily to flumazenil, but the usefulness of the drug in patients with hepatic encephalopathy and alcohol overdose is debatable. The use of flumazenil results in complete awakening with restoration of upper airway protective reflexes, thus enabling gastric lavage to be performed and transfer of the patient from the emergency room to another hospital department. Resumption of effective spontaneous respiration allows for expeditious extubation, weaning off mechanical ventilation or the avoidance of endotracheal intubation. While flumazenil is not associated with haemodynamic adverse effects, caution should be exercised when using this agent in patients who have co-ingested chloral hydrate to carbamazepine or whose ECG shows abnormalities typical to those seen after overdose with tricyclic antidepressants (TCAs); the use of flumazenil in the presence of these drugs can sometimes induce treatable cardiac dysrrhythmia. Flumazenil per se does not induce adverse effects. Coma reversal by flumazenil may cause mild, short-lived reactions caused by sudden awakening. Withdrawal symptoms in long term benzodiazepine users and seizures in patients who have taken an overdose of TCA or carbamazepine and a benzodiazepine can occur with flumazenil; these symptoms are avoidable by utilising slow flumazenil dose titration.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "369cc5a5643045aebe426287af31c52b", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[64, 64], [224, 224], [355, 355], [395, 395], [202, 202], [404, 404], [329, 329], [343, 343], [280, 280], [34, 34], [111, 111]], "char_spans": [[435, 444], [1295, 1304], [2151, 2160], [2394, 2403], [1166, 1175], [2453, 2462], [1988, 1997], [2083, 2092], [1688, 1697], [200, 209], [689, 698]]}]}], "context_tokens": [["The", 0], ["worldwide", 4], ["expansion", 14], ["in", 24], ["the", 27], ["use", 31], ["of", 35], ["benzodiazepines", 38], ["has", 54], ["led", 58], ["to", 62], ["their", 65], ["frequent", 71], [",", 79], ["and", 81], ["often", 85], ["inappropriate", 91], [",", 104], ["use", 106], ["and", 110], ["to", 114], ["increase", 117], ["in", 126], ["their", 129], ["involvement", 135], ["in", 147], ["self", 150], ["-", 154], ["induced", 155], ["poisoning", 163], ["and", 173], ["iatrogenic", 177], ["overdosing", 188], [".", 198], ["Flumazenil", 200], ["is", 211], ["a", 214], ["specific", 216], ["and", 225], ["competitive", 229], ["antagonist", 241], ["at", 252], ["the", 255], ["central", 259], ["benzodiazepine", 267], ["receptor", 282], [",", 290], ["reversing", 292], ["all", 302], ["effects", 306], ["of", 314], ["benzodiazepine", 317], ["agonists", 332], ["without", 341], ["tranquillising", 349], ["or", 364], ["anticonvulsant", 367], ["actions", 382], [".", 389], ["Incremental", 391], ["intravenous", 403], ["bolus", 415], ["injections", 421], ["of", 432], ["flumazenil", 435], ["0.1", 446], ["to", 450], ["0.3", 453], ["mg", 457], ["are", 460], ["the", 464], ["most", 468], ["effective", 473], ["and", 483], ["well", 487], ["tolerated", 492], ["in", 502], ["the", 505], ["diagnosis", 509], ["and", 519], ["treatment", 523], ["of", 533], ["pure", 536], ["benzodiazepine", 541], ["overdose", 556], [";", 564], ["additional", 566], ["boluses", 577], ["or", 585], ["an", 588], ["infusion", 591], ["(", 600], ["0.3", 601], ["to", 605], ["0.5", 608], ["mg", 612], ["/", 614], ["h", 615], [")", 616], ["can", 618], ["be", 622], ["given", 625], ["to", 631], ["prevent", 634], ["patients", 642], ["from", 651], ["relapsing", 656], ["into", 666], ["coma", 671], [".", 675], ["Intravenous", 677], ["flumazenil", 689], ["10", 700], ["to", 703], ["20", 706], ["micrograms", 709], ["/", 719], ["kg", 720], ["is", 723], ["effective", 726], ["in", 736], ["neonates", 739], ["and", 748], ["small", 752], ["children", 758], [".", 766], ["Intramuscular", 768], [",", 781], ["oral", 783], ["(", 788], ["20", 789], ["to", 792], ["25", 795], ["mg", 798], ["3", 801], ["times", 803], ["daily", 809], ["or", 815], ["as", 818], ["required", 821], [")", 829], ["and", 831], ["rectal", 835], ["administration", 842], ["may", 857], ["be", 861], ["used", 864], ["as", 869], ["alternatives", 872], ["in", 885], ["long", 888], ["term", 893], ["regimens", 898], [".", 906], ["Patients", 908], ["with", 917], ["mixed", 922], ["-", 927], ["drug", 928], ["overdose", 933], ["require", 942], ["higher", 950], ["doses", 957], ["(", 963], ["up", 964], ["to", 967], ["2", 970], ["mg", 972], ["bolus", 975], [",", 980], ["approximately", 982], ["equal", 996], ["to", 1002], ["1", 1005], ["mg", 1007], ["/", 1009], ["h", 1010], ["infusion", 1012], [")", 1020], ["to", 1022], ["regain", 1025], ["consciousness", 1032], [".", 1045], ["Children", 1047], ["and", 1056], ["the", 1060], ["elderly", 1064], [",", 1071], ["chronically", 1073], ["ill", 1085], ["patients", 1089], [",", 1097], ["and", 1099], ["pregnant", 1103], ["women", 1112], ["and", 1118], ["their", 1122], ["fetuses", 1128], ["all", 1136], ["respond", 1140], ["satisfactorily", 1148], ["to", 1163], ["flumazenil", 1166], [",", 1176], ["but", 1178], ["the", 1182], ["usefulness", 1186], ["of", 1197], ["the", 1200], ["drug", 1204], ["in", 1209], ["patients", 1212], ["with", 1221], ["hepatic", 1226], ["encephalopathy", 1234], ["and", 1249], ["alcohol", 1253], ["overdose", 1261], ["is", 1270], ["debatable", 1273], [".", 1282], ["The", 1284], ["use", 1288], ["of", 1292], ["flumazenil", 1295], ["results", 1306], ["in", 1314], ["complete", 1317], ["awakening", 1326], ["with", 1336], ["restoration", 1341], ["of", 1353], ["upper", 1356], ["airway", 1362], ["protective", 1369], ["reflexes", 1380], [",", 1388], ["thus", 1390], ["enabling", 1395], ["gastric", 1404], ["lavage", 1412], ["to", 1419], ["be", 1422], ["performed", 1425], ["and", 1435], ["transfer", 1439], ["of", 1448], ["the", 1451], ["patient", 1455], ["from", 1463], ["the", 1468], ["emergency", 1472], ["room", 1482], ["to", 1487], ["another", 1490], ["hospital", 1498], ["department", 1507], [".", 1517], ["Resumption", 1519], ["of", 1530], ["effective", 1533], ["spontaneous", 1543], ["respiration", 1555], ["allows", 1567], ["for", 1574], ["expeditious", 1578], ["extubation", 1590], [",", 1600], ["weaning", 1602], ["off", 1610], ["mechanical", 1614], ["ventilation", 1625], ["or", 1637], ["the", 1640], ["avoidance", 1644], ["of", 1654], ["endotracheal", 1657], ["intubation", 1670], [".", 1680], ["While", 1682], ["flumazenil", 1688], ["is", 1699], ["not", 1702], ["associated", 1706], ["with", 1717], ["haemodynamic", 1722], ["adverse", 1735], ["effects", 1743], [",", 1750], ["caution", 1752], ["should", 1760], ["be", 1767], ["exercised", 1770], ["when", 1780], ["using", 1785], ["this", 1791], ["agent", 1796], ["in", 1802], ["patients", 1805], ["who", 1814], ["have", 1818], ["co", 1823], ["-", 1825], ["ingested", 1826], ["chloral", 1835], ["hydrate", 1843], ["to", 1851], ["carbamazepine", 1854], ["or", 1868], ["whose", 1871], ["ECG", 1877], ["shows", 1881], ["abnormalities", 1887], ["typical", 1901], ["to", 1909], ["those", 1912], ["seen", 1918], ["after", 1923], ["overdose", 1929], ["with", 1938], ["tricyclic", 1943], ["antidepressants", 1953], ["(", 1969], ["TCAs", 1970], [")", 1974], [";", 1975], ["the", 1977], ["use", 1981], ["of", 1985], ["flumazenil", 1988], ["in", 1999], ["the", 2002], ["presence", 2006], ["of", 2015], ["these", 2018], ["drugs", 2024], ["can", 2030], ["sometimes", 2034], ["induce", 2044], ["treatable", 2051], ["cardiac", 2061], ["dysrrhythmia", 2069], [".", 2081], ["Flumazenil", 2083], ["per", 2094], ["se", 2098], ["does", 2101], ["not", 2106], ["induce", 2110], ["adverse", 2117], ["effects", 2125], [".", 2132], ["Coma", 2134], ["reversal", 2139], ["by", 2148], ["flumazenil", 2151], ["may", 2162], ["cause", 2166], ["mild", 2172], [",", 2176], ["short", 2178], ["-", 2183], ["lived", 2184], ["reactions", 2190], ["caused", 2200], ["by", 2207], ["sudden", 2210], ["awakening", 2217], [".", 2226], ["Withdrawal", 2228], ["symptoms", 2239], ["in", 2248], ["long", 2251], ["term", 2256], ["benzodiazepine", 2261], ["users", 2276], ["and", 2282], ["seizures", 2286], ["in", 2295], ["patients", 2298], ["who", 2307], ["have", 2311], ["taken", 2316], ["an", 2322], ["overdose", 2325], ["of", 2334], ["TCA", 2337], ["or", 2341], ["carbamazepine", 2344], ["and", 2358], ["a", 2362], ["benzodiazepine", 2364], ["can", 2379], ["occur", 2383], ["with", 2389], ["flumazenil", 2394], [";", 2404], ["these", 2406], ["symptoms", 2412], ["are", 2421], ["avoidable", 2425], ["by", 2435], ["utilising", 2438], ["slow", 2448], ["flumazenil", 2453], ["dose", 2464], ["titration", 2469], [".", 2478]]}
{"context": "Histone methyltransferase (HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is histone methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf7e56357754453da53cec3c83cb7ef2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[22, 23], [134, 135]], "char_spans": [[150, 159], [799, 808]]}]}], "context_tokens": [["Histone", 0], ["methyltransferase", 8], ["(", 26], ["HMT)(1", 27], [")", 33], ["class", 35], ["enzymes", 41], ["that", 49], ["methylate", 54], ["lysine", 64], ["residues", 71], ["of", 80], ["histones", 83], ["or", 92], ["proteins", 95], ["contain", 104], ["a", 112], ["conserved", 114], ["catalytic", 124], ["core", 134], ["termed", 139], ["the", 146], ["SET", 150], ["domain", 154], [",", 160], ["which", 162], ["shares", 168], ["sequence", 175], ["homology", 184], ["with", 193], ["an", 198], ["independently", 201], ["described", 215], ["sequence", 225], ["motif", 234], [",", 239], ["the", 241], ["PR", 245], ["domain", 248], [".", 254], ["Intact", 256], ["PR", 263], ["or", 266], ["SET", 269], ["sequence", 273], ["is", 282], ["required", 285], ["for", 294], ["tumor", 298], ["suppression", 304], ["functions", 316], [",", 325], ["but", 327], ["it", 331], ["remains", 334], ["unclear", 342], ["whether", 350], ["it", 358], ["is", 361], ["histone", 364], ["methyltransferase", 372], ["activity", 390], ["that", 399], ["underlies", 404], ["tumor", 414], ["suppression", 420], [".", 431], ["We", 433], ["now", 436], ["show", 440], ["that", 445], ["tumor", 450], ["suppressor", 456], ["RIZ1", 467], ["(", 472], ["PRDM2", 473], [")", 478], ["methylates", 480], ["histone", 491], ["H3", 499], ["on", 502], ["lysine", 505], ["9", 512], [",", 513], ["and", 515], ["this", 519], ["activity", 524], ["is", 533], ["reduced", 536], ["by", 544], ["mutations", 547], ["in", 557], ["the", 560], ["PR", 564], ["domain", 567], ["found", 574], ["in", 580], ["human", 583], ["cancers", 589], [".", 596], ["Also", 598], [",", 602], ["S", 604], ["-", 605], ["adenosylhomocysteine", 606], ["or", 627], ["methyl", 630], ["donor", 637], ["deficiency", 643], ["inhibits", 654], ["RIZ1", 663], ["and", 668], ["other", 672], ["H3", 678], ["lysine", 681], ["9", 688], ["methylation", 690], ["activities", 702], [".", 712], ["These", 714], ["results", 720], ["support", 728], ["the", 736], ["hypothesis", 740], ["that", 751], ["H3", 756], ["lysine", 759], ["9", 766], ["methylation", 768], ["activities", 780], ["of", 791], ["a", 794], ["PR", 796], ["/", 798], ["SET", 799], ["domain", 803], ["have", 810], ["tumor", 815], ["suppression", 821], ["functions", 833], ["and", 843], ["may", 847], ["underlie", 851], ["carcinogenesis", 860], ["associated", 875], ["with", 886], ["dietary", 891], ["methyl", 899], ["donor", 906], ["deficiency", 912], [".", 922]]}
{"context": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels. Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec. Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0641e4745b234652b621a99faaec9192", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[145, 147], [161, 163], [20, 22], [270, 272], [53, 55], [26, 28], [104, 106], [328, 330], [346, 348], [194, 196], [128, 130], [115, 117]], "char_spans": [[794, 800], [899, 905], [127, 133], [1479, 1485], [290, 296], [147, 153], [585, 591], [1812, 1818], [1917, 1923], [1065, 1071], [699, 705], [638, 644]]}]}], "context_tokens": [["The", 0], ["cytogenetic", 4], ["characteristic", 16], ["of", 31], ["Chronic", 34], ["Myeloid", 42], ["Leukemia", 50], ["(", 59], ["CML", 60], [")", 63], ["is", 65], ["the", 68], ["formation", 72], ["of", 82], ["the", 85], ["Philadelphia", 89], ["chromosome", 102], ["gene", 113], ["product", 118], [",", 125], ["BCR", 127], ["-", 130], ["ABL", 131], [".", 134], ["Given", 136], ["that", 142], ["BCR", 147], ["-", 150], ["ABL", 151], ["is", 155], ["the", 158], ["specific", 162], ["target", 171], ["of", 178], ["Gleevec", 181], ["in", 189], ["CML", 192], ["treatment", 196], [",", 205], ["we", 207], ["investigated", 210], ["the", 223], ["regulation", 227], ["of", 238], ["the", 241], ["catalytic", 245], ["component", 255], ["of", 265], ["telomerase", 268], [",", 278], ["hTERT", 280], [",", 285], ["by", 287], ["BCR", 290], ["-", 293], ["ABL", 294], ["at", 298], ["multiple", 301], ["levels", 310], ["in", 317], ["K562", 320], ["cells", 325], [".", 330], ["Molecular", 332], ["techniques", 342], ["such", 353], ["as", 358], ["over", 361], ["expression", 366], [",", 376], ["knockdown", 378], [",", 387], ["real", 389], ["-", 393], ["time", 394], ["PCR", 399], [",", 402], ["immunoprecipitation", 404], [",", 423], ["western", 425], ["blotting", 433], [",", 441], ["reporter", 443], ["assay", 452], [",", 457], ["confocal", 459], ["microscopy", 468], [",", 478], ["telomerase", 480], ["assays", 491], ["and", 498], ["microarray", 502], ["were", 513], ["used", 518], ["to", 523], ["suggest", 526], ["that", 534], ["hTERT", 539], ["expression", 545], ["and", 556], ["activity", 560], ["is", 569], ["modulated", 572], ["by", 582], ["BCR", 585], ["-", 588], ["ABL", 589], ["at", 593], ["multiple", 596], ["levels", 605], [".", 611], ["Our", 613], ["results", 617], ["suggest", 625], ["that", 633], ["BCR", 638], ["-", 641], ["ABL", 642], ["plays", 646], ["an", 652], ["important", 655], ["role", 665], ["in", 670], ["regulating", 673], ["hTERT", 684], ["in", 690], ["K562", 693], ["(", 698], ["BCR", 699], ["-", 702], ["ABL", 703], ["positive", 707], ["human", 716], ["leukemia", 722], [")", 730], ["cells", 732], [".", 737], ["When", 739], ["Gleevec", 744], ["inhibited", 752], ["the", 762], ["tyrosine", 766], ["kinase", 775], ["activity", 782], ["of", 791], ["BCR", 794], ["-", 797], ["ABL", 798], [",", 801], ["phosphorylation", 803], ["of", 819], ["hTERT", 822], ["was", 828], ["downregulated", 832], [",", 845], ["therefore", 847], ["suggesting", 857], ["a", 868], ["positive", 870], ["correlation", 879], ["between", 891], ["BCR", 899], ["-", 902], ["ABL", 903], ["and", 907], ["hTERT", 911], [".", 916], ["Gleevec", 918], ["treatment", 926], ["inhibited", 936], ["hTERT", 946], ["at", 952], ["mRNA", 955], ["level", 960], ["and", 966], ["significantly", 970], ["reduced", 984], ["telomerase", 992], ["activity", 1003], ["(", 1012], ["TA", 1013], [")", 1015], ["in", 1017], ["K562", 1020], ["cells", 1025], [",", 1030], ["but", 1032], ["not", 1036], ["in", 1040], ["HL60", 1043], ["or", 1048], ["Jurkat", 1051], ["cells", 1058], ["(", 1064], ["BCR", 1065], ["-", 1068], ["ABL", 1069], ["negative", 1073], ["cells", 1082], [")", 1087], [".", 1088], ["We", 1090], ["also", 1093], ["demonstrated", 1098], ["that", 1111], ["the", 1116], ["transcription", 1120], ["factor", 1134], ["STAT5a", 1141], ["plays", 1148], ["a", 1154], ["critical", 1156], ["role", 1165], ["in", 1170], ["hTERT", 1173], ["gene", 1179], ["regulation", 1184], ["in", 1195], ["K562", 1198], ["cells", 1203], [".", 1208], ["Knockdown", 1210], ["of", 1220], ["STAT5a", 1223], [",", 1229], ["but", 1231], ["not", 1235], ["STAT5b", 1239], [",", 1245], ["resulted", 1247], ["in", 1256], ["a", 1259], ["marked", 1261], ["downregulation", 1268], ["of", 1283], ["hTERT", 1286], ["mRNA", 1292], ["level", 1297], [",", 1302], ["TA", 1304], ["and", 1307], ["hTERT", 1311], ["protein", 1317], ["level", 1325], ["in", 1331], ["K562", 1334], ["cells", 1339], [".", 1344], ["Furthermore", 1346], [",", 1357], ["translocation", 1359], ["of", 1373], ["hTERT", 1376], ["from", 1382], ["nucleoli", 1387], ["to", 1396], ["nucleoplasm", 1399], ["was", 1411], ["observed", 1415], ["in", 1424], ["K562", 1427], ["cells", 1432], ["induced", 1438], ["by", 1446], ["Gleevec", 1449], [".", 1456], ["Our", 1458], ["data", 1462], ["reveal", 1467], ["that", 1474], ["BCR", 1479], ["-", 1482], ["ABL", 1483], ["can", 1487], ["regulate", 1491], ["TA", 1500], ["at", 1503], ["multiple", 1506], ["levels", 1515], [",", 1521], ["including", 1523], ["transcription", 1533], [",", 1546], ["post", 1548], ["-", 1552], ["translational", 1553], ["level", 1567], [",", 1572], ["and", 1574], ["proper", 1578], ["localization", 1585], [".", 1597], ["Thus", 1599], [",", 1603], ["suppression", 1605], ["of", 1617], ["cell", 1620], ["growth", 1625], ["and", 1632], ["induction", 1636], ["of", 1646], ["apoptosis", 1649], ["by", 1659], ["Gleevec", 1662], ["treatment", 1670], ["may", 1680], ["be", 1684], ["partially", 1687], ["due", 1697], ["to", 1701], ["TA", 1704], ["inhibition", 1707], [".", 1717], ["Additionally", 1719], [",", 1731], ["we", 1733], ["have", 1736], ["identified", 1741], ["STAT5a", 1752], ["as", 1759], ["critical", 1762], ["mediator", 1771], ["of", 1780], ["the", 1783], ["hTERT", 1787], ["gene", 1793], ["expression", 1798], ["in", 1809], ["BCR", 1812], ["-", 1815], ["ABL", 1816], ["positive", 1820], ["CML", 1829], ["cells", 1833], [",", 1838], ["suggesting", 1840], ["that", 1851], ["targeting", 1856], ["STAT5a", 1866], ["may", 1873], ["be", 1877], ["a", 1880], ["promising", 1882], ["therapeutic", 1892], ["strategy", 1904], ["for", 1913], ["BCR", 1917], ["-", 1920], ["ABL", 1921], ["positive", 1925], ["CML", 1934], ["patients", 1938], [".", 1946]]}
{"context": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB). These defects were unaltered in rrm3 sir2 cells. When the RFB binding Fob1p was deleted, rrm3-generated defects at the RFB were eliminated, but defects at other rDNA sites were not affected. Thus, specific protein-DNA complexes make replication Rrm3p-dependent. Because rrm3-induced increases in recombination and cell cycle length were only partially suppressed in rrm3 fob1 cells, which still required checkpoint and fork restart activities for viability, non-RFB rrm3-induced defects contribute to rDNA fragility and genome instability.", "qas": [{"question": "What is the effect of the absence of Saccharomyces cerevisiae Rrm3p?", "answers": ["Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB)."], "qid": "04968485f4484dcc9b26ebe6b289ca4e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["the", 22], ["absence", 26], ["of", 34], ["Saccharomyces", 37], ["cerevisiae", 51], ["Rrm3p", 62], ["?", 67]], "detected_answers": [{"text": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB).", "token_spans": [[0, 27]], "char_spans": [[0, 156]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["the", 8], ["yeast", 12], ["Rrm3p", 18], ["DNA", 24], ["helicase", 28], ["causes", 37], ["replication", 44], ["defects", 56], ["at", 64], ["multiple", 67], ["sites", 76], ["within", 82], ["ribosomal", 89], ["DNA", 99], ["(", 103], ["rDNA", 104], [")", 108], [",", 109], ["including", 111], ["at", 121], ["the", 124], ["replication", 128], ["fork", 140], ["barrier", 145], ["(", 153], ["RFB", 154], [")", 157], [".", 158], ["These", 160], ["defects", 166], ["were", 174], ["unaltered", 179], ["in", 189], ["rrm3", 192], ["sir2", 197], ["cells", 202], [".", 207], ["When", 209], ["the", 214], ["RFB", 218], ["binding", 222], ["Fob1p", 230], ["was", 236], ["deleted", 240], [",", 247], ["rrm3-generated", 249], ["defects", 264], ["at", 272], ["the", 275], ["RFB", 279], ["were", 283], ["eliminated", 288], [",", 298], ["but", 300], ["defects", 304], ["at", 312], ["other", 315], ["rDNA", 321], ["sites", 326], ["were", 332], ["not", 337], ["affected", 341], [".", 349], ["Thus", 351], [",", 355], ["specific", 357], ["protein", 366], ["-", 373], ["DNA", 374], ["complexes", 378], ["make", 388], ["replication", 393], ["Rrm3p", 405], ["-", 410], ["dependent", 411], [".", 420], ["Because", 422], ["rrm3-induced", 430], ["increases", 443], ["in", 453], ["recombination", 456], ["and", 470], ["cell", 474], ["cycle", 479], ["length", 485], ["were", 492], ["only", 497], ["partially", 502], ["suppressed", 512], ["in", 523], ["rrm3", 526], ["fob1", 531], ["cells", 536], [",", 541], ["which", 543], ["still", 549], ["required", 555], ["checkpoint", 564], ["and", 575], ["fork", 579], ["restart", 584], ["activities", 592], ["for", 603], ["viability", 607], [",", 616], ["non", 618], ["-", 621], ["RFB", 622], ["rrm3-induced", 626], ["defects", 639], ["contribute", 647], ["to", 658], ["rDNA", 661], ["fragility", 666], ["and", 676], ["genome", 680], ["instability", 687], [".", 698]]}
{"context": "Polycomb gene silencing requires histone methyltransferase activity of Polycomb repressive complex 2 (PRC2), which methylates lysine 27 of histone H3. Information on how PRC2 works is limited by lack of structural data on the catalytic subunit, Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain. Here we analyze missense alleles of Drosophila E(z), selected for molecular study because of their dominant genetic effects. Four missense alleles identify key E(Z) SET domain residues, and a fifth is located in the adjacent CXC domain. Analysis of mutant PRC2 complexes in vitro, and H3-K27 methylation in vivo, shows that each SET domain mutation disrupts PRC2 histone methyltransferase. Based on known SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group. In contrast, the CXC mutant retains catalytic activity, Lys-27 specificity, and trimethylation capacity. Deletion analysis also reveals a functional requirement for a conserved E(Z) domain N-terminal to CXC and SET. These results identify critical SET domain residues needed for PRC2 enzyme function, and they also emphasize functional inputs from outside the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "94917b06092641a5af6b7e211171d69d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[134, 135], [60, 61], [123, 124], [217, 218], [91, 92], [235, 236]], "char_spans": [[742, 751], [325, 334], [666, 675], [1235, 1244], [502, 511], [1347, 1356]]}]}], "context_tokens": [["Polycomb", 0], ["gene", 9], ["silencing", 14], ["requires", 24], ["histone", 33], ["methyltransferase", 41], ["activity", 59], ["of", 68], ["Polycomb", 71], ["repressive", 80], ["complex", 91], ["2", 99], ["(", 101], ["PRC2", 102], [")", 106], [",", 107], ["which", 109], ["methylates", 115], ["lysine", 126], ["27", 133], ["of", 136], ["histone", 139], ["H3", 147], [".", 149], ["Information", 151], ["on", 163], ["how", 166], ["PRC2", 170], ["works", 175], ["is", 181], ["limited", 184], ["by", 192], ["lack", 195], ["of", 200], ["structural", 203], ["data", 214], ["on", 219], ["the", 222], ["catalytic", 226], ["subunit", 236], [",", 243], ["Enhancer", 245], ["of", 254], ["zeste", 257], ["(", 263], ["E(Z", 264], [")", 267], [")", 268], [",", 269], ["and", 271], ["the", 275], ["paucity", 279], ["of", 287], ["E(z", 290], [")", 293], ["mutant", 295], ["alleles", 302], ["that", 310], ["alter", 315], ["its", 321], ["SET", 325], ["domain", 329], [".", 335], ["Here", 337], ["we", 342], ["analyze", 345], ["missense", 353], ["alleles", 362], ["of", 370], ["Drosophila", 373], ["E(z", 384], [")", 387], [",", 388], ["selected", 390], ["for", 399], ["molecular", 403], ["study", 413], ["because", 419], ["of", 427], ["their", 430], ["dominant", 436], ["genetic", 445], ["effects", 453], [".", 460], ["Four", 462], ["missense", 467], ["alleles", 476], ["identify", 484], ["key", 493], ["E(Z", 497], [")", 500], ["SET", 502], ["domain", 506], ["residues", 513], [",", 521], ["and", 523], ["a", 527], ["fifth", 529], ["is", 535], ["located", 538], ["in", 546], ["the", 549], ["adjacent", 553], ["CXC", 562], ["domain", 566], [".", 572], ["Analysis", 574], ["of", 583], ["mutant", 586], ["PRC2", 593], ["complexes", 598], ["in", 608], ["vitro", 611], [",", 616], ["and", 618], ["H3-K27", 622], ["methylation", 629], ["in", 641], ["vivo", 644], [",", 648], ["shows", 650], ["that", 656], ["each", 661], ["SET", 666], ["domain", 670], ["mutation", 677], ["disrupts", 686], ["PRC2", 695], ["histone", 700], ["methyltransferase", 708], [".", 725], ["Based", 727], ["on", 733], ["known", 736], ["SET", 742], ["domain", 746], ["structures", 753], [",", 763], ["the", 765], ["mutations", 769], ["likely", 779], ["affect", 786], ["either", 793], ["the", 800], ["lysine", 804], ["-", 810], ["substrate", 811], ["binding", 821], ["pocket", 829], [",", 835], ["the", 837], ["binding", 841], ["site", 849], ["for", 854], ["the", 858], ["adenosylmethionine", 862], ["methyl", 881], ["donor", 888], [",", 893], ["or", 895], ["a", 898], ["critical", 900], ["tyrosine", 909], ["predicted", 918], ["to", 928], ["interact", 931], ["with", 940], ["the", 945], ["substrate", 949], ["lysine", 959], ["epsilon", 966], ["-", 973], ["amino", 974], ["group", 980], [".", 985], ["In", 987], ["contrast", 990], [",", 998], ["the", 1000], ["CXC", 1004], ["mutant", 1008], ["retains", 1015], ["catalytic", 1023], ["activity", 1033], [",", 1041], ["Lys-27", 1043], ["specificity", 1050], [",", 1061], ["and", 1063], ["trimethylation", 1067], ["capacity", 1082], [".", 1090], ["Deletion", 1092], ["analysis", 1101], ["also", 1110], ["reveals", 1115], ["a", 1123], ["functional", 1125], ["requirement", 1136], ["for", 1148], ["a", 1152], ["conserved", 1154], ["E(Z", 1164], [")", 1167], ["domain", 1169], ["N", 1176], ["-", 1177], ["terminal", 1178], ["to", 1187], ["CXC", 1190], ["and", 1194], ["SET", 1198], [".", 1201], ["These", 1203], ["results", 1209], ["identify", 1217], ["critical", 1226], ["SET", 1235], ["domain", 1239], ["residues", 1246], ["needed", 1255], ["for", 1262], ["PRC2", 1266], ["enzyme", 1271], ["function", 1278], [",", 1286], ["and", 1288], ["they", 1292], ["also", 1297], ["emphasize", 1302], ["functional", 1312], ["inputs", 1323], ["from", 1330], ["outside", 1335], ["the", 1343], ["SET", 1347], ["domain", 1351], [".", 1357]]}
{"context": "The eukaryotic cell encounters more than one million various kinds of DNA lesions per day. The nucleotide excision repair (NER) pathway is one of the most important repair mechanisms that removes a wide spectrum of different DNA lesions. NER operates through two sub pathways: global genome repair (GGR) and transcription-coupled repair (TCR). GGR repairs the DNA damage throughout the entire genome and is initiated by the HR23B/XPC complex, while the CSB protein-governed TCR process removes DNA lesions from the actively transcribed strand. The sequence of events and the role of particular NER proteins are currently being extensively discussed. NER proteins also participate in other cellular processes like replication, transcription, chromatin maintenance and protein turnover. Defects in NER underlay severe genetic disorders: xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD).", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "ffeaee2811f94587ba59b0c3f1305a3a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[97, 98]], "char_spans": [[524, 541]]}]}], "context_tokens": [["The", 0], ["eukaryotic", 4], ["cell", 15], ["encounters", 20], ["more", 31], ["than", 36], ["one", 41], ["million", 45], ["various", 53], ["kinds", 61], ["of", 67], ["DNA", 70], ["lesions", 74], ["per", 82], ["day", 86], [".", 89], ["The", 91], ["nucleotide", 95], ["excision", 106], ["repair", 115], ["(", 122], ["NER", 123], [")", 126], ["pathway", 128], ["is", 136], ["one", 139], ["of", 143], ["the", 146], ["most", 150], ["important", 155], ["repair", 165], ["mechanisms", 172], ["that", 183], ["removes", 188], ["a", 196], ["wide", 198], ["spectrum", 203], ["of", 212], ["different", 215], ["DNA", 225], ["lesions", 229], [".", 236], ["NER", 238], ["operates", 242], ["through", 251], ["two", 259], ["sub", 263], ["pathways", 267], [":", 275], ["global", 277], ["genome", 284], ["repair", 291], ["(", 298], ["GGR", 299], [")", 302], ["and", 304], ["transcription", 308], ["-", 321], ["coupled", 322], ["repair", 330], ["(", 337], ["TCR", 338], [")", 341], [".", 342], ["GGR", 344], ["repairs", 348], ["the", 356], ["DNA", 360], ["damage", 364], ["throughout", 371], ["the", 382], ["entire", 386], ["genome", 393], ["and", 400], ["is", 404], ["initiated", 407], ["by", 417], ["the", 420], ["HR23B", 424], ["/", 429], ["XPC", 430], ["complex", 434], [",", 441], ["while", 443], ["the", 449], ["CSB", 453], ["protein", 457], ["-", 464], ["governed", 465], ["TCR", 474], ["process", 478], ["removes", 486], ["DNA", 494], ["lesions", 498], ["from", 506], ["the", 511], ["actively", 515], ["transcribed", 524], ["strand", 536], [".", 542], ["The", 544], ["sequence", 548], ["of", 557], ["events", 560], ["and", 567], ["the", 571], ["role", 575], ["of", 580], ["particular", 583], ["NER", 594], ["proteins", 598], ["are", 607], ["currently", 611], ["being", 621], ["extensively", 627], ["discussed", 639], [".", 648], ["NER", 650], ["proteins", 654], ["also", 663], ["participate", 668], ["in", 680], ["other", 683], ["cellular", 689], ["processes", 698], ["like", 708], ["replication", 713], [",", 724], ["transcription", 726], [",", 739], ["chromatin", 741], ["maintenance", 751], ["and", 763], ["protein", 767], ["turnover", 775], [".", 783], ["Defects", 785], ["in", 793], ["NER", 796], ["underlay", 800], ["severe", 809], ["genetic", 816], ["disorders", 824], [":", 833], ["xeroderma", 835], ["pigmentosum", 845], ["(", 857], ["XP", 858], [")", 860], [",", 861], ["Cockayne", 863], ["syndrome", 872], ["(", 881], ["CS", 882], [")", 884], ["and", 886], ["trichothiodystrophy", 890], ["(", 910], ["TTD", 911], [")", 914], [".", 915]]}
{"context": "Embryonic neuroepithelia and adult subventricular zone (SVZ) stem and progenitor cells express nestin. We characterized a transgenic line that expresses enhanced green fluorescent protein (eGFP) specified to neural tissue by the second intronic enhancer of the nestin promoter that had several novel features. During embryogenesis, the dorsal telencephalon contained many and the ventral telencephalon few eGFP+ cells. eGFP+ cells were found in postnatal and adult neurogenic regions. eGFP+ cells in the SVZ expressed multiple phenotype markers, glial fibrillary acidic protein, Dlx, and neuroblast-specific molecules suggesting the transgene is expressed through the lineage. eGFP+ cell numbers increased in the SVZ after cortical injury, suggesting this line will be useful in probing postinjury neurogenesis. In non-neurogenic regions, eGFP was strongly expressed in oligodendrocyte progenitors, but not in astrocytes, even when they were reactive. This eGFP+ mouse will facilitate studies of proliferative neuroepithelia and adult neurogenesis, as well as of parenchymal oligodendrocytes.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "1f13212b55544ebc9031055963334233", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[41, 41], [14, 14]], "char_spans": [[261, 266], [95, 100]]}]}], "context_tokens": [["Embryonic", 0], ["neuroepithelia", 10], ["and", 25], ["adult", 29], ["subventricular", 35], ["zone", 50], ["(", 55], ["SVZ", 56], [")", 59], ["stem", 61], ["and", 66], ["progenitor", 70], ["cells", 81], ["express", 87], ["nestin", 95], [".", 101], ["We", 103], ["characterized", 106], ["a", 120], ["transgenic", 122], ["line", 133], ["that", 138], ["expresses", 143], ["enhanced", 153], ["green", 162], ["fluorescent", 168], ["protein", 180], ["(", 188], ["eGFP", 189], [")", 193], ["specified", 195], ["to", 205], ["neural", 208], ["tissue", 215], ["by", 222], ["the", 225], ["second", 229], ["intronic", 236], ["enhancer", 245], ["of", 254], ["the", 257], ["nestin", 261], ["promoter", 268], ["that", 277], ["had", 282], ["several", 286], ["novel", 294], ["features", 300], [".", 308], ["During", 310], ["embryogenesis", 317], [",", 330], ["the", 332], ["dorsal", 336], ["telencephalon", 343], ["contained", 357], ["many", 367], ["and", 372], ["the", 376], ["ventral", 380], ["telencephalon", 388], ["few", 402], ["eGFP+", 406], ["cells", 412], [".", 417], ["eGFP+", 419], ["cells", 425], ["were", 431], ["found", 436], ["in", 442], ["postnatal", 445], ["and", 455], ["adult", 459], ["neurogenic", 465], ["regions", 476], [".", 483], ["eGFP+", 485], ["cells", 491], ["in", 497], ["the", 500], ["SVZ", 504], ["expressed", 508], ["multiple", 518], ["phenotype", 527], ["markers", 537], [",", 544], ["glial", 546], ["fibrillary", 552], ["acidic", 563], ["protein", 570], [",", 577], ["Dlx", 579], [",", 582], ["and", 584], ["neuroblast", 588], ["-", 598], ["specific", 599], ["molecules", 608], ["suggesting", 618], ["the", 629], ["transgene", 633], ["is", 643], ["expressed", 646], ["through", 656], ["the", 664], ["lineage", 668], [".", 675], ["eGFP+", 677], ["cell", 683], ["numbers", 688], ["increased", 696], ["in", 706], ["the", 709], ["SVZ", 713], ["after", 717], ["cortical", 723], ["injury", 732], [",", 738], ["suggesting", 740], ["this", 751], ["line", 756], ["will", 761], ["be", 766], ["useful", 769], ["in", 776], ["probing", 779], ["postinjury", 787], ["neurogenesis", 798], [".", 810], ["In", 812], ["non", 815], ["-", 818], ["neurogenic", 819], ["regions", 830], [",", 837], ["eGFP", 839], ["was", 844], ["strongly", 848], ["expressed", 857], ["in", 867], ["oligodendrocyte", 870], ["progenitors", 886], [",", 897], ["but", 899], ["not", 903], ["in", 907], ["astrocytes", 910], [",", 920], ["even", 922], ["when", 927], ["they", 932], ["were", 937], ["reactive", 942], [".", 950], ["This", 952], ["eGFP+", 957], ["mouse", 963], ["will", 969], ["facilitate", 974], ["studies", 985], ["of", 993], ["proliferative", 996], ["neuroepithelia", 1010], ["and", 1025], ["adult", 1029], ["neurogenesis", 1035], [",", 1047], ["as", 1049], ["well", 1052], ["as", 1057], ["of", 1060], ["parenchymal", 1063], ["oligodendrocytes", 1075], [".", 1091]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disorder characterized by the appearance of intracytoplasmic inclusions called Lewy bodies (LB) in dopamine neurons in the substantia nigra and the progressive loss of these neurons. Recently, mutations in the alpha-synuclein gene have been identified in early-onset familial PD, and alpha-synuclein has been shown to be a major component of LB in all patients. Yet, the pathophysiological function of alpha-synuclein remains unknown. In this report, we have investigated the toxic effects of adenovirus-mediated alpha-synuclein overexpression on dopamine neurons in rat primary mesencephalic cultures and in a rat dopaminergic cell line - the large T-antigen immortalized, mesencephalon-derived 1RB3AN27 (N27). Adenovirus-transduced cultures showed high-level expression of alpha-synuclein within the cells. Overexpression of human mutant alpha-synuclein (Ala(53)Thr) selectively induced apoptotic programmed cell death of primary dopamine neurons as well as N27 cells. The mutant protein also potentiated the neurotoxicity of 6-hydroxydopamine (6-OHDA). By contrast, overexpression of wild-type human alpha-synuclein was not directly neurotoxic but did increase cell death after 6-OHDA. Overexpression of wild-type rat alpha-synuclein had no effect on dopamine cell survival or 6-OHDA neurotoxicity. These results indicate that overexpression of human mutant alpha-synuclein directly leads to dopamine neuron death, and overexpression of either human mutant or human wild-type alpha-synuclein renders dopamine neurons more vulnerable to neurotoxic insults.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d46479c4ece34bc181a6026e994a86e9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[81, 83], [222, 224], [244, 246], [101, 103], [157, 159], [58, 60], [201, 203], [265, 267], [146, 148], [43, 45]], "char_spans": [[450, 464], [1269, 1283], [1409, 1423], [561, 575], [888, 902], [332, 346], [1151, 1165], [1527, 1541], [823, 837], [258, 272]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disorder", 48], ["characterized", 57], ["by", 71], ["the", 74], ["appearance", 78], ["of", 89], ["intracytoplasmic", 92], ["inclusions", 109], ["called", 120], ["Lewy", 127], ["bodies", 132], ["(", 139], ["LB", 140], [")", 142], ["in", 144], ["dopamine", 147], ["neurons", 156], ["in", 164], ["the", 167], ["substantia", 171], ["nigra", 182], ["and", 188], ["the", 192], ["progressive", 196], ["loss", 208], ["of", 213], ["these", 216], ["neurons", 222], [".", 229], ["Recently", 231], [",", 239], ["mutations", 241], ["in", 251], ["the", 254], ["alpha", 258], ["-", 263], ["synuclein", 264], ["gene", 274], ["have", 279], ["been", 284], ["identified", 289], ["in", 300], ["early", 303], ["-", 308], ["onset", 309], ["familial", 315], ["PD", 324], [",", 326], ["and", 328], ["alpha", 332], ["-", 337], ["synuclein", 338], ["has", 348], ["been", 352], ["shown", 357], ["to", 363], ["be", 366], ["a", 369], ["major", 371], ["component", 377], ["of", 387], ["LB", 390], ["in", 393], ["all", 396], ["patients", 400], [".", 408], ["Yet", 410], [",", 413], ["the", 415], ["pathophysiological", 419], ["function", 438], ["of", 447], ["alpha", 450], ["-", 455], ["synuclein", 456], ["remains", 466], ["unknown", 474], [".", 481], ["In", 483], ["this", 486], ["report", 491], [",", 497], ["we", 499], ["have", 502], ["investigated", 507], ["the", 520], ["toxic", 524], ["effects", 530], ["of", 538], ["adenovirus", 541], ["-", 551], ["mediated", 552], ["alpha", 561], ["-", 566], ["synuclein", 567], ["overexpression", 577], ["on", 592], ["dopamine", 595], ["neurons", 604], ["in", 612], ["rat", 615], ["primary", 619], ["mesencephalic", 627], ["cultures", 641], ["and", 650], ["in", 654], ["a", 657], ["rat", 659], ["dopaminergic", 663], ["cell", 676], ["line", 681], ["-", 686], ["the", 688], ["large", 692], ["T", 698], ["-", 699], ["antigen", 700], ["immortalized", 708], [",", 720], ["mesencephalon", 722], ["-", 735], ["derived", 736], ["1RB3AN27", 744], ["(", 753], ["N27", 754], [")", 757], [".", 758], ["Adenovirus", 760], ["-", 770], ["transduced", 771], ["cultures", 782], ["showed", 791], ["high", 798], ["-", 802], ["level", 803], ["expression", 809], ["of", 820], ["alpha", 823], ["-", 828], ["synuclein", 829], ["within", 839], ["the", 846], ["cells", 850], [".", 855], ["Overexpression", 857], ["of", 872], ["human", 875], ["mutant", 881], ["alpha", 888], ["-", 893], ["synuclein", 894], ["(", 904], ["Ala(53)Thr", 905], [")", 915], ["selectively", 917], ["induced", 929], ["apoptotic", 937], ["programmed", 947], ["cell", 958], ["death", 963], ["of", 969], ["primary", 972], ["dopamine", 980], ["neurons", 989], ["as", 997], ["well", 1000], ["as", 1005], ["N27", 1008], ["cells", 1012], [".", 1017], ["The", 1019], ["mutant", 1023], ["protein", 1030], ["also", 1038], ["potentiated", 1043], ["the", 1055], ["neurotoxicity", 1059], ["of", 1073], ["6-hydroxydopamine", 1076], ["(", 1094], ["6-OHDA", 1095], [")", 1101], [".", 1102], ["By", 1104], ["contrast", 1107], [",", 1115], ["overexpression", 1117], ["of", 1132], ["wild", 1135], ["-", 1139], ["type", 1140], ["human", 1145], ["alpha", 1151], ["-", 1156], ["synuclein", 1157], ["was", 1167], ["not", 1171], ["directly", 1175], ["neurotoxic", 1184], ["but", 1195], ["did", 1199], ["increase", 1203], ["cell", 1212], ["death", 1217], ["after", 1223], ["6-OHDA", 1229], [".", 1235], ["Overexpression", 1237], ["of", 1252], ["wild", 1255], ["-", 1259], ["type", 1260], ["rat", 1265], ["alpha", 1269], ["-", 1274], ["synuclein", 1275], ["had", 1285], ["no", 1289], ["effect", 1292], ["on", 1299], ["dopamine", 1302], ["cell", 1311], ["survival", 1316], ["or", 1325], ["6-OHDA", 1328], ["neurotoxicity", 1335], [".", 1348], ["These", 1350], ["results", 1356], ["indicate", 1364], ["that", 1373], ["overexpression", 1378], ["of", 1393], ["human", 1396], ["mutant", 1402], ["alpha", 1409], ["-", 1414], ["synuclein", 1415], ["directly", 1425], ["leads", 1434], ["to", 1440], ["dopamine", 1443], ["neuron", 1452], ["death", 1459], [",", 1464], ["and", 1466], ["overexpression", 1470], ["of", 1485], ["either", 1488], ["human", 1495], ["mutant", 1501], ["or", 1508], ["human", 1511], ["wild", 1517], ["-", 1521], ["type", 1522], ["alpha", 1527], ["-", 1532], ["synuclein", 1533], ["renders", 1543], ["dopamine", 1551], ["neurons", 1560], ["more", 1568], ["vulnerable", 1573], ["to", 1584], ["neurotoxic", 1587], ["insults", 1598], [".", 1605]]}
{"context": "Recently, bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia. A male infant developed severe hyperglycemia (446\u2009mg/dL) within 24\u2009h of birth. Acute abdominal concerns by day five necessitated exploratory surgery that revealed duodenal atresia, gallbladder agenesis, annular pancreas and intestinal malrotation. He also exhibited chronic diarrhea and feeding intolerance, cholestatic jaundice, and subsequent liver failure. He died of sepsis at four months old while awaiting liver transplantation. The phenotype of neonatal diabetes with intestinal atresia and biliary agenesis clearly pointed to RFX6 as the causative gene; indeed, whole exome sequencing revealed a novel homozygous RFX6 mutation c.779A>C; p.Lys260Thr (K260T). This missense mutation also changes the consensus 5' splice donor site before intron 7 and is thus predicted to cause disruption in splicing. Both parents, who were not known to be related, were heterozygous carriers. Targeted genetic testing based on consideration of phenotypic features may reveal a cause among the many genes now associated with heterogeneous forms of monogenic neonatal diabetes. Our study demonstrates the feasibility of using modern sequencing technology to identify one such rare cause. Continued research is needed to determine the possible cost-effectiveness of this approach, especially when clear phenotypic clues are absent. Further study of patients with RFX6 mutations should clarify its role in pancreatic, intestinal and enteroendocrine cellular development and explain features such as the diarrhea exhibited in our case.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "2e07fab624c345f486c1445ba1811034", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[120, 120], [135, 135], [261, 261], [10, 10]], "char_spans": [[750, 753], [837, 840], [1567, 1570], [59, 62]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["bi", 10], ["-", 12], ["allelic", 13], ["mutations", 21], ["in", 31], ["the", 34], ["transcription", 38], ["factor", 52], ["RFX6", 59], ["were", 64], ["described", 69], ["as", 79], ["the", 82], ["cause", 86], ["of", 92], ["a", 95], ["rare", 97], ["condition", 102], ["characterized", 112], ["by", 126], ["neonatal", 129], ["diabetes", 138], ["with", 147], ["pancreatic", 152], ["and", 163], ["biliary", 167], ["hypoplasia", 175], ["and", 186], ["duodenal", 190], ["/", 198], ["jejunal", 199], ["atresia", 207], [".", 214], ["A", 216], ["male", 218], ["infant", 223], ["developed", 230], ["severe", 240], ["hyperglycemia", 247], ["(", 261], ["446", 262], ["mg", 266], ["/", 268], ["dL", 269], [")", 271], ["within", 273], ["24", 280], ["h", 283], ["of", 285], ["birth", 288], [".", 293], ["Acute", 295], ["abdominal", 301], ["concerns", 311], ["by", 320], ["day", 323], ["five", 327], ["necessitated", 332], ["exploratory", 345], ["surgery", 357], ["that", 365], ["revealed", 370], ["duodenal", 379], ["atresia", 388], [",", 395], ["gallbladder", 397], ["agenesis", 409], [",", 417], ["annular", 419], ["pancreas", 427], ["and", 436], ["intestinal", 440], ["malrotation", 451], [".", 462], ["He", 464], ["also", 467], ["exhibited", 472], ["chronic", 482], ["diarrhea", 490], ["and", 499], ["feeding", 503], ["intolerance", 511], [",", 522], ["cholestatic", 524], ["jaundice", 536], [",", 544], ["and", 546], ["subsequent", 550], ["liver", 561], ["failure", 567], [".", 574], ["He", 576], ["died", 579], ["of", 584], ["sepsis", 587], ["at", 594], ["four", 597], ["months", 602], ["old", 609], ["while", 613], ["awaiting", 619], ["liver", 628], ["transplantation", 634], [".", 649], ["The", 651], ["phenotype", 655], ["of", 665], ["neonatal", 668], ["diabetes", 677], ["with", 686], ["intestinal", 691], ["atresia", 702], ["and", 710], ["biliary", 714], ["agenesis", 722], ["clearly", 731], ["pointed", 739], ["to", 747], ["RFX6", 750], ["as", 755], ["the", 758], ["causative", 762], ["gene", 772], [";", 776], ["indeed", 778], [",", 784], ["whole", 786], ["exome", 792], ["sequencing", 798], ["revealed", 809], ["a", 818], ["novel", 820], ["homozygous", 826], ["RFX6", 837], ["mutation", 842], ["c.779A", 851], [">", 857], ["C", 858], [";", 859], ["p", 861], [".", 862], ["Lys260Thr", 863], ["(", 873], ["K260", 874], ["T", 878], [")", 879], [".", 880], ["This", 882], ["missense", 887], ["mutation", 896], ["also", 905], ["changes", 910], ["the", 918], ["consensus", 922], ["5", 932], ["'", 933], ["splice", 935], ["donor", 942], ["site", 948], ["before", 953], ["intron", 960], ["7", 967], ["and", 969], ["is", 973], ["thus", 976], ["predicted", 981], ["to", 991], ["cause", 994], ["disruption", 1000], ["in", 1011], ["splicing", 1014], [".", 1022], ["Both", 1024], ["parents", 1029], [",", 1036], ["who", 1038], ["were", 1042], ["not", 1047], ["known", 1051], ["to", 1057], ["be", 1060], ["related", 1063], [",", 1070], ["were", 1072], ["heterozygous", 1077], ["carriers", 1090], [".", 1098], ["Targeted", 1100], ["genetic", 1109], ["testing", 1117], ["based", 1125], ["on", 1131], ["consideration", 1134], ["of", 1148], ["phenotypic", 1151], ["features", 1162], ["may", 1171], ["reveal", 1175], ["a", 1182], ["cause", 1184], ["among", 1190], ["the", 1196], ["many", 1200], ["genes", 1205], ["now", 1211], ["associated", 1215], ["with", 1226], ["heterogeneous", 1231], ["forms", 1245], ["of", 1251], ["monogenic", 1254], ["neonatal", 1264], ["diabetes", 1273], [".", 1281], ["Our", 1283], ["study", 1287], ["demonstrates", 1293], ["the", 1306], ["feasibility", 1310], ["of", 1322], ["using", 1325], ["modern", 1331], ["sequencing", 1338], ["technology", 1349], ["to", 1360], ["identify", 1363], ["one", 1372], ["such", 1376], ["rare", 1381], ["cause", 1386], [".", 1391], ["Continued", 1393], ["research", 1403], ["is", 1412], ["needed", 1415], ["to", 1422], ["determine", 1425], ["the", 1435], ["possible", 1439], ["cost", 1448], ["-", 1452], ["effectiveness", 1453], ["of", 1467], ["this", 1470], ["approach", 1475], [",", 1483], ["especially", 1485], ["when", 1496], ["clear", 1501], ["phenotypic", 1507], ["clues", 1518], ["are", 1524], ["absent", 1528], [".", 1534], ["Further", 1536], ["study", 1544], ["of", 1550], ["patients", 1553], ["with", 1562], ["RFX6", 1567], ["mutations", 1572], ["should", 1582], ["clarify", 1589], ["its", 1597], ["role", 1601], ["in", 1606], ["pancreatic", 1609], [",", 1619], ["intestinal", 1621], ["and", 1632], ["enteroendocrine", 1636], ["cellular", 1652], ["development", 1661], ["and", 1673], ["explain", 1677], ["features", 1685], ["such", 1694], ["as", 1699], ["the", 1702], ["diarrhea", 1706], ["exhibited", 1715], ["in", 1725], ["our", 1728], ["case", 1732], [".", 1736]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Osteoporosis is characterised by a progressive loss of bone mass and microarchitecture which leads to increased fracture risk. Some of the drugs available to date have shown reductions in vertebral and non-vertebral fracture risk. However, in the ageing population of industrialised countries, still more fractures happen today than are avoided, which highlights the large medical need for new treatment options, models, and strategies. Recent insights into bone biology, have led to a better understanding of bone cell functions and crosstalk between osteoblasts, osteoclasts, and osteocytes at the molecular level. In the future, the armamentarium against osteoporotic fractures will likely be enriched by (1.) new bone anabolic substances such as antibodies directed against the endogenous inhibitors of bone formation sclerostin and dickkopf-1, PTH and PTHrp analogues, and possibly calcilytics; (2.) new inhibitors of bone resorption such as cathepsin K inhibitors which may suppress osteoclast function without impairing osteoclast viability and thus maintain bone formation by preserving the osteoclast-osteoblast crosstalk, and denosumab, an already widely available antibody against RANKL which inhibits osteoclast formation, function, and survival; and (3.) new therapeutic strategies based on an extended understanding of the pathophysiology of osteoporosis which may include sequential therapies with two or more bone active substances aimed at optimising the management of bone capital acquired during adolescence and maintained during adulthood in terms of both quantity and quality. Finally, one of the future challenges will be to identify those patients and patient populations expected to benefit the most from a given drug therapy or regimen. The WHO fracture risk assessment tool FRAX\u00ae and improved access to bone mineral density measurements by DXA will play a key role in this regard.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "66863c5ce37e431c8b6c293c8776da2d", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[194, 194]], "char_spans": [[1192, 1196]]}]}], "context_tokens": [["Osteoporosis", 0], ["is", 13], ["characterised", 16], ["by", 30], ["a", 33], ["progressive", 35], ["loss", 47], ["of", 52], ["bone", 55], ["mass", 60], ["and", 65], ["microarchitecture", 69], ["which", 87], ["leads", 93], ["to", 99], ["increased", 102], ["fracture", 112], ["risk", 121], [".", 125], ["Some", 127], ["of", 132], ["the", 135], ["drugs", 139], ["available", 145], ["to", 155], ["date", 158], ["have", 163], ["shown", 168], ["reductions", 174], ["in", 185], ["vertebral", 188], ["and", 198], ["non", 202], ["-", 205], ["vertebral", 206], ["fracture", 216], ["risk", 225], [".", 229], ["However", 231], [",", 238], ["in", 240], ["the", 243], ["ageing", 247], ["population", 254], ["of", 265], ["industrialised", 268], ["countries", 283], [",", 292], ["still", 294], ["more", 300], ["fractures", 305], ["happen", 315], ["today", 322], ["than", 328], ["are", 333], ["avoided", 337], [",", 344], ["which", 346], ["highlights", 352], ["the", 363], ["large", 367], ["medical", 373], ["need", 381], ["for", 386], ["new", 390], ["treatment", 394], ["options", 404], [",", 411], ["models", 413], [",", 419], ["and", 421], ["strategies", 425], [".", 435], ["Recent", 437], ["insights", 444], ["into", 453], ["bone", 458], ["biology", 463], [",", 470], ["have", 472], ["led", 477], ["to", 481], ["a", 484], ["better", 486], ["understanding", 493], ["of", 507], ["bone", 510], ["cell", 515], ["functions", 520], ["and", 530], ["crosstalk", 534], ["between", 544], ["osteoblasts", 552], [",", 563], ["osteoclasts", 565], [",", 576], ["and", 578], ["osteocytes", 582], ["at", 593], ["the", 596], ["molecular", 600], ["level", 610], [".", 615], ["In", 617], ["the", 620], ["future", 624], [",", 630], ["the", 632], ["armamentarium", 636], ["against", 650], ["osteoporotic", 658], ["fractures", 671], ["will", 681], ["likely", 686], ["be", 693], ["enriched", 696], ["by", 705], ["(", 708], ["1", 709], [".", 710], [")", 711], ["new", 713], ["bone", 717], ["anabolic", 722], ["substances", 731], ["such", 742], ["as", 747], ["antibodies", 750], ["directed", 761], ["against", 770], ["the", 778], ["endogenous", 782], ["inhibitors", 793], ["of", 804], ["bone", 807], ["formation", 812], ["sclerostin", 822], ["and", 833], ["dickkopf-1", 837], [",", 847], ["PTH", 849], ["and", 853], ["PTHrp", 857], ["analogues", 863], [",", 872], ["and", 874], ["possibly", 878], ["calcilytics", 887], [";", 898], ["(", 900], ["2", 901], [".", 902], [")", 903], ["new", 905], ["inhibitors", 909], ["of", 920], ["bone", 923], ["resorption", 928], ["such", 939], ["as", 944], ["cathepsin", 947], ["K", 957], ["inhibitors", 959], ["which", 970], ["may", 976], ["suppress", 980], ["osteoclast", 989], ["function", 1000], ["without", 1009], ["impairing", 1017], ["osteoclast", 1027], ["viability", 1038], ["and", 1048], ["thus", 1052], ["maintain", 1057], ["bone", 1066], ["formation", 1071], ["by", 1081], ["preserving", 1084], ["the", 1095], ["osteoclast", 1099], ["-", 1109], ["osteoblast", 1110], ["crosstalk", 1121], [",", 1130], ["and", 1132], ["denosumab", 1136], [",", 1145], ["an", 1147], ["already", 1150], ["widely", 1158], ["available", 1165], ["antibody", 1175], ["against", 1184], ["RANKL", 1192], ["which", 1198], ["inhibits", 1204], ["osteoclast", 1213], ["formation", 1224], [",", 1233], ["function", 1235], [",", 1243], ["and", 1245], ["survival", 1249], [";", 1257], ["and", 1259], ["(", 1263], ["3", 1264], [".", 1265], [")", 1266], ["new", 1268], ["therapeutic", 1272], ["strategies", 1284], ["based", 1295], ["on", 1301], ["an", 1304], ["extended", 1307], ["understanding", 1316], ["of", 1330], ["the", 1333], ["pathophysiology", 1337], ["of", 1353], ["osteoporosis", 1356], ["which", 1369], ["may", 1375], ["include", 1379], ["sequential", 1387], ["therapies", 1398], ["with", 1408], ["two", 1413], ["or", 1417], ["more", 1420], ["bone", 1425], ["active", 1430], ["substances", 1437], ["aimed", 1448], ["at", 1454], ["optimising", 1457], ["the", 1468], ["management", 1472], ["of", 1483], ["bone", 1486], ["capital", 1491], ["acquired", 1499], ["during", 1508], ["adolescence", 1515], ["and", 1527], ["maintained", 1531], ["during", 1542], ["adulthood", 1549], ["in", 1559], ["terms", 1562], ["of", 1568], ["both", 1571], ["quantity", 1576], ["and", 1585], ["quality", 1589], [".", 1596], ["Finally", 1598], [",", 1605], ["one", 1607], ["of", 1611], ["the", 1614], ["future", 1618], ["challenges", 1625], ["will", 1636], ["be", 1641], ["to", 1644], ["identify", 1647], ["those", 1656], ["patients", 1662], ["and", 1671], ["patient", 1675], ["populations", 1683], ["expected", 1695], ["to", 1704], ["benefit", 1707], ["the", 1715], ["most", 1719], ["from", 1724], ["a", 1729], ["given", 1731], ["drug", 1737], ["therapy", 1742], ["or", 1750], ["regimen", 1753], [".", 1760], ["The", 1762], ["WHO", 1766], ["fracture", 1770], ["risk", 1779], ["assessment", 1784], ["tool", 1795], ["FRAX", 1800], ["\u00ae", 1804], ["and", 1806], ["improved", 1810], ["access", 1819], ["to", 1826], ["bone", 1829], ["mineral", 1834], ["density", 1842], ["measurements", 1850], ["by", 1863], ["DXA", 1866], ["will", 1870], ["play", 1875], ["a", 1880], ["key", 1882], ["role", 1886], ["in", 1891], ["this", 1894], ["regard", 1899], [".", 1905]]}
{"context": "To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes. We prospectively compiled data on a series of 338 patients with diabetes with 356 episodes of foot infection who were hospitalized in the Diabetic Foot Unit of La Paloma Hospital from 1 October 2002 to 31 April 2010. For each patient we did a probe-to-bone test at the time of the initial evaluation and then obtained plain X-rays of the involved foot. All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture. We calculated the sensitivity, specificity, predictive values and likelihood ratios of the procedures, using the histopathological diagnosis of osteomyelitis as the criterion standard. Overall, 72.4% of patients had histologically proven osteomyelitis, 85.2% of whom had positive bone culture. The performance characteristics of both the probe-to-bone test and plain X-rays were excellent. The sequential diagnostic approach had a sensitivity of 0.97, specificity of 0.92, positive predictive value of 0.97, negative predictive value of 0.93, positive likelihood ratio of 12.8 and negative likelihood ratio of 0.02. Only 6.6% of patients with negative results on both diagnostic studies had osteomyelitis. Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "a31831baf7b64813bd2cd193e35c0c77", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[285, 287]], "char_spans": [[1597, 1623]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["accuracy", 19], ["of", 28], ["the", 31], ["sequential", 35], ["combination", 46], ["of", 58], ["the", 61], ["probe", 65], ["-", 70], ["to", 71], ["-", 73], ["bone", 74], ["test", 79], ["and", 84], ["plain", 88], ["X", 94], ["-", 95], ["rays", 96], ["for", 101], ["diagnosing", 105], ["osteomyelitis", 116], ["in", 130], ["the", 133], ["foot", 137], ["of", 142], ["patients", 145], ["with", 154], ["diabetes", 159], [".", 167], ["We", 169], ["prospectively", 172], ["compiled", 186], ["data", 195], ["on", 200], ["a", 203], ["series", 205], ["of", 212], ["338", 215], ["patients", 219], ["with", 228], ["diabetes", 233], ["with", 242], ["356", 247], ["episodes", 251], ["of", 260], ["foot", 263], ["infection", 268], ["who", 278], ["were", 282], ["hospitalized", 287], ["in", 300], ["the", 303], ["Diabetic", 307], ["Foot", 316], ["Unit", 321], ["of", 326], ["La", 329], ["Paloma", 332], ["Hospital", 339], ["from", 348], ["1", 353], ["October", 355], ["2002", 363], ["to", 368], ["31", 371], ["April", 374], ["2010", 380], [".", 384], ["For", 386], ["each", 390], ["patient", 395], ["we", 403], ["did", 406], ["a", 410], ["probe", 412], ["-", 417], ["to", 418], ["-", 420], ["bone", 421], ["test", 426], ["at", 431], ["the", 434], ["time", 438], ["of", 443], ["the", 446], ["initial", 450], ["evaluation", 458], ["and", 469], ["then", 473], ["obtained", 478], ["plain", 487], ["X", 493], ["-", 494], ["rays", 495], ["of", 500], ["the", 503], ["involved", 507], ["foot", 516], [".", 520], ["All", 522], ["patients", 526], ["with", 535], ["positive", 540], ["results", 549], ["on", 557], ["either", 560], ["the", 567], ["probe", 571], ["-", 576], ["to", 577], ["-", 579], ["bone", 580], ["test", 585], ["or", 590], ["plain", 593], ["X", 599], ["-", 600], ["ray", 601], ["underwent", 605], ["an", 615], ["appropriate", 618], ["surgical", 630], ["procedure", 639], [",", 648], ["which", 650], ["included", 656], ["obtaining", 665], ["a", 675], ["bone", 677], ["specimen", 682], ["that", 691], ["was", 696], ["processed", 700], ["for", 710], ["histology", 714], ["and", 724], ["culture", 728], [".", 735], ["We", 737], ["calculated", 740], ["the", 751], ["sensitivity", 755], [",", 766], ["specificity", 768], [",", 779], ["predictive", 781], ["values", 792], ["and", 799], ["likelihood", 803], ["ratios", 814], ["of", 821], ["the", 824], ["procedures", 828], [",", 838], ["using", 840], ["the", 846], ["histopathological", 850], ["diagnosis", 868], ["of", 878], ["osteomyelitis", 881], ["as", 895], ["the", 898], ["criterion", 902], ["standard", 912], [".", 920], ["Overall", 922], [",", 929], ["72.4", 931], ["%", 935], ["of", 937], ["patients", 940], ["had", 949], ["histologically", 953], ["proven", 968], ["osteomyelitis", 975], [",", 988], ["85.2", 990], ["%", 994], ["of", 996], ["whom", 999], ["had", 1004], ["positive", 1008], ["bone", 1017], ["culture", 1022], [".", 1029], ["The", 1031], ["performance", 1035], ["characteristics", 1047], ["of", 1063], ["both", 1066], ["the", 1071], ["probe", 1075], ["-", 1080], ["to", 1081], ["-", 1083], ["bone", 1084], ["test", 1089], ["and", 1094], ["plain", 1098], ["X", 1104], ["-", 1105], ["rays", 1106], ["were", 1111], ["excellent", 1116], [".", 1125], ["The", 1127], ["sequential", 1131], ["diagnostic", 1142], ["approach", 1153], ["had", 1162], ["a", 1166], ["sensitivity", 1168], ["of", 1180], ["0.97", 1183], [",", 1187], ["specificity", 1189], ["of", 1201], ["0.92", 1204], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["of", 1236], ["0.97", 1239], [",", 1243], ["negative", 1245], ["predictive", 1254], ["value", 1265], ["of", 1271], ["0.93", 1274], [",", 1278], ["positive", 1280], ["likelihood", 1289], ["ratio", 1300], ["of", 1306], ["12.8", 1309], ["and", 1314], ["negative", 1318], ["likelihood", 1327], ["ratio", 1338], ["of", 1344], ["0.02", 1347], [".", 1351], ["Only", 1353], ["6.6", 1358], ["%", 1361], ["of", 1363], ["patients", 1366], ["with", 1375], ["negative", 1380], ["results", 1389], ["on", 1397], ["both", 1400], ["diagnostic", 1405], ["studies", 1416], ["had", 1424], ["osteomyelitis", 1428], [".", 1441], ["Clinicians", 1443], ["seeing", 1454], ["patients", 1461], ["in", 1470], ["a", 1473], ["setting", 1475], ["similar", 1483], ["to", 1491], ["ours", 1494], ["(", 1499], ["specialized", 1500], ["diabetic", 1512], ["foot", 1521], ["unit", 1526], ["with", 1531], ["a", 1536], ["high", 1538], ["prevalence", 1543], ["of", 1554], ["osteomyelitis", 1557], [")", 1570], ["can", 1572], ["confidently", 1576], ["diagnose", 1588], ["diabetic", 1597], ["foot", 1606], ["osteomyelitis", 1611], ["when", 1625], ["either", 1630], ["the", 1637], ["probe", 1641], ["-", 1646], ["to", 1647], ["-", 1649], ["bone", 1650], ["test", 1655], ["or", 1660], ["a", 1663], ["plain", 1665], ["X", 1671], ["-", 1672], ["ray", 1673], [",", 1676], ["or", 1678], ["especially", 1681], ["both", 1692], [",", 1696], ["are", 1698], ["positive", 1702], [".", 1710]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "This case report is about an elderly man who presented with a long-standing history of high-grade fever and weight loss. He initially had only hepatosplenomegaly, but then developed jaundice. He also had pancytopenia and raised liver enzymes. His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus. The liver biopsy showed sinusoidal phagocytosis and the subsequent bone marrow aspiration and biopsy showed significant hemophagocytosis, hence Hemophagocytic syndrome was diagnosed. The fever was refractory to antibiotic and anti-tuberculosis therapy, but it responded only partially to steroids. Full response was only noticed following anti-viral treatment in the form of intravenous Ganciclovir. The patient's general condition, liver enzymes, bilirubin, hematological parameters and even the weight returned back to their normal range 2 weeks after Ganciclovir therapy. Cessation of this drug resulted in relapse of his symptoms and oral antivirals did not help. Splenectomy, steroid pulse therapy and immunosuppressive treatment were only partially helpful. Reintroduction of Ganciclovir did help for a short period. We conclude that our patient had virus-associated hemophagocytic syndrome most likely related to Epstein-Barr virus infection, which was then confirmed by the splenic biopsy, and that Ganciclovir can be of great help in eradicating the virus and treating the disease, provided that it is given for a long enough period.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "27f01386fc37446ab4eaa091c48db4f9", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[62, 65], [212, 215]], "char_spans": [[336, 353], [1276, 1293]]}]}], "context_tokens": [["This", 0], ["case", 5], ["report", 10], ["is", 17], ["about", 20], ["an", 26], ["elderly", 29], ["man", 37], ["who", 41], ["presented", 45], ["with", 55], ["a", 60], ["long", 62], ["-", 66], ["standing", 67], ["history", 76], ["of", 84], ["high", 87], ["-", 91], ["grade", 92], ["fever", 98], ["and", 104], ["weight", 108], ["loss", 115], [".", 119], ["He", 121], ["initially", 124], ["had", 134], ["only", 138], ["hepatosplenomegaly", 143], [",", 161], ["but", 163], ["then", 167], ["developed", 172], ["jaundice", 182], [".", 190], ["He", 192], ["also", 195], ["had", 200], ["pancytopenia", 204], ["and", 217], ["raised", 221], ["liver", 228], ["enzymes", 234], [".", 241], ["His", 243], ["septic", 247], ["screen", 254], ["was", 261], ["negative", 265], [",", 273], ["but", 275], ["he", 279], ["had", 282], ["a", 286], ["positive", 288], ["Monospot", 297], ["test", 306], ["and", 311], ["immunoglobulin", 315], ["G", 330], ["for", 332], ["Epstein", 336], ["-", 343], ["Barr", 344], ["virus", 349], [".", 354], ["The", 356], ["liver", 360], ["biopsy", 366], ["showed", 373], ["sinusoidal", 380], ["phagocytosis", 391], ["and", 404], ["the", 408], ["subsequent", 412], ["bone", 423], ["marrow", 428], ["aspiration", 435], ["and", 446], ["biopsy", 450], ["showed", 457], ["significant", 464], ["hemophagocytosis", 476], [",", 492], ["hence", 494], ["Hemophagocytic", 500], ["syndrome", 515], ["was", 524], ["diagnosed", 528], [".", 537], ["The", 539], ["fever", 543], ["was", 549], ["refractory", 553], ["to", 564], ["antibiotic", 567], ["and", 578], ["anti", 582], ["-", 586], ["tuberculosis", 587], ["therapy", 600], [",", 607], ["but", 609], ["it", 613], ["responded", 616], ["only", 626], ["partially", 631], ["to", 641], ["steroids", 644], [".", 652], ["Full", 654], ["response", 659], ["was", 668], ["only", 672], ["noticed", 677], ["following", 685], ["anti", 695], ["-", 699], ["viral", 700], ["treatment", 706], ["in", 716], ["the", 719], ["form", 723], ["of", 728], ["intravenous", 731], ["Ganciclovir", 743], [".", 754], ["The", 756], ["patient", 760], ["'s", 767], ["general", 770], ["condition", 778], [",", 787], ["liver", 789], ["enzymes", 795], [",", 802], ["bilirubin", 804], [",", 813], ["hematological", 815], ["parameters", 829], ["and", 840], ["even", 844], ["the", 849], ["weight", 853], ["returned", 860], ["back", 869], ["to", 874], ["their", 877], ["normal", 883], ["range", 890], ["2", 896], ["weeks", 898], ["after", 904], ["Ganciclovir", 910], ["therapy", 922], [".", 929], ["Cessation", 931], ["of", 941], ["this", 944], ["drug", 949], ["resulted", 954], ["in", 963], ["relapse", 966], ["of", 974], ["his", 977], ["symptoms", 981], ["and", 990], ["oral", 994], ["antivirals", 999], ["did", 1010], ["not", 1014], ["help", 1018], [".", 1022], ["Splenectomy", 1024], [",", 1035], ["steroid", 1037], ["pulse", 1045], ["therapy", 1051], ["and", 1059], ["immunosuppressive", 1063], ["treatment", 1081], ["were", 1091], ["only", 1096], ["partially", 1101], ["helpful", 1111], [".", 1118], ["Reintroduction", 1120], ["of", 1135], ["Ganciclovir", 1138], ["did", 1150], ["help", 1154], ["for", 1159], ["a", 1163], ["short", 1165], ["period", 1171], [".", 1177], ["We", 1179], ["conclude", 1182], ["that", 1191], ["our", 1196], ["patient", 1200], ["had", 1208], ["virus", 1212], ["-", 1217], ["associated", 1218], ["hemophagocytic", 1229], ["syndrome", 1244], ["most", 1253], ["likely", 1258], ["related", 1265], ["to", 1273], ["Epstein", 1276], ["-", 1283], ["Barr", 1284], ["virus", 1289], ["infection", 1295], [",", 1304], ["which", 1306], ["was", 1312], ["then", 1316], ["confirmed", 1321], ["by", 1331], ["the", 1334], ["splenic", 1338], ["biopsy", 1346], [",", 1352], ["and", 1354], ["that", 1358], ["Ganciclovir", 1363], ["can", 1375], ["be", 1379], ["of", 1382], ["great", 1385], ["help", 1391], ["in", 1396], ["eradicating", 1399], ["the", 1411], ["virus", 1415], ["and", 1421], ["treating", 1425], ["the", 1434], ["disease", 1438], [",", 1445], ["provided", 1447], ["that", 1456], ["it", 1461], ["is", 1464], ["given", 1467], ["for", 1473], ["a", 1477], ["long", 1479], ["enough", 1484], ["period", 1491], [".", 1497]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "L-DOPA-induced dyskinesia is a common side effect developed after chronic treatment with 3,4-dihydroxyphenyl-l-alanine (l-DOPA) in Parkinson's disease. The biological mechanisms behind this side effect are not fully comprehended although involvement of dopaminergic, serotonergic, and glutamatergic systems has been suggested. The present study utilizes in vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and l-DOPA (4 mg/kg, including benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats. Recordings were performed before and after local L-DOPA application in the striatum. In addition, effects from the 5-HT(1A) receptor agonist (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OHDPAT; 1 mg/kg) was assessed on glutamate release and on dyskinetic behavior. The results revealed a bilateral \u2248 30% reduction of basal extracellular glutamate concentration and attenuated potassium-evoked glutamate release after a unilateral dopamine-depletion in L-DOPA na\u00efve animals. In dyskinetic subjects, basal glutamate concentration was comparable to normal controls, although potassium-evoked glutamate release was reduced to similar levels as in drug na\u00efve dopamine-lesioned animals. Furthermore, acute striatal L-DOPA administration attenuated glutamate release in all groups, except in the dopamine-lesioned striatum of dyskinetic animals. Co-administration of 8-OHDPAT and L-DOPA decreased dyskinesia in dopamine-lesioned animals, but did not affect potassium-evoked glutamate release, which was seen in normal animals. These findings indicate altered glutamate transmission upon dopamine-depletion and dyskinesia.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "51cc9b8c720b4a8da80558914feaa7f7", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[258, 260], [22, 24], [116, 118], [230, 232], [72, 74], [0, 2], [187, 189]], "char_spans": [[1542, 1547], [120, 125], [699, 704], [1378, 1383], [446, 451], [0, 5], [1121, 1126]]}]}], "context_tokens": [["L", 0], ["-", 1], ["DOPA", 2], ["-", 6], ["induced", 7], ["dyskinesia", 15], ["is", 26], ["a", 29], ["common", 31], ["side", 38], ["effect", 43], ["developed", 50], ["after", 60], ["chronic", 66], ["treatment", 74], ["with", 84], ["3,4-dihydroxyphenyl", 89], ["-", 108], ["l", 109], ["-", 110], ["alanine", 111], ["(", 119], ["l", 120], ["-", 121], ["DOPA", 122], [")", 126], ["in", 128], ["Parkinson", 131], ["'s", 140], ["disease", 143], [".", 150], ["The", 152], ["biological", 156], ["mechanisms", 167], ["behind", 178], ["this", 185], ["side", 190], ["effect", 195], ["are", 202], ["not", 206], ["fully", 210], ["comprehended", 216], ["although", 229], ["involvement", 238], ["of", 250], ["dopaminergic", 253], [",", 265], ["serotonergic", 267], [",", 279], ["and", 281], ["glutamatergic", 285], ["systems", 299], ["has", 307], ["been", 311], ["suggested", 316], [".", 325], ["The", 327], ["present", 331], ["study", 339], ["utilizes", 345], ["in", 354], ["vivo", 357], ["amperometry", 362], ["to", 374], ["investigate", 377], ["the", 389], ["impact", 393], ["from", 400], ["unilateral", 405], ["6-hydroxydopamine", 416], ["lesions", 434], ["and", 442], ["l", 446], ["-", 447], ["DOPA", 448], ["(", 453], ["4", 454], ["mg", 456], ["/", 458], ["kg", 459], [",", 461], ["including", 463], ["benserazide", 473], ["15", 485], ["mg", 488], ["/", 490], ["kg", 491], [")", 493], ["-induced", 495], ["dyskinetic", 504], ["behavior", 515], ["on", 524], ["striatal", 527], ["basal", 536], ["extracellular", 542], ["glutamate", 556], ["concentration", 566], ["and", 580], ["potassium", 584], ["-", 593], ["evoked", 594], ["glutamate", 601], ["release", 611], ["in", 619], ["urethane", 622], ["-", 630], ["anesthetized", 631], ["rats", 644], [".", 648], ["Recordings", 650], ["were", 661], ["performed", 666], ["before", 676], ["and", 683], ["after", 687], ["local", 693], ["L", 699], ["-", 700], ["DOPA", 701], ["application", 706], ["in", 718], ["the", 721], ["striatum", 725], [".", 733], ["In", 735], ["addition", 738], [",", 746], ["effects", 748], ["from", 756], ["the", 761], ["5-HT(1A", 765], [")", 772], ["receptor", 774], ["agonist", 783], ["(", 791], ["2R)-(+)-8-hydroxy-2-(di", 792], ["-", 815], ["n", 816], ["-", 817], ["propylamino)tetralin", 818], ["hydrobromide", 839], ["(", 852], ["8-OHDPAT", 853], [";", 861], ["1", 863], ["mg", 865], ["/", 867], ["kg", 868], [")", 870], ["was", 872], ["assessed", 876], ["on", 885], ["glutamate", 888], ["release", 898], ["and", 906], ["on", 910], ["dyskinetic", 913], ["behavior", 924], [".", 932], ["The", 934], ["results", 938], ["revealed", 946], ["a", 955], ["bilateral", 957], ["\u2248", 967], ["30", 969], ["%", 971], ["reduction", 973], ["of", 983], ["basal", 986], ["extracellular", 992], ["glutamate", 1006], ["concentration", 1016], ["and", 1030], ["attenuated", 1034], ["potassium", 1045], ["-", 1054], ["evoked", 1055], ["glutamate", 1062], ["release", 1072], ["after", 1080], ["a", 1086], ["unilateral", 1088], ["dopamine", 1099], ["-", 1107], ["depletion", 1108], ["in", 1118], ["L", 1121], ["-", 1122], ["DOPA", 1123], ["na\u00efve", 1128], ["animals", 1134], [".", 1141], ["In", 1143], ["dyskinetic", 1146], ["subjects", 1157], [",", 1165], ["basal", 1167], ["glutamate", 1173], ["concentration", 1183], ["was", 1197], ["comparable", 1201], ["to", 1212], ["normal", 1215], ["controls", 1222], [",", 1230], ["although", 1232], ["potassium", 1241], ["-", 1250], ["evoked", 1251], ["glutamate", 1258], ["release", 1268], ["was", 1276], ["reduced", 1280], ["to", 1288], ["similar", 1291], ["levels", 1299], ["as", 1306], ["in", 1309], ["drug", 1312], ["na\u00efve", 1317], ["dopamine", 1323], ["-", 1331], ["lesioned", 1332], ["animals", 1341], [".", 1348], ["Furthermore", 1350], [",", 1361], ["acute", 1363], ["striatal", 1369], ["L", 1378], ["-", 1379], ["DOPA", 1380], ["administration", 1385], ["attenuated", 1400], ["glutamate", 1411], ["release", 1421], ["in", 1429], ["all", 1432], ["groups", 1436], [",", 1442], ["except", 1444], ["in", 1451], ["the", 1454], ["dopamine", 1458], ["-", 1466], ["lesioned", 1467], ["striatum", 1476], ["of", 1485], ["dyskinetic", 1488], ["animals", 1499], [".", 1506], ["Co", 1508], ["-", 1510], ["administration", 1511], ["of", 1526], ["8-OHDPAT", 1529], ["and", 1538], ["L", 1542], ["-", 1543], ["DOPA", 1544], ["decreased", 1549], ["dyskinesia", 1559], ["in", 1570], ["dopamine", 1573], ["-", 1581], ["lesioned", 1582], ["animals", 1591], [",", 1598], ["but", 1600], ["did", 1604], ["not", 1608], ["affect", 1612], ["potassium", 1619], ["-", 1628], ["evoked", 1629], ["glutamate", 1636], ["release", 1646], [",", 1653], ["which", 1655], ["was", 1661], ["seen", 1665], ["in", 1670], ["normal", 1673], ["animals", 1680], [".", 1687], ["These", 1689], ["findings", 1695], ["indicate", 1704], ["altered", 1713], ["glutamate", 1721], ["transmission", 1731], ["upon", 1744], ["dopamine", 1749], ["-", 1757], ["depletion", 1758], ["and", 1768], ["dyskinesia", 1772], [".", 1782]]}
{"context": "Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 trials with malaria vaccine candidate RTS,S/AS01 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria. RTS,S targets the pre-erythrocytic phase of the disease and induces high antibody titers against the P. falciparum circumsporozoite protein (CSP) and a moderate CD4(+) T cell response. The individual contribution of these adaptive immune responses to protection from infection remains unknown. Here, we found that prophylactic administration of anti-CSP mAbs derived from an RTS,S-vaccinated recipient fully protected mice with humanized livers from i.v.- and mosquito bite\u2013delivered P. falciparum sporozoite challenge. Titers of anti-CSP that conveyed full protection were within the range observed in human RTS,S vaccine recipients. Increasing anti-CSP titers resulted in a dose-dependent reduction of the liver parasite burden. These data indicate that RTS,S-induced antibodies are protective and provide sterilizing immunity against P. falciparum infection when reaching or exceeding a critical plasma concentration.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "bff1390d69824f58b4c462e5805f90f1", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[0, 0], [35, 35], [58, 58]], "char_spans": [[0, 6], [196, 202], [314, 320]]}]}], "context_tokens": [["Malaria", 0], [",", 7], ["which", 9], ["is", 15], ["the", 18], ["result", 22], ["of", 29], ["Plasmodium", 32], ["falciparum", 43], ["infection", 54], [",", 63], ["is", 65], ["a", 68], ["global", 70], ["health", 77], ["threat", 84], ["that", 91], ["resulted", 96], ["in", 105], ["655,000", 108], ["deaths", 116], ["and", 123], ["216", 127], ["million", 131], ["clinical", 139], ["cases", 148], ["in", 154], ["2010", 157], ["alone", 162], [".", 167], ["Recent", 169], ["phase", 176], ["3", 182], ["trials", 184], ["with", 191], ["malaria", 196], ["vaccine", 204], ["candidate", 212], ["RTS", 222], [",", 225], ["S", 226], ["/", 227], ["AS01", 228], ["(", 233], ["RTS", 234], [",", 237], ["S", 238], [")", 239], ["in", 241], ["children", 244], ["has", 253], ["demonstrated", 257], ["modest", 270], ["efficacy", 277], ["against", 286], ["clinical", 294], ["and", 303], ["severe", 307], ["malaria", 314], [".", 321], ["RTS", 323], [",", 326], ["S", 327], ["targets", 329], ["the", 337], ["pre", 341], ["-", 344], ["erythrocytic", 345], ["phase", 358], ["of", 364], ["the", 367], ["disease", 371], ["and", 379], ["induces", 383], ["high", 391], ["antibody", 396], ["titers", 405], ["against", 412], ["the", 420], ["P.", 424], ["falciparum", 427], ["circumsporozoite", 438], ["protein", 455], ["(", 463], ["CSP", 464], [")", 467], ["and", 469], ["a", 473], ["moderate", 475], ["CD4(+", 484], [")", 489], ["T", 491], ["cell", 493], ["response", 498], [".", 506], ["The", 508], ["individual", 512], ["contribution", 523], ["of", 536], ["these", 539], ["adaptive", 545], ["immune", 554], ["responses", 561], ["to", 571], ["protection", 574], ["from", 585], ["infection", 590], ["remains", 600], ["unknown", 608], [".", 615], ["Here", 617], [",", 621], ["we", 623], ["found", 626], ["that", 632], ["prophylactic", 637], ["administration", 650], ["of", 665], ["anti", 668], ["-", 672], ["CSP", 673], ["mAbs", 677], ["derived", 682], ["from", 690], ["an", 695], ["RTS", 698], [",", 701], ["S", 702], ["-", 703], ["vaccinated", 704], ["recipient", 715], ["fully", 725], ["protected", 731], ["mice", 741], ["with", 746], ["humanized", 751], ["livers", 761], ["from", 768], ["i.v.-", 773], ["and", 779], ["mosquito", 783], ["bite", 792], ["\u2013", 796], ["delivered", 797], ["P.", 807], ["falciparum", 810], ["sporozoite", 821], ["challenge", 832], [".", 841], ["Titers", 843], ["of", 850], ["anti", 853], ["-", 857], ["CSP", 858], ["that", 862], ["conveyed", 867], ["full", 876], ["protection", 881], ["were", 892], ["within", 897], ["the", 904], ["range", 908], ["observed", 914], ["in", 923], ["human", 926], ["RTS", 932], [",", 935], ["S", 936], ["vaccine", 938], ["recipients", 946], [".", 956], ["Increasing", 958], ["anti", 969], ["-", 973], ["CSP", 974], ["titers", 978], ["resulted", 985], ["in", 994], ["a", 997], ["dose", 999], ["-", 1003], ["dependent", 1004], ["reduction", 1014], ["of", 1024], ["the", 1027], ["liver", 1031], ["parasite", 1037], ["burden", 1046], [".", 1052], ["These", 1054], ["data", 1060], ["indicate", 1065], ["that", 1074], ["RTS", 1079], [",", 1082], ["S", 1083], ["-", 1084], ["induced", 1085], ["antibodies", 1093], ["are", 1104], ["protective", 1108], ["and", 1119], ["provide", 1123], ["sterilizing", 1131], ["immunity", 1143], ["against", 1152], ["P.", 1160], ["falciparum", 1163], ["infection", 1174], ["when", 1184], ["reaching", 1189], ["or", 1198], ["exceeding", 1201], ["a", 1211], ["critical", 1213], ["plasma", 1222], ["concentration", 1229], [".", 1242]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical areas. The disease is responsible for migraine with aura and ischemic strokes, and is associated with various degrees of cognitive impairment and with mood disturbances. CADASIL is considered as a unique model to investigate what is known as \"subcortical ischemic vascular dementia.\" Recent data suggest that the number of lacunar infarctions and severity of cerebral atrophy are the main magnetic resonance imaging markers associated with cognitive and motor disabilities in this disorder. Mood disturbances are reported in 10% to 20% of patients, most often in association with cognitive alterations. Their exact origin remains unknown; the presence of ischemic lesions within the basal ganglia or the frontal white matter may promote the occurrence of these symptoms. Further studies are needed to better understand the relationships between cerebral lesions and both cognitive and psychiatric symptoms in this small-vessel disease of the brain.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "b2f73e6827624d46a50622245bc0bc8c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[182, 192]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["small", 117], ["-", 122], ["artery", 123], ["disease", 130], ["of", 138], ["mid", 141], ["-", 144], ["adulthood", 145], ["caused", 155], ["by", 162], ["mutations", 165], ["of", 175], ["the", 178], ["NOTCH3", 182], ["gene", 189], [".", 193], ["The", 195], ["disease", 199], ["is", 207], ["responsible", 210], ["for", 222], ["widespread", 226], ["white", 237], ["-", 242], ["matter", 243], ["lesions", 250], ["associated", 258], ["with", 269], ["lacunar", 274], ["infarctions", 282], ["in", 294], ["various", 297], ["subcortical", 305], ["areas", 317], [".", 322], ["The", 324], ["disease", 328], ["is", 336], ["responsible", 339], ["for", 351], ["migraine", 355], ["with", 364], ["aura", 369], ["and", 374], ["ischemic", 378], ["strokes", 387], [",", 394], ["and", 396], ["is", 400], ["associated", 403], ["with", 414], ["various", 419], ["degrees", 427], ["of", 435], ["cognitive", 438], ["impairment", 448], ["and", 459], ["with", 463], ["mood", 468], ["disturbances", 473], [".", 485], ["CADASIL", 487], ["is", 495], ["considered", 498], ["as", 509], ["a", 512], ["unique", 514], ["model", 521], ["to", 527], ["investigate", 530], ["what", 542], ["is", 547], ["known", 550], ["as", 556], ["\"", 559], ["subcortical", 560], ["ischemic", 572], ["vascular", 581], ["dementia", 590], [".", 598], ["\"", 599], ["Recent", 601], ["data", 608], ["suggest", 613], ["that", 621], ["the", 626], ["number", 630], ["of", 637], ["lacunar", 640], ["infarctions", 648], ["and", 660], ["severity", 664], ["of", 673], ["cerebral", 676], ["atrophy", 685], ["are", 693], ["the", 697], ["main", 701], ["magnetic", 706], ["resonance", 715], ["imaging", 725], ["markers", 733], ["associated", 741], ["with", 752], ["cognitive", 757], ["and", 767], ["motor", 771], ["disabilities", 777], ["in", 790], ["this", 793], ["disorder", 798], [".", 806], ["Mood", 808], ["disturbances", 813], ["are", 826], ["reported", 830], ["in", 839], ["10", 842], ["%", 844], ["to", 846], ["20", 849], ["%", 851], ["of", 853], ["patients", 856], [",", 864], ["most", 866], ["often", 871], ["in", 877], ["association", 880], ["with", 892], ["cognitive", 897], ["alterations", 907], [".", 918], ["Their", 920], ["exact", 926], ["origin", 932], ["remains", 939], ["unknown", 947], [";", 954], ["the", 956], ["presence", 960], ["of", 969], ["ischemic", 972], ["lesions", 981], ["within", 989], ["the", 996], ["basal", 1000], ["ganglia", 1006], ["or", 1014], ["the", 1017], ["frontal", 1021], ["white", 1029], ["matter", 1035], ["may", 1042], ["promote", 1046], ["the", 1054], ["occurrence", 1058], ["of", 1069], ["these", 1072], ["symptoms", 1078], [".", 1086], ["Further", 1088], ["studies", 1096], ["are", 1104], ["needed", 1108], ["to", 1115], ["better", 1118], ["understand", 1125], ["the", 1136], ["relationships", 1140], ["between", 1154], ["cerebral", 1162], ["lesions", 1171], ["and", 1179], ["both", 1183], ["cognitive", 1188], ["and", 1198], ["psychiatric", 1202], ["symptoms", 1214], ["in", 1223], ["this", 1226], ["small", 1231], ["-", 1236], ["vessel", 1237], ["disease", 1244], ["of", 1252], ["the", 1255], ["brain", 1259], [".", 1264]]}
{"context": "Mowat-Wilson syndrome is a recently delineated autosomal dominant developmental anomaly, whereby heterozygous mutations in the ZFHX1B gene cause mental retardation, delayed motor development, epilepsy and a wide spectrum of clinically heterogeneous features, suggestive of neurocristopathies at the cephalic, cardiac and vagal levels. However, our understanding of the etiology of this condition at the cellular level remains vague. This study presents the Zfhx1b protein expression domain in mouse embryos and correlates this with a novel mouse model involving a conditional mutation in the Zfhx1b gene in neural crest precursor cells. These mutant mice display craniofacial and gastrointestinal malformations that show resemblance to those found in human patients with Mowat-Wilson syndrome. In addition to these clinically recognized alterations, we document developmental defects in the heart, melanoblasts and sympathetic and parasympathetic anlagen. The latter observations in our mouse model for Mowat-Wilson suggest a hitherto unknown role for Zfhx1b in the development of these particular neural crest derivatives, which is a set of observations that should be acknowledged in the clinical management of this genetic disorder.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "9095328339f447188880bc5412e035d4", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[163, 163], [92, 92], [71, 71], [18, 18]], "char_spans": [[1052, 1057], [592, 597], [457, 462], [127, 132]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["recently", 27], ["delineated", 36], ["autosomal", 47], ["dominant", 57], ["developmental", 66], ["anomaly", 80], [",", 87], ["whereby", 89], ["heterozygous", 97], ["mutations", 110], ["in", 120], ["the", 123], ["ZFHX1B", 127], ["gene", 134], ["cause", 139], ["mental", 145], ["retardation", 152], [",", 163], ["delayed", 165], ["motor", 173], ["development", 179], [",", 190], ["epilepsy", 192], ["and", 201], ["a", 205], ["wide", 207], ["spectrum", 212], ["of", 221], ["clinically", 224], ["heterogeneous", 235], ["features", 249], [",", 257], ["suggestive", 259], ["of", 270], ["neurocristopathies", 273], ["at", 292], ["the", 295], ["cephalic", 299], [",", 307], ["cardiac", 309], ["and", 317], ["vagal", 321], ["levels", 327], [".", 333], ["However", 335], [",", 342], ["our", 344], ["understanding", 348], ["of", 362], ["the", 365], ["etiology", 369], ["of", 378], ["this", 381], ["condition", 386], ["at", 396], ["the", 399], ["cellular", 403], ["level", 412], ["remains", 418], ["vague", 426], [".", 431], ["This", 433], ["study", 438], ["presents", 444], ["the", 453], ["Zfhx1b", 457], ["protein", 464], ["expression", 472], ["domain", 483], ["in", 490], ["mouse", 493], ["embryos", 499], ["and", 507], ["correlates", 511], ["this", 522], ["with", 527], ["a", 532], ["novel", 534], ["mouse", 540], ["model", 546], ["involving", 552], ["a", 562], ["conditional", 564], ["mutation", 576], ["in", 585], ["the", 588], ["Zfhx1b", 592], ["gene", 599], ["in", 604], ["neural", 607], ["crest", 614], ["precursor", 620], ["cells", 630], [".", 635], ["These", 637], ["mutant", 643], ["mice", 650], ["display", 655], ["craniofacial", 663], ["and", 676], ["gastrointestinal", 680], ["malformations", 697], ["that", 711], ["show", 716], ["resemblance", 721], ["to", 733], ["those", 736], ["found", 742], ["in", 748], ["human", 751], ["patients", 757], ["with", 766], ["Mowat", 771], ["-", 776], ["Wilson", 777], ["syndrome", 784], [".", 792], ["In", 794], ["addition", 797], ["to", 806], ["these", 809], ["clinically", 815], ["recognized", 826], ["alterations", 837], [",", 848], ["we", 850], ["document", 853], ["developmental", 862], ["defects", 876], ["in", 884], ["the", 887], ["heart", 891], [",", 896], ["melanoblasts", 898], ["and", 911], ["sympathetic", 915], ["and", 927], ["parasympathetic", 931], ["anlagen", 947], [".", 954], ["The", 956], ["latter", 960], ["observations", 967], ["in", 980], ["our", 983], ["mouse", 987], ["model", 993], ["for", 999], ["Mowat", 1003], ["-", 1008], ["Wilson", 1009], ["suggest", 1016], ["a", 1024], ["hitherto", 1026], ["unknown", 1035], ["role", 1043], ["for", 1048], ["Zfhx1b", 1052], ["in", 1059], ["the", 1062], ["development", 1066], ["of", 1078], ["these", 1081], ["particular", 1087], ["neural", 1098], ["crest", 1105], ["derivatives", 1111], [",", 1122], ["which", 1124], ["is", 1130], ["a", 1133], ["set", 1135], ["of", 1139], ["observations", 1142], ["that", 1155], ["should", 1160], ["be", 1167], ["acknowledged", 1170], ["in", 1183], ["the", 1186], ["clinical", 1190], ["management", 1199], ["of", 1210], ["this", 1213], ["genetic", 1218], ["disorder", 1226], [".", 1234]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery. They are essential for the elongation and closure of the phagophore into a proper autophagosome. Moreover, Atg8-family proteins are associated with the phagophore from the initiation of the autophagic process to, or just prior to, the fusion between autophagosomes with lysosomes. In addition to their implication in autophagosome biogenesis, they are crucial for selective autophagy through their ability to interact with selective autophagy receptor proteins necessary for the specific targeting of substrates for autophagic degradation. In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy. Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins. These proteins are referred to as LIR-containing proteins (LIRCPs). So far, many experimental efforts have been carried out to identify new LIRCPs, leading to the characterization of some of them in the past 10\u00a0years. Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis. Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.", "qas": [{"question": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "answers": ["The iLIR database"], "qid": "16c89e69edec4f89b7e12d57432d4b48", "question_tokens": [["Which", 0], ["web", 6], ["resource", 10], ["for", 19], ["LIR", 23], ["motif", 27], ["-", 32], ["containing", 33], ["proteins", 44], ["in", 53], ["eukaryotes", 56], ["has", 67], ["been", 71], ["developed", 76], ["?", 85]], "detected_answers": [{"text": "The iLIR database", "token_spans": [[230, 231]], "char_spans": [[1416, 1428]]}]}], "context_tokens": [["Atg8-family", 0], ["proteins", 12], ["are", 21], ["the", 25], ["best", 29], ["-", 33], ["studied", 34], ["proteins", 42], ["of", 51], ["the", 54], ["core", 58], ["autophagic", 63], ["machinery", 74], [".", 83], ["They", 85], ["are", 90], ["essential", 94], ["for", 104], ["the", 108], ["elongation", 112], ["and", 123], ["closure", 127], ["of", 135], ["the", 138], ["phagophore", 142], ["into", 153], ["a", 158], ["proper", 160], ["autophagosome", 167], [".", 180], ["Moreover", 182], [",", 190], ["Atg8-family", 192], ["proteins", 204], ["are", 213], ["associated", 217], ["with", 228], ["the", 233], ["phagophore", 237], ["from", 248], ["the", 253], ["initiation", 257], ["of", 268], ["the", 271], ["autophagic", 275], ["process", 286], ["to", 294], [",", 296], ["or", 298], ["just", 301], ["prior", 306], ["to", 312], [",", 314], ["the", 316], ["fusion", 320], ["between", 327], ["autophagosomes", 335], ["with", 350], ["lysosomes", 355], [".", 364], ["In", 366], ["addition", 369], ["to", 378], ["their", 381], ["implication", 387], ["in", 399], ["autophagosome", 402], ["biogenesis", 416], [",", 426], ["they", 428], ["are", 433], ["crucial", 437], ["for", 445], ["selective", 449], ["autophagy", 459], ["through", 469], ["their", 477], ["ability", 483], ["to", 491], ["interact", 494], ["with", 503], ["selective", 508], ["autophagy", 518], ["receptor", 528], ["proteins", 537], ["necessary", 546], ["for", 556], ["the", 560], ["specific", 564], ["targeting", 573], ["of", 583], ["substrates", 586], ["for", 597], ["autophagic", 601], ["degradation", 612], [".", 623], ["In", 625], ["the", 628], ["past", 632], ["few", 637], ["years", 641], ["it", 647], ["has", 650], ["been", 654], ["revealed", 659], ["that", 668], ["Atg8-interacting", 673], ["proteins", 690], ["include", 699], ["not", 707], ["only", 711], ["receptors", 716], ["but", 726], ["also", 730], ["components", 735], ["of", 746], ["the", 749], ["core", 753], ["autophagic", 758], ["machinery", 769], [",", 778], ["proteins", 780], ["associated", 789], ["with", 800], ["vesicles", 805], ["and", 814], ["their", 818], ["transport", 824], [",", 833], ["and", 835], ["specific", 839], ["proteins", 848], ["that", 857], ["are", 862], ["selectively", 866], ["degraded", 878], ["by", 887], ["autophagy", 890], [".", 899], ["Atg8-interacting", 901], ["proteins", 918], ["contain", 927], ["a", 935], ["short", 937], ["linear", 943], ["LC3-interacting", 950], ["region", 966], ["/", 972], ["LC3", 973], ["recognition", 977], ["sequence", 989], ["/", 997], ["Atg8-interacting", 998], ["motif", 1015], ["(", 1021], ["LIR", 1022], ["/", 1025], ["LRS", 1026], ["/", 1029], ["AIM", 1030], [")", 1033], ["motif", 1035], ["which", 1041], ["is", 1047], ["responsible", 1050], ["for", 1062], ["their", 1066], ["interaction", 1072], ["with", 1084], ["Atg8-family", 1089], ["proteins", 1101], [".", 1109], ["These", 1111], ["proteins", 1117], ["are", 1126], ["referred", 1130], ["to", 1139], ["as", 1142], ["LIR", 1145], ["-", 1148], ["containing", 1149], ["proteins", 1160], ["(", 1169], ["LIRCPs", 1170], [")", 1176], [".", 1177], ["So", 1179], ["far", 1182], [",", 1185], ["many", 1187], ["experimental", 1192], ["efforts", 1205], ["have", 1213], ["been", 1218], ["carried", 1223], ["out", 1231], ["to", 1235], ["identify", 1238], ["new", 1247], ["LIRCPs", 1251], [",", 1257], ["leading", 1259], ["to", 1267], ["the", 1270], ["characterization", 1274], ["of", 1291], ["some", 1294], ["of", 1299], ["them", 1302], ["in", 1307], ["the", 1310], ["past", 1314], ["10", 1319], ["years", 1322], [".", 1327], ["Given", 1329], ["the", 1335], ["need", 1339], ["for", 1344], ["the", 1348], ["identification", 1352], ["of", 1367], ["LIRCPs", 1370], ["in", 1377], ["various", 1380], ["organisms", 1388], [",", 1397], ["we", 1399], ["developed", 1402], ["the", 1412], ["iLIR", 1416], ["database", 1421], ["(", 1430], ["https://ilir.warwick.ac.uk", 1432], [")", 1459], ["as", 1461], ["a", 1464], ["freely", 1466], ["available", 1473], ["web", 1483], ["resource", 1487], [",", 1495], ["listing", 1497], ["all", 1505], ["the", 1509], ["putative", 1513], ["canonical", 1522], ["LIRCPs", 1532], ["identified", 1539], ["in", 1550], ["silico", 1553], ["in", 1560], ["the", 1563], ["proteomes", 1567], ["of", 1577], ["8", 1580], ["model", 1582], ["organisms", 1588], ["using", 1598], ["the", 1604], ["iLIR", 1608], ["server", 1613], [",", 1619], ["combined", 1621], ["with", 1630], ["a", 1635], ["Gene", 1637], ["Ontology", 1642], ["(", 1651], ["GO", 1652], [")", 1654], ["term", 1656], ["analysis", 1661], [".", 1669], ["Additionally", 1671], [",", 1683], ["a", 1685], ["curated", 1687], ["text", 1695], ["-", 1699], ["mining", 1700], ["analysis", 1707], ["of", 1716], ["the", 1719], ["literature", 1723], ["permitted", 1734], ["us", 1744], ["to", 1747], ["identify", 1750], ["novel", 1759], ["putative", 1765], ["LICRPs", 1774], ["in", 1781], ["mammals", 1784], ["that", 1792], ["have", 1797], ["not", 1802], ["previously", 1806], ["been", 1817], ["associated", 1822], ["with", 1833], ["autophagy", 1838], [".", 1847]]}
{"context": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids. Three distinct stages in the mechanism can be recognized. Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus. Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence. Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation. In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "3b60bd7ce68145749fb65cfe5ee7d2cf", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3]], "char_spans": [[4, 13]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["/", 10], ["Cas", 11], ["system", 15], ["in", 22], ["prokaryotes", 25], ["provides", 37], ["resistance", 46], ["against", 57], ["invading", 65], ["viruses", 74], ["and", 82], ["plasmids", 86], [".", 94], ["Three", 96], ["distinct", 102], ["stages", 111], ["in", 118], ["the", 121], ["mechanism", 125], ["can", 135], ["be", 139], ["recognized", 142], [".", 152], ["Initially", 154], [",", 163], ["fragments", 165], ["of", 175], ["invader", 178], ["DNA", 186], ["are", 190], ["integrated", 194], ["as", 205], ["new", 208], ["spacers", 212], ["into", 220], ["the", 225], ["repetitive", 229], ["CRISPR", 240], ["locus", 247], [".", 252], ["Subsequently", 254], [",", 266], ["the", 268], ["CRISPR", 272], ["is", 279], ["transcribed", 282], ["and", 294], ["the", 298], ["transcript", 302], ["is", 313], ["cleaved", 316], ["by", 324], ["a", 327], ["Cas", 329], ["protein", 333], ["within", 341], ["the", 348], ["repeats", 352], [",", 359], ["generating", 361], ["short", 372], ["RNAs", 378], ["(", 383], ["crRNAs", 384], [")", 390], ["that", 392], ["contain", 397], ["the", 405], ["spacer", 409], ["sequence", 416], [".", 424], ["Finally", 426], [",", 433], ["crRNAs", 435], ["guide", 442], ["the", 448], ["Cas", 452], ["protein", 456], ["machinery", 464], ["to", 474], ["a", 477], ["complementary", 479], ["invader", 493], ["target", 501], [",", 507], ["either", 509], ["DNA", 516], ["or", 520], ["RNA", 523], [",", 526], ["resulting", 528], ["in", 538], ["inhibition", 541], ["of", 552], ["virus", 555], ["or", 561], ["plasmid", 564], ["proliferation", 572], [".", 585], ["In", 587], ["this", 590], ["article", 595], [",", 602], ["we", 604], ["discuss", 607], ["our", 615], ["current", 619], ["understanding", 627], ["of", 641], ["this", 644], ["fascinating", 649], ["adaptive", 661], ["and", 670], ["heritable", 674], ["defense", 684], ["system", 692], [",", 698], ["and", 700], ["describe", 704], ["functional", 713], ["similarities", 724], ["and", 737], ["differences", 741], ["with", 753], ["RNAi", 758], ["in", 763], ["eukaryotes", 766], [".", 776]]}
{"context": "Plasmids are ubiquitous mobile elements that serve as a pool of many host beneficial traits such as antibiotic resistance in bacterial communities. To understand the importance of plasmids in horizontal gene transfer, we need to gain insight into the 'evolutionary history' of these plasmids, i.e. the range of hosts in which they have evolved. Since extensive data support the proposal that foreign DNA acquires the host's nucleotide composition during long-term residence, comparison of nucleotide composition of plasmids and chromosomes could shed light on a plasmid's evolutionary history. The average absolute dinucleotide relative abundance difference, termed delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids. Here, we introduce the Mahalanobis distance, which takes into account the variance-covariance structure of the chromosome signatures. We demonstrate that the Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts. We illustrate the usefulness of this metric for proposing candidate long-term hosts for plasmids, focusing on the virulence plasmids pXO1 from Bacillus anthracis, and pO157 from Escherichia coli O157:H7, as well as the broad host range multi-drug resistance plasmid pB10 from an unknown host.", "qas": [{"question": "Which is the most common measure of differences between dinucleotide relative abundance \"genomic signatures\"", "answers": ["delta-distance"], "qid": "082b7ea2976047d8b572fd00bfddec04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["measure", 25], ["of", 33], ["differences", 36], ["between", 48], ["dinucleotide", 56], ["relative", 69], ["abundance", 78], ["\"", 88], ["genomic", 89], ["signatures", 97], ["\"", 107]], "detected_answers": [{"text": "delta-distance", "token_spans": [[108, 110], [167, 169]], "char_spans": [[666, 679], [1023, 1036]]}]}], "context_tokens": [["Plasmids", 0], ["are", 9], ["ubiquitous", 13], ["mobile", 24], ["elements", 31], ["that", 40], ["serve", 45], ["as", 51], ["a", 54], ["pool", 56], ["of", 61], ["many", 64], ["host", 69], ["beneficial", 74], ["traits", 85], ["such", 92], ["as", 97], ["antibiotic", 100], ["resistance", 111], ["in", 122], ["bacterial", 125], ["communities", 135], [".", 146], ["To", 148], ["understand", 151], ["the", 162], ["importance", 166], ["of", 177], ["plasmids", 180], ["in", 189], ["horizontal", 192], ["gene", 203], ["transfer", 208], [",", 216], ["we", 218], ["need", 221], ["to", 226], ["gain", 229], ["insight", 234], ["into", 242], ["the", 247], ["'", 251], ["evolutionary", 252], ["history", 265], ["'", 272], ["of", 274], ["these", 277], ["plasmids", 283], [",", 291], ["i.e.", 293], ["the", 298], ["range", 302], ["of", 308], ["hosts", 311], ["in", 317], ["which", 320], ["they", 326], ["have", 331], ["evolved", 336], [".", 343], ["Since", 345], ["extensive", 351], ["data", 361], ["support", 366], ["the", 374], ["proposal", 378], ["that", 387], ["foreign", 392], ["DNA", 400], ["acquires", 404], ["the", 413], ["host", 417], ["'s", 421], ["nucleotide", 424], ["composition", 435], ["during", 447], ["long", 454], ["-", 458], ["term", 459], ["residence", 464], [",", 473], ["comparison", 475], ["of", 486], ["nucleotide", 489], ["composition", 500], ["of", 512], ["plasmids", 515], ["and", 524], ["chromosomes", 528], ["could", 540], ["shed", 546], ["light", 551], ["on", 557], ["a", 560], ["plasmid", 562], ["'s", 569], ["evolutionary", 572], ["history", 585], [".", 592], ["The", 594], ["average", 598], ["absolute", 606], ["dinucleotide", 615], ["relative", 628], ["abundance", 637], ["difference", 647], [",", 657], ["termed", 659], ["delta", 666], ["-", 671], ["distance", 672], [",", 680], ["has", 682], ["been", 686], ["commonly", 691], ["used", 700], ["to", 705], ["measure", 708], ["differences", 716], ["in", 728], ["dinucleotide", 731], ["composition", 744], [",", 755], ["or", 757], ["'", 760], ["genomic", 761], ["signature", 769], ["'", 778], [",", 779], ["between", 781], ["bacterial", 789], ["chromosomes", 799], ["and", 811], ["plasmids", 815], [".", 823], ["Here", 825], [",", 829], ["we", 831], ["introduce", 834], ["the", 844], ["Mahalanobis", 848], ["distance", 860], [",", 868], ["which", 870], ["takes", 876], ["into", 882], ["account", 887], ["the", 895], ["variance", 899], ["-", 907], ["covariance", 908], ["structure", 919], ["of", 929], ["the", 932], ["chromosome", 936], ["signatures", 947], [".", 957], ["We", 959], ["demonstrate", 962], ["that", 974], ["the", 979], ["Mahalanobis", 983], ["distance", 995], ["is", 1004], ["better", 1007], ["than", 1014], ["the", 1019], ["delta", 1023], ["-", 1028], ["distance", 1029], ["at", 1038], ["measuring", 1041], ["genomic", 1051], ["signature", 1059], ["differences", 1069], ["between", 1081], ["plasmids", 1089], ["and", 1098], ["chromosomes", 1102], ["of", 1114], ["potential", 1117], ["hosts", 1127], [".", 1132], ["We", 1134], ["illustrate", 1137], ["the", 1148], ["usefulness", 1152], ["of", 1163], ["this", 1166], ["metric", 1171], ["for", 1178], ["proposing", 1182], ["candidate", 1192], ["long", 1202], ["-", 1206], ["term", 1207], ["hosts", 1212], ["for", 1218], ["plasmids", 1222], [",", 1230], ["focusing", 1232], ["on", 1241], ["the", 1244], ["virulence", 1248], ["plasmids", 1258], ["pXO1", 1267], ["from", 1272], ["Bacillus", 1277], ["anthracis", 1286], [",", 1295], ["and", 1297], ["pO157", 1301], ["from", 1307], ["Escherichia", 1312], ["coli", 1324], ["O157:H7", 1329], [",", 1336], ["as", 1338], ["well", 1341], ["as", 1346], ["the", 1349], ["broad", 1353], ["host", 1359], ["range", 1364], ["multi", 1370], ["-", 1375], ["drug", 1376], ["resistance", 1381], ["plasmid", 1392], ["pB10", 1400], ["from", 1405], ["an", 1410], ["unknown", 1413], ["host", 1421], [".", 1425]]}
{"context": "In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a marked and long-lasting decrease of the extracellular levels of homovanillic acid (HVA) and 3-methoxytyramine with a concomitant increase of 3,4-dihydroxyphenylacetic acid (DOPAC). The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine. The co-administration of tolcapone (30 mg/kg p.o.) further increased dopamine and DOPAC levels, whereas HVA and 3-methoxytyramine effluxes were reduced. These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "08994280294d46b78596738f2a8bd39a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[33, 35], [161, 163], [124, 126], [91, 93], [260, 262], [270, 272], [185, 187], [151, 153]], "char_spans": [[189, 194], [787, 792], [641, 646], [522, 527], [1315, 1320], [1383, 1388], [904, 909], [730, 735]]}]}], "context_tokens": [["In", 0], ["vivo", 3], ["brain", 8], ["microdialysis", 14], ["was", 28], ["used", 32], ["to", 37], ["assess", 40], ["the", 47], ["effects", 51], ["of", 59], ["tolcapone", 62], [",", 71], ["a", 73], ["novel", 75], ["central", 81], ["and", 89], ["peripheral", 93], ["inhibitor", 104], ["of", 114], ["catechol", 117], ["-", 125], ["O", 126], ["-", 127], ["methyltransferase", 128], ["on", 146], ["striatal", 149], ["3,4-dihydroxyphenyl", 158], ["-", 177], ["L", 178], ["-", 179], ["alanine", 180], ["(", 188], ["L", 189], ["-", 190], ["dopa", 191], [")", 195], ["and", 197], ["dopamine", 201], ["metabolism", 210], [".", 220], ["The", 222], ["oral", 226], ["administration", 231], ["of", 246], ["30", 249], ["mg", 252], ["/", 254], ["kg", 255], ["of", 258], ["tolcapone", 261], ["failed", 271], ["to", 278], ["change", 281], ["dopamine", 288], ["output", 297], ["but", 304], ["elicited", 308], ["a", 317], ["marked", 319], ["and", 326], ["long", 330], ["-", 334], ["lasting", 335], ["decrease", 343], ["of", 352], ["the", 355], ["extracellular", 359], ["levels", 373], ["of", 380], ["homovanillic", 383], ["acid", 396], ["(", 401], ["HVA", 402], [")", 405], ["and", 407], ["3-methoxytyramine", 411], ["with", 429], ["a", 434], ["concomitant", 436], ["increase", 448], ["of", 457], ["3,4-dihydroxyphenylacetic", 460], ["acid", 486], ["(", 491], ["DOPAC", 492], [")", 497], [".", 498], ["The", 500], ["administration", 504], ["of", 519], ["L", 522], ["-", 523], ["dopa", 524], ["(", 529], ["20", 530], ["and", 533], ["60", 537], ["mg", 540], ["/", 542], ["kg", 543], ["p.o", 546], [".", 549], [")", 550], ["+", 552], ["benserazide", 554], ["(", 566], ["15", 567], ["mg", 570], ["/", 572], ["kg", 573], ["p.o", 576], [".", 579], [")", 580], ["resulted", 582], ["in", 591], ["dose", 594], ["-", 598], ["dependent", 599], ["increase", 609], ["of", 618], ["dialysate", 621], ["levels", 631], ["of", 638], ["L", 641], ["-", 642], ["dopa", 643], ["and", 648], ["3-O", 652], ["-", 655], ["methyl", 656], ["-", 662], ["DOPA", 663], [".", 667], ["Tolcapone", 669], ["(", 679], ["30", 680], ["mg", 683], ["/", 685], ["kg", 686], ["p.o", 689], [".", 692], [")", 693], [",", 694], ["given", 696], ["as", 702], ["adjunct", 705], ["to", 713], ["both", 716], ["doses", 721], ["of", 727], ["L", 730], ["-", 731], ["dopa", 732], [",", 736], ["markedly", 738], ["enhanced", 747], ["the", 756], ["elevation", 760], ["or", 770], ["extracellular", 773], ["L", 787], ["-", 788], ["dopa", 789], [",", 793], ["while", 795], ["it", 801], ["completely", 804], ["prevented", 815], ["the", 825], ["formation", 829], ["of", 839], ["3-O", 842], ["-", 845], ["methyl", 846], ["-", 852], ["DOPA", 853], [".", 857], ["In", 859], ["another", 862], ["experiment", 870], [",", 880], ["the", 882], ["administration", 886], ["of", 901], ["L", 904], ["-", 905], ["dopa", 906], ["+", 911], ["benserazide", 913], ["(", 925], ["30", 926], ["+", 929], ["15", 931], ["mg", 934], ["/", 936], ["kg", 937], ["p.o", 940], [".", 943], [")", 944], ["resulted", 946], ["in", 955], ["increased", 958], ["extracellular", 968], ["levels", 982], ["of", 989], ["dopamine", 992], [",", 1000], ["DOPAC", 1002], [",", 1007], ["HVA", 1009], ["and", 1013], ["3-methoxytyramine", 1017], [".", 1034], ["The", 1036], ["co", 1040], ["-", 1042], ["administration", 1043], ["of", 1058], ["tolcapone", 1061], ["(", 1071], ["30", 1072], ["mg", 1075], ["/", 1077], ["kg", 1078], ["p.o", 1081], [".", 1084], [")", 1085], ["further", 1087], ["increased", 1095], ["dopamine", 1105], ["and", 1114], ["DOPAC", 1118], ["levels", 1124], [",", 1130], ["whereas", 1132], ["HVA", 1140], ["and", 1144], ["3-methoxytyramine", 1148], ["effluxes", 1166], ["were", 1175], ["reduced", 1180], [".", 1187], ["These", 1189], ["findings", 1195], ["support", 1204], ["the", 1212], ["notion", 1216], ["that", 1223], ["tolcapone", 1228], ["has", 1238], ["the", 1242], ["ability", 1246], ["to", 1254], ["enhance", 1257], ["striatal", 1265], ["dopamine", 1274], ["neurotransmission", 1283], ["by", 1301], ["increasing", 1304], ["L", 1315], ["-", 1316], ["dopa", 1317], ["bioavailability", 1322], ["through", 1338], ["peripheral", 1346], ["and", 1357], ["central", 1361], ["inhibition", 1369], ["of", 1380], ["L", 1383], ["-", 1384], ["dopa", 1385], ["O", 1390], ["-", 1391], ["methylation", 1392], [",", 1403], ["as", 1405], ["well", 1408], ["as", 1413], ["by", 1416], ["blocking", 1419], ["the", 1428], ["central", 1432], ["conversion", 1440], ["of", 1451], ["dopamine", 1454], ["into", 1463], ["3-methoxytyramine", 1468], [".", 1485]]}
{"context": "Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Beh\u00e7et disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "a00c444bb61f44519190db6046039820", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["is", 21], ["a", 24], ["pleiotropic", 26], ["cytokine", 38], ["implicated", 47], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["immune", 86], ["-", 92], ["mediated", 93], ["disorders", 102], ["including", 112], ["several", 122], ["types", 130], ["of", 136], ["non", 139], ["-", 142], ["infectious", 143], ["uveitis", 154], [".", 161], ["These", 163], ["uveitic", 169], ["conditions", 177], ["include", 188], ["Vogt", 196], ["-", 200], ["Koyanagi", 201], ["-", 209], ["Harada", 210], ["syndrome", 217], [",", 225], ["uveitis", 227], ["associated", 235], ["with", 246], ["Beh\u00e7et", 251], ["disease", 258], [",", 265], ["and", 267], ["sarcoidosis", 271], [".", 282], ["This", 284], ["review", 289], ["summarizes", 296], ["the", 307], ["role", 311], ["of", 316], ["IL-6", 319], ["in", 324], ["immunity", 327], [",", 335], ["highlighting", 337], ["its", 350], ["effect", 354], ["on", 361], ["Th17", 364], [",", 368], ["Th1", 370], [",", 373], ["and", 375], ["plasmablast", 379], ["differentiation", 391], [".", 406], ["It", 408], ["reviews", 411], ["the", 419], ["downstream", 423], ["mediators", 434], ["activated", 444], ["in", 454], ["the", 457], ["process", 461], ["of", 469], ["IL-6", 472], ["binding", 477], ["to", 485], ["its", 488], ["receptor", 492], ["complex", 501], [".", 508], ["This", 510], ["review", 515], ["also", 522], ["summarizes", 527], ["the", 538], ["biologics", 542], ["targeting", 552], ["either", 562], ["IL-6", 569], ["or", 574], ["the", 577], ["IL-6", 581], ["receptor", 586], [",", 594], ["including", 596], ["tocilizumab", 606], [",", 617], ["sarilumab", 619], [",", 628], ["sirukumab", 630], [",", 639], ["olokizumab", 641], [",", 651], ["clazakizumab", 653], [",", 665], ["and", 667], ["siltuximab", 671], [".", 681], ["The", 683], ["target", 687], [",", 693], ["dosage", 695], [",", 701], ["potential", 703], ["side", 713], ["effects", 718], [",", 725], ["and", 727], ["potential", 731], ["uses", 741], ["of", 746], ["these", 749], ["biologics", 755], ["are", 765], ["summarized", 769], ["in", 780], ["this", 783], ["article", 788], ["based", 796], ["on", 802], ["the", 805], ["existing", 809], ["literature", 818], [".", 828], ["In", 830], ["summary", 833], [",", 840], ["anti", 842], ["-", 846], ["IL-6", 847], ["therapy", 852], ["for", 860], ["non", 864], ["-", 867], ["infectious", 868], ["uveitis", 879], ["shows", 887], ["promise", 893], ["in", 901], ["terms", 904], ["of", 910], ["efficacy", 913], ["and", 922], ["side", 926], ["effect", 931], ["profile", 938], [".", 945]]}
{"context": "The precise regulation of microRNA (miRNA) transcription and processing is important for eukaryotic development. Plant miRNAs are first transcribed as stem-loop primary miRNAs (pri-miRNAs) by RNA polymerase II,then cleaved in the nucleus into mature miRNAs by Dicer-like 1 (DCL1). We identified a cycling DOF transcription factor, CDF2, which interacts with DCL1 and regulates the accumulation of a population of miRNAs. CDF2 binds directly to the promoters of some miRNAs and works as a transcription activator or repressor for these miRNA genes. CDF2 binds preferentially to the pri-miRNAs regulated by itself and affects DCL1-mediated processing of these pri-miRNAs. Genetically, CDF2 works in the same pathway as miR156 or miR172 to control flowering. We conclude that CDF2 regulates a group of pri-miRNAs at both the transcriptional and posttranscriptional levels to maintain proper levels of their mature miRNAs to control plant development.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "0d62867611e34119b3f038886614e0ab", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[34, 36]], "char_spans": [[192, 208]]}]}], "context_tokens": [["The", 0], ["precise", 4], ["regulation", 12], ["of", 23], ["microRNA", 26], ["(", 35], ["miRNA", 36], [")", 41], ["transcription", 43], ["and", 57], ["processing", 61], ["is", 72], ["important", 75], ["for", 85], ["eukaryotic", 89], ["development", 100], [".", 111], ["Plant", 113], ["miRNAs", 119], ["are", 126], ["first", 130], ["transcribed", 136], ["as", 148], ["stem", 151], ["-", 155], ["loop", 156], ["primary", 161], ["miRNAs", 169], ["(", 176], ["pri", 177], ["-", 180], ["miRNAs", 181], [")", 187], ["by", 189], ["RNA", 192], ["polymerase", 196], ["II", 207], [",", 209], ["then", 210], ["cleaved", 215], ["in", 223], ["the", 226], ["nucleus", 230], ["into", 238], ["mature", 243], ["miRNAs", 250], ["by", 257], ["Dicer", 260], ["-", 265], ["like", 266], ["1", 271], ["(", 273], ["DCL1", 274], [")", 278], [".", 279], ["We", 281], ["identified", 284], ["a", 295], ["cycling", 297], ["DOF", 305], ["transcription", 309], ["factor", 323], [",", 329], ["CDF2", 331], [",", 335], ["which", 337], ["interacts", 343], ["with", 353], ["DCL1", 358], ["and", 363], ["regulates", 367], ["the", 377], ["accumulation", 381], ["of", 394], ["a", 397], ["population", 399], ["of", 410], ["miRNAs", 413], [".", 419], ["CDF2", 421], ["binds", 426], ["directly", 432], ["to", 441], ["the", 444], ["promoters", 448], ["of", 458], ["some", 461], ["miRNAs", 466], ["and", 473], ["works", 477], ["as", 483], ["a", 486], ["transcription", 488], ["activator", 502], ["or", 512], ["repressor", 515], ["for", 525], ["these", 529], ["miRNA", 535], ["genes", 541], [".", 546], ["CDF2", 548], ["binds", 553], ["preferentially", 559], ["to", 574], ["the", 577], ["pri", 581], ["-", 584], ["miRNAs", 585], ["regulated", 592], ["by", 602], ["itself", 605], ["and", 612], ["affects", 616], ["DCL1-mediated", 624], ["processing", 638], ["of", 649], ["these", 652], ["pri", 658], ["-", 661], ["miRNAs", 662], [".", 668], ["Genetically", 670], [",", 681], ["CDF2", 683], ["works", 688], ["in", 694], ["the", 697], ["same", 701], ["pathway", 706], ["as", 714], ["miR156", 717], ["or", 724], ["miR172", 727], ["to", 734], ["control", 737], ["flowering", 745], [".", 754], ["We", 756], ["conclude", 759], ["that", 768], ["CDF2", 773], ["regulates", 778], ["a", 788], ["group", 790], ["of", 796], ["pri", 799], ["-", 802], ["miRNAs", 803], ["at", 810], ["both", 813], ["the", 818], ["transcriptional", 822], ["and", 838], ["posttranscriptional", 842], ["levels", 862], ["to", 869], ["maintain", 872], ["proper", 881], ["levels", 888], ["of", 895], ["their", 898], ["mature", 904], ["miRNAs", 911], ["to", 918], ["control", 921], ["plant", 929], ["development", 935], [".", 946]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "The clinical efficacy of different doses of the specific benzodiazepine antagonist flumazenil was studied in a total of 72 patients with benzodiazepine or ethanol overdose. In a randomized double-blind study, 18 patients (group 1) and eight patients (group 2) with suspected benzodiazepine overdose received 5 mg (group 1) or 1 mg (group 2) flumazenil or placebo, respectively. The stage of coma, heart rate, blood pressure and respiratory rate were monitored within the following 15 min. If no change in the stage of coma was observed, 5 mg (group 1) or 1 mg (group 2) flumazenil were given, and the stage of coma, heart rate and blood pressure were again monitored. In a similar way, the effect of 5 and 1 mg flumazenil was investigated in 13 patients (group 3) and four patients (group 4) with ethanol intoxication. In an open trial, the clinical efficacy of flumazenil for the diagnosis of benzodiazepine or ethanol overdose was studied in 29 patients (group 5). In all patients, a toxicological screening confirmed benzodiazepine or ethanol overdose. None of the patients receiving placebo showed effects on stage of coma, heart rate, blood pressure or respiratory rate. Patients with benzodiazepine overdose who received 5 mg flumazenil regained consciousness about 1-2 min after the end of injection. The effect of 1 mg flumazenil (group 2) on benzodiazepine-induced coma was less pronounced. In patients with ethanol overdose (group 3), ethanol-induced coma was reversed after 5 mg flumazenil more slowly than in patients of group 1. No effect of flumazenil on ethanol-induced coma was observed in group 4. In group 5, flumazenil proved to be useful for diagnosing benzodiazepine or ethanol intoxication. In one patient with coma due to carbamazepine overdose, flumazenil was also found to be effective. Additionally, a possible analytical interference of flumazenil and its metabolites with the identification of other benzodiazepines by a toxicological screening procedure was studied. Even after an oral dose of 200 mg flumazenil, no interference with immunological benzodiazepine assays (EMIT, TDX, and RIA) was found. A metabolite and an artifact of flumazenil could be identified in urine by gas chromatography/mass spectrometry.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "09099c4d930143fdb85f846a03675594", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[304, 304], [320, 320], [147, 147], [11, 11], [177, 177], [291, 291], [342, 342], [357, 357], [116, 116], [383, 383], [408, 408], [258, 258], [239, 239], [65, 65]], "char_spans": [[1555, 1564], [1627, 1636], [711, 720], [83, 92], [862, 871], [1490, 1499], [1769, 1778], [1864, 1873], [570, 579], [2030, 2039], [2163, 2172], [1327, 1336], [1232, 1241], [341, 350]]}]}], "context_tokens": [["The", 0], ["clinical", 4], ["efficacy", 13], ["of", 22], ["different", 25], ["doses", 35], ["of", 41], ["the", 44], ["specific", 48], ["benzodiazepine", 57], ["antagonist", 72], ["flumazenil", 83], ["was", 94], ["studied", 98], ["in", 106], ["a", 109], ["total", 111], ["of", 117], ["72", 120], ["patients", 123], ["with", 132], ["benzodiazepine", 137], ["or", 152], ["ethanol", 155], ["overdose", 163], [".", 171], ["In", 173], ["a", 176], ["randomized", 178], ["double", 189], ["-", 195], ["blind", 196], ["study", 202], [",", 207], ["18", 209], ["patients", 212], ["(", 221], ["group", 222], ["1", 228], [")", 229], ["and", 231], ["eight", 235], ["patients", 241], ["(", 250], ["group", 251], ["2", 257], [")", 258], ["with", 260], ["suspected", 265], ["benzodiazepine", 275], ["overdose", 290], ["received", 299], ["5", 308], ["mg", 310], ["(", 313], ["group", 314], ["1", 320], [")", 321], ["or", 323], ["1", 326], ["mg", 328], ["(", 331], ["group", 332], ["2", 338], [")", 339], ["flumazenil", 341], ["or", 352], ["placebo", 355], [",", 362], ["respectively", 364], [".", 376], ["The", 378], ["stage", 382], ["of", 388], ["coma", 391], [",", 395], ["heart", 397], ["rate", 403], [",", 407], ["blood", 409], ["pressure", 415], ["and", 424], ["respiratory", 428], ["rate", 440], ["were", 445], ["monitored", 450], ["within", 460], ["the", 467], ["following", 471], ["15", 481], ["min", 484], [".", 487], ["If", 489], ["no", 492], ["change", 495], ["in", 502], ["the", 505], ["stage", 509], ["of", 515], ["coma", 518], ["was", 523], ["observed", 527], [",", 535], ["5", 537], ["mg", 539], ["(", 542], ["group", 543], ["1", 549], [")", 550], ["or", 552], ["1", 555], ["mg", 557], ["(", 560], ["group", 561], ["2", 567], [")", 568], ["flumazenil", 570], ["were", 581], ["given", 586], [",", 591], ["and", 593], ["the", 597], ["stage", 601], ["of", 607], ["coma", 610], [",", 614], ["heart", 616], ["rate", 622], ["and", 627], ["blood", 631], ["pressure", 637], ["were", 646], ["again", 651], ["monitored", 657], [".", 666], ["In", 668], ["a", 671], ["similar", 673], ["way", 681], [",", 684], ["the", 686], ["effect", 690], ["of", 697], ["5", 700], ["and", 702], ["1", 706], ["mg", 708], ["flumazenil", 711], ["was", 722], ["investigated", 726], ["in", 739], ["13", 742], ["patients", 745], ["(", 754], ["group", 755], ["3", 761], [")", 762], ["and", 764], ["four", 768], ["patients", 773], ["(", 782], ["group", 783], ["4", 789], [")", 790], ["with", 792], ["ethanol", 797], ["intoxication", 805], [".", 817], ["In", 819], ["an", 822], ["open", 825], ["trial", 830], [",", 835], ["the", 837], ["clinical", 841], ["efficacy", 850], ["of", 859], ["flumazenil", 862], ["for", 873], ["the", 877], ["diagnosis", 881], ["of", 891], ["benzodiazepine", 894], ["or", 909], ["ethanol", 912], ["overdose", 920], ["was", 929], ["studied", 933], ["in", 941], ["29", 944], ["patients", 947], ["(", 956], ["group", 957], ["5", 963], [")", 964], [".", 965], ["In", 967], ["all", 970], ["patients", 974], [",", 982], ["a", 984], ["toxicological", 986], ["screening", 1000], ["confirmed", 1010], ["benzodiazepine", 1020], ["or", 1035], ["ethanol", 1038], ["overdose", 1046], [".", 1054], ["None", 1056], ["of", 1061], ["the", 1064], ["patients", 1068], ["receiving", 1077], ["placebo", 1087], ["showed", 1095], ["effects", 1102], ["on", 1110], ["stage", 1113], ["of", 1119], ["coma", 1122], [",", 1126], ["heart", 1128], ["rate", 1134], [",", 1138], ["blood", 1140], ["pressure", 1146], ["or", 1155], ["respiratory", 1158], ["rate", 1170], [".", 1174], ["Patients", 1176], ["with", 1185], ["benzodiazepine", 1190], ["overdose", 1205], ["who", 1214], ["received", 1218], ["5", 1227], ["mg", 1229], ["flumazenil", 1232], ["regained", 1243], ["consciousness", 1252], ["about", 1266], ["1", 1272], ["-", 1273], ["2", 1274], ["min", 1276], ["after", 1280], ["the", 1286], ["end", 1290], ["of", 1294], ["injection", 1297], [".", 1306], ["The", 1308], ["effect", 1312], ["of", 1319], ["1", 1322], ["mg", 1324], ["flumazenil", 1327], ["(", 1338], ["group", 1339], ["2", 1345], [")", 1346], ["on", 1348], ["benzodiazepine", 1351], ["-", 1365], ["induced", 1366], ["coma", 1374], ["was", 1379], ["less", 1383], ["pronounced", 1388], [".", 1398], ["In", 1400], ["patients", 1403], ["with", 1412], ["ethanol", 1417], ["overdose", 1425], ["(", 1434], ["group", 1435], ["3", 1441], [")", 1442], [",", 1443], ["ethanol", 1445], ["-", 1452], ["induced", 1453], ["coma", 1461], ["was", 1466], ["reversed", 1470], ["after", 1479], ["5", 1485], ["mg", 1487], ["flumazenil", 1490], ["more", 1501], ["slowly", 1506], ["than", 1513], ["in", 1518], ["patients", 1521], ["of", 1530], ["group", 1533], ["1", 1539], [".", 1540], ["No", 1542], ["effect", 1545], ["of", 1552], ["flumazenil", 1555], ["on", 1566], ["ethanol", 1569], ["-", 1576], ["induced", 1577], ["coma", 1585], ["was", 1590], ["observed", 1594], ["in", 1603], ["group", 1606], ["4", 1612], [".", 1613], ["In", 1615], ["group", 1618], ["5", 1624], [",", 1625], ["flumazenil", 1627], ["proved", 1638], ["to", 1645], ["be", 1648], ["useful", 1651], ["for", 1658], ["diagnosing", 1662], ["benzodiazepine", 1673], ["or", 1688], ["ethanol", 1691], ["intoxication", 1699], [".", 1711], ["In", 1713], ["one", 1716], ["patient", 1720], ["with", 1728], ["coma", 1733], ["due", 1738], ["to", 1742], ["carbamazepine", 1745], ["overdose", 1759], [",", 1767], ["flumazenil", 1769], ["was", 1780], ["also", 1784], ["found", 1789], ["to", 1795], ["be", 1798], ["effective", 1801], [".", 1810], ["Additionally", 1812], [",", 1824], ["a", 1826], ["possible", 1828], ["analytical", 1837], ["interference", 1848], ["of", 1861], ["flumazenil", 1864], ["and", 1875], ["its", 1879], ["metabolites", 1883], ["with", 1895], ["the", 1900], ["identification", 1904], ["of", 1919], ["other", 1922], ["benzodiazepines", 1928], ["by", 1944], ["a", 1947], ["toxicological", 1949], ["screening", 1963], ["procedure", 1973], ["was", 1983], ["studied", 1987], [".", 1994], ["Even", 1996], ["after", 2001], ["an", 2007], ["oral", 2010], ["dose", 2015], ["of", 2020], ["200", 2023], ["mg", 2027], ["flumazenil", 2030], [",", 2040], ["no", 2042], ["interference", 2045], ["with", 2058], ["immunological", 2063], ["benzodiazepine", 2077], ["assays", 2092], ["(", 2099], ["EMIT", 2100], [",", 2104], ["TDX", 2106], [",", 2109], ["and", 2111], ["RIA", 2115], [")", 2118], ["was", 2120], ["found", 2124], [".", 2129], ["A", 2131], ["metabolite", 2133], ["and", 2144], ["an", 2148], ["artifact", 2151], ["of", 2160], ["flumazenil", 2163], ["could", 2174], ["be", 2180], ["identified", 2183], ["in", 2194], ["urine", 2197], ["by", 2203], ["gas", 2206], ["chromatography", 2210], ["/", 2224], ["mass", 2225], ["spectrometry", 2230], [".", 2242]]}
